

## A. PTH

It has been suggested that HDM is caused by raised levels of PTH associated with secondary hyperparathyroidism, rather vitamin D deficiency itself [91]. Fatigue and muscular weakness are classically associated with primary hyperparathyroidism [92–95], and successful parathyroid surgery results in significant improvement of these muscular symptoms [92,94,96]. In addition, muscle biopsies obtained from patients with primary hyperparathyroidism reveal type II fiber atrophy, very much like the changes seen in HDM. Treatment with PTH reduces the intracellular content of inorganic phosphate, creatine phosphate, and CaATPase [97], which are exactly the findings we reported after analysis of muscle biopsies and  $^{31}\text{P}$ -MR-spectroscopy in patients with HDM [23,66]. Furthermore, mitochondrial oxygen consumption and the activity of creatine phosphokinase and CaATPase are reduced and oxidation of long-chain fatty acids impaired by PTH [98].

Thus, many parallels exist between myopathy caused by primary hyperparathyroidism and HDM. However, muscle weakness is not always present in patients with primary hyperparathyroidism [3,99], and HDM can be present despite normal PTH levels [9]. Further, improvements in muscle strength after surgery for primary hyperparathyroidism do not correlate to postoperative decreases in PTH or calcium [94,100].

If PTH was the only effector on skeletal muscle, reversal of secondary hyperparathyroidism by a high intake of calcium should reverse the muscular symptoms. However, in their rat study Rodman and Baker [45] detected severe perturbations of muscle function in vitamin D-deficient rats despite high serum levels of calcium and phosphate (Fig. 4). Furthermore, in a study on type II fiber size in hip fracture patients, Sato *et al.* [54] reported a significant correlation between serum levels of 25OHD and fiber size—no correlation to PTH was reported.

Generally, clinical studies [8,56,89] report inverse correlations between PTH and muscle symptoms, and positive correlations to 25OHD [8,56,58,59,89]. In a comment accompanying the study of Stein *et al.* [56], Birge [83] suggested that PTH might be a better biological marker for vitamin D deficiency at the tissue level than serum levels of 25OHD, and this could be the reason why PTH and not 25OHD come out as significant determinants in multiple regression analyses. In this context, however, the significant interaction between 25OHD and PTH has to be taken into account.

In conclusion: There is strong evidence for a direct effect of vitamin D on muscle both in clinical and experimental studies. It is possible, however, that secondary hyperparathyroidism may exert additive or synergistic effects on HDM development.

## B. $1,25(\text{OH})_2\text{D}$

Theoretically,  $1,25(\text{OH})_2\text{D}$  concentrations should be the most likely effector of vitamin D effects on muscle—and indeed, a large amount of experimental data support this notion (see Chapter 55). In clinical studies, however, this expected relationship finds less support [59]. Glerup *et al.* [8,23] found no correlation between muscle function and  $1,25(\text{OH})_2\text{D}$  ( $r = -0.14$ , NS), whereas maximal knee extension strength correlated significantly to 25OHD ( $r = 0.34$ ,  $p < 0.01$ ). In fact, it is common to see severe symptoms of HDM with normal or even elevated values of  $1,25(\text{OH})_2\text{D}$ . Furthermore, hypovitaminosis D-related symptoms (diffuse muscle pain, deep bone pain, paresthesia, fatigue, muscle cramps, joint pain) all correlated to 25OHD (Kruskal-Wallis ANOVA:  $p < 0.001$ ) but not to  $1,25(\text{OH})_2\text{D}$  (NS). The absence of correlations to  $1,25(\text{OH})_2\text{D}$  is probably explained by several factors. First, renal  $1\text{-}\alpha$ -hydroxylase activity is under tight control by PTH levels, resulting in normal or even elevated levels of  $1,25(\text{OH})_2\text{D}$ , despite very low levels of 25OHD. Second, serum levels of  $1,25(\text{OH})_2\text{D}$  don't necessarily tell anything about the intracellular levels of the hormone in muscle cells. Third, Geusens *et al.* [67] have shown clinical importance of VDR-genotypes, which support an *in vivo* effect of VDR-mediated effects. Thus,  $1,25(\text{OH})_2\text{D}$  seems to be involved in the pathogenesis of HDM. One hypothesis may reconcile the inconsistencies outlined above, namely the purported presence of intracellular, autocrine production of  $1,25(\text{OH})_2\text{D}$  from 25OHD in muscle cells [68]. There is an increasing amount of evidence suggesting the clinical importance of extrarenal  $1,25(\text{OH})_2\text{D}$  synthesis [101–107] (see Chapter 79). Two features distinguish extrarenal from renal synthesis of  $1,25(\text{OH})_2\text{D}$ : 1) it is not under control of PTH, but is dependent on the availability of the substrate 25OHD; 2) local  $1,25(\text{OH})_2\text{D}$  synthesis has been shown to take place in the mitochondria [101]. Muscle has a very high content of mitochondria, which makes muscle a very likely site of extrarenal  $1,25(\text{OH})_2\text{D}$  synthesis. Intracellular production of  $1,25(\text{OH})_2\text{D}$  could explain the correlation between 25OHD and the muscular effects of vitamin D. Further, this pathway still requires  $1,25(\text{OH})_2\text{D}$  to be the final effector of vitamin D's muscular effects. It has been argued that local  $1,25(\text{OH})_2\text{D}$  synthesis in muscle should result in increased serum levels of  $1,25(\text{OH})_2\text{D}$ . Significant local  $1,25(\text{OH})_2\text{D}$  production has been identified in other tissues (endothelium [102], prostate [106], bone cells, liver cells, skin, etc. [103]), but these sites do not result in increased serum levels of  $1,25(\text{OH})_2\text{D}$ . The absence of increased  $1,25(\text{OH})_2\text{D}$  in these instances is most likely explained by the presence of highly-induced intracellular  $24\text{-hydroxylase}$

activity, ensuring degradation of  $1,25\text{OH}_2\text{D}$  before it reaches the circulation. Also, failure of release of  $1,25(\text{OH})_2\text{D}$  into the circulation may be an additional factor.

### C. 25OHD

25OHD is considered to be the storage and circulating form of vitamin D, and measurement of serum levels of 25OHD best reflect the vitamin D status of the body. 25OHD has been presumed to be biologically inert, but recent data challenge this notion. As already mentioned above, serum levels of 25OHD correlate to the biological effects of vitamin D *in vivo*. The effects of 25OHD on muscle cells could be mediated in several ways. 25OHD has some affinity for VDR, but the affinity of  $1,25(\text{OH})_2\text{D}$  for VDR is approximately 1000-fold higher than 25OHD. The serum concentration of 25OHD is about 500–1000 times higher than  $1,25(\text{OH})_2\text{D}$ , but most is bound to vitamin D binding protein (DBP) (see Chapter 8). Competitive binding of the two vitamin D metabolites to VDR might be possible under some circumstances [108–110]. No specific receptor for 25OHD has been identified. As mentioned in the paragraph above, a more likely explanation is the local synthesis of  $1,25(\text{OH})_2\text{D}$  from 25OHD as substrate.

Finally, it is possible that 25OHD could exert direct effects on muscle via an effector-mechanism, which is still under investigation. Recently, Nykjaer *et al.* [111–113] (see Chapter 10) identified the cubilin-megalin receptor system as being responsible for renal reuptake of vitamin D metabolites bound to DBP. Muscle tissue possesses receptors of the LDL receptor family, which potentially could be involved in tissue specific uptake of 25OHD, but this still needs to be investigated (personal communication A. Nykjaer).

## VIII. OTHER POSSIBLE MUSCULAR EFFECTS OF VITAMIN D

### A. Insulin Resistance in Vitamin D Deficiency — Due To HDM?

Vitamin D deficiency has been reported to increase the risk of developing insulin resistance and abnormal oral glucose tolerance tests (OGTT) [114–117]. Striated muscle is central in the pathogenesis of Type 2 diabetes. GLUT4 is the most important glucose transporter in muscle [118–120]. The GLUT4 content of muscles declines with age [118,120], especially in the fast type II muscle fibers. Furthermore, GLUT4

is reduced in type 2 diabetes [119]. More research is necessary to establish a possible effect of vitamin D on the GLUT4 content of the muscle.

In type 2 diabetes, serum levels of free fatty acids are elevated [121,122]. Significant perturbations in the energy metabolism of mitochondria in muscle has been described in hypovitaminosis D [66], as well as in the presence of increased levels of PTH [97]. Additional research is warranted on the possible effects of vitamin D and PTH on fatty oxidation in striated muscle.

### B. Possible Effects of Vitamin D on Muscle Regeneration

During exercise, serum levels of  $1,25(\text{OH})_2\text{D}$  have been reported to increase temporarily [123–127]. Exercise damages the muscle fibers and induces regeneration and growth of the muscle through enhanced satellite cell proliferation [128,129]. It could be speculated that  $1,25\text{OH}_2\text{D}$  might be of importance in the regeneration process of muscle. Furthermore, reduced IGF-I levels seem to play a role in age-related muscle degeneration. A possible interrelationship between IGF-I levels and vitamin D levels should be investigated [130].

## IX. SUMMARY

In this chapter we have reviewed the increasing evidence pointing to direct effects of vitamin D on striated muscle, making striated muscle an important target organ for vitamin D. Hypovitaminosis D myopathy (HDM) is a reversible disease that can recover completely, usually with significant improvement within a few weeks to a month after beginning vitamin D treatment [7,131,132]. Full restoration of severe HDM, however, may take 6 to 12 months of treatment with vitamin D [10]. Moreover, there is strong evidence for the prophylactic effects of vitamin D to reduce the risk of falls through improved muscular function and thereby to decrease the incidence of fractures. A daily dose of at least 800 IU (20  $\mu\text{g}$ ) cholecalciferol preferably in combination with 1000–1200 mg calcium seems to be the most effective treatment. Consequently combined vitamin D and calcium prophylaxis should be considered to combat hip fractures in the elderly. All patients at risk for vitamin D deficiency (i.e., lack of sunlight exposure) should be suspected to suffer from HDM. Those patients suspected of having HDM should have a blood test performed for measurement of 25OHD and PTH. In severe cases of HDM, treatment

should be initiated with a higher dose of vitamin D in order to speed up recovery. 300,000 IU cholecalciferol or ergocalciferol can be given either as an oral dose or intramuscular injection. This can be given as a single dose or repeated every month for three months. The high dose vitamin D should be combined with a daily supply of calcium.

In order to avoid HDM, the serum levels of 25OHD should be kept above 50 nmol/l and PTH levels should be suppressed to the normal range. Maintenance of normal 25OHD levels in the elderly should have a high priority, as hip fractures and disability carry a high cost for society as well as for the individual patients. Treatment of HDM results in significant improvement in quality of life. However, vitamin D is not the solution to every musculoskeletal problem in the aging population. The age-related loss of muscle power (approximately 1.5% per year [32]) seems to be obligatory and unrelated to vitamin D deficiency.

The data summarized in this review, lead to new questions, of which the ones, we consider most important are listed below:

1. Do muscle cells have the capacity to synthesize 1,25(OH)<sub>2</sub>D from 25OHD?
2. Is hydroxylation of 25OHD to 1,25(OH)<sub>2</sub>D necessary in order to mediate its effect on muscle, or does 25OHD have an effect of its own?
3. How do elevated PTH levels interact with vitamin D in muscle?
4. Finally, is the uptake of 25OHD and 1,25(OH)<sub>2</sub>D in muscle a matter of simple diffusion, or do muscle cells possess a system for facilitated uptake of the compounds?

## References

1. Prineas W, Stuart-Mason A, Henson, RA 1965 Myopathy in metabolic bone disease. *BMJ* **I**:1034–1036.
2. Smith R, Stern G 1967 Myopathy, osteomalacia, and hyperparathyroidism. *Brain* **90**:593–602.
3. Smith R, Stern G 1969 Muscular weakness in osteomalacia and hyperparathyroidism. *J Neurol Sci* **8**:511–520.
4. Chalmers J, Conacher WDH, Gardner DL, Scott PJ, 1967 Osteomalacia—A common disease in elderly women. *J Bone Joint Surg* **49B**:403–423.
5. Schott GD, Wills MR, 1976 Muscle weakness in osteomalacia. *Lancet* **1**:626–629.
6. Skaria J, Katiyar BC, Srivastava TP, Dube B 1975 Myopathy and neuropathy associated with osteomalacia. *Acta Neurol Scand* **51**:37–58.
7. Russell JA 1994 Osteomalacic myopathy. *Muscle Nerve* **17**:578–580.
8. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H, Charles P, Eriksen EF 2000 Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. *Calcif Tissue Int* **66**(6):419–424.
9. Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, Begerow B, Lew RA, Conzelmann M 2003 Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. *J Bone Miner Res* **18**:343–351.
10. Young A, Edwards RHT, Jones DA, Brenton DP, 1981 Quadriceps muscle strength and fiber size during the treatment of osteomalacia. In: IAF Stokes (ed) *Mechanical factors and the skeleton*.
11. Young A, Brenton, DP, Edwards R 1978 Analysis of muscle weakness in osteomalacia. *Clin Sci Mol Med* **54**(2): p. 31.
12. Mallette LE, Patten BM, Engel WK 1975 Neuromuscular disease in secondary hyperparathyroidism. *Ann Intern Med* **82**:474–483.
13. Dastur DK, Gagrut BM, Wadia NH, Desai M, Bharucha EP 1975 Nature of muscular change in osteomalacia: light- and electron-microscope observations. *J Pathol* **117**:211–228.
14. Yoshikawa S, Nakamura T, Tanabe H, Imamura T 1979 Osteomalacic myopathy. *Endocrinol Jpn* **26**:65–72.
15. Sorensen OH, Lund B, Saltin B, Andersen RB, Hjorth L, Melsen F, Mosekilde L 1979 Myopathy in bone loss of aging: improvement by treatment with 1 alpha-hydroxy-cholecalciferol and calcium. *Clin Sci* **56**:157–161.
16. Birge SJ, Haddad JG, 1975 25-hydroxycholecalciferol stimulation of muscle metabolism. *J Clin Invest* **56**: 1100–1107.
17. Pointon JJ, Francis MJ, Smith R 1979 Effect of vitamin D deficiency on sarcoplasmic reticulum function and troponin C concentration of rabbit skeletal muscle. *Clin Sci* **57**: 257–263.
18. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ, 1992 Vitamin D<sub>3</sub> and calcium to prevent hip fractures in the elderly women. *N Engl J Med* **327**:1637–1642.
19. Lips P, van Ginkel FC, Jongen MJ, Rubertus F, van der Vijgh WJ, Netelenbos JC 1987 Determinants of vitamin D status in patients with hip fracture and in elderly control subjects. *Am J Clin Nutr* **46**:1005–1010.
20. Lund B, Sorensen OH, Melsen F, Mosekilde, L 1982 Vitamin D metabolism and osteomalacia in patients with fractures of the proximal femur. *Acta Orthop Scand* **53**:251–254.
21. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J 1999 Occult vitamin D deficiency in postmenopausal U.S. women with acute hip fracture. *JAMA* **281**: 1505–1511.
22. Glerup H, Eriksen EF 1999 Osteomalacia and severe vitamin D deficiency—A review of the clinical and paraclinical findings and guidelines for the treatment with vitamin D. *Ugeskr Laeger* **161**:2515–2521.
23. Glerup H 1999 Investigations on the role of vitamin D in muscle function—A study of muscle function in vitamin D-deficient humans and the effect of treatment with vitamin D, PhD Thesis, University of Aarhus, Denmark.
24. Glerup H, Eriksen EF 1999 Acroparaesthesia—a typical finding in vitamin D deficiency. *Br J Rheumatol* **38**:482.
25. Jones DA, Round JM 1992 Skeletal muscle in health and disease—a textbook of muscle physiology. Manchester University Press: Manchester, UK.
26. Gayton AC 1996 Textbook of medical physiology W.B. Saunders: Philadelphia.
27. White A, Handler P, Smith EL 1985 Muscle. Chap 36. *Principles of Biochemistry* 6th edn. McGraw-Hill.
28. Dulhunty AF, Junankar PR, Eager KR, Ahern GP, Laver DR, 1996 Ion channels in the sarcoplasmic reticulum of striated muscle. *Acta Physiol Scand* **156**:375–385.

29. Murphy RA, Muscle. In: RM Berne, MN Levy (eds) Physiology, Mosby: St. Louis.
30. Yano K, Zarain Herzberg A 1994 Sarcoplasmic reticulum calsequestrins: structural and functional properties. *Mol Cell Biochem* **135**:61–70.
31. Milner RE, Famulski KS, Michalak M 1992 Calcium-binding proteins in the sarcoplasmic/endoplasmic reticulum of muscle and nonmuscle cells. *Mol Cell Biochem* **112**:1–13.
32. McComas AJ 1996 Skeletal muscle—Form and function, Human Kinetics: Champaign, IL.
33. Dulhunty AF, Banyard MR, Medveczky CJ 1987 Distribution of calcium ATPase in the sarcoplasmic reticulum of fast- and slow-twitch muscles determined with monoclonal antibodies. *J Membr Biol* **99**:79–92.
34. Maier A, Leberer E, Pette D 1986 Distribution of sarcoplasmic reticulum Ca-ATPase and of calsequestrin in rabbit and rat skeletal muscle fibers. *Histochemistry* **86**:63–69.
35. Costa EM, Blau HM, Feldman D 1986 1,25-dihydroxyvitamin D<sub>3</sub> receptors and hormonal responses in cloned human skeletal muscle cells. *Endocrinology* **119**:2214–2220.
36. Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stahelin HB, Dick W 2001 *In situ* detection of 1,25-dihydroxyvitamin D<sub>3</sub> receptor in human skeletal muscle tissue. *Histochem J* **33**:19–24.
37. Boland R, Norman A, Ritz E, Hasselbach W 1985 Presence of a 1,25-dihydroxyvitamin D<sub>3</sub> receptor in chick skeletal muscle myoblasts. *Biochem Biophys Res Commun* **128**:305–311.
38. Simpson RU, Thomas GA, Arnold AJ 1985 Identification of 1,25-dihydroxyvitamin D<sub>3</sub> receptors and activities in muscle. *J Biol Chem* **260**:8882–8891.
39. de Boland AR, Albornoz LE, Boland R 1983 The effect of cholecalciferol *in vivo* on proteins and lipids of skeletal muscle from rachitic chicks. *Calcif Tissue Int* **35**:798–805.
40. de Boland AR, Boland RL 1984 Effects of vitamin D<sub>3</sub> on *in vivo* labeling of chick skeletal muscle proteins with [3H]leucine. *Z Naturforsch C* **39**:1015–1016.
41. Boland R 1986 Role of vitamin D in skeletal muscle function. *Endocr Rev* **7**:434–448.
42. de Boland AR, Boland RL 1987 Rapid changes in skeletal muscle calcium uptake induced *in vitro* by 1,25-dihydroxyvitamin D<sub>3</sub> are suppressed by calcium channel blockers. *Endocrinology* **120**:1858–1864.
43. de Boland AR, Boland RL 1994 Nongenomic signal transduction pathway of vitamin D in muscle. *Cell Signal* **6**:717–724.
44. Curry OB, Basten JF, Francis MJ, Smith R 1974 Calcium uptake by sarcoplasmic reticulum of muscle from vitamin D-deficient rabbits. *Nature* **249**:83–84.
45. Rodman JS, Baker T 1978 Changes in the kinetics of muscle contraction in vitamin D-depleted rats. *Kidney Int* **13**:189–193.
46. Matthews C, Heimberg KW, Ritz E, Agostini B, Fritzsche J, Hasselbach W 1977 Effect of 1,25-dihydroxycholecalciferol on impaired calcium transport by the sarcoplasmic reticulum in experimental uremia. *Kidney Int* **11**:227–235.
47. Boland R, de Boland AR, Ritz E, Hasselbach W 1983 Effect of 1,25-dihydroxycholecalciferol on sarcoplasmic reticulum calcium transport in strontium-fed chicks. *Calcif Tissue Int* **35**:190–194.
48. Boland R, Matthews C, de Boland AR, Ritz E, Hasselbach W 1983 Reversal of decreased phosphorylation of sarcoplasmic reticulum calcium transport ATPase by 1,25-dihydroxycholecalciferol in experimental uremia. *Calcif Tissue Int* **35**:195–201.
49. Sjostrom M, Lorentzon R, Larsson SE, Holmlund, D 1978 The influence of 1,25-dihydroxycholecalciferol on the ultrastructural organization of skeletal muscle fibers. Morphometric analyses on vitamin D-deficient or calcium-deficient growing rats. *Med Biol* **56**:209–215.
50. Pleasure D, Wyszynski B, Sumner A, Schotland D, Feldman B, Nugent N, Hitz K, Goodman DB 1979 Skeletal muscle calcium metabolism and contractile force in vitamin D-deficient chicks. *J Clin Invest* **64**:1157–1167.
51. Toury R, Stelly N, Boissonneau E, Convert M, Dupuis Y 1990 Relationship between vitamin D status and deposition of bound calcium in skeletal muscle of the rat. *Biol Cell* **69**:179–189.
52. Ronin DI, Wu Y, Sahgal V, MacLean IC 1991. Intractable muscle pain syndrome, osteomalacia, axonopathy in long-term use of phenytoin. *Arch Phys Med Rehabil* **72**(10):755–758.
53. Ruff RL, Weissmann J 1988 Endocrine myopathies. *Neurol Clin* **6**:575–592.
54. Sato Y, Inose M, Higuchi I, Higuchi F, Kondo, I 2002 Changes in the supporting muscles of the fractured hip in elderly women. *Bone* **30**:325–330.
55. Pfeifer M, Minne HW 1999 Vitamin D and hip fracture. *Trends Endocrinol Metab* **10**:417–420.
56. Stein MS, Wark JD, Scherer SC, Walton SL, Chick P, Di Carantonio M, Zajac JD, Flicker L 1999 Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. *J Am Geriatr Soc* **47**:1195–1201.
57. Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW, Duursma SA 2000 Muscle strength, functional mobility, and vitamin D in older women. *Aging (Milano)* **12**:455–460.
58. Mowe M, Haug E, Bohmer T 1999 Low serum calcidiol concentration in older adults with reduced muscular function. *J Am Geriatr Soc* **47**:220–226.
59. Bischoff HA, Stahelin HB, Urscheler N, Ehrensam R, Vonthein R, Perrig-Chiello P, Tyndall A, Theiler R 1999 Muscle strength in the elderly: its relation to vitamin D metabolites. *Arch Phys Med Rehabil* **80**:54–58.
60. Gloth FM, Smith CE, Hollis BW, Tobin JD 1995 Functional improvement with vitamin D replenishment in a cohort of frail, vitamin D-deficient older people. *J Am Geriatr Soc* **43**:1269–1271.
61. Corless D, Dawson E, Fraser F, Ellis M, Evans SJ, Perry JD, Reisner C, Silver CP, Beer M, Boucher BJ 1985 Do vitamin D supplements improve the physical capabilities of elder hospital patients? *Age Ageing* **14**:76–84.
62. Verreault R, Semba RD, Volpato S, Ferrucci L, Fried LP, Guralnik JM 2002 Low serum vitamin D does not predict new disability or loss of muscle strength in older women. *J Am Geriatr Soc* **50**:912–917.
63. Boonen S, Lysens R, Verbeke G, Joosten E, Dejaeger E, Pelemans WK, Flamaing J, Bouillon R 1998 Relation between age-associated endocrine deficiencies and muscle function in elderly women: a cross-sectional study. *Age Ageing* **27**:449–454.
64. Grady D, Halloran B, Cummings S, Leveille S, Wells L, Black D, Byl N 1991 1,25-dihydroxyvitamin D<sub>3</sub> and muscle strength in the elderly: a randomized controlled trial. *J Clin Endocrinol Metab* **73**:1111–1117.
65. Glerup H, Thomsen J, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Charles P, Eriksen EF 2000 Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. *J Intern Med* **247**:260–268.

66. Glerup H, Stødkilde-Jørgensen H, Eriksen EF 2001 Hypovitaminosis D myopathy characterized by  $^{31}\text{P}$  MR spectroscopy. *Bone* **28** (Suppl 5):S121.
67. Geusens P, Vandevyver C, Vanhoof J, Cassiman JJ, Boonen S, Raus J 1997 Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. *J Bone Miner Res* **12**:2082–2088.
68. Janssen HC, Samson MM, Verhaar HJ 2002 Vitamin D deficiency, muscle function, and falls in elderly people. *Am J Clin Nutr* **75**:611–615.
69. Pfeifer M, Begerow B, Minne HW 2002 Vitamin D and muscle function. *Osteoporos Int* **13**:187–194.
70. Cummings SR, Nevitt MC 1989 A hypothesis: the causes of hip fractures. *J Gerontol* **44**:M107–111.
71. Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O'Brien LA, Hoffman S, Kaplan F 1991 Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. *N Engl J Med* **324**:1326–1331.
72. Tinetti ME, Williams CS 1997 Falls, injuries due to falls, and the risk of admission to a nursing home. *N Engl J Med* **337**:1279–1284.
73. Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH, Bassey EJ 1988 Falls by elderly people at home: prevalence and associated factors. *Age Ageing* **17**:365–372.
74. Graafmans WC, Ooms ME, Hofstee HM, Bezemer PD, Bouter LM, Lips P 1996 Falls in the elderly: a prospective study of risk factors and risk profiles. *Am J Epidemiol* **143**:1129–1136.
75. Dawson Hughes B, Harris S, Krall EA, Dallal GE 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* **337**:670–676.
76. Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA 1992 Annual injection of vitamin D and fractures of aged bones. *Calcif Tissue Int* **51**:105–110.
77. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM 1996 Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. *Ann Intern Med* **124**:400–406.
78. Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI 2002 Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. *J Bone Miner Res* **17**:709–715.
79. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA 1991 Seasonal variation in the incidence of hip fracture among white persons aged 65 years and older in the United States, 1984–1987. *Am J Epidemiol* **133**:996–1004.
80. Douglas S, Bunyan A, Chiu KH, Twaddle B, Maffulli N 2000 Seasonal variation of hip fracture at three latitudes. *Injury* **31**(1):11–19.
81. Bacon WE, Smith GS, Baker DL 1989 Geographical variation in the occurrence of hip fractures among elderly white US population. *Am J Public Health* **79**(11):1556–1558.
82. Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sorensen OH 2001 Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure, and serum parathyroid hormone. *Br J Nutr* **86**(Suppl 1):S97–S103.
83. Birge SJ 1999 Can falls and hip fracture be prevented in frail older adults? *J Am Geriatr Soc* **47**:1265–1266.
84. van der Wielen RP, Lowik MR, van dB, de GL, Haller J, Moreiras O, van SW 1995 Serum vitamin D concentrations among elderly people in Europe. *Lancet* **346**:207–210.
85. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ 1997 Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* **7**:439–443.
86. Holick MF 1994 McCollum Award Lecture, 1994: vitamin D—new horizons for the 21st century. *Am J Clin Nutr* **60**:619–630.
87. Dhesi JK, Moniz C, Close JC, Jackson SH, Allain TJ 2002 A rationale for vitamin D prescribing in a falls clinic population. *Age Ageing* **31**:267–271.
88. Flicker L, Mead K, Nowson CA, Scherer SC, Stein MS, Thomas J, Hopper JL, Wark JD 2001 Risk factors for falls in older women in residential care in Australia. *J Bone Miner Res* **16**(Suppl 1):S170.
89. Dhesi JK, Bearne LM, Moniz C, Hurley MV, Jackson SH, Swift CG, Allain TJ 2002 Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. *J Bone Miner Res* **17**:891–897.
90. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C 2000 Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *J Bone Miner Res* **15**:1113–1118.
91. McCarty MF 2002 Vitamin D status and muscle strength. *Am J Clin Nutr* **76**:1454–1455.
92. Colliander EB, Strigard K, Westblad P, Rolf C, Nordenstrom J 1998 Muscle strength and endurance after surgery for primary hyperparathyroidism. *Eur J Surg* **164**:489–494.
93. Turken SA, Cafferty M, Silverberg SJ, De La Cruz L, Cimino C, Lange DJ, Lovelace RE, Bilezikian JP 1989 Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. *Am J Med* **87**:553–557.
94. Kristoffersson A, Bjerle P, Stjernberg N, Järhult J 1988 Pre- and postoperative respiratory muscle strength in primary hyperparathyroidism. *Acta Chir Scand* **154**:415–418.
95. Patten MP, Mallette LE, Prince A, Aurbach GD, Belezikian JP, King Engel W 1974 Neuromuscular disease in primary hyperparathyroidism. *Ann Intern Med* **80**:182–193.
96. Deutch SR, Jensen MB, Christiansen PM, Hesseov I 2000 Muscular performance and fatigue in primary hyperparathyroidism. *World J Surg* **24**:102–107.
97. Baczynski R, Massry SG, Magott M, el Belbessi S, Kohan R, Brautbar N 1985 Effect of parathyroid hormone on energy metabolism of skeletal muscle. *Kidney Int* **28**:722–727.
98. Smogorzewski M, Piskorska G, Borum PR, Massry SG 1988 Chronic renal failure, parathyroid hormone, and fatty acids oxidation in skeletal muscle. *Kidney Int* **33**:555–560.
99. Jansson S, Grimby G, Hagne I, Hedman I, Tisell LE 1991 Muscle structure and function before and after surgery for primary hyperparathyroidism. *Eur J Surg* **157**:13–16.
100. Chou FF, Sheen Chen SM, Leong CP 1995 Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. *Surgery* **117**:18–25.
101. Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, Hewison M, Stewart PM 1999 Expression of 25-hydroxyvitamin D<sub>3</sub>-1 $\alpha$ -hydroxylase in the human kidney. *J Am Soc Nephrol* **10**:2465–2473.
102. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M 2002 Synthesis of 1,25-dihydroxyvitamin D<sub>3</sub> by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. *J Am Soc Nephrol* **13**:621–629.

103. Dusso A, Brown A, Slatopolsky E 1994 Extrarenal production of calcitriol. *Semin Nephrol* **14**:144–155.
104. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E 1988 Extrarenal production of calcitriol in chronic renal failure. *Kidney Int* **34**:368–375.
105. Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, Slatopolsky E 1991 Extrarenal production of calcitriol in normal and uremic humans. *J Clin Endocrinol Metab* **72**:157–164.
106. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF 1998 Human prostate cells synthesize 1,25-dihydroxyvitamin D<sub>3</sub> from 25-hydroxyvitamin D<sub>3</sub>. *Cancer Epidemiol Biomarkers Prev* **7**:391–395.
107. Barreto AM, Schwartz GG, Woodruff R, Cramer SD 2000 25-hydroxyvitamin D<sub>3</sub>, the prohormone of 1,25-dihydroxyvitamin D<sub>3</sub>, inhibits the proliferation of primary prostatic epithelial cells. *Cancer Epidemiol Biomarkers Prev* **9**:265–270.
108. Reichel H, Koeffler HP, Norman AW 1989 The role of the vitamin D endocrine system in health and disease. *N Engl J Med* **320**:980–991.
109. Barger-Lux MJ, Heaney RP, Lanspa SJ, Healy JC, DeLuca HF 1995 An investigation of sources of variation in calcium absorption efficiency. *J Clin Endocrinol Metab* **80**:406–411.
110. Barger-Lux MJ, Heaney RP, Dowell S, Bierman J 1996 Relative molar potency of 25-hydroxyvitamin D indicates a major role in calcium absorption. *J Bone Miner Res* **11**:S423.
111. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE 1999 An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D<sub>3</sub>. *Cell* **96**:507–515.
112. Nykjaer A, Fyfe JC, Kozyraki R, Leheste JR, Jacobsen C, Nielsen MS, Verroust PJ, Aminoff M, de la CA, Moestrup SK, Ray R, Gliemann J, Willnow TE, Christensen EI 2001 Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D<sub>3</sub>. *Proc Natl Acad Sci USA* **20**:98, 13895–13900.
113. Leheste JR, Melsen F, Wellner M, Jansen P, Schlichting U, Renner-Muller I, Andreassen TT, Wolf E, Bachmann S, Nykjaer A, Willnow TE 2002 Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. *Faseb J*
114. Boucher BJ 1998 Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? *Br J Nutr* **79**:315–327.
115. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ 1995 Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. *Diabetologia* **38**:1239–1245.
116. Baynes KCR, Boucher BJ, Feskens EJM, Kromhout D 1999 Vitamin D, glucose tolerance, and insulinemia in elderly men. *Diabetologia* **40**:344–347.
117. Rudnicki PM, Molsted-Pedersen L 1997 Effect of 1,25-dihydroxycholecalciferol on glucose metabolism in gestational diabetes mellitus. *Diabetologia* **40**:40–44.
118. Rittweger J, Rauch F 2000 What is new in musculoskeletal interactions. *J Musculoskel Neuron Interact* **1**:171–176.
119. Gaster M, Staehr P, Beck-Nielsen H, Schroder HD, Handberg A 2001 GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? *Diabetes* **50**:1324–1329.
120. Gaster M, Poulsen P, Handberg A, Schroder HD, Beck-Nielsen H 2000 Direct evidence of fiber type-dependent GLUT-4 expression in human skeletal muscle. *Am J Physiol Endocrinol Metab* **278**:E910–E916.
121. Jensen MD 2002 Fatty acid oxidation in human skeletal muscle. *J Clin Invest* **110**:1607–1609.
122. Rasmussen BB, Holmback UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR 2002 Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. *J Clin Invest* **110**:1687–1693.
123. Klausen T, Breum L, Sorensen HA, Schifter S, Sonne B 1993 Plasma levels of parathyroid hormone, vitamin D, calcitonin, and calcium in association with endurance exercise. *Calcif Tissue Int* **52**:205–208.
124. Zittermann A, Sabatschus O, Jantzen S, Platen P, Danz A, Stehle P 2002 Evidence for an acute rise of intestinal calcium absorption in response to aerobic exercise. *Eur J Nutr* **41**:189–196.
125. Bell NH, Godsen RN, Henry DP, Shary J, Epstein S 1988 The effects of muscle-building exercise on vitamin D and mineral metabolism. *J Bone Miner Res* **3**:369–373.
126. Zittermann A, Sabatschus O, Jantzen S, Platen P, Danz A, Dimitriou T, Scheld K, Klein K, Stehle P 2000 Exercise-trained young men have higher calcium absorption rates and plasma calcitriol levels compared with age-matched sedentary controls. *Calcif Tissue Int* **67**:215–219.
127. Nelson ME, Meredith CN, Dawson-Hughes B, Evans WJ 1988 Hormone and bone mineral status in endurance-trained and sedentary postmenopausal women. *J Clin Endocrinol Metab* **66**:927–933.
128. Smith HK, Maxwell L, Rodgers CD, McKee NH, Plyley MJ 2001 Exercise-enhanced satellite cell proliferation and new myonuclear accretion in rat skeletal muscle. *J Appl Physiol* **90**:1407–1414.
129. Zammit PS, Heslop L, Hudon V, Rosenblatt JD, Tajbakhsh S, Buckingham ME, Beauchamp JR, Partridge TA 2002 Kinetics of myoblast proliferation show that resident satellite cells are competent to fully regenerate skeletal muscle fibers. *Exp Cell Res* **281**:39–49.
130. Grounds MD 2002 Reasons for the degeneration of aging skeletal muscle: a central role for IGF-1 signaling. *Biogerontology* **3**:19–24.
131. Prabhala A, Garg R, Dandona P 2000 Severe myopathy associated with vitamin D deficiency in western New York. *Arch Intern Med* **160**:1199–1203.
132. Mingrone G, Greco AV, Castagneto M, Gasbarrini G 1999 A woman who left her wheelchair. *Lancet* **353**:806.

# Renal Failure and Secondary Hyperparathyroidism

MASAFUMI FUKAGAWA Division of Nephrology & Dialysis Center,  
Kobe University School of Medicine, Kobe, Japan

KIYOSHI KUROKAWA Research Center for Advanced Science and Technology,  
The University of Tokyo, Tokyo, Japan

- I. Role of Vitamin D in the Development of Hyperparathyroidism in Renal Failure
- II. Resistance to  $1,25(\text{OH})_2\text{D}$  as a Cause of Severe Secondary Hyperparathyroidism in Chronic Renal Failure

- III. Management of Severe Hyperparathyroidism Refractory to Medical Therapy
  - IV. Future Roles of Vitamin D Analogs in Chronic Renal Failure
- References

## I. ROLE OF VITAMIN D IN THE DEVELOPMENT OF HYPERPARATHYROIDISM IN RENAL FAILURE

The kidney is the main organ for the production of active vitamin D,  $1,25\text{-dihydroxyvitamin D}_3$  ( $1,25(\text{OH})_2\text{D}_3$ ) [1], a process that is catalyzed by  $25\text{-hydroxyvitamin D}_3$   $1\alpha$ -hydroxylase ( $1\alpha$ -hydroxylase) in the proximal tubule cells [2–4]. Activity of this enzyme is attenuated in chronic renal failure due to phosphate load [5,6] as well as to the decreased numbers of viable nephrons [1]. Furthermore, it has recently been shown that fibroblast growth factor-23 (FGF-23) may suppress activation of vitamin D [7]. FGF-23 is a newly discovered phosphaturic factor (see Chapters 26 and 29) and increased serum levels have been reported in patients with renal dysfunction [8].

In addition to the decreased production of  $1,25(\text{OH})_2\text{D}_3$  in the kidney, the importance of vitamin D deficiency has been recognized again, especially in chronic kidney disease (CKD) stages 3 and 4 [9]. Vitamin D deficiency is reflected by decreased serum concentrations of  $25(\text{OH})\text{D}$  [10]. Such decrease of  $25(\text{OH})\text{D}$  level may result from the loss of vitamin D-binding protein into the urine [11] as well as malnutrition [12]. In addition, a decrease of megalin on the brush border of proximal tubules has been reported [13], which results in diminished reuptake of filtered  $25(\text{OH})\text{D}$  [14] (see Chapter 10).

In chronic renal failure, the secretion of parathyroid hormone (PTH) is stimulated by several factors, primarily hypocalcemia and reduced production of  $1,25(\text{OH})_2\text{D}_3$  [1]. In addition, direct stimulatory

action of phosphate on parathyroid has recently been demonstrated [15–17]. Thus, secondary hyperparathyroidism develops almost inevitably in patients with chronic renal failure without appropriate therapy [1]. Excess PTH accelerates bone turnover and results in a typical bone abnormality known as osteitis fibrosa [18].

Vitamin D metabolites suppress the secretion of PTH by correcting hypocalcemia and also by direct action on parathyroid cells in patients of chronic renal failure [19,20]. However, it is still difficult to suppress PTH secretion in substantial numbers of patients by vitamin D treatment. Such patients usually have marked parathyroid hyperplasia [21]. Since conventional uses of vitamin D in mild and advanced renal failure, including  $1,25(\text{OH})_2\text{D}_3$  pulse therapy, are discussed in the Chapter 76 by Dusso, Brown, and Slatopolsky, we will focus on patients with severe disease that are refractory to medical therapy and summarize the new therapeutic uses of vitamin D metabolites.

## II. RESISTANCE TO $1,25(\text{OH})_2\text{D}$ AS A CAUSE OF SEVERE SECONDARY HYPERPARATHYROIDISM IN CHRONIC RENAL FAILURE

### A. Resistance to $1,25(\text{OH})_2\text{D}$ in Chronic Renal Failure

Despite physiological plasma concentrations of  $1,25(\text{OH})_2\text{D}$ , as well as those of calcium ion obtained by routine treatment, there are still many patients with elevated plasma PTH levels. Some of these patients respond to supraphysiological concentration of  $1,25(\text{OH})_2\text{D}_3$

achieved either by intravenous or oral intermittent high doses of  $1,25(\text{OH})_2\text{D}_3$ , which is also referred to as “ $1,25(\text{OH})_2\text{D}_3$  pulse therapy” [22–24]. These observations suggest that the resistance of parathyroid cells to  $1,25(\text{OH})_2\text{D}$  may play a major role in the pathogenesis of severe secondary hyperparathyroidism in chronic renal failure [25].

Resistance to physiological concentrations of  $1,25(\text{OH})_2\text{D}$  may develop during the early phase of chronic renal failure. In rat models of mild renal failure, PTH secretion, synthesis, and parathyroid cell proliferation were all enhanced even in the presence of a normal plasma concentration of calcium and  $1,25(\text{OH})_2\text{D}$  [26]. Hyperparathyroidism returned to normal with pharmacological doses of  $1,25(\text{OH})_2\text{D}_3$  without the induction of hypercalcemia. In these rats,  $1,25(\text{OH})_2\text{D}$  receptor (VDR) density in parathyroid glands, detected by Western blot, was decreased compared to levels seen in normal rats. Such reduction of VDR density in parathyroid glands also has been demonstrated in enlarged parathyroid glands of chronic dialysis patients [27], as well as in animal models of chronic uremia [28,29]. This abnormality, reduced VDR concentration, is currently considered the central feature responsible for the resistance of parathyroid glands to  $1,25(\text{OH})_2\text{D}$  in chronic renal failure [30].

In addition to the decreased density of VDR, several mechanisms have been proposed (Fig. 1). Decreased density of retinoid receptor X (RXR), which forms heterodimers with VDR, has been suspected [31]; however, the significance of this observation still remains unclear. Hsu and associates have been focused

on the possible inhibition of  $1,25(\text{OH})_2\text{D}$  action by uremic toxins [32]. They have shown that serum from uremic patients inhibited the interaction between the  $1,25(\text{OH})_2\text{D}$ -VDR complex and DNA [33], possibly through the formation of a Schiff base [33]. Although they have examined the effects of glyoxylate [35], other uremic toxins responsible for this inhibition still remain to be identified [36]. In addition, calreticulin has been shown to inhibit the binding of the  $1,25(\text{OH})_2\text{D}$ -VDR complex to the vitamin D responsive element (VDRE) in the PTH gene promoter [37]. Hypocalcemia was found to induce increased concentrations of calreticulin exclusively in parathyroid glands. It is possible that this molecule plays some role in the regulation of VDR function by extracellular calcium [38,39]. Decreased action of  $1,25(\text{OH})_2\text{D}$  due to these mechanisms finally results in disturbed up-regulation of VDR, which further increases resistance to  $1,25(\text{OH})_2\text{D}$  in chronic renal failure (Fig. 1) [40–42]. Such a vicious cycle may be prevented by early vitamin D treatment as suggested by the animal models [43].

## B. Advantages and Limitations of Intravenous Calcitriol Therapy

Considering that these abnormalities cause vitamin D resistance, it is quite reasonable that supraphysiological concentrations of  $1,25(\text{OH})_2\text{D}$  have been shown effective in suppressing PTH secretion in chronic dialysis patients resistant to conventional oral calcitriol [22–24]. Since the peak concentration of  $1,25(\text{OH})_2\text{D}$  is more important




FIGURE 1 Mechanisms of resistance to  $1,25(\text{OH})_2\text{D}$  in chronic renal failure. Several steps of  $1,25(\text{OH})_2\text{D}$  action are disturbed in chronic renal failure, leading to further reduction of VDR.



for the suppression of PTH secretion than the total dose of calcitriol, as shown in dialysis patients [22] and in experimental animals [44], higher doses of calcitriol theoretically should be more effective. However, high doses of calcitriol often cause hypercalcemia and hyperphosphatemia, resulting in reduction or discontinuation of therapy. High  $\text{Ca} \times \text{Pi}$  product leads to metastatic calcification including within blood vessels, which may result in a higher mortality risk [45]. This has been the main reason why less calcemic vitamin D analogs, such as 19-nor-1,25(OH)<sub>2</sub>D<sub>2</sub> [46] and 22-oxa-1,25(OH)<sub>2</sub>D<sub>3</sub> [47], have been developed (see Section VIII of this book). Even with these less calcemic vitamin D analogs, PTH secretion is still difficult to control in some patients.

### C. Parathyroid Size as a Marker for the Prognosis of Vitamin D Therapy

In order to avoid unnecessary vitamin D treatment and metastatic calcification, it is certainly necessary to have a good predictor of the prognosis of vitamin D therapy for parathyroid suppression in these patients. Although recent data suggest that serum FGF-23 levels may be a marker for the future prognosis of hyperparathyroidism [48], parathyroid gland size assessed by ultrasonography is the most simple and useful marker at this time.

Marked parathyroid gland hyperplasia is a unique feature of secondary hyperparathyroidism in chronic dialysis patients [49]. Although the size of each of the four glands is usually different, even in the same patient, it has been recognized by experience that the size of the largest gland roughly correlates with the length and severity of uremia and with the degree of prevailing plasma and stimulated peak PTH levels [50,51]. The size also correlates with the degree of abnormal control of PTH secretion [52,53], which may be normalized by calcitriol pulse therapy [54].

Clinical observations of dialysis patients suggest that the size of the largest gland is the critical marker for the long-term prognosis of vitamin D therapy [55]. If the largest gland is larger than 1 cm in diameter or about 0.5 cm<sup>3</sup> in volume, it is usually difficult to suppress PTH secretion by calcitriol pulse therapy. In such patients, secondary hyperparathyroidism always persists or relapses even if it initially responded to calcitriol pulse therapy. By contrast, patients with only smaller glands usually respond well to calcitriol pulse therapy, and parathyroid gland function can be controlled then with oral active vitamin D sterols. Thus, the size of the parathyroid gland may have more relevance than plasma PTH levels in assessment of calcitriol pulse

therapy [37]. Furthermore, Tominaga *et al.* demonstrated in patients treated by surgical parathyroidectomy that autoimplantation of tissue fragments from glands heavier than 0.5 g resulted in frequent relapse of hyperparathyroidism [56]. Thus, the critical size for the management strategy for hyperparathyroidism in chronic dialysis patients seems to be less than 0.5 cm<sup>3</sup> in volume.

The correlation between the gland size and the resistance to calcitriol can be explained by the degree of decrease of VDR density. VDR density is inversely correlated with the weight of enlarged glands [57]. Large parathyroid glands are usually composed of nodular hyperplasia, a more advanced type of pathology than diffuse hyperplasia seen in small glands [58]. It has been reported that cells in nodular hyperplasia glands have higher proliferative potentials [59,60,62] and more abnormal regulation of PTH secretion [63] than cells in diffuse hyperplasia glands. We and others have clearly shown that the VDR number was decreased more in nodular hyperplasia than in diffuse hyperplasia [57,64]. Since 90% of the glands heavier than 0.5 g were composed of nodular hyperplasia as shown by Tominaga and Takagi [61], the difference in the response to calcitriol that is dependent upon gland size can be explained by the difference in the type of hyperplasia in the larger glands.

In nodular hyperplasia, decreased density of the calcium-sensing receptor also has been demonstrated [65,66]. Although it is still controversial whether this decrease is the cause or the result of secondary hyperparathyroidism, a direct correlation between cell proliferation and decrease of calcium-sensing receptor has been suggested [67,68]. Thus, glands with nodular hyperplasia are less responsive to the suppressive effect of ambient calcium. This may partially explain the empirical finding of high PTH levels in the presence of hypercalcemia in patients with nodular hyperplasia. The progression of parathyroid hyperplasia is summarized in Fig. 2.

It is of note that some enlarged glands smaller than 0.5 cm<sup>3</sup> may be composed of nodular hyperplasia [61]. Nodule formation may be recognized by the shape of the glands detected by the latest models of ultrasonography devices [70]. Furthermore, Onoda *et al.* recently reported that positive blood supply detected inside the gland was highly suggestive of nodular hyperplasia [71].

### III. MANAGEMENT OF SEVERE HYPERPARATHYROIDISM REFRACTORY TO MEDICAL THERAPY

Prevention of parathyroid hyperplasia from the early phase of chronic renal failure is the most important




FIGURE 2 Progression of parathyroid hyperplasia in chronic renal failure. Cells with more severe reduction of VDR receptor and calcium-sensing receptor within diffuse hyperplasia form small nodules leading to nodular hyperplasia.

strategy for the management of secondary hyperparathyroidism in chronic renal failure. This can be achieved by dietary phosphate restriction and the early use of phosphate binders and cautious use of active vitamin D sterols as described in Chapter 76. Recent data suggest that the direct effects of phosphate on parathyroid cells is especially important in the early phase of chronic renal failure [72].

#### A. Selective Percutaneous Ethanol Injection Therapy (PEIT)

Although the introduction of new vitamin D analogs and calcimimetics may be promising in the treatment of secondary hyperparathyroidism, what can be done for patients with nodular hyperplasia? Do they have any choice other than surgical parathyroidectomy [73,74].

The ongoing discussion indicates that small glands composed of diffuse hyperplasia should still be responsive to calcitriol even in such patients. However, what about the patients that have already progressed to nodular hyperplasia?

For patients with nodular hyperplasia, two new techniques have been established. The first technique is the selective percutaneous ethanol injection therapy (PEIT) [75–77]. The second technique is direct vitamin D injection therapy (see below).

In PEIT, glands with nodular hyperplasia are “selectively” destroyed by ethanol injection under ultrasonographic guidance. Other glands with diffuse hyperplasia are then controlled by medical therapy (Fig. 3). Recently, this technique has become more powerful and safer than ever and has become widely used, especially in Japan. According to the guideline by Japanese Society for Parathyroid Intervention [78],




FIGURE 3 Parathyroid intervention under ultrasonographic guidance. Glands with nodular hyperplasia (hatched circle) are treated by intervention using percutaneous ethanol injection therapy (PEIT). Other glands with diffuse hyperplasia (open circle) are then controlled by medical therapy.

patients having one or two glands with nodular hyperplasia are the best candidates for PEIT. After the initial ethanol injection, PTH levels and recurrence should be monitored carefully. More importantly, after the successful destruction of nodular hyperplasia, residual glands with diffuse hyperplasia should be managed by appropriate medical therapy, including dietary phosphorus restriction. Thus, good compliance of the patients to medical therapy and regular check-ups after PEIT is essential.

In the largest study by Kakuta *et al.*, 46 patients were treated by selective PEIT on an outpatient basis followed by appropriate medical therapy. PTH levels in 80% of the patients remained within the target range at one year after initial treatment [79]. Long-term follow-up (three years) after PEIT has been also reported by this group [80].

Failure of PTH suppression despite successful ablation of glands with nodular hyperplasia suggests the existence of another gland containing nodular hyperplasia beyond the reach of ultrasonography [81]. If ectopic glands are recognized before the procedure is performed, initial surgical parathyroidectomy is indicated. Thus, it may be reasonable to search for ectopic glands

before PEIT in patients with more than three glands of critical size.

Recurrent nerve palsy due to leakage of ethanol is one of the most important complications of PEIT [77]. It is also suspected that adhesions in the tissue surrounding the parathyroids may be caused by leakage of ethanol. This could be a major problem if surgical parathyroidectomy will be needed in the future. With the routine use of color Doppler flow mapping by ultrasonography, the volume of ethanol used for PEIT has become minimal, leading to the lower rate of such complications [79]. Nevertheless, skilled operators and appropriate equipments are certainly required for successful and safe PEIT [78].

## B. Direct Vitamin D Injection Therapy

The second technique for treating nodular hyperplasia is direct calcitriol injection therapy under ultrasonographic guidance (PCIT) [82]. In this therapy, very high local concentration of  $1,25(\text{OH})_2\text{D}_3$  or other vitamin D metabolites is achieved exclusively in injected parathyroid glands. As already reported, direct calcitriol injection therapy not only suppressed PTH secretion, but also restored the responsiveness to medical therapy. Such effects have been confirmed by other studies with different protocols [83–85]. Furthermore, direct injections of 22-oxacalcitriol have also been tried with favorable results [86].

In contrast to PEIT, the risk of recurrent nerve palsy is extremely low with PCIT. However, a recent report suggested that direct injection of 22-oxacalcitriol might evoke inflammation, resulting in adhesions of the surrounding tissue [87]. The use of vitamin D analogs is promising and such risks should be avoidable with improvements in technique. Future development may allow direct injection of new calcimimetics and even adenovirus-mediated gene transfer to treat parathyroid hyperplasia, as has been shown recently in animal models [88].

## C. Regression of Parathyroid Hyperplasia: Is It Really Possible?

The cell cycle of parathyroid cells is usually very slow, even in the hyperplastic glands [89]. Although prevention of parathyroid hyperplasia by several therapeutic modalities has been demonstrated in rat models of chronic kidney disease [90], suppression of PTH secretion may not lead to the complete normalization of parathyroid cell function including proliferation site in patients with secondary hyperparathyroidism [91,92].

Thus, it is still an unsettled issue whether hyperplastic parathyroid glands do regress after proper medical therapy or after kidney transplantation.

Regression of parathyroid hyperplasia has been reported in chronic dialysis patients treated by oral calcitriol pulse therapy [93–95], although controversial data have been also reported [96]. Such a regression was observed not only in cases with successful PTH suppression, but also in small glands even in cases without significant suppression of PTH [55,97]. Thus, in our opinion it is reasonable to conclude that glands with diffuse hyperplasia regress after effective medical therapy. In contrast, as discussed above, glands with nodular hyperplasia do not regress except for a few cases in which spontaneous apoplexy of the gland was suspected [98,99].

Due to the lack of established parathyroid cell lines for *in vitro* studies, mechanisms of regression have not yet been satisfactorily elucidated [100]. In order to achieve regression of hyperplastic glands, suppression of cell proliferation may not be sufficient. Negative cell balance by increased apoptosis may be needed. However, in rats, it has been very hard to demonstrate the apoptosis of parathyroid cells, which takes place in a limited number of cells during cell turnover [101–104]. Moreover, interpretation of apoptotic cells demonstrated in surgically removed parathyroid glands in dialysis patients has been controversial [100].

In a 1977 report by Henry *et al.* [105], reduction of parathyroid cell number was clearly demonstrated in three-month-old vitamin D-deficient chickens treated with vitamin D replacement. In contrast,  $1,25(\text{OH})_2\text{D}_3$  treatment suppressed parathyroid cell proliferation, but did not reverse hyperplasia in experimental uremia, as demonstrated by Szabo *et al.* [106]. In recent animal studies by Lewin *et al.* [107,108], hyperparathyroidism induced by long-term uremia returned to normal following kidney transplantation. However, parathyroid hyperplasia was persistent. Such a suppression of PTH secretion with persistent hyperplasia has also been demonstrated in rat models of secondary hyperparathyroidism induced by high phosphorus diet, by switching to low phosphorus diet. In these animal models, reversal of reduced VDR or calcium-sensing receptor has not been confirmed at least in the short term.

As discussed above, it has been suggested recently that regression of nodular hyperplasia may be induced by direct vitamin D injection therapy, originally performed with calcitriol [82]. By injecting directly into enlarged glands under ultrasonography, very high local concentration of vitamin D or analog can be achieved transiently. Shiizaki *et al.* recently reported that direct injection of 22-oxa-calcitriol solution into enlarged glands in patients leads to the regression of hyperplasia [84].

By repeated parathyroid biopsy before and after the therapy, they clearly demonstrated the induction of apoptosis of parathyroid cells in the injected glands. They also suggested that such a regression was associated with up-regulation of VDR and the calcium-sensing receptor. These data suggest that direct vitamin D injection therapy not only induces apoptosis of parathyroid cells, but also restores the responsiveness of residual parathyroid cells to medical therapy, leading to normalization of parathyroid hyperplasia. It may be possible that such specific effects of vitamin D on parathyroid cells may also be achieved by oral or intravenous preparations, if vitamin D analogs with these specific actions can be designed in the future.

It is also of note that increased 25-hydroxyvitamin  $\text{D}_3$   $1\alpha$ -hydroxylase and reduced 25-hydroxyvitamin  $\text{D}_3$  24-hydroxylase expression have been reported in parathyroid tumors [109]. Thus, parathyroid is not only a target organ of vitamin D, but it also metabolizes vitamin D. Since parathyroid glands possess  $1\alpha$ -hydroxylase, it may become possible to develop new vitamin D metabolites that use this system to be activated only in parathyroid.

#### IV. FUTURE ROLES OF VITAMIN D ANALOGS IN CHRONIC RENAL FAILURE

##### A. Design of Vitamin D Analogs with Specific Actions on Specific Tissues in Chronic Renal Failure

The parathyroid glands are not the only target organ of vitamin D therapy in patients with chronic renal failure. The skin and the immune system are other examples; however, the role of vitamin D treatment on these systems, as well as other organs, has not been fully clarified yet [110,111]. A recent report suggests that paricalcitol treatment leads to better survival than calcitriol treatment in chronic dialysis patients [112]. It is still unclear whether such a difference is due to the less calcemic effect of paricalcitol or to its effects on other organ systems.

Bone is a representative classic target organ of vitamin D. Thus, different effects of 22-oxacalcitriol versus calcitriol on bone turnover have been noted in animal models of chronic renal failure [113] (see Chapter 86). As recently suggested, the different effects of vitamin D analogs on bone, seen in *in vitro* and *in vivo* experiments, might be clues that help in the future elucidation of the mechanism for the differential actions of analogs in various tissues [114]. 22-oxacalcitriol was originally developed as an analog

with potent activity on the differentiation of leukemic cell lines [115]. Such an activity has also been examined with paricalcitol [116]. Recently, it has been demonstrated that different vitamin D analogs utilize specific cofactors for target gene regulation [117]. Different cofactors bind to different genes, evoking different actions on the same cell. Thus, it is expected that design of vitamin D analogs with differential actions in specific organs will become possible [118]. For example, it may be possible to design analogs that specifically induce apoptosis of parathyroid cells as well as less calcemic analogs.

## B. Possible Treatment of Chronic Kidney Disease by Vitamin D Analogs

The kidney is not only the site of active vitamin D production, but also is its target organ. As intensively discussed in several previous chapters, vitamin D metabolites modulate the activity of the enzymes involved in vitamin D synthesis and degradation. Calcium-binding proteins [119] are also induced by vitamin D in the distal tubules of the kidney. VDRs have been identified in various parts of the kidney and no doubt are regulated by vitamin D metabolites [120]. Inhibition of renal cell proliferation by vitamin D was initially demonstrated in renal cell carcinoma lines [121]. It has also been shown that  $1,25(\text{OH})_2\text{D}_3$  diminished  $^3\text{H}$ -thymidine incorporation, cell counts, and TGF- $\beta$  secretion into the supernatant of cultured proximal tubular cell lines [122–124] and in cultured human mesangial cells [125]. Regulation of mesangial cell smooth muscle phenotype has also been suggested [126].

*In vivo*,  $1,25(\text{OH})_2\text{D}_3$  reduced renal weight, protein content, DNA content, and the number of mitoses in the remnant kidney with compensatory hypertrophy after uninephrectomy [127]. On the contrary,  $1,25(\text{OH})_2\text{D}_3$  may induce type IV collagen synthesis, possibly through up-regulation of TGF- $\beta$  type II receptor [126] and up-regulation of protein-1 [128].

It may be possible that vitamin D ameliorates glomerular injury seen in chronic kidney disease, although the effects may depend on the phase of renal injury. It has recently been shown that  $1,25(\text{OH})_2\text{D}_3$  inhibited progressive glomerulosclerosis in subtotal nephrectomized rats [129] and reduced proteinuria, glomerular hyper-cellularity and inflammatory infiltration in anti-Thy-1.1 nephritis [130]. Similar suppressive effects have been also demonstrated with retinoic acids [131,132].

These studies suggest the possibility that vitamin D may alter the rate of progression of CKD. In contrast, there has been a concern that oral vitamin D treatment

in CKD patients may increase the risk of accelerating the progression of renal dysfunction by increasing urinary calcium excretion. In this respect, the less-calcemic vitamin D analogs may be more suitable for this purpose [133].

22-oxa-calcitriol is one such less-calcemic vitamin D compound used for the treatment of severe secondary hyperparathyroidism in chronic dialysis patients [134], as extensively reviewed in Chapter 86. It has recently been shown that 22-oxa-calcitriol also effectively ameliorated glomerular sclerosis in two rat models of chronic kidney disease without affecting calcium and phosphorus levels [135,136]. Although further studies are needed, a vitamin D analog with such properties may be a promising agent for the treatment of chronic kidney disease in the near future.

## Acknowledgements

This work was partly supported by grants from Renal Osteodystrophy Foundation and from Renal Anemia Foundation, Japan.

Authors are grateful to Ms Tomoko Nii-Kono for her secretarial assistance and art work.

## References

1. Coburn JW, Llach F 1994 Renal osteodystrophy. In "Clinical Disorders of Fluid and Electrolyte Metabolism, 5th ed" (R. Narins, Ed), pp. 1299–1377, McGraw Hill Book Co.: New York, New York.
2. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S 1997 25-Hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase and vitamin D synthesis. *Science* **277**:1827–1830.
3. Murayama A, Takeyama K, Kitanaka S, Kadera Y, Kawaguchi Y, Hosoya T, Kato S 1999 Positive and negative regulations of the renal 25-hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase gene by parathyroid hormone, calcitonin, and 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> in intact animals. *Endocrinology* **140**: 2224–2231.
4. Miller WL, Portale AA 2003 Vitamin D biosynthesis and vitamin D 1 $\alpha$ -hydroxylase deficiency. *Endocr Dev* **6**:156–174.
5. Portale AA, Booth BE, Halloran BP, Morris RC Jr. 1984 Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. *J Clin Invest* **73**:1580–1589.
6. Zhang MY, Wang X, Wang JT, Compagnone NA, Mellon SH, Olson JL, Tenenhouse HS, Miller WL, Portale AA 2002 Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1 $\alpha$ -hydroxylase gene expression in the proximal renal tubule. *Endocrinology* **143**:587–595.
7. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. *Proc Natl Acad Sci USA* **98**:6500–6505.

8. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M 2004 Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. *Am J Kidney Dis* **44**:250–256.
9. Cannata-Andia JB, Alonzo CG 2002 Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. *Nephrol Dial Transplant* **17**:1875–1878.
10. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H 1999 Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. *Kidney Int* **55**:1019–1027.
11. Mittal SK, Dash SC, Tiwari SC, Agarwal SK, Saxena S, Fishbane S 1999 Bone histology in patients with nephrotic syndrome and normal renal function. *Kidney Int* **55**:1912–1919.
12. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS 1998 Hypovitaminosis D in medical inpatients. *N Engl J Med* **338**:777–783.
13. Takemoto F, Shinki T, Yokoyama K, Inokami T, Hara S, Yamada A, Kurokawa K, Uchida S 2003 Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. *Kidney Int* **64**:414–420.
14. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE 1999 An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D<sub>3</sub>. *Cell* **96**:507–515.
15. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ 1996 Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion *in vitro*. *J Clin Invest* **97**:2534–2540.
16. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M 1996 Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands *in vitro*. *J Bone Miner Res* **11**:970–976.
17. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K 1995 Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. *Nephron* **70**:242–248.
18. Malluche H, Faugere MC 1990 Renal bone disease 1990: An unmet challenge for the nephrologist. *Kidney Int* **38**:193–211.
19. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J 1990 Regulation of 1,25-dihydroxyvitamin D<sub>3</sub> receptor gene expression by 1,25-dihydroxyvitamin D<sub>3</sub> in the parathyroid *in vitro*. *J Clin Invest* **86**:1968–1975.
20. Silver J, Kilav R, Naveh-Many T 2002 Mechanisms of secondary hyperparathyroidism. *Am J Physiol Renal Physiol* **283**:F367–F376.
21. Fukagawa M 1999 Cell biology of parathyroid hyperplasia in uremia. *Am J Med Sci* **317**:377–382.
22. Slatopolsky EA, Weerts C, Thielan J, Horst R, Harter H, Martin KJ 1984 Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. *J Clin Invest* **74**:2136–2143.
23. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ 1989 Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. *N Engl J Med* **321**:274–279.
24. Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kitawada R, Marumo F 1990 The 'Oral 1,25-dihydroxyvitamin D<sub>3</sub> pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. *Nephron* **56**:368–373.
25. Fukagawa M, Fukuda N, Yi H, Kurokawa K 1995 Resistance to calcitriol as a cause of parathyroid hyperfunction in chronic renal failure. *Nephrol Dial Transplant* **10**:316–319.
26. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K 1991 Regulation of parathyroid hormone synthesis in chronic renal failure in rats. *Kidney Int* **39**:874–881.
27. Korkor AB 1987 Reduced binding of [<sup>3</sup>H]1,25-dihydroxyvitamin D<sub>3</sub> in the parathyroid glands of patients with renal failure. *N Engl J Med* **316**:1573–1577.
28. Merke J, Hugel U, Zlotowski A, Szabo A, Bommer J, Mall G, Ritz E 1987 Diminished parathyroid 1,25(OH)<sub>2</sub>D<sub>3</sub> receptors in experimental uremia. *Kidney Int* **32**:350–353.
29. Brown A, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky EA 1989 1,25(OH)<sub>2</sub>D<sub>3</sub> receptors are decreased in parathyroid glands from chronically uremic dogs. *Kidney Int* **35**:19–23.
30. Dusso AS 2003 Vitamin D receptor: Mechanisms for vitamin D resistance in renal failure. *Kidney Int (Suppl)* **85**:6–9.
31. Sawaya BP, Koszewski NJ, Qi Q, Langub MC, Monier-Faugere MC, Malluche HH 1997 Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. *J Am Soc Nephrol* **8**:271–278.
32. Hsu CH, Patel SR 1997 Uremic toxins and vitamin D metabolism. *Kidney Int (Suppl)* **62**:S65–S68.
33. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH 1995 Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. *J Clin Invest* **96**:50–59.
34. Patel SR, Koenig RJ, Hsu CH 1996 Effect of Schiff base formation on the function of the calcitriol receptor. *Kidney Int* **50**:1539–1545.
35. Patel SR, Xu Y, Koenig RJ, Hsu CH 1997 Effect of glyoxylate on the function of the calcitriol receptor and vitamin D metabolism. *Kidney Int* **52**:39–44.
36. Canalejo A, Almaden Y, De Smet R, Glorieux G, Garfia B, Luque F, Vanholder R, Rodriguez M 2003 Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. *Kidney Int* **63**:732–737.
37. Sela-Brown A, Russell J, Koszewski NJ, Michalak M, Naveh-Many T, Silver J 1998 Calcitriol inhibits vitamin D's action on the PTH gene *in vitro* and may prevent vitamin D's effect *in vivo* in hypocalcemic rats. *Mol Endocrinol* **12**:1193–1200.
38. Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E 1995 The roles of calcium and 1,25-dihydroxyvitamin D<sub>3</sub> in the regulation of vitamin D receptor expression by rat parathyroid glands. *Endocrinology* **136**:1419–1425.
39. Garfia B, Canadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, Rodriguez M 2002 Regulation of parathyroid vitamin D receptor expression by extracellular calcium. *J Am Soc Nephrol* **13**:2945–2952.
40. Strom M, Sandgrin ME, Brown TA, DeLuca HF 1989 1,25-dihydroxyvitamin D<sub>3</sub> up-regulates the 1,25-dihydroxyvitamin D<sub>3</sub> receptor *in vivo*. *Proc Natl Acad Sci USA* **86**:9770–9773.
41. Shvil Y, Naveh-Many T, Brach P, Silver J 1990 Regulation of parathyroid cell gene expression in experimental uremia. *J Am Soc Nephrol* **1**:99–104.
42. Koyama H, Nishizawa Y, Inaba M, Hino M, Pahl JM, DeLuca HF, Morii H 1994 Impaired homologous up-regulation of vitamin D receptor in rats with chronic renal failure. *Am J Physiol* **266**:F706–F712.

43. Denda M, Finch J, Brown AJ, Nishii Y, Kubodera N, Slatopolsky E 1996 1,25-dihydroxyvitamin D<sub>3</sub> and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. *Kidney Int* **50**:34–39.
44. Reichel H, Szabo A, Uhl J, Pesian S, Schmultz A, Schmidt-Gayk H, Ritz E 1993 Intermittent versus continuous administration of 1,25-dihydroxyvitamin D<sub>3</sub> in experimental renal hyperparathyroidism. *Kidney Int* **44**:1259–1265.
45. Block GA, Hulbert-Shearon TE, Levin NW, Port FK 1998 Association of serum phosphorus and calcium  $\times$  phosphate product with mortality risk in chronic hemodialysis patients: a national study. *Am J Kidney Dis* **31**:607–617.
46. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J 1998 19-Nor-1- $\alpha$ -25-dihydroxyvitamin D<sub>2</sub> (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. *J Am Soc Nephrol* **9**:1427–1432.
47. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E 1989 The noncalcemic analog of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. *J Clin Invest* **84**:728–732.
48. Kazama JJ, Gejyo F, Shigematsu T, Fukumoto S, Yamashita T, Nakanishi S, Fukagawa M 2003 Circulating fibroblast growth factor-23 (FGF-23) levels predict the development of secondary hyperparathyroidism in long-term dialysis patients (abstract). *J Am Soc Nephrol*, **14**:209A.
49. Drüeke TB 2000 Cell biology of parathyroid gland hyperplasia in chronic renal failure. *J Am Soc Nephrol* **11**:1141–1152.
50. Malmaeus J, Grimelius L, Johansson G, Akerstrom G, Ljunghall S 1984 Parathyroid pathology in hyperparathyroidism secondary to chronic renal failure. *Scand J Urol Nephrol* **18**:157–166.
51. McCarron DA, Muther RS, Lenfesty B, Bennett WM 1982 Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. *Kidney Int* **22**:662–670.
52. Wallfelt CH, Larsson R, Gylfe E, Ljunghall S, Rasted J, Akerstrom G 1988 Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparathyroidism: Implication for parathyroid autotransplantation. *World J Surg* **12**:431–438.
53. Felsenfeld AJ, Llach F 1993 Parathyroid function in chronic renal failure. *Kidney Int* **43**:771–789.
54. Delmez JA, Tindra C, Grooms P, Dusso A, Windus DW, Slatopolsky E 1989 Parathyroid hormone suppression by intravenous 1,25(OH)<sub>2</sub> vitamin D. A role for increased sensitivity to calcium. *J Clin Invest* **83**:1349–1355.
55. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K 1994 Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. *Nephron* **68**:221–228.
56. Tominaga Y, Sato K, Tanaka Y, Numano M, Uchida K, Takagi H 1995 Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. *Clin Nephrol* **44**:S42–S47.
57. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y 1993 Decreased 1,25-dihydroxyvitamin D<sub>3</sub> receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. *J Clin Invest* **92**:1436–1443.
58. Åkerstrom G, Malmaeus J, Grimelius L, Ljunghall S, Bergstrom R 1984 Histological changes in parathyroid glands in subclinical and clinical renal disease. *Scand J Urol Nephrol* **18**:75–84.
59. Tominaga Y, Grimelius L, Falkmer UG, Johansson H, Falkmer S 1991 DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse. *Analyt Cell Pathol* **3**:325–333.
60. Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K, Falkmer U, Grimelius L, Johansson H, Takagi H 1992 Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. *World J Surg* **16**:595–603.
61. Tominaga Y, Takagi H 1996 Molecular genetics of hyperparathyroid disease. *Current Opinions Nephrol Hypertens* **5**:336–341.
62. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H 2002 Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. *Kidney Int* **62**:1196–1207.
63. Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick SP 1982 Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. *J Clin Endocrinol Metab* **54**:172–179.
64. Carling T, Rastad J, Szabo E, Westin G, Akerstrom G 2000 Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. *J Clin Endocrinol Metab* **85**:2000–2003.
65. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB 1997 Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. *Kidney Int* **51**:328–336.
66. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA 1999 Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. *Kidney Int* **55**:1284–1292.
67. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, Maeda S, Kitazawa R 2000 Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. *Kidney Int* **58**:1980–1986.
68. Ritter CS, Finch JL, Slatopolsky EA, Brown AJ 2001 Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. *Kidney Int* **60**:1737–1744.
69. Canaff L, Hendy GN 2002 Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. *J Biol Chem* **277**:30337–30350.
70. Fukagawa M, Kitaoka M, Kurokawa K 1997 Value of parathyroid sonography in secondary hyperparathyroidism (letter). *Nephrol Dial Transplant* **12**:2461.
71. Onoda N, Kurihara S, Sakurai Y, Owada K, Osono E, Adachi H, Suga M, Yoneshima H 2003 Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology. *Nephrol Dial Transplant* **18**(Suppl 3):iii34–iii37.
72. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez-Cruz L, Campistol JM, Torres A, Rodriguez M 1998 High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue *in vitro*. *J Am Soc Nephrol* **9**:1845–1852.
73. Fukagawa M, Kazama JJ, Shigematsu T 2002 Management of the patients with advanced secondary hyperparathyroidism: the Japanese approach. *Nephrol Dial Transplant* **17**:1553–1557.
74. Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K 1999 Medical and surgical aspects of parathyroidectomy. *Kidney Int* **56**(Suppl 73):S65–S69.

75. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K 1994 Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. *Kidney Int* **46**:1110–1117.
76. Giangrande A, Castiglioni A, Sorbiati L, Allaria P 1992 Ultrasound guided percutaneous fine needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. *Nephrol Dial Transplant* **7**:412–421.
77. Kitaoka M 2003 Ultrasonographic diagnosis of parathyroid glands and percutaneous ethanol injection therapy. *Nephrol Dial Transplant* **18**(Suppl 3):iii27–iii30.
78. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kurokawa K, for Japanese Society for Parathyroid Intervention 2003 Guidelines for percutaneous ethanol injection therapy (PEIT) of the parathyroid glands in chronic dialysis patients. *Nephrol Dial Transplant* **18**(Suppl 3):31–33.
79. Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A 1999 Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients. *Am J Kidney Dis* **33**:1091–1099.
80. Tanaka R, Kakuta T, Fujisaki T, Tanaka S, Sakai H, Kurokawa K, Saito A 2003 Long-term (three years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by color Doppler ultrasonography. *Nephrol Dial Transplant* **18**(Suppl 3):iii58–iii61.
81. Fukagawa M, Nakanishi S 2003 Role of parathyroid intervention in the management of secondary hyperparathyroidism in chronic renal failure. *Nephrol Dial Transplant* **18**(Suppl 3):23–26.
82. Kitaoka M, Fukagawa M, Kurokawa K 1995 Direct injection of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. *Nephrology* **1**:563–568.
83. Kitaoka M, Onoda N, Kitamura H, Koiwa M, Tanaka M, Fukagawa M 2003 Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. *Nephrol Dial Transplant* **18**(Suppl 3):iii38–iii41.
84. Shiizaki K, Negi S, Mizobuchi M, Hatamura I, Narukawa N, Sakaguchi T, Kitabata Y, Sumikado S, Akizawa T 2003 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uremic patients. *Nephrol Dial Transplant* **18**(Suppl 3):iii42–iii46.
85. Nakanishi S, Yano S, Nomura R, Tsukamoto T, Shimizu Y, Shin J, Fukagawa M 2003 Efficacy of direct injection of calcitriol into the parathyroid glands in uremic patients with moderate to severe secondary hyperparathyroidism. *Nephrol Dial Transplant* **18**(Suppl 3):iii47–iii49.
86. Shiizaki K, Hatamura I, Negi S, Narukawa N, Mizobuchi M, Sakaguchi T, Ooshima A, Akizawa T 2003 Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. *Kidney Int* **64**:992–1003.
87. Yamamoto H, Katoh N, Takeyama H, Ikeda M, Yokoyama K, Shigematsu T, Kawaguchi Y, Hosoya T 2003 Surgical verification of percutaneous maxacalcitriol injection therapy on enlarged parathyroid glands in chronic dialysis patients. *Nephrol Dial Transplant* **18**(Suppl 3):iii50–iii52.
88. Iwasaki Y, Kakuta T, Haruguchi H, Fukuda N, Kurokawa K, Fukagawa M 2003 Adenovirus-mediated functional gene transfer into parathyroid cells *in vivo* and *in vitro*. *Nephrol Dial Transplant* **18**(Suppl 3):iii18–iii22.
89. Parfitt AM 1982 Hypercalcemic hyperparathyroidism following renal transplantation: Differential diagnosis, management, and implications for cell population control in the parathyroid gland. *Mineral Electrolyte Metab* **8**:92–112.
90. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J 2000 Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. *Kidney Int* **57**:50–58.
91. Takahashi F, Denda M, Finch JL, Brown AJ, Slatopolsky E 2002 Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. *Kidney Int* **6**:1332–1338.
92. Ritter CS, Martin DR, Lu Y, Slatopolsky E, Brown AJ 2002 Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. *J Bone Miner Res* **17**:2206–2213.
93. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K 1990 Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. *N Engl J Med* **323**:421–422.
94. Hyodo T, Koumi T, Ueda M, Miyagawa I, Kodani K, Doi S, Ishibashi M, Takemoto M 1991 Can oral 1,25(OH)<sub>2</sub>D<sub>3</sub> therapy reduce parathyroid hyperplasia? *Nephron* **59**:171–172.
95. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, De Grandi R, Augeri C, Claudiani F, Di Maio G 1994 Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. *Kidney Int* **46**:1124–1132.
96. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA 1994 Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. *Kidney Int* **45**:1710–1721.
97. Fukagawa M, Fukuda N, Yi H, Kitaoka M, Kurokawa K 1996 Derangement of parathyroid function in renal failure: Biological and clinical aspects. *J Nephrol* **9**:219–224.
98. Nylen E, Shah A, Hall J 1996 Spontaneous remission of primary hyperparathyroidism from parathyroid apoplexy. *J Clin Endocrinol Metab* **81**:1326–1328.
99. Chaffanjon PC, Chavanis N, Chabre O, Brichon PY 2003 Extracapsular hematoma of the parathyroid glands. *World J Surg* **27**:14–17.
100. Druke TB, Zhang P, Gogusev J 1997 Apoptosis: background and possible role in secondary hyperparathyroidism. *Nephrol Dial Transplant* **12**:2228–2233.
101. Naveh-Many T, Rahamimov R, Livni N, Silver J 1995 Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. *J Clin Invest* **96**:1786–1793.
102. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A, Druke TB 2000 Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. *Kidney Int* **57**:437–445.
103. Canalejo A, Almaden Y, Torregrosa V, Gomez-Villamandos JC, Ramos B, Campistol JM, Felsenfeld AJ, Rodriguez M 2000 The *in vitro* effect of calcitriol on parathyroid cell proliferation and apoptosis. *J Am Soc Nephrol* **11**:1865–1872.
104. Jara A, Gonzalez S, Felsenfeld AJ, Chacon C, Valdivieso A, Jalil R, Chuaqui B 2001 Failure of high doses of calcitriol and hypercalcemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats. *Nephrol Dial Transplant* **16**:506–512.
105. Henry HL, Taylor AN, Norman AW 1977 Response of chick parathyroid glands to the vitamin D metabolites, 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol. *J Nutr* **107**:1918–1926.
106. Szabo A, Merke J, Beier E, Mall G, Ritz E 1989 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> inhibits parathyroid cell proliferation in experimental uremia. *Kidney Int* **35**:1049–1056.



107. Lewin E, Wang W, Olgaard K 1997 Reversibility of experimental secondary hyperparathyroidism. *Kidney Int* **52**:1232–1241.
108. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K 2003 Persistent down-regulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. *J Am Soc Nephrol* **13**:2110–2116.
109. Correa P, Segersten U, Hellman P, Akerstrom G, Westin G 2002 Increased 25-hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase and reduced 25-hydroxyvitamin D<sub>3</sub> 24-hydroxylase expression in parathyroid tumors—new prospects for treatment of hyperparathyroidism with vitamin D. *J Clin Endocrinol Metab* **87**:5826–5829.
110. Mathieu C, Van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D, Verstuyf A, Bouillon R 2001 *In vitro* and *in vivo* analysis of the immune system of vitamin D receptor knockout mice. *J Bone Miner Res* **16**:2057–2065.
111. Kira M, Kobayashi T, Yoshikawa K 2003 Vitamin D and the skin. *J Dermatol* **30**:429–437.
112. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R 2003 Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. *N Engl J Med* **349**:446–456.
113. Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH 1999 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. *Kidney Int* **55**:821–832.
114. Shibata T, Shira-Ishi A, Sato T, Masaki T, Masuda A, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito MO, Ito M, Ogata E, Watanabe K, Ikeda K 2002 Vitamin D hormone inhibits osteoclastogenesis *in vivo* by decreasing the pool of osteoclast precursors in bone marrow. *J Bone Miner Res* **17**:622–629.
115. Abe J, Morikawa M, Miyamoto K, Kaiho S, Fukushima M, Miyaura C, Abe E, Nishii Y 1987 Synthetic analogs of vitamin D<sub>3</sub> with an oxygen atom in the side chain skeleton. *FEBS Lett* **226**:58–62.
116. Molnar I, Kute T, Willingham MC, Powell BL, Dodge WH, Schwartz GG 2003 19-nor-1 $\alpha$ ,25-dihydroxyvitamin D<sub>2</sub> (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. *J Cancer Res Clin Oncol* **129**:35–42.
117. Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, Suzawa M, Yanagisawa J, Kato S 1999 Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. *Mol Cell Biol* **19**:1049–1055.
118. Fujishima T, Kittaka A, Yamaoka K, Takeyama K, Kato S, Takayama H 2003 Synthesis of 2,2-dimethyl-1,25-dihydroxyvitamin D<sub>3</sub>: A-ring structural motif that modulates interactions of vitamin D receptor with transcriptional coactivators. *Org Biomol Chem* **1**:1863–1869.
119. Christakos S, Barletta F, Huening M, Dhawan P, Liu Y, Porta A, Peng X 2003 Vitamin D target proteins: function and regulation. *J Cell Biochem* **88**:238–244.
120. Iida K, Shinki T, Yamaguchi A, DeLuca HF, Kurokawa K, Suda T 1995 A possible role of vitamin D receptors in regulating vitamin D activation in the kidney. *Proc Natl Acad Sci USA* **92**:6112–6116.
121. Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H 1986 Inhibitory effect of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> on the growth of the renal carcinoma cell line. *Kidney Int* **29**:834–840.
122. Weih M, Orth S, Weinreich T, Reichel H, Ritz E 1994 Inhibition of growth by calcitriol in a proximal tubular cell line (OK). *Nephrol Dial Transplant* **9**:1390–1394.
123. Weinreich T, Landolt M, Booy C, Wuthrich R, Binswanger U 1999 1,25-dihydroxyvitamin D<sub>3</sub> stimulates transforming growth factor- $\beta$ 1 synthesis by mouse renal proximal tubular cells. *Kidney Blood Press Res* **22**:99–105.
124. Weinreich T, Muller A, Wuthrich RP, Booy C, Binswanger U 1996 1,25-dihydroxyvitamin D<sub>3</sub> and the synthetic vitamin D analog, KH 1060, modulate the growth of mouse proximal tubular cells. *Kidney Blood Press Res* **19**:325–331.
125. Weinreich T, Merke J, Schonermark M, Reichel H, Diebold M, Hansch GM, Ritz E 1991 Actions of 1,25-dihydroxyvitamin D<sub>3</sub> on human mesangial cells. *Am J Kidney Dis* **18**:359–366.
126. Abe H, Iehara N, Utsunomiya K, Kita T, Doi T 1999 A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor  $\beta$  type II receptor-mediated manner. *J Biol Chem* **274**:20874–20878.
127. Matthias S, Busch R, Merke J, Mall G, Thomasset M, Ritz E 1991 Effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> on compensatory renal growth in the growing rat. *Kidney Int* **40**:212–218.
128. Kobayashi T, Uehara S, Ikeda T, Itadani H, Kotani H 2003 Vitamin D<sub>3</sub> up-regulated protein-1 regulates collagen expression in mesangial cells. *Kidney Int* **64**:1632–1642.
129. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E 1998 Effect of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> on glomerulosclerosis in subtotaly nephrectomized rats. *Kidney Int* **53**:1696–1705.
130. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G 2001 Effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> in experimental mesangial proliferative nephritis in rats. *Kidney Int* **60**:87–95.
131. Datta PK, Lianos EA 1999 Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. *Kidney Int* **56**:486–493.
132. Xu Q, Konta T, Kitamura M 2002 Retinoic acid regulation of mesangial cell apoptosis. *Exp Nephrol* **10**:171–175.
133. Hirata M, Katsumata K, Endo K, Fukushima N, Ohkawa H, Fukagawa M 2003 In subtotaly nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub>. *Nephrol Dial Transplant* **18**:1770–1776.
134. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, Slatopolsky E, Kurokawa K 2002 Long-term effect of 1,25-dihydroxy-22-oxavitamin D<sub>3</sub> on secondary hyperparathyroidism in hemodialysis patients. One-year administration study. *Nephrol Dial Transplant* **17**(Suppl) **10**:28–36.
135. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T 2001 A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. *Am J Pathol* **158**:1733–1741.
136. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima N, Doi T 2002 22-oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotaly nephrectomized rats. *Nephrol Dial Transplant* **17**:2132–2137.

# Inhibition of Benign Prostatic Hyperplasia by Vitamin D Receptor Ligands

MARIO MAGGI Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy

CLARA CRESCIOLI Endocrinology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy

LUCIANO ADORINI BioXell, Milan, Italy

- |   |   |
|---|---|
| I. Introduction   | V. Antiproliferative Effects of BXL-353 on Human BPH Cells  |
| II. Pathogenesis of BPH   | VI. Inhibition of <i>in Vivo</i> Prostate Growth by BXL-353 |
| III. Effects of Androgens and Growth Factors on Human BPH Cells | VII. Conclusions  |
| IV. Vitamin D Receptor Expression in Prostate Cells             | References  |

## I. INTRODUCTION

The prostate is a gland surrounding the male urethra below the neck of the bladder and producing the prostatic fluid, a secretion which contributes 30% to the total ejaculate. The prostatic fluid is rich in fibrinolytic enzymes, such as prostatic-specific antigen (PSA), acid phosphatase, citric acid, and zinc. In humans, the prostate gland is composed of 40 to 50 ducts distributed essentially in three distinct zones: peripheral, central, and transitional or periurethral. While cell transformation in the peripheral zone gives rise to prostate cancer, cell growth in the periurethral zone leads to the most common age-related disease of the male: benign prostatic hyperplasia (BPH). The prostate weight is only a few grams at birth, and it increases during puberty, reaching approximately 20 g in the young adult. In contrast to the pubertal growth phase, which involves the entire gland, during the fifth decade of life, in the majority of men, there is a second growth phase selectively involving the periurethral zone leading to BPH [1]. The prevalence of BPH increases with age so that by age 80, about 90% of men have histological evidence of BPH [1]. In a subset of elderly men (27–35%), BPH can cause lower urinary tract symptoms (LUTS), which may require medical or surgical treatment [2] due to the compression by the enlarged prostate of the prostatic urethra, which decreases bladder outflow. In the earliest stages, this obstruction is compensated by an increased activity of the bladder detrusor muscular system but eventually complete voiding of the bladder is prevented, due to the slackening of the neck musculature. Urinary obstruction

and even renal insufficiency might follow. This may lead to emergency surgery for acute urinary retention with an increased risk of morbidity and even death when compared to elective surgery [3].

## II. PATHOGENESIS OF BPH

Periurethral prostate overgrowth involves both epithelial and stromal components, including both fibroblasts and smooth muscle cells, in various combinations. One of the earliest events in BPH development is the reduction of the epithelium/stroma ratio, most probably due to an imbalance between growth and death programs. Indeed, in the hyperplastic prostate, the epithelium regularly undergoes apoptosis, whereas stromal cells escape it [4], with a consequent increase in the stromal volume [5]. In addition, stromal growth factors (GFs) induce epithelial overgrowth and glandular hyperplasia [6,7]. All these events are clearly androgen-dependent, as shown by the observation that BPH does not develop in hypogonadal men, and that either surgical or pharmacological castration results in a decrease gland size [8–10]. However, BPH develops mainly in older men, when circulating testosterone, and in particular free testosterone, is progressively decreasing. Therefore, it is possible that sensitivity to androgens, rather than circulating androgen levels, are involved in BPH pathogenesis. A higher transcriptional activity of the androgen receptor (AR) due to a decreased number of CAG repeats in exon 1 has been reported in the majority [11–13], although not in all studies [14,15]. Interestingly, in hypogonadal

patients the effect of androgen substitution on prostate growth was inversely related to the extent of CAG residues [16]. In addition, a recent study has indicated a decreased expression of the AR co-repressor DAX-1 in BPH [17]. These studies support the view that AR activity is up-regulated in the prostate of BPH patients. Therefore, blocking AR activity represents a promising approach in the treatment of BPH. This could be achieved by reducing androgen levels, for example, blocking their formation with GnRH analogs or by antagonizing androgen activity at the receptor level using AR antagonists. Although both these strategies might be indeed effective, in clinical practice they are unacceptable because of the major side effects caused by complete androgen ablation in otherwise healthy individuals. Wilson 1972 [18], first hypothesized that the main androgen inducing prostate hyperplasia was not testosterone (T), but its highly biologically active metabolite dihydrotestosterone (DHT), which is formed locally by two  $5\alpha$ -reducing iso-enzymes ( $5\alpha$ -reductase type 1 and 2, the latter being predominant, see [19] for review). Interestingly, intra-prostatic DHT content is not decreased as a function of age [20–22]. According to Wilson's original hypothesis, blocking DHT formation with a type 2 selective (finasteride) or with a dual (dutasteride) inhibitor of  $5\alpha$ -reductase isoforms is, indeed, an effective treatment for BPH [23,24]. However, prostate size reduction obtained with this strategy is relatively limited (about 25%). Also some men experience sexual side effects related to partial androgen deficiency (decreased libido and impotence) that are not well tolerated, in particular in the ageing male [3,25]. It is possible that the limited clinical response to  $5\alpha$ -reductase inhibitors is due to a compensatory increase in intra-prostatic growth factor (GF) receptors, which follows androgen deprivation [26,27]. Therefore, an alternative strategy to reduce age-related prostate overgrowth is to decrease the activity of androgen-induced prostatic GFs, which are considered to mediate, at least partially, the proliferative activity of sex steroids in the gland [7,28,29]. It is interesting to note that the prostate gland is one of the few androgen targets retaining a proliferative responsiveness to androgens in adulthood. Therefore disrupting androgen-induced, intra-prostatic GF signaling is an attractive option to obtain a selective, and sexual side-effect free, therapy for BPH.


### III. EFFECTS OF ANDROGENS AND GROWTH FACTORS ON HUMAN BPH CELLS

In the human prostate, the AR is expressed in both the epithelial and the stromal compartments and regulates


mutual interactions between the two compartments (reviewed in [30]). However, as discussed above, stromal rather than epithelial cells are thought to be primarily involved in the pathogenesis of BPH. As shown in Fig. 1, BPH-derived stromal cells (BPH cells) express the AR gene and protein, with a high affinity for the ligand ( $K_d = 72 \pm 34$  pM), as well as both isoforms of  $5\alpha$ -reductase [31]. In addition, they respond to androgens with an increased growth ( $EC_{50} = 380 \pm 200$  pM, [31]). An increase in BPH cell proliferation was also obtained with addition of specific GFs, such as epidermal growth factor (EGF [32]), keratinocyte-GF (KGF [32,33]), and insulin-like growth factor-I (IGF-I [34]). Data in Fig. 2 show the maximal stimulatory activity of KGF (10 ng/ml), Des (1–3) IGF-I (an IGF-I analog which does not bind to binding proteins, 10 ng/ml) and T (10 nM) on BPH cell proliferation. KGF- and Des [1–3] IGF-I-induced proliferation was completely blocked only by specific antibodies, but not by unrelated antibodies or immunoglobulins (Fig. 2). Conversely, testosterone-induced cell growth was completely abolished not only by an AR antagonist (cyproterone acetate) or by a type 2  $5\alpha$ -reductase inhibitor (finasteride), but also by antibodies against the receptors for KGF (KGFR) and IGF-I (IGFR1) (Fig. 2). This indicates that T-induced proliferative activity in BPH cells is at least partially mediated by KGFR and IGFR1. This finding is consistent with data from organ cultures of neonatal rat ventral prostates, in which exogenous administration of KGF completely replaces the requirement of T for prostate growth and branching morphogenesis [35]. In addition, KGF has been also shown to replace androgen in eliciting growth and differentiation of seminal vesicles [36]. Hence, KGF, the predominant fibroblast GF (FGF) in human prostate [37], is considered one of the main prostatic andromedins, that is mediators of androgen-induced growth [38]. Also, the IGF system has been implicated in the pathogenesis of BPH. IGFR1 and IGF-II expression were higher in the periurethral zone of the human prostate than in other zones, and IGF-II levels were strictly correlated with the intra-prostatic androgen level [39]. Patients with the highest circulating levels of IGF-I have an elevated risk of BPH [40] and transgenic mice overexpressing IGF-I protein in the prostate show sign of hyperplasia in the ventral lobe, the most androgen-dependent zone [41].

### IV. VITAMIN D RECEPTOR EXPRESSION IN PROSTATE CELLS

The aforementioned experimental and clinical studies indicate that an ideal medical treatment for BPH might be an agent able to disrupt the intra-prostatic



**FIGURE 1** Expression of AR, 5 $\alpha$ -reductase and VDR in human BPH cells. **Panel A:** homologous competition curve for  $[^3\text{H}]\text{R1881}$  binding. R1881 binds with high affinity ( $K_d = 72 \pm 34$  pM) and low capacity ( $B_{\text{max}} = 2.64 \pm 0.5$  fM) to a single class of sites. *Ordinate:* B/T, Bound to total ratio for  $[^3\text{H}]\text{R1881}$ ; *Abscissa:* Total concentration (molar) of labeled and unlabeled R1881. Inset: RT-PCR detection of the AR gene. Products are derived from total RNA using specific primers for AR (upper panel) and GAPDH (lower panel). **Panel B:** RT-PCR amplimers from total RNA of BPH cells, prostate tissue, CHO 1827 (transfected with 5 $\alpha$ -reductase 1, 5 $\alpha$ -R1, gene) or CHO 1829 (transfected with 5 $\alpha$ -reductase 2, 5 $\alpha$ -R2 gene), CHO cells, human fetal penile smooth muscle cells (hfPSMC), using specific primers for 5 $\alpha$ -R1 (upper panel), 5 $\alpha$ -R2 (second panel), VDR (third panel) and GAPDH (bottom panel). CHO 1827 or 1829, hfPSMC and human prostate were used as positive controls for 5 $\alpha$ -R1, 5 $\alpha$ -R2 and AR. GAPDH mRNA amplification was performed to verify the integrity and loading of the extracted total RNA. MW, molecular weight markers; NC, negative control. The blots are representative of three separate experiments.



**FIGURE 2** Antiproliferative effect of BXL-353 on BPH cell growth induced by GFs or testosterone (T). Incubation for 48 h with KGF (10 ng/ml), Des [1–3] IGF-I (10 ng/ml) or T (10 nM) significantly induced BPH cell proliferation. Anti-androgens such as the 5 $\alpha$ -R2 inhibitor, finasteride (F, 1 nM), or the AR antagonist cyproterone acetate (Cyp, 100 nM) completely reverted T-induced stimulation of BPH cell growth, but they did not exert any effect on basal cell growth. Specific antibodies against KGFR (Anti-KGFR, 1  $\mu\text{g}/\text{ml}$ ) and IGFR1 (Anti-IGFR1, 1  $\mu\text{g}/\text{ml}$ ) blocked cell growth stimulated by their cognate GFs. T-induced cell proliferation was blunted by both types of anti-GF receptor antibodies. Immunoglobulin controls (IgG 1  $\mu\text{g}/\text{ml}$ ) failed to block either GF- or T-stimulated proliferation. BXL-353 (10 nM) was able to block BPH cell growth both in basal condition and in the presence of T or GFs. Results are expressed as percent increase (mean  $\pm$  SEM) over their relative controls in 4 different experiments performed in quadruplicate (\*  $P < 0.01$  vs control; °  $P < 0.01$  vs GF- or T- treated cells by one-way ANOVA and paired or unpaired Student's t tests). The data are derived from Crescioli *et al.*, 2003.

cross-talk between AR and GFs but devoid of anti-androgenic properties. Calcitriol analogs might comply with such criteria. The strict inter-relationships between vitamin D and prostate have been extensively described. Vitamin D deficiency has been proposed to be a risk factor for prostate cancer [42,43], because prostate cancer mortality in the USA increases as the availability of ultraviolet light exposure, and therefore of vitamin D formation, decreases [44] (see Chapter 90). Polymorphisms in the VDR gene have also been associated with increased risk of prostate cancer in some studies [45–47] (see Chapter 68). Malignant prostate cells express the VDR, and treatments with calcitriol, or less-hypercalcemic analogs, can inhibit prostate cancer proliferation and invasiveness (see Chapter 94 and ref. [48,49] for review). Interestingly, also epithelial and stromal cells of both human [50,51] (see also Figs. 1 and 2) and rat [51] normal prostate cells express the VDR, and addition of  $1,25(\text{OH})_2\text{D}_3$  inhibits cell growth [50].


## V. ANTIPROLIFERATIVE EFFECTS OF BXL-353 ON HUMAN BPH CELLS

We have extensively studied the antiproliferative effects of VDR ligands, and in particular of  $1,25$ -dihydroxy- $16$ -ene- $23$ -yne  $\text{D}_3$  (BXL-353 or analog V), a compound 30-fold less calcemic than calcitriol, on human stromal prostate cells (BPH cells). BPH cells were obtained from prostate tissues derived from patients, who underwent suprapubic adenomectomy for BPH and did not receive any pharmacological treatment in the three months preceding surgery [33]. BPH cells showed positive staining for smooth-muscle actin, vimentin, and desmin, suggesting fibromuscular morphological features. Conversely, they were negative for epithelial and endothelial markers such as cytokeratin and factor VIII [33]. As shown in Fig. 2 BXL-353 completely inhibited GF- or T-induced BPH cell proliferation and also decreased the growth of unstimulated cells [31,33,34]. To better understand the antiproliferative effect of BXL-353, we have studied its effects on the cell cycle distribution of partially synchronized BPH cells after a 24 h culture with medium or KGF (10 ng/ml). As shown in Fig. 3, after serum starvation, more than 75% of the cells were in  $\text{G}_0/\text{G}_1$ -early S phase, as indicated by fluorescence emission of propidium iodide-stained nuclei. Treatment with KGF allowed the cells to progress through the cell cycle with a statistically significant decrease in the proportion of cells accumulated in  $\text{G}_0/\text{G}_1$ -early S and an increase in cells traversing the  $\text{G}_2/\text{M}$  phase. The simultaneous addition of BXL-353 completely antagonized the KGF-induced effects on cell-cycle progression.

In BPH cells GFs and steroids not only stimulated DNA synthesis and cell proliferation but also prolonged cell survival, via induction of the anti-apoptotic protein Bcl-2 [31,33,34] (see also Fig. 4). Members of the Bcl-2 family are essential mediators of cell survival and apoptosis, and include both anti- and pro-apoptotic intracellular proteins residing at the mitochondrial outer membrane [52–55]. Their classification is based on the presence or absence of Bcl-2 homology (BH) domains: BH1, BH2, BH3, and BH4 [56]. In particular, Bcl-2 and Bcl-XL members, both containing all four BH domains, inhibit apoptosis and promote cell survival [57]. Bcl-2 activity, derived by integrating signals from survival and death stimuli, seems to be regulated by several different mechanisms, like homo- and heterodimerization with other family members, or post-translational modifications such as phosphorylation and proteolysis [52,58]. BXL-353 not only dramatically reduced GF- or T-induced Bcl-2 overexpression and survival, but also in the presence of these anti-apoptotic factors was able to stimulate a sustained death program (Fig. 4). Hence, in BPH cells, BXL-353 induced a decrease in the progression through the cell cycle and an increase in the rate of programmed cell death. Similar results were observed with calcitriol in breast cancer cells [59], in the androgen-dependent prostate cancer cell line LNCaP [60,61] as well as in metastatic Dunning rat prostate carcinoma [62]. Interestingly, in LNCaP cells, overexpression of Bcl-2 completely blocked calcitriol-induced apoptosis but only partially affected cell cycle arrest [61], indicating that partially independent pathways mediate the effects of calcitriol on cell proliferation and cell death.

The inhibitory effect of BXL-353 on prostate growth and survival is at least partially explained by the inhibition of GF-induced receptor activation. We have found that a rapid incubation of both benign [33] and malignant [63] prostate cells with BXL-353 dramatically reduces agonist-induced KGF-R auto-phosphorylation, one of the earliest event of KGF signaling. Because this effect was rapid, induced in a few minutes, and accompanied by an increase in intracellular calcium concentrations [33], we speculated the involvement of a nontranscriptional mechanism which, in agreement with recent results in chick myoblast [64], might involve the same VDR translocated from the nucleus to the microsomal fraction. Other studies have shown that rapid effects of calcitriol are mediated by a binding protein different from the VDR [65–68].

It has also been shown [69] that the VDR, upon ligand binding, physically interacts with the catalytic subunit of protein phosphatases PP1 and PP2Ac, thereby promoting their enzymatic activities with the consequent inactivation of  $\text{p}70^{\text{S}6\text{k}}$ , a kinase essential



**FIGURE 3** Effect of BXL-353 on cell cycle distribution of BPH cells. **Panel A** shows the effect of 24 h treatment with KGF (10 ng/ml) with or without BXL-353 (10 nM) on partially synchronized (24 h serum starvation) BPH cells. KGF significantly reduced the number of BPH cell accumulated in the G<sub>0</sub>/G<sub>1</sub> phase, thereby increasing the percentage of nuclei in G<sub>2</sub>/M. Simultaneous treatment with BXL-353 completely blocked the mitogenic activity of KGF. Results are expressed as cell cycle phase percentage. \*  $P < 0.01$  vs. control by one-way ANOVA and paired or unpaired Student's *t* tests. For assay method see ref. [86]. **Panel B** shows results from a typical experiment.


in G<sub>0</sub>/G<sub>1</sub> transition. VDR ligands not only induced a prompt decrease in phosphorylated KGFR [33,63], but also in phospho-Erk and phospho-Akt [70,71]. Hence, it is possible that calcitriol and related analogs might activate the catalytic subunit of distinct families of phosphatases, leading to antiproliferative effects by targeting GF signaling. Interestingly, in the human epidermoid A431 cells, overexpressing an autocrine growth loop for EGF, calcitriol not only induced a rapid alteration of EGFR auto-phosphorylation (as previously observed by us on KGFR), but also impaired EGFR membrane trafficking and signaling via the classic VDR-dependent mechanism [72]. In conclusion, it is possible that genomic (nuclear VDR-dependent) as well as rapid or nongenomic (cytoplasmic VDR-dependent?) mechanisms simultaneously contribute to the growth-suppressing activity of VDR ligands on prostate cells.

## VI. INHIBITION OF *IN VIVO* PROSTATE GROWTH BY BXL-353

To investigate whether calcitriol analogs might represent a new opportunity to decrease prostate cell


overgrowth and, therefore, to treat BPH, we carried out a series of studies using the rat as an experimental model. Taking advantage of the high sensitivity to androgens of the ventral prostate, castrated rats were supplemented with T with or without increasing doses of BXL-353 for various time periods [31]. Changes in ventral prostate volume and morphology, along with measurements of calcemia and hormonal values were studied. BXL-353 has a maximum tolerated dose of 30 µg/Kg, and at any dose tested never caused hypercalcemia. One week treatment with BXL-353 was sufficient to decrease significantly and dose-dependently ventral prostate weight, with an IC<sub>50</sub> = 1.5 ± 1 µg/Kg (Fig. 5, panel A). Similar results were obtained with a two-week treatment of BXL-353 (Fig. 5, panel B). A 30% reduction of ventral prostate weight was induced by one month treatment with BXL-353 to intact adult rats (Fig. 5, panel C). It is interesting to note that prostate weight reduction induced by BXL-353 (~50% decrease) is similar to that obtained in similar experimental models with 10 mg/Kg finasteride [31].

Because we observed that human BPH stromal cells underwent apoptosis even after short-term *in vitro* exposure to BXL-353, we investigated the fate of rat



**FIGURE 4** Effect of BXL-353 on apoptosis and Bcl-2 expression in BPH cells. The effect of 48 h treatment with BXL-353 (10 nM) alone or in combination with GFs (KGF and Des [1–3] IGF-I, 10 ng/ml) or T (10 nM) is reported on apoptosis (**panel A**) and Bcl-2 expression (**panel B**). Apoptotic index was obtained from *in situ* end labeling (ISEL) experiments and represents the number of stained nuclei over total cells in each of at least 5 separate fields per slide. Percentage of Bcl-2 stained cells was calculated by counting the number of immunopositive BPH cells over total cells in each of at least 5 separate fields per slide. Treatment with GFs or T significantly decreased the number of apoptotic cells (panel A), while it increased Bcl-2 positivity (panel B). Simultaneous treatment with GFs or T and BXL-353 significantly blunted the effect of both GFs and T on the number of ISEL (panel A) and Bcl-2 (panel B) positive cells. A 48 h exposure to BXL-353 induced a massive increase in apoptotic index (panel A), while Bcl-2 expression decreased (panel B). \* $P < 0.01$  vs. control; ° $P < 0.01$  vs. GF- or T-treated cells by one-way ANOVA and paired or unpaired Student's *t* tests. The data are partially derived from Crescioli *et al.*, 2000; 2002; 2003.





**FIGURE 5** Effect of BXL-353 on rat ventral prostate weight. **Panel A:** Castrated rats were supplemented with a single injection of T enanthate (30 mg/Kg/week) and orally treated for 4 days with vehicle or increasing concentrations of BXL-353 (1–30  $\mu\text{g/Kg}$ ). Ventral prostate weight is expressed as % variation (mean  $\pm$  SEM) of the weight of T-replaced castrated rats, in two separate experiments.  $^{\wedge}P < 0.05$  and  $^{*}P < 0.01$  vs T-supplemented vehicle-treated rats by one-way ANOVA and paired or unpaired Student's *t* tests. **Panel B:** Castrated rats were injected with T enanthate (15 mg/Kg/week) and orally treated for 5 day/week for two consecutive weeks with vehicle or increasing concentrations of BXL-353 (3–30  $\mu\text{g/Kg}$ ). Ventral prostate weight is expressed as % variation (mean  $\pm$  SEM) of the weight of T-replaced castrated rats ( $n = 4$ ).  $^{*}P < 0.01$  vs. T-supplemented vehicle-treated rats by one-way ANOVA and paired or unpaired Student's *t* tests. **Panel C:** Intact adult rats were orally treated for over one month (5 times/week for a total of 27 administrations) with vehicle (control) or increasing concentrations of BXL-353 (3–30  $\mu\text{g/Kg}$ ). Ventral prostate weight is expressed as % variation (mean  $\pm$  SEM) of the weight of control rats ( $n = 4$ ) ( $^{*}P < 0.01$  vs control rats). Data are derived from Crescioli *et al.*, 2003.

prostate cells after sub-acute (7–14 days, castrated rats) or prolonged (1 month, intact rats) treatment with the analog. By using terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick end-labeling (TUNEL), we observed the typical hallmark of nuclear fragmentation in both the epithelial and stromal cells of the BXL-353-treated prostate in all the experimental protocols studied [31]. In addition, we found that BXL-353 treatments induced a dose- and time-dependent up-regulation of clusterin gene and protein. Clusterin (CLU), or testosterone-repressed message 2 (TRPM-2), is an ubiquitous, puzzling protein expressed also in the rat prostate [73–75], which is down-regulated by androgens and up-regulated by growth arrest and cell

death (see in [76]). CLU has different intracellular and extracellular functions. As an extracellular, secretory glycoprotein, it has a chaperone-like role, binding a wide range of unrelated molecules and probably clearing cellular debris. Conversely, the intracellular ~49 kDa protein, after appropriate stimuli, is transported from the cytoplasm to the nucleus, where it binds DNA helicases, as Ku70/Ku86, thereby reducing DNA repair and allowing cell death [77]. Hence, CLU is generally considered an androgen-regulated, pro-apoptotic protein. We confirmed that in the rat prostate, CLU expression was increased by castration and finasteride administration [73,75], and we found that BXL-353 induced a sustained increase in CLU gene and protein



expression [31]. Interestingly, CLU-positive cells were more apparent in the glands of BXL-353 treated rats showing the more pronounced features of involution and atrophy.

In conclusion, studies in the rat strongly support findings in human BPH cells: BXL-353, similar to finasteride, counteracts the growth promoting effect of T, by inducing growth cell arrest and apoptosis. However, BXL-353, at variance with finasteride, is not an anti-androgen. It does not bind to the AR, as demonstrated by competition studies using the synthetic androgen [<sup>3</sup>H] R1881 on BPH homogenates, and it does not inhibit 5 $\alpha$ -reductase activity, as shown by the failure to interfere with DHT formation in CHO cells transfected with type 1 or type 2 5 $\alpha$ -reductase iso-enzymes [31]. In addition, BXL-353 did not affect the gonadal or pituitary secretion of testosterone or gonadotrophin [31]. Hence it should act downstream of the AR receptor ligand interaction. The activated AR is a multiple phosphorylated protein and some of its phosphorylation sites (as Ser 650) are required for full transcriptional activity (see ref. [78]). Hence, it is possible that BXL-353 might activate the catalytic subunit of distinct families of phosphatases, therefore exerting its antiproliferative effects acting on AR-dependent signaling. Alternatively, BXL-353 may disrupt androgen-dependent GF-mediated survival pathways, thus hampering T-induced BPH cell growth.

## VII. CONCLUSIONS

A large proportion of aging males develop BPH and, until recently, the only options for treatment were surgical intervention or watchful waiting. During the last 10 years, progress in medical therapy of BPH has resulted in effective treatments patterns leading to a significant improvement in the quality of life of affected patients. At present, two different classes of agents are available for BPH treatment:  $\alpha$ -blockers and 5 $\alpha$ -reductase inhibitors. Although sexual related side effects are more often reported with 5 $\alpha$ -reductase inhibitors than with  $\alpha$ -blockers [79], the reverse is true for reduction in risk of BPH-related surgeries [80]. A population-based cohort study, conducted in more than 5000 patients, receiving either  $\alpha$ -blockers or 5 $\alpha$ -reductase inhibitors (finasteride), showed that the incidence of BPH-related surgery was higher in  $\alpha$ -blocker-treated patients than in 5 $\alpha$ -reductase inhibitor-treated ones [80]. Similar results, obtained from a retrospective analysis of patients' data, demonstrated that the risk of experiencing serious complication related to BPH progression (catheterization, acute urinary retention, surgery) was significantly lower in finasteride-treated patients compared to

patients using  $\alpha$ -blockers [81]. A possible mechanism of action underlying the risk reduction of BPH-related surgery by finasteride is that 5 $\alpha$ -reductase inhibitors, by blocking DHT formation, shrink the prostate volume, which, in turn, is shown to be itself an important risk factor for BPH progression and, consequently, BPH-related surgery [80,82]. In fact, although many variables make it difficult to predict an individual's clinical course, prostatic size is reported to be one of the most important risk factors along with age and prostatic specific antigen (PSA) value [83]. Hence, the ideal treatment for BPH should include a medication that reduces prostate volume without interfering with androgen activity. Actually, patient compliance for finasteride may be limited by consistent sexual side effects, such as decreased libido, altered sexual potency, or ejaculatory dysfunction [84], especially in men with borderline erectile function [85]. Well-tolerated calcitriol analogs, such as BXL-353, might represent such a new class of drugs, because they decrease AR-mediated prostate growth, acting downstream of the AR on the GF-mediated proliferation pathways. Based on the data reviewed here, a double-blind, placebo-controlled phase II study is currently ongoing in Italy to evaluate the effects of a nonhypercalcemic calcitriol analog in patients with BPH.

## References

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL 1984 The development of human benign prostatic hyperplasia with age. *J Urol* **132**:474–479.
2. Jacobsen SJ, Girman CJ, Guess HA, Panser LA, Chute CG, Oesterling JE, Lieber MM 1995 Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? *Urology* **45**:64–69.
3. Thorpe A, Neal D 2003 Benign prostatic hyperplasia. *Lancet* **361**:1359–1367.
4. Claus S, Berges R, Senge T, Schulze H 1997 Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. *J Urol* **158**:217–221.
5. Shapiro E, Becich MJ, Hartanto V, Lepor H 1992 The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. *J Urol* **147**:1293–1297.
6. McNeal JE 1978 Origin and evolution of benign prostatic enlargement. *Invest Urol* **15**:340–345.
7. Serio M, Fiorelli G 1991 Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. *Mol Cell Endocrinol* **78**:C77–C81.
8. Peters CA, Walsh PC 1987 The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. *N Engl J Med* **317**:599–604.
9. McConnell JD 1990 Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. *Urol Clin North Am* **17**:661–670.
10. Schroder FH 1994 5 alpha-reductase inhibitors and prostatic disease. *Clin Endocrinol* **41**:139–147.

11. Giovannucci E, Stampfer MJ, Chan A, Krithivas K, Gann PH, Hennekens CH, Kantoff PW 1999 CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. *Prostate* **39**:130–134.
12. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O, Ogawa O 1999 Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. *Prostate* **41**:253–257.
13. Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM 2001 Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement. *J Urol* **166**:1560–1564.
14. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, de La Rosette JJ, Kiemeny LA 2000 Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. *Eur Urol* **37**:234–238.
15. Azzouzi AR, Cochand-Priollet B, Mangin P, Fournier G, Berthon P, Latil A, Cussenot O 2002 Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. *Eur J Endocrinol* **147**:479–484.
16. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E 2003 Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. *J Clin Endocrinol Metab* **88**:2049–2054.
17. AgoulNIK IU, Krause WC, Bingman WE 3rd, Rahman HT, Amrikachi M, Ayala GE, Weigel NL 2003 Repressors of androgen and progesterone receptor action. *J Biol Chem* (in press).
18. Wilson JD 1972 Recent studies on the mechanism of action of testosterone. *N Engl J Med* **287**:1284–1291.
19. Carson C, Rittmaster R 2003 The role of dihydrotestosterone in benign prostatic hyperplasia. *Urology* **61**:2–7.
20. Siiteri PK, Wilson JD 1970 Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. *J Clin Invest* **49**:1737–1745.
21. Hammond GL, Kontturi M, Vihko P, Vihko R 1978 Serum steroids in normal males and patients with prostatic diseases. *Clin Endocrinol (Oxf)* **9**:113–121.
22. Walsh PC, Lepor H, Eggleston JC 1983 Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. *Prostate* **4**:473–485.
23. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J 1998 The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. *N Engl J Med* **338**:557–563.
24. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators 2002 Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology* **60**:434–441.
25. Steers W 2001 5alpha-reductase activity in the prostate. *Urology* **58**:17–24.
26. Fiorelli G, De Bellis A, Longo A, Natali A, Costantini A, Serio M 1989 Epidermal growth factor receptors in human hyperplastic prostate tissue and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. *J Clin Endocrinol Metab* **68**:740–743.
27. Fiorelli G, De Bellis A, Longo A, Giannini S, Natali A, Costantini A, Vannelli GB, Serio M 1991 Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. *J Clin Endocrinol Metab* **72**:740–746.
28. Cunha GR 1996 Growth factors as mediators of androgen action during male urogenital development. *Prostate Suppl* **6**:22–25.
29. Gnanapragasam VJ, McCahy PJ, Neal DE, Robson CN 2000 Insulin-like growth factor II and androgen receptor expression in the prostate. *BJU Int* **86**:731–735.
30. Marcelli M, Cunningham GR 1999 Hormonal signaling in prostatic hyperplasia and neoplasia. *J Clin Endocrinol Metab* **84**:3463–3468.
31. Crescioli C, Ferruzzi P, Caporali A, Mancina R, Comerci A, Muratori M, Scaltriti M, Vannelli GB, Smirollo S, Mariani R, Villari D, Bettuzzi S, Serio M, Adorini L, Maggi M 2003 Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. *Endocrinology* **144**:3046–3057.
32. De Bellis A, Crescioli C, Grappon C, Milani S, Ghiandi P, Forti G, Serio M 1998 Expression and cellular localization of keratinocyte growth factor and its receptor in human hyperplastic prostate tissue. *J Clin Endocrinol Metab* **83**:2186–2191.
33. Crescioli C, Maggi M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M 2000 Effect of a vitamin D<sub>3</sub> analog on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. *J Clin Endocrinol Metab* **85**:2576–2583.
34. Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB, Adorini L, Salerno R, Serio M, Maggi M 2002 Des (1–3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D<sub>3</sub> analogue. *Mol Cell Endocrinol* **198**:69–75.
35. Sugimura Y, Cunha GR, Hayward N, Hayashi N, Arima K, Kawamura J, Rubin J, Aaronson S 1993 Keratinocyte growth factor (KGF) is a mediator of testosterone-induced prostatic development. *Mol Cell Differ* **1**:423–426.
36. Alarid ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, Cunha GR 1994 Keratinocyte growth factor function in epithelial induction during seminal vesicle development. *Proc Natl Acad Sci USA* **91**:1074–1078.
37. Ittman M, Mansukhani A 1997 Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. *J Urol* **157**:351–356.
38. Lopez-Otin C, Diamandis EP 1998 Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. *Endocr Rev* **19**:365–396.
39. Monti S, Di Silveri F, Iraci R, Martini C, Zanzara S, Falasco P, Poggi M, Stigliano A, Sciarra F, Toscano V 2001 Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. *J Clin Endocrinol Metab* **86**:1700–1706.
40. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW 2002 Insulin-like growth factors and risk of benign prostatic hyperplasia. *Prostate* **52**:98–105.
41. Konno-Takahashi N, Takeuchi T, Shimizu T, Nishimatsu H, Fukuhara H, Kamijo T, Moriyama N, Tejima S, Kitamura T 2003 Engineered IGF-I expression induces glandular enlargement in the murine prostate. *J Endocrinol* **177**:389–398.
42. Schwartz GG, Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). *Anticancer Res* **10**:1307–1311.
43. Hanchette CL, Schwartz CG 1992 Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. *Cancer* **70**:2861–2869.

44. Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW, Strange RC 2001 Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. *Lancet* **358**:641–642.
45. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA 1996 Association of prostate cancer with vitamin D receptor gene polymorphism. *Cancer Res* **56**:4108–4110.
46. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T 2000 Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. *Cancer Res* **60**:5710–5713.
47. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW 1998 Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. *Cancer Res* **58**:1620–1623.
48. Peehl DM, Feldman D 2003 International Congress on Hormonal Steroids and Hormones and Cancer: The role of vitamin D and retinoids in controlling prostate cancer progression. *Endocr Relat Cancer* **10**:131–140.
49. Krishnan AV, Peehl DM, Feldman D 2003 Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. *J Cell Biochem* **88**:363–371.
50. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D 1994 Antiproliferative effects of 1,25-dihydroxyvitamin D<sub>3</sub> on primary cultures of human prostatic cells. *Cancer Res* **54**:805–810.
51. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P 1998 Localization of 1,25-dihydroxyvitamin D<sub>3</sub> receptor (VDR) expression in human prostate. *J Steroid Biochem Mol Biol* **66**:121–127.
52. Gross A, McDonnell JM, Korsmeyer SJ 1999 BCL-2 family members and the mitochondria in apoptosis. *Genes Dev* **13**:1899–1911.
53. Li H, Yuan J 1999 Deciphering the pathways of life and death. *Curr Opin Cell Biol* **11**:261–266.
54. Wang E, Marcotte R, Petroulakis E 1999 Signaling pathway for apoptosis: a racetrack for life or death. *J Cell Biochem (Suppl 32–33)*:95–102.
55. Ashkenazi A, Dixit VM 1999 Apoptosis control by death and decoy receptors. *Curr Opin Cell Biol* **11**:255–260.
56. Fesik SW 2000 Insights into programmed cell death through structural biology. *Cell* **103**:273–282.
57. Huang DC, Strasser A 2000 BH3-only proteins essential initiators of apoptotic cell death. *Cell* **103**:839–842.
58. Van Hoof C, Goris J 2003 Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. *Biochim Biophys Acta* **1640**:97–104.
59. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J 1997 Comparative effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. *Breast Cancer Res Treat* **42**:31–41.
60. Blutt SE, Allegretto EA, Pike JW, Weigel NL 1997 1,25-dihydroxyvitamin D<sub>3</sub> and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. *Endocrinology* **138**:1491–1497.
61. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL 2000 A calcitriol analog, EB1089, inhibits the growth of LNCaP tumors in nude mice. *Cancer Res* **60**:779–782.
62. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Aciermo JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS 1997 Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. *Urology* **50**:999–1006.
63. Crescioli C, Maggi M, Luconi M, Vannelli GB, Salerno R, Sinisi AA, Bonaccorsi L, Ferruzzi P, Barni T, Forti G, Serio M 2002 Vitamin D<sub>3</sub> analog inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. *Prostate* **50**:15–26.
64. Capiati D, Benassati S, Boland RL 2002 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> induces translocation of the vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells. *J Cell Biochem* **86**:128–135.
65. Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW 1994 Identification of a specific binding protein for 1α,25-dihydroxyvitamin D<sub>3</sub> in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. *J Biol Chem* **269**:23750–23756.
66. Nemere I, Szego CM 1998 Early action of parathyroid hormone and 1,25-dihydroxycholecalciferol on isolated epithelial cells from rat intestine: I. Limited lysosomal enzyme release and calcium uptake. *Endocrinology* **108**:1450–1462.
67. Nemere I, Ray R, McManus W 2000 Immunochemical studies on the putative plasmalemmal receptor for 1,25(OH)<sub>2</sub>D<sub>3</sub>. I. Chick intestine. *Am J Physiol Endocrinol Metab* **278**:E1104–E1114.
68. Jia Z, Nemere I 1999 Immunochemical studies on the putative plasmalemmal receptor for 1,25-dihydroxyvitamin D<sub>3</sub>. II. Chick kidney and brain. *Steroids* **64**:541–550.
69. Bettoun DJ, Buck DW 2nd, Lu J, Khalifa B, Chin WW, Nagpal S 2002 A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. *J Biol Chem* **277**:24847–24850.
70. McGuire TF, Trump DL, Johnson CS 2001 Vitamin D<sub>3</sub>-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. *J Biol Chem* **276**:26365–26373.
71. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL 2002 Antiproliferative effects of 1α,25-dihydroxyvitamin D<sub>3</sub> and vitamin D analogs on tumor-derived endothelial cells. *Endocrinology* **143**:2508–2514.
72. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A 2002 1,25-dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. *J Biol Chem* **277**:38965–38971.
73. Bettuzzi S, Hiipakka RA, Gilna P, Liao S 1989 Identification of an androgen-repressed mRNA in rat ventral prostate as coding for Sulphated Glycoprotein 2 by cDNA cloning and sequence analysis. *Biochem J* **257**:293–296.
74. Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, Wong P, O'Sullivan J, Tenniswood M 1998 Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. *J Biol Chem* **273**:27887–27895.
75. Astancole S, Guidetti G, Pinna C, Corti A, Bettuzzi S 2000 Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment. *J Endocrinol* **167**:197–204.
76. Trougakos IP, Gonos ES 2002 Clusterin/apolipoprotein J in human aging and cancer. *Int J Biochem Cell Biol* **34**:1430–1448.
77. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA 2003 Synthesis and functional analyses of nuclear clusterin, a cell death protein. *J Biol Chem* **278**:11590–11600.
78. Gelmann EP 2002 Molecular biology of the androgen receptor. *J Clin Oncol* **20**:3001–3015.
79. Kassabian VS 2003 Sexual function in patients treated for benign prostatic hyperplasia. *Lancet* **361**:60–62.
80. Souverein PC, Erkens JA, de la Rosette JJ, Leufkens HG, Herings RM 2003 Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. *Eur Urol* **43**:528–534.

81. Boyle P, Roehrborn CG, Harkaway R, de la Rosette J, Emberton M, Logie J 2002 5- $\alpha$  reductase inhibitors (5ARIs) provide superior benefits to alpha-blockers in preventing acute urinary retention and surgery. *BJU Int* **90**(Suppl S2):18.
82. Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F *et al.* 2000 Prostate volume and serum prostate specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. *Eur Urol* **38**:563–568.
83. Djavan B, Nickel JC, de la Rosette J, Abrams P 2002 The urologist view of BPH progression: results of an international survey. *Eur Urol* **41**:490–496.
84. Barry MJ, Roehrborn CG 2001 Benign prostatic hyperplasia. *Br Med J* **323**:1042–1046.
85. Steers W, Guay AT, Leriche A, Gingell C, Hargreave TB, Wright PJ, Price DE, Feldman RA 2001 Assessment of the efficacy and safety of Viagra (sildenafilcitrate) in men with erectile dysfunction during long-term treatment. *Int J Impot Res* **13**:261–267.
86. Maggi M, Bonaccorsi L, Finetti G, Carloni V, Muratori M, Laffi G, Forti G, Serio M, Baldi E 1994 Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A. *Cancer Res* **54**:4777–4784.

# Index

## A

- AC. *See* Adenylyl cyclase
- ACE. *See* Angiotensin-converting enzyme
- Acidemia, rickets/osteomalacia features evident in, 984
- Acidosis,  $1\alpha$ -hydroxylase inhibited by, 1316
- Actin, 142
  - DBP sequestering, 147–148, 148f
- Actin-scavenger system, 143
  - DBP-actin complex implications for, 148–149
- Activating domain (AD), AF-2, 279, 280f
- Activation function (AF-2) domain
  - D analogs changing conformation of, 1452f, 1453
  - mutations v. D analogs, 1456
  - NCoA62/SKIP/VDR interaction independent of, 296
  - in NR LBDs, 279, 280f
  - in  $1,25(\text{OH})_2\text{D}_3$  transactivation of VDR, 1472
  - VDR LBD coactivator binding site v., 1473, 1473f
  - WSTF coactivating ligand-induced, 309, 310f
- Activator protein (AP-1), in  $1,25(\text{OH})_2\text{D}_3$ -induced differentiation, 1640
- AD. *See* Activating domain; Addison's disease; Alzheimer's disease
- Adaptor proteins, receptors requiring, 159
- Addison's disease (AD), VDR polymorphisms v., 1148
- Adenylyl cyclase (AC), in  $1\alpha,25(\text{OH})_2\text{D}_3/\text{Ca}^{2+}$  mechanism, 890f, 891
- ADH. *See* Antidiuretic hormone
- ADHR. *See* Autosomal dominant hypophosphatemic rickets
- Adjusted apposition rate (Aj.AR)
  - FP v., 1034
  - MAR v. osteoid surface in, 956–957
  - O.Th v., 1035, 1035f
- Adults
  - acute hypocalcemia therapy for, 1058
  - $\text{D}_3$  dosage considerations for, 1003–1005, 1009t
  - D insufficiency in, 1091–1092, 1091f, 1096–1097
  - elderly
    - D insufficiency in, 825–826, 1092–1094, 1092f
    - D supplementation v. bone loss in, 825–826
    - insufficiency v. hip fracture risk in, 1089
    - intestinal D absorption reduced in, 1087–1088
  - infant  $\text{D}_3$  dosage v., 1003
  - minuscule  $\text{D}_3$  intake recommendations for, 1008
- AF-2. *See* Activation function domain
- AFM. *See* Atomic force microscopy
- Africans. *See also specific nationalities*
  - VDR polymorphism allele frequencies in, 1128t, 1129
  - VDR polymorphisms v. PCa in, 1139t, 1145
- Aging
  - cutaneous D production v., 823–824
  - D metabolism v., 823–833
  - D tissue responsiveness in, 831–833
  - dietary D/intestinal absorption v., 824–826
  - FCA in response to free  $1,25(\text{OH})_2\text{D}$  v., 832, 832f
  - 25OHD serum concentration v., 826–827
  - $1,25(\text{OH})_2\text{D}$  synthesis/metabolism v., 826–831
  - 25OHD synthesis v., 826
  - PCa incidence v., 1679, 1680
  - as PCa risk factor, 1601, 1601t
  - PTH/ $1,25(\text{OH})_2\text{D}$  v., 828, 828f
- Agonists. *See also specific agonists*
  - action mechanism of selective, 1478–1480, 1479f
  - assessment of noncalcemic selective, 1478
  - differential VDR activation by noncalcemic selective, 1478–1480
  - nonsecosteroid VDR, 1557–1567
- AIDS, granulomatous disease incidence increasing with, 1391
- AIPC. *See* Androgen-independent prostate cancer
- Aj.AR. *See* Adjusted apposition rate
- Al. *See* Aluminum
- Alaskans, D deficiency in child/infant, 795
- Alcohol. *See* Ethanol
- Alcoholic liver disease
  - bone disorders associated with, 1306
  - clinical features of, 1306
  - D metabolism impaired in, 1306, 1306f
  - management, 1306
- Alcoholics, inadequate dietary D/sunlight exposure in, 1266
- Alcoholism
  - hypophosphatemia in, 1177
  - magnesium in, 1177
- Alendronate
  - bone loss prevented by, 1248
  - Ca absorption/bone formation suppression v., 1244
- Alfacalcidol. *See*  $1\alpha$ -Hydroxyvitamin  $\text{D}_3$
- Algerians, sunlight exposure v. rickets in, 1066–1067
- Alien, NR co-repressor, 299
- Alkaline phosphatase
  - Ca entry v., 416
  - mineral properties in KO animals, 479t

- Alkaline phosphatase (*Continued*)  
 in mineralization, 479t  
 in mineralization v.  $1\alpha,25(\text{OH})_2\text{D}_3$ , 716  
 $1\alpha(\text{OH})\text{ase}$ -null mice demonstrating elevated, 438  
 $1,25(\text{OH})_2\text{D}_3$  elevating matrix vesicle, 590–591  
 tissue's ability to calcify associated with, 580
- Alkalosis, serum phosphate depressed by, 1177
- All-trans-retinoic acid (ATRA), in leukemia combination therapy, 1733
- Allograft rejection  
 Geminis inhibiting, 1519–1521  
 immunoregulatory mechanisms inhibiting, 642  
 19-nor Gemini v. vascularized heart, 1520–1521, 1520t, 1521f  
 $1,25(\text{OH})_2\text{D}_3$ /analogs inhibiting acute, 640–641, 641t  
 orally active VDR ligand treatments for, 643  
 VDR ligands/ $1,25(\text{OH})_2\text{D}_3$  analogs inhibiting chronic, 642  
 VDR ligands v., 640–642
- Alopecia  
 in HVDRR, 1208, 1208f, 1210  
 HVDRR associated with, 1229–1230  
 in HVDRR phenotype, 621  
 HVDRR severity correlating with, 1210  
 in VDR-ablated mice with normal mineral ions, 542  
 VDR locus mutation/expression in, 1404  
 VDR-null mice having progressive, 346–347  
 VDR RXR $\alpha$  heteropartner role supported by, 233
- Aluminum (Al)  
 D metabolism influenced by, 1255t, 1270–1271  
 in osteomalacia, 1270  
 toxicity from chronic renal disease, 979–981
- Alzheimer's disease (AD), 1779–1780  
 D analogs treating, 1785
- Ameloblasts  
 calbindin-D<sub>9K</sub>/D<sub>28K</sub> in, 724–725, 730t  
 D-dependent molecules in, 602–604, 603f  
 enamel elaborated by, 599
- American Indians, metabolic bone disease v. lactose intolerance in, 917t
- Analogues. *See also* Agonists; Antagonists; Deltanoids; Geminis; Superagonists  
 2-carbon-modified 19-Nor- $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub>, 1543–1554  
 aromatic rings in, 1495, 1497t  
 autoimmunity v.  $1,25(\text{OH})_2\text{D}_3$ , animal models of, 1756, 1757t  
 bone diseases v., 1501–1502  
 breast cancer cell apoptosis induced by  $1,25(\text{OH})_2\text{D}_3$ , 1665–1666, 1666f, 1672f  
 breast cancer cells/tumors v., 1668–1669  
 breast cancer cells v.  $1,25(\text{OH})_2\text{D}_3$ , 1663–1667, 1664t  
 breast cancer v.  $1,25(\text{OH})_2\text{D}_3$ , 1663–1672  
 breast cancer v. preclinical/clinical trials of, 1668–1669  
 C-ring, 1562, 1563f  
   structures/activities of, 1562, 1564t  
 calcemic v. antiproliferative effect of  $1,25(\text{OH})_2\text{D}_3$ , 1573, 1575t  
 cancer models v., 1499–1500  
 catabolism v. selectivity of, 1459–1461, 1460f  
 cell-specific catabolism of, 1459–1460  
 cell-surface receptor v. nongenomic activity of, 1461–1462  
 chronic kidney disease treated with, 1827  
 chronic renal failure v. action/tissue specificity of, 1826–1827  
 chronic renal failure v. future roles of, 1826–1827  
 clinical development of LEO, 1502–1505  
 clinical studies of cancer v., 1574  
 colon cancer cells v. antiproliferative activity by, 1521–1522, 1522f, 1523f, 1523t  
 colon cell proliferation/differentiation/apoptosis v.
- Analogues (*Continued*)  
 clinical studies of, 1715  
*in vitro*, 1713–1714  
*in vivo* animal models for, 1714–1715
- D-ring, 1562, 1563f  
 structures/activities of, 1562, 1565t
- DBP affinity v. side chain modifications in, 1457
- dermal inflammation/epidermal proliferation/differentiation v., 1781
- developing new, 1489–1505  
 basic screening strategy for, 1489–1490  
 strategy for, 1489–1492  
 synthesis strategy for, 1490–1492
- development of OCT/ED-71, 1525–1539
- dialysis patient PTH secretion controlled by, 1822–1823
- differential initiation complex recruitment by, 1455–1456
- differential VDR activation by, 1475–1482, 1476f
- differentiating/antiproliferative v. calcemic activities in, 1449
- DNA binding v. selectivity of, 1455
- E-ring, 1562–1565, 1563f  
 structures/activities of, 1562–1564, 1566t
- EAE treated with, 1784
- efficacy/safety in clinical development of, 1504–1505
- 20-epi  $1,25(\text{OH})_2\text{D}_3$ , 1494–1495, 1496t, 1511–1522  
 transcriptional activity of, 1511
- epidermal proliferation marker modulation v. topical, 1781, 1783f
- in future HVDRR therapy, 1229
- hyperproliferative skin disorders v. less calcemic, 1788–1789
- hypertension v. low calcemic, 1514–1516
- IDBP interactions v. selectivity of, 1462–1463
- identifying selective, 1449–2900
- immunological diseases v., 1500–1501
- immunosuppressive agents synergistically influencing  $1,25(\text{OH})_2\text{D}_3$ , 1520
- implications for action mechanism of, 1441–1442
- kidney stone formation v., 1351–1352
- leukemia v., 1734–1736
- leukemia v. 20-epi, 1730t, 1735
- leukemia v. C-16-ene, 1730t, 1734–1735
- leukemic cell lines v., 1730t
- level of selectivity in, 1451–1452
- ligand binding determining selectivity of, 1452f, 1453
- mechanisms for selective actions by, 1449–2911
- metabolism of, 1423–1443  
   biological systems in studying, 1428–1429, 1428t  
   drug design implications in, 1442  
   examples for, 1429–1440  
   general considerations in, 1423–1429  
   implications from studying, 1440–1443  
   invalid comparisons of *in vivo/in vitro*, 1442  
   non-D-related enzymes in, 1428–1429  
   pharmacokinetic information correlating with, 1440–1441, 1441t  
   questionably valid assumptions regarding, 1442  
   radioactive analogs in studying, 1428–1429  
   specific analogs exemplifying, 1429–1440
- metabolism of 20-epi-/20-methyl, 1433–1434, 1433f, 1435f
- metabolism of cyclopropane-ring containing, 1431–1433, 1432f
- metabolism of homologated, 1434–1436
- metabolism of oxa-group containing, 1438
- metabolism of unsaturated, 1436–1437
- molecular basis for differential action of, 1471–1483
- non-psoriatic skin diseases v., 1787–1788
- nonsecosteroid CD ring modifications in, 1562–1565
- nonsteroidal, 1557–1567

## Analog (Continued)

- in normal/psoriatic skin, 1781–1784
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1423–1424, 1425t–1426t
    - animal model diabetes prevented by, 1768–1772
    - biological activities of, 1495–1502
    - bisphenols v., 1565
    - clinical trials of, 1742–1743
    - diabetes/auto-immune diabetes v., 1772–1773
    - diabetes early intervention using, 1768–1770, 1768t
    - diabetes v. immune modulators combined with, 1771–1772, 1771t
    - early trials of, 1742
    - oncology using, 1741–1747
    - secondary hyperparathyroidism in chronic renal failure v., 1331–1332, 1332f
    - tumors v., 1741–1742
    - VDR binding/gene expression v., 1495–1498, 1511, 1512f
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> side chain, 1490–1492, 1490f, 1491f, 1492f
    - chain length v. structure-activity of, 1492, 1493t
    - diabetes v., 1768t, 1770–1771
    - double/triple bonds in, 1492–1493
    - structure-activity relationships in, 1492–1495
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> structure in secosteroid, 1558, 1558f
  - overview of, 1403–1404
  - PCa treatment clinical trials of, 1698–1699
  - PCa v., 1689–1690
  - PD/AD treated with, 1785
  - pharmacokinetic data describing, 1440–1441, 1441t
  - pharmacokinetics/metabolism in clinical development of, 1502–1503
  - preclinical experience with, 1499–1502
  - prodrug, 1423–1424, 1424t
  - prodrug/1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> analog classification of, 1423
  - protein interactions v. *in vivo* selectivity of, 1452–1463, 1452f
  - psoriasis treated with, 1450
  - psoriasis v. biological effects of, 1781, 1781f
  - psoriasis v. clinical use of 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1784–1787
  - psoriasis v. topical 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1784–1785
  - PTH-suppressing/noncalcemic, 1449–2898
  - quantifying selectivity of, 1451
  - rat kidney perfusion in studying D<sub>3</sub>, 1513–1514, 1516f
  - selection criteria for, 1543–1544
  - serum DBP interacting with, 1456–1459
  - stabilization/increased VDR v. activity of, 1456
  - strong/weak calcemic/noncalcemic, 1440–1441
  - synthesizing 20-epi, 1491, 1491f, 1492f, 1496t, 1497t
  - synthesizing 22-oxa, 1490–1491, 1492f, 1496t
  - target cell enzymes activating/deactivating, 1441–1442
  - toxicity due to synthetic, 1357–1359
  - VDR/coactivator interaction enhanced by 20-epi, 1497–1498
  - VDR conformational change v. selectivity in, 1452f, 1453
  - VDR interactions v. binding of 20-epi, 1477–1478, 1478f
  - VDR modulated by, 1482–1483
  - VDR phosphorylation possibly influenced by, 1454
  - VDR stabilized by, 1456
  - VDR transcriptional activity v. 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>, 1474–1475, 1474t
- Androgen
- human BPH cells v., 1834
  - in PCa treatment, 1679–1680
  - PCa v. D interaction with, 1687–1688
- Androgen-independent prostate cancer (AIPC)
- high dose intermittent 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1745
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/taxane combinations v., 1745–1746
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1742
- Androgen receptor (AR)
- in human BPH cells, 1834, 1835f
  - in PCa, 1679–1680

- Anemia, in hemodialysis patients associated with VDR polymorphism, 246
  - Angiogenesis, D compounds v., 1574–1576, 1693
  - Angiotensin-converting enzyme (ACE), in RAS cascade, 871, 871f
  - Anonymous polymorphisms, VDR gene analysis v., 1138
- Antagonists
- assessment of, 1480–1481
  - 26-carboxylic ester, 1481f, 1482
  - differential VDR activation by, 1480–1482
  - lactone, 1481–1482, 1481f
  - structure of representative, 1481, 1481f
- Anthropometry, VDR gene polymorphisms v., 1143
- Anticonvulsants, D metabolism influenced by, 1255t, 1264–1265
- Antidiuretic hormone (ADH)
- IMCD water reabsorption increased by, 558
  - in RAS cascade, 871–872, 871f
- Antigen presenting cells (APCs)
- immunosuppressive treatments not targeting, 1519
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/analog autoimmunity v., 1756
- Antimycotics, kidney 1 $\alpha$ -hydroxylase activity regulated by, 78
- Antioxidant, 1,25(OH)<sub>2</sub>D<sub>3</sub> as, 764t, 765–767
- Antituberculous agents, D metabolism influenced by, 1255t, 1271
- AP-1. *See* Activator protein
- Apa polymorphisms, 1131t–1132t, 1135–1137
- BMD v., 1142–1143
- Apatite
- hydroxyapatite v., 477, 478–480, 478f
  - vertebrate tissues with largest/smallest crystals of, 477
- APCs. *See* Antigen presenting cells
- APLs. *See* Promyelocytic leukemias
- Apoptosis
- BXL-353/GFs v. BPH cell, 1836–1837, 1838f
  - calbindin-D<sub>28K</sub> regulating, 727
  - calbindin-D<sub>28K</sub> v. bone cell, 725, 725f
  - 20-epi D analogs inducing, 1498
  - hypertrophic chondrocyte, 577
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibiting tumor cells through, 1580
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> protecting epidermal keratinocytes from, 766–767
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> protecting HL-60 cells from, 1732
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. PCa cell, 1691
  - oncogenes/tumor suppressor genes in, 1577–1580
- AR. *See* Androgen receptor
- Arabs
- D metabolism in United Arab Emirates/non-Gulf, 794
  - MVC v. D in veiled Danish, 1812, 1812f
- Area under the curve (AUC), high dose intermittent regimen v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1742–1743, 1743f
- Aromatase, 858
- D v. expression of, 859
- Asian Indians
- bone histomorphometry of, 793
  - bone mass in, 793
  - D metabolism in, 790t, 792–793
  - low 25OHD in immigrant, 1026
  - sunlight exposure v. rickets in, 1066–1067
  - VDR polymorphisms v. diabetes in, 1146
- Asians
- high hVDR gene frequency in, 244–245
  - metabolic bone disease v. lactose intolerance in, 917t
  - PCa risk in, 1601, 1601t
  - rickets in immigrant Southeast, 968–971
  - VDR polymorphism allele frequencies in, 1128t, 1129
- Astrocytes, in brain antioxidative/detoxification processes, 766
- Atomic force microscopy (AFM), bone crystals imaged by, 482
- ATP, muscle cell energy from, 1808
- ATRA. *See* All-trans-retinoic acid
- Australians, D deficiency in, 795

- Autoimmune disorders  
 calbindin-D<sub>28K</sub> Ca buffering v., 726  
 as D analog therapeutic target, 1451  
 D analogs treating, 1451  
 orally active VDR ligand treatments for, 643  
 VDR ligand immunomodulation mechanisms in models of, 636–640, 637t  
 VDR polymorphisms v., 1146–1148  
 VDR-RXR heterodimer-activating ligands v., 241  
 Autoimmune polyglandular syndrome type 1, hypocalcemia v., 1053  
 Autoimmunity, 1753–1759  
 D<sub>3</sub> in, 1753–1759  
 immune mechanisms in, 1753–1754  
 1,25(OH)<sub>2</sub>D<sub>3</sub> action mechanisms in, 1754–1756  
 regulatory T cells in, 1754  
 Autosomal dominant hypophosphatemic rickets (ADHR), 463t, 467–468  
 clinical features, 1189–1190  
 as disorder of phosphate metabolism, 1189–1190  
 as hypophosphatemic disease, 1163

## B

- B lymphocytes, antigens recognized by, 631  
 BAF. *See* Brahma/SWI2-related gene 1 associated factor  
 Basal cell carcinoma, VDR polymorphisms v., 1146  
 Basic multicellular units (BMUs)  
 conditions for progress by, 504–505  
 as instrument of bone remodeling, 501–506, 502f, 503f, 504f  
 originations/progressions/terminations in, 503  
 posttarget progression by, 503, 505f  
 Bedouins  
 HHRH linkage analysis in, 469  
 osteomalacia/Ca deficiency in, 1077  
 serum 25OHD in dark-skinned, 794–795  
 vitamin D deficiency in, 41  
 Benign prostatic hyperplasia (BPH)  
 1 $\alpha$ -hydroxylase in cells derived from, 1608–1609, 1610f  
 pathogenesis, 1833–1834  
 VDR ligands inhibiting, 1833–1840  
 Beri-beri, nutrition v., 3  
 $\beta$  cells  
 clinical trials of D metabolites v., 1765–1767  
 D deficiency v. *in vivo*, 1764  
 D influencing characteristics of, 1767  
 D metabolites v. *in vitro*, 1764–1765  
 D v., 1764–1767  
 D's metabolic influences on, 1764–1767  
 BFR. *See* Bone formation rate  
 Bile, inactive polar D derivatives in, 1295  
 Bile acids  
 enterohepatic circulation reclaiming, 863–864  
 fate of, 863  
 in lipid digestion/absorption, 863  
 NRs regulating metabolism of, 865–866  
 production of secondary, 864–865, 864f  
 VDR as sensor for carcinogenic, 863–869  
 Binding proteins, intracellular VDRE, 351–361  
 Binding sites  
 proposed for regulatory trans-proteins, 94–95, 95f  
 rat *CYP24A1* proximal promoter region, 93–97, 94f  
 Biopsy, bone, 951–952  
 Bisphenols, 1557–1561  
 antiproliferative potency of nonsecosteroid, 1559, 1559t  
 Bisphenols (*Continued*)  
 identification/structure/synthesis of nonsecosteroid, 1557–1558  
 metabolic properties altered in, 1567  
 mutant VDR v. nonsecosteroid, 1561–1562  
 1,25(OH)<sub>2</sub>D<sub>3</sub> template v., 1565  
*in vitro* characterization of nonsecosteroid, 1558–1560, 1559t  
*in vivo* nonsecosteroid, 1560–1561  
 Bisphosphonates, D metabolism influenced by, 1255t, 1268  
 Blacks. *See also* Africans  
 age-adjusted PCa mortality in, 1600, 1600f  
 bone histomorphometry of, 792  
 bone mass in, 791–792  
 colon cancer v. skin pigmentation in, 1709–1710  
 D metabolism in, 790–791, 790t  
 dietary calcium reduction response by, 778  
 hypertension v. D deficiency in, 899–900  
 metabolic bone disease v. lactose intolerance in, 917t  
 25OHD concentration/vitamin D deficiency in, 38–39  
 osteoporosis/atraumatic fractures in, 792  
 osteoporosis/Ca absorption in, 816  
 PCa in Caucasians/Nigerians/American, 1680–1681  
 PCa mortality/incidence in American, 1625  
 PCa risk in, 1601, 1601t  
 PTH-stimulated bone resorption in, 778  
 Blood cells, VDR in, 1728–1729  
 Blood pressure. *See also* Hypertension  
 D endocrine system regulating, 291, 873  
 RAS regulating, 871  
 regulation v. D<sub>3</sub>, 999t  
 sunlight/D v., 873–874, 874f  
 in VDR-null mice, 345  
 BMAR. *See* Bone mineral apposition rate  
 BMC. *See* Bone mineral content  
 BMD. *See* Bone mineral density  
 2BMD. *See* 2 $\beta$ -Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D<sub>3</sub>  
 BMUs. *See* Basic multicellular units  
 Bone, 565–768  
 activation frequency v. turnover, 959, 1034  
 age-related loss of, 506–508  
 age v. thickness of trabecular, 500  
 aging v. D responsiveness by, 833, 833t  
 apposition rates influenced by 1,25(OH)<sub>2</sub>D<sub>3</sub>, 656–657  
 biopsy, 951–952  
 black/Caucasian formation rate of, 792  
 Ca in formation of, 411  
 calbindin-D<sub>9K</sub>/D<sub>28K</sub> in, 724–725  
 cancellous, marrow composition for, 500–501, 501t  
 CaR in, 558  
 CKD with low 1,25(OH)<sub>2</sub>D<sub>3</sub> or 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR resistance in, 1325  
 collagen synthesis regulation in, 704–705  
 D action redundant on, 429  
 D actions on mineralization of, 565–566  
 D analog nongenomic pathway in, 1462  
 D/D metabolites acting on, 565–571  
 D deficiency impairing resorption of, 776, 777, 777f  
 D-deficient, 487–488  
 D direct/indirect effects on, 1042–1044  
 D insufficiency impact on, 1089–1090  
 D intake v. winter loss of, 1090t  
 D mobilizing mineral in, 665–666, 666f  
 D modulating formation of, 327–328  
 deformities caused by D deficiency, 972f–973f, 973, 974f  
 density correlated with VDR gene polymorphisms, 184, 200  
 density influenced by exercise, 796  
 density seasonal decline v. D/Ca, 998



Bone (*Continued*)

dento-alveolar complex of, 599–605  
 development v. perturbed D metabolism, 107–108  
 disease in gastrointestinal disorders, 1297–1299  
 disorders v. gastrointestinal/hepatobiliary disease, 1293–1307  
 driving transfers of  $\text{Ca}^{2+}$  in mineralization of, 774, 775f  
 estrogen/PTH/D metabolism v. age-related loss of, 1107–1109  
 evolution of D-related disease of, 1035–1039  
 formation rates, 958  
 formation selectively induced by dantanoid, 1415f, 1416  
 fracture  
   aluminum toxicity associated with, 980–981  
    $\text{D}_3$  dose preventing, 997, 998f  
   in Looser's zones, 973  
   manifesting osteoporosis, 1101  
   normal 25OHD v., 1022–1023  
   rate v. D supplementation, 1094–1096, 1095f, 1096f  
   repair influenced by 24,25(OH) $_2\text{D}$ , 108  
   risk v. aging/activity level, 508  
   risk v. D, 1813–1814  
   risk v. serum 25OHD, 1370, 1370f  
   VDR polymorphisms v., 1143–1144  
   in vertebrae v. 12523, 1111–1112  
 glucocorticoid therapy causing loss of, 1239  
 growth in central skeleton, 499, 500f  
 health supporting higher D levels, 1370  
 hydroxide-deficient apatite crystals in, 477  
 24-hydroxylase enzyme regulation in, 92  
 irreversible loss of, 506, 507f, 508f  
 length, 499–500  
 loss  
   influenced by age-related PTH increase, 1107, 1108f  
   partitioned into horizontal/vertical components, 506–507, 509f  
   VDR polymorphisms associated with alveolar, 246  
 marrow rejection inhibited by 1,25(OH) $_2\text{D}_3$ /analogs, 641t  
 matrix proteins influenced by D, 479t, 484–487  
 matrix synthesis gene expression v. 1 $\alpha$ ,25(OH) $_2\text{D}_3$ , 715  
 metabolism v. ED-71/17 $\beta$ -estradiol, 1536, 1536f  
 mineral content/density v. pregnancy, 840–841  
 mineral metabolism influenced by HEP 187, 1493, 1494t  
 mineralization assessed by histomorphometry, 954–957  
 mineralization mechanisms in, 480  
 mineralization v. vitamin D, 5–6  
 modeling v. remodeling, 497–498, 498t  
 OCT influence on, 1527–1529, 1529t  
 OCT v. formation rate of cortical, 1531, 1533f  
 1,25(OH) $_2\text{D}_3$  regulating type I collagen expression in, 703–705  
 1,25(OH) $_2\text{D}_3$  v. mineral homeostasis in, 220–221, 221f  
 1,25(OH) $_2\text{D}_3$  v. 24,25(OH) $_2\text{D}_3$  in endochondral formation of, 583  
 1 $\alpha$ ,25(OH) $_2\text{D}_3$  VDR $_{\text{nuc}}$  in, 385t  
 osteocalcin gene expression modulation during, 328–329  
 osteomalacia v. properties of, 489–490, 490f  
 $\text{P}_i$  flux in human, 453–455, 454f  
 $\text{P}_i$  transport in, 465–467  
 progenitor cell commitment v. 1,25(OH) $_2\text{D}_3$ , 650f, 655–656  
 PTHrP expression in, 739t  
 remodeling, 497–511  
   activation frequency, 504–505  
   balance assessment, 959–961  
   BMUs, 501–506, 502f, 503f, 504f  
   bone age/mineral density v., 503f, 506  
   cycle in cancellous bone, 506, 507f  
   cycles v. bone loss, 507, 509f  
   focal imbalance, 506, 508f  
   influences mediated by strain, 508  
   initiated by fatigue microdamage, 503

Bone (*Continued*)

osteonal/hemioosteonal, 502–503  
 purpose, 500–501  
   in structural/metabolic bone, 501, 501t  
 remodeling markers, 921t  
 remodeling periods, 959  
 renal osteodystrophy v. periosteal formation of, 979  
 resorption/formation v. ED-71, 1537, 1537f, 1538  
 resorption in GHS rats, 1349  
 resorption *in vitro* v. 1,25(OH) $_2\text{D}_3$ , 568–569, 569f  
 resorption *in vivo* v. D, 569–570, 570f  
 resorption induced by 1,25(OH) $_2\text{D}_3$ , 680–681, 681f  
 resorption influenced by D, 568–570  
 resorption rates, 958  
 resorption signal transduced by RANKL/ODF, 672–673  
 RUNX2 $\Delta\text{C}$ -homozygous mice not forming, 335  
 steroid receptors/actions in, 1239–1241  
 strength structural determinants, 961  
 structural/cellular basis for growth of, 498–500  
 structure assessed by histomorphometry, 961–963  
 target genes v. D, 566–568  
 turnover, 497  
   assessment, 958–959  
   dissimilarly affected by PTH/1,25(OH) $_2\text{D}_3$ , 510  
 turnover/density v. D insufficiency in elderly, 825  
 two types mineralization in, 1030–1031  
 VDR in growth/maturation/remodeling of, 430f, 433  
 VDR overexpression strengthening, 488–489, 489f  
 volume v. VDR ablation, 343, 344t  
 Bone cells. *See also* Osteoblasts; Osteoclasts  
   in bone modeling/remodeling, 497–511  
   calbindin- $\text{D}_{28\text{K}}$  v. degeneration of, 725  
   coordinated activities of, 497, 498t  
 Bone disease. *See also specific bone diseases*  
   approaching patients with metabolic, 913–928  
   D analogs v., 1501–1502  
   gastrointestinal conditions associated with, 1299–1303  
   gastrointestinal disease with metabolic, 1298–1299  
   non-Ca/D factors in gastrointestinal disease-associated, 1298  
 Bone formation rate (BFR)  
   in HVO, 1035–1036  
   OCT v., 1528, 1529t  
 Bone histomorphometry, 951–963  
   biopsy, 951–952  
   adverse effects, 952  
   indications, 952  
   procedure, 951–952, 951f  
   bone remodeling indices in  
     derived, 953, 953t  
     primary, 953, 953t  
   bone structure assessment by, 961–963  
     three-dimensional, 962–963  
     two-dimensional, 961–962  
   dynamic indices from mineralizing perimeter/surface, 958  
   future developments in, 963  
   limitations, 954  
   methodology, 952  
   remodeling balance assessment by, 959–961  
     bone formation v., 959–960, 959f  
     bone resorption v., 960–961, 960f  
   terminology, 952–954  
     referents/abbreviations, 952–953, 953t  
     theoretical considerations influencing, 952  
   *in vivo* tetracycline labeling in, 954, 955, 955f  
 Bone mass  
   D in GIO treatment v., 1245–1247

- Bone mass (*Continued*)  
 ED-71 v. ovariectomized rat, 1537, 1537f  
 IH patients having low, 1342–1343  
 loss reduced by D supplementation, 1094  
 2MD v. ovariectomized rat, 1547, 1548f
- Bone matrix proteins, 712, 712f  
 $1\alpha,25(\text{OH})_2\text{D}_3$  regulating, 712, 713t  
 target genes in, 711–717  
 VDREs identified in, 712, 713t
- Bone mineral apposition rate (BMAR), D metabolites influencing, 656–657
- Bone mineral content (BMC)  
 maternal D status v. infant, 842–843  
 $1,25(\text{OH})_2\text{D}_3$  restoring PDDR, 1202, 1202f
- Bone mineral densitometry, in evaluating bone metabolic disease, 922–924
- Bone mineral density (BMD)  
 alendronate v., 1248  
 Cdx2 polymorphism v., 1130  
 corticosteroid/Ca/D v., 1245–1247, 1247f  
 D metabolites v., 1245, 1246t  
 in defining normal serum 25OHD, 1022, 1022f  
 in ED-71 clinical trials, 1538–1539, 1538f  
 intestinal CA absorption/VDR polymorphisms v., 1141–1142  
 $1,25(\text{OH})_2\text{D}_3$  v., 1107  
 $1\alpha\text{OHD}_3$  v., 1247–1248  
 in osteoporosis/fracture, 1141, 1143–1144  
 prednisone/Ca/D v., 1245, 1246f  
 VDR gene polymorphism v. lumbar spine, 243  
 VDR gene polymorphism v. women's, 243  
 VDR polymorphisms v., 1142–1143
- Bone scintigraphy, skeletal abnormalities uncovered with, 922
- Bone sialoprotein (BSP)  
 expression suppressed by  $1,25(\text{OH})_2\text{D}_3$ , 486  
 $1\alpha,25(\text{OH})_2\text{D}_3$  suppressing, 715  
 production v. D, 567–568
- BPH. *See* Benign prostatic hyperplasia
- BPH cells  
 AR/5 $\alpha$ -reductase/VDR in, 1834, 1835f  
 BXL-353/GFs v. apoptosis/Bcl-2 expression in, 1836–1837, 1838f  
 BXL-353 v., 1836–1837, 1837f  
 KGF/IGF-I/T v., 1834, 1835f
- Brahma/SWI2-related gene 1 associated factor (BAF)  
 components in WINAC, 308, 308f  
 in  $1,25(\text{OH})_2\text{D}_3$ -liganded VDR-RXR heterodimer transactivation, 238, 239f
- Brain  
 detoxification v.  $1,25(\text{OH})_2\text{D}_3$ , 1783  
 development influenced by  $\text{D}_3$ , 999t  
 homeostasis v. 12523, 1784, 1785f  
 $1,25(\text{OH})_2\text{D}_3$  antioxidant activities in, 764t  
 $1,25(\text{OH})_2\text{D}_3$  in development/disorders of, 1779–1785, 1785f  
 $1,25(\text{OH})_2\text{D}_3$  v. tumors in, 1783–1784  
 PTHrP expression in, 739t
- Breast cancer  
 angiogenesis/invasion/metastasis v.  $1,25(\text{OH})_2\text{D}_3$ , 1666–1667  
 cell proliferation v. D analogs, 1451  
 $\text{D}_3$  protecting against, 999t  
 D sensitivity, 1667–1668  
 EB1089 v., 1499  
 epidemiology of D v., 1671  
 natural ligands v. synthetic analogs treating, 1668  
 $1,25(\text{OH})_2\text{D}_3$ /analog antiproliferative effects v., 1459, 1460f  
 $1,25(\text{OH})_2\text{D}_3$ /analog v., 1663–1672  
 $1,25(\text{OH})_2\text{D}_3$  prooxidant activities in, 764–765, 764t
- Breast cancer (*Continued*)  
 $1,25(\text{OH})_2\text{D}_3$ /VDR modulating cell proliferation/apoptosis in, 857–858  
 preclinical studies of D preventing, 1670  
 prevention and D, 1669–1672, 1670t  
 prognosis v. tumor VDR expression, 1668  
 PTHrP expression in, 739t  
 PTHrP production v., 742  
 PTHrP v. osteolytic bone metastasis in, 744  
 risk, for nationality, 245  
 risk v. VDR polymorphisms, 1671–1672  
 VDR polymorphisms v., 1145
- Breast cancer cells  
 apoptosis-independent  $1,25(\text{OH})_2\text{D}_3$  inhibition of, 1580  
 apoptosis induced by  $1,25(\text{OH})_2\text{D}_3$ /analog v., 1665–1666, 1666f, 1672f  
 D compounds v. oncogenes/tumor suppressor genes in, 1664–1665  
 D resistance in, 1667–1668  
 EB1089 inhibiting IGF-I-stimulated, 1498  
 EB1089 v., 1669  
 $1,25(\text{OH})_2\text{D}_3$ /analog actions on, 1663–1667, 1664t  
 $1,25(\text{OH})_2\text{D}_3$ /deltanoid-induced differentiation modeled in, 1637t  
 $1,25(\text{OH})_2\text{D}_3$ /EB1089 arresting progression of, 1663–1664, 1672f  
 $1,25(\text{OH})_2\text{D}_3$ /EB1089 v. estrogen action in MCF-7, 1665  
 $1,25(\text{OH})_2\text{D}_3$  v. proliferation of, 1663–1665, 1672f  
 VDR expression/regulation in, 1667
- Breast milk  
 Ca absorption fraction from, 813, 814t  
 maternal D/Ca intake v. D/Ca in, 846–847  
 neonatal hypocalcemia incidence v., 841–842, 842f  
 substitutes v. rickets risk, 1066
- Brown tumors, in hyperparathyroidism, 978f, 979
- Brush border  
 membrane lipids v. Ca entry, 415–416  
 membrane  $\text{Na}/\text{P}_i$  transport reduced in *Npr2a* KO mice, 462  
 membrane  $\text{P}_i$  transport, 455  
 permeability increased by D, 414
- Bsm polymorphisms, 1131t–1132t, 1135–1137  
 BMD v., 1142–1143
- BSP. *See* Bone sialoprotein
- Burns, hypophosphatemia associated with, 1177
- BXL-353. *See*  $1,25$ -Dihydroxy-16-ene-23-yne  $\text{D}_3$

## C

- C-3 epimerization,  $1,25(\text{OH})_2\text{D}_3$ , 24, 25f
- C-24 oxidation pathway, to calcitric acid, 1424–1427, 1426f
- C-cells, CaR stimulating CT secretion by, 556
- c-Fos, osteoclastogenesis v. RANKL-induced expression of, 677–678
- c-Src family proteins, osteoclast differentiation v., 677, 677f
- $\text{C}_{27}$  sterol 27-hydroxylase, 54–55  
 mitochondrial  $\text{D}_3$  25-hydroxylase is, 55
- C-terminal extension (CTE), hVDR DBD/VDRE alternative positions, 231f, 232
- Ca. *See* Calcium
- Caffeine, D metabolism influenced by, 1255t, 1271–1272
- Calbindin, 417–419, 721–730  
 Ca absorption v., 418  
 Ca entry process initiation v., 418–419  
 in cytosolic Ca diffusion, 419  
 distribution, 730t  
 EF-hand HLH structural motif characterizing, 722, 722f

- Calbindin (*Continued*)  
 functions of, 418–419  
 gene expression regulation, 728–730  
 localization/functional significance, 722–728  
 1,25(OH)<sub>2</sub>D<sub>3</sub> v. in brain, 1781  
 synthesis, 418  
 VDR<sub>nuc</sub> responsible for production of, 384–385
- Calbindin-D<sub>9K</sub>, 523–525, 721–730  
 in placenta/yolk sac/uterus, 726, 730t  
 structure, 524
- Calbindin-D<sub>28K</sub>, 523–525, 721–730  
 EF hands contained in, 722, 723f  
 in egg shell gland, 726  
 enzymes activated by, 727–728  
 in nervous system, 726–727  
 PMCa pump regulated by, 524  
 regulatory function v. apoptosis, 727  
 structure, 524
- Calbindin-D<sub>9K</sub> gene  
 genomic organization, 729  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating, 729  
 steroids/other factors regulating, 729–730
- Calbindin-D<sub>28K</sub> gene  
 genomic organization, 728  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating, 728  
 regulation, 728–729  
 steroids/other factors regulating, 728–729
- Calcidiol. *See* 25-Hydroxycholecalciferol
- Calcimimetics, CaR activated by, 554
- Calcipotriol  
 breast cancer cells/tumors v., 1668  
 discovery, 1489  
 face/skin flexures treated with, 1786  
 leukemic cells v., 1734  
 metabolism, 1431–1433, 1432f  
 monotherapy/combination therapy v. psoriasis, 1504, 1504t  
 as noncalcemic analog, 1440, 1441t  
 pharmacokinetics/metabolism in clinical development of, 1495t, 1502–1503  
 psoriasis treated with OCT v., 1533, 1533f  
 psoriasis treated with topical, 1784  
 psoriatic lesions v. topical, 1450  
 scalp psoriasis treated with, 1785–1786  
 skin irritation in psoriasis treatment with, 1785  
 structure-activity relationships, 1493–1494, 1495t  
 toxicity, 1358–1359  
 Wittig reaction in synthesis of, 1490, 1491f, 1495t
- Calcitonin (CT)  
 C cells producing CGRP and, 689  
 CaR stimulating C-cell secretion of, 556  
 CYP24A1 expression regulated by, 93, 94f  
 CYP24A1 promoter expression increased by, 100  
 D metabolism influenced by, 1254t, 1256–1257  
 hypocalcemia from overzealous use of, 1057  
 induction during CYP24A1 promoter mutational analysis, 96–97, 97f  
 intestinal CYP24 expression v., 21  
 kidney 1 $\alpha$ -hydroxylase activity regulated by, 77  
 levels regulated by D<sub>3</sub>, 689–691  
 PTHrP expression/production stimulated by, 741t  
 renal P<sub>i</sub> excretion decreased by, 516t
- Calcitonin (CT) gene  
 D influencing thyroid C cell, 687–697  
 model system for 1,25(OH)<sub>2</sub>D<sub>3</sub> v. transcription of, 690–691  
 transcription down-regulated by D, 693–696  
 transcriptional regulation, 689, 690f, 691–693
- $\alpha$ -Calcitonin gene-related peptide (CGRP), C cells producing CT and, 689
- Calcitriol. *See* 1,25-Dihydroxyvitamin D<sub>3</sub>
- Calcitroic acid  
 C-24 oxidation pathway to, 1424–1427, 1426f  
 in calcipotriol metabolism, 1432, 1432f  
 1,25(OH)<sub>2</sub>D<sub>2</sub> metabolism to, 25–26
- Calcium (CA), 1,25(OH)<sub>2</sub>D<sub>3</sub> v. intestinal transport of, 679f
- Calcium (Ca). *See also* Calciuria; Eucalcemia; Familial hypocalciuria; hypercalcemia; Hereditary hypophosphatemic rickets with hypercalciuria; Hypercalcemia; Hypercalciuria; Hypocalcemia; Normocalcemia; Transcaltachia; Vascular calcification; Williams syndrome  
 absorption by paracellular path, 421–422  
 absorption by VDR-null mice  
   functional aspects of, 433–435, 434f  
   molecular aspects of, 435–437  
 absorption enhancers in food, 818  
 absorption in infancy/childhood, 811–818  
 absorption in Npt2-null/Hyp mice, 440  
 absorption in postmenopausal/age-related osteoporosis, 1110  
 absorption increased by alendronate, 1244  
 absorption influenced by 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR binding, 220–221, 221f  
 absorption location/timing in gut, 778–779, 779f  
 absorption v. IH, 1341, 1341f  
 absorption v. intake, 779–781, 779f, 780f  
 absorption v. prednisone/glucocorticoids, 1244–1245, 1245f  
 absorption v. serum 1,25(OH)<sub>2</sub>D in IH, 1342, 1343f  
 absorption v. VDR polymorphism/BMD relationship, 1141–1142  
 absorption v. vitamin D<sub>3</sub>, 5  
 absorptive efficiency v. transit time, 778  
 absorptive input, 778–782  
 active/passive absorption of, 781–782  
 adolescents v. inadequate intake of, 816  
 adult human body, 773  
 aging v. intestinal absorption of, 831–832  
 aging v. total/ionized, 829, 829t  
 balance disordered in sarcoidosis, 1381–1387  
 balance v. lactation, 4  
 binding proteins in brain v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1781  
 biological importance of, 411  
 in cancer risk epidemiology, 1617–1629  
 case-control/cohort studies of colorectal cancer v., 1622  
 CKD impairing 1 $\alpha$ -hydroxylase induction by, 1315–1316  
 colorectal adenoma v., 1622–1623  
 colorectal cancer v., 1621–1624  
 cytosolic transfer of, 417–419  
   calbindins in, 419  
 D deprivation/repletion v. muscle, 1810f, 1811  
 D enhancing paracellular absorption of, 412f, 421–422  
 D<sub>3</sub> improving absorption of, 999t  
 D/25OHD<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub> influencing renal handling of, 518–519  
 in dairy products v. PCa, 1627–1629  
 demand response of ECR, 776–778  
 dietary deficiency of, 1074–1076  
 duodenal/ileal transcellular/paracellular absorption of, 422–424, 423f  
 ECaC1/2 expression in fine-tuning transport of, 432  
 in eggshells/embryos, 851  
 entry step v. absorption, 416–417, 417f  
 entry step v. calbindins, 418–419  
 extrusion across basolateral membrane, 419–421, 420f  
 falls v. D<sub>3</sub> and, 1814, 1814f  
 fetuses/neonates v. low maternal intake of, 843, 843f  
 food fortification with, 817–818

Calcium (*Continued*)

- fractional absorption from human milk/formula, 813, 814t
- GHS rat response to low dietary, 1349, 1350f
- homeostasis in muscle cells, 1807–1808, 1808f
- homeostasis v. caffeine, 1271–1272
- homeostasis v. cardiovascular disease, 901
- in HVDRR therapy, 1227–1228
- IH decreasing renal reabsorption of, 1342
- IH v. restricted dietary, 1351
- intake/absorption v. age, 1103–1106
- intake v. absorption, 412–413, 412f, 413f, 782, 782f, 783–784, 784f
- intervention studies of colorectal adenoma v., 1623–1624
  - evidence interpretation in, 1623
  - implications of, 1624
  - mechanism in, 1623–1624
- intestinal absorption of
  - estrogens' genomic effects v., 444–445
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 411–424
  - VDR WT/KO mouse gestation and, 440–442, 441f, 441t, 442f
  - VDR WT/KO mouse lactation and, 441f, 441t, 442–444, 442f, 443f
- jejuno-ileal bypasses reducing serum, 1303
- in keratinocyte differentiation, 615–619, 615f
- keratinocyte differentiation v. intracellular, 616
- kidney/parathyroid VDR regulated by, 522–523, 525t
- KO mice/human intestinal absorption of, 429–437, 446t
- long-term OCT administration v., 1530–1531, 1530f
- low Ca intake v. total body, 781
- macrophages unresponsive to, 1382–1383, 1383f
- malabsorption in gastrointestinal disease, 1297
- maternal Ca intake v. breast milk, 847, 847f
- mechanisms of age-related changes in, 1104–1106
- metabolism during lactation/weaning, 843–846
- metabolism during pregnancy, 839–840
- metabolism v. IH therapeutics, 1351
- molecular bases for entry of, 415–416
- 2MP/2MbisP/2Mpregna v. serum, 1552–1553, 1553f
- nuclear import regulated by, 371–374
- obligatory losses of, 774–776
- OCT v. renal failure rat, 1527, 1528f
- 1,25(OH)<sub>2</sub>D<sub>3</sub> promoting absorption of, 291
- 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> regulating muscle, 886–887
- 1,25(OH)<sub>2</sub>D synthesis influenced by, 828
- 1,25(OH)<sub>2</sub>D<sub>3</sub> v. intestinal transport of, 678–680
- oral supplements, 1059t
- PTH defending serum, 1050
- PTH/1,25(OH)<sub>2</sub>D<sub>3</sub> in maternal regulation of, 859
- PTH v., 552, 553f
- PTHrP expression/production stimulated by, 741t
- reabsorption by kidney, 515–516
- regulation in ECF, 774–778, 775f
- renal reabsorption, 6
- reproduction v. active absorption of, 440–445
- restriction/24-hydroxylase catabolism in D toxicity, 1365–1367, 1366t
- restriction v. renal 1 $\alpha$ -hydroxylase in D toxicity, 1365, 1365t
- serum 25OHD values v. intake of, 1023–1024
- supplementation in metabolic bone disease, 927
- systemic/intracellular homeostasis of, 751
- transcellular absorption of, 414–421
  - Ca entry v., 415–417, 417f
  - calbindin v., 418
  - cytosolic transfer, 417–419
  - D in initiating, 414
  - extrusion across basolateral membrane in, 419–421, 420f

Calcium (*Continued*)

- in intestine, 414
- model for, 423f, 424
- thermodynamic parameters, 414
- transport in GHS rats, 1348, 1348f, 1348t
- VDR ablation v., 341
- VDR expression affected by, 202t, 204–205
- vesicular transport of, 422
- VSCCs inactivated by, 755–756, 756f
- Calcium channel blockers, D metabolism influenced by, 1255t, 1269
- Calcium deficiency, hypocalcemia due to dietary, 1056
- Calcium economy, 773–778
  - body calcium compartments in, 773–774
  - D in, 773–785
  - fetal bone mineral accretion v., 841, 841f
  - HVDRR Ca absorption efficiency v., 782
- Calcium-sensing receptor (CaR), 551–559
  - amino acids allosterically activating, 554
  - as “calciostat,” 552–554
  - fetal role of, 854
  - intracellular signaling, 551–554
    - pathways modulated by, 554
  - isolation, 551
  - keratinocytes' alternately spliced variant of, 616
  - in keratinocytes' Ca response, 615f, 616–617, 620f
  - in kidney, 556–558
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating, 543
  - parathyroid cell proliferation v., 545
  - in parathyroid gland, 554–556
  - parathyroid VDR interacting with, 556, 556t
  - in placental Ca transport, 853–854
  - predicted structure, 551–552, 552f
  - PTH secretion and, 537–538
- Calcium transport
  - ECaC1/2 expression in fine-tuning, 432, 432f, 432t
  - genes, VDR-null mouse Ca absorption v. expression of, 435–437, 436t, 437t
  - in GHS rats, 1348
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. intestinal, 678–680, 679f
  - vesicular, 422
- Calciuria, calbindin-D<sub>28K</sub> in, 724
- Calcospherulites, 1030
- Calmodulin
  - Ca entry v., 416
  - in keratinocyte growth/differentiation, 619
- Calreticulin, 543
  - increased in hypocalcemic rats, 544
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> PTH gene regulation v., 543–544
  - VDR DBD mutations in binding site of, 1220
- Cancer. *See also specific types of cancer*
  - clinical studies of D analogs v., 1574
  - clinical studies of D compounds v., 1573–1574
  - D analog therapy v., 1450–1451
  - D v., 1571–1577
    - epidemiology of, 1571–1573
  - diet/Ca intake/D relationship with, 1572
  - EB1089 v., 1499–1500
  - efficacy/safety of D analogs treating, 1504–1505
  - growth/development v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1573, 1574t, 1575t
  - Hopkins QW-1624F<sub>2</sub>-2 hybrid deltanoid v., 1417, 1417f
  - hVDR gene polymorphisms v., 245
  - models v. D analogs, 1499–1500
  - nonsecosteroidal D mimics v., 1565
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/analog therapeutic potential v., 169
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/carboplatin combinations v. advanced, 1745, 1746f

- Cancer (*Continued*)  
 risk epidemiology v. D/Ca, 1617–1629  
 soy consumption/*CYP24A1* expression v., 98  
 sunlight/vitamin D v., 42  
 VDR in, 1571, 1572t  
 VDR polymorphisms v., 1145–1146
- Cancer cells  
 D resistance/metabolism in, 1583–1584  
 EB1089 v. PTHrP production in, 744  
 24-hydroxylase enzyme regulation in, 93  
 1 $\alpha$ -hydroxylase v. 1,25(OH) $_2$ D $_3$  PTHrP inhibition in, 744, 745f  
 1,25(OH) $_2$ D $_3$  inducing apoptosis of, 1580  
 PTHrP expressed by normal/cancer, 739–740, 739t  
 PTHrP stimulators/inhibitors in normal/cancer, 740–742, 741f
- CaP. *See* Prostate cancer
- CaR. *See* Calcium-sensing receptor
- CaR gene, abnormalities v. hypocalcemia, 1053
- Carbonate, in bone apatite, 480
- Carboplatin, 1,25(OH) $_2$ D $_3$  in combination with, 1745, 1746f
- Cardiomyocytes, D signaling in, 903
- Cardiovascular disease, VDR polymorphisms v., 1148
- Cardiovascular medicine, 899–905  
 D dose/response curve, 905, 905f
- Cardiovascular system  
 D signaling in health of, 899–901  
 epidemiology of, 899–900  
 functions v. D, 874–875  
 indirect D actions on, 901–902  
 VDR genetics v. disease of, 900–901
- Cartilage. *See also* Growth plates  
 bone forming from calcified, 575  
 Ca/Phosphate supply v. D metabolites in, 581  
 calbindin-D $_{9K}$ /D $_{28K}$  in, 730t  
 changes during maturation, 577–578  
 embryonic variations in, 575  
 genomic/nongenomic regulation by 1,25(OH) $_2$ D $_3$ /24,25(OH) $_2$ D $_3$ , 575–591  
 metabolism regulated by D, 579–582, 581t  
 mineralization mechanisms in, 480  
 1,25(OH) $_2$ D $_3$  v. 24,25(OH) $_2$ D $_3$  in, 582–583
- Cartilage oligomeric matrix protein (COMP), D metabolites bound by, 579
- Catabolism, 1,25(OH) $_2$ D $_3$ , 1424–1427  
 C-26 hydroxylation/26,23-lactone formation in, 1427, 1427f
- Caucasians. *See also* Whites; *specific nationalities*  
 age-adjusted PCa mortality in, 1600, 1600f  
 bone mass in, 793  
 Cdx2 polymorphism in, 1125f, 1126  
 D deficiency in American juvenile, 1067  
 graphical LD display across VDR gene in, 1127, 1128f  
 low hVDR gene frequency in, 244–245  
 osteoporosis/atraumatic fractures in, 792  
 osteoporosis/Ca absorption in, 816  
 UV v. PCa in American, 1601–1602, 1602f, 1603f  
 VDR gene association studies in, 1141  
 VDR polymorphism allele frequencies in, 1128t, 1129  
 VDR polymorphisms v. breast cancer in, 1145  
 VDR polymorphisms v. colon cancer in, 1145–1146  
 VDR polymorphisms v. diabetes in, 1146  
 VDR polymorphisms v. PCa in, 1139t, 1145  
 VDR polymorphisms v. psoriasis in, 1146
- CB1093, metastasis v., 1576
- CB 966, synthesis, 1490, 1491f, 1494t
- CC. *See* Chief complaint
- Cdk5, in monocytic differentiation marker expression, 1639
- Cdk inhibitory (CDKI) proteins  
 Cdk regulated by, 1643–1644, 1643f  
 1,25(OH) $_2$ D $_3$ /deltanoids up-regulating, 1646–1649, 1647t–1648t
- Cdk5/p35 pathway, in 1,25(OH) $_2$ D $_3$  differentiation signal propagation, 1639
- CDKIs. *See* Cdk inhibitory proteins
- Cdks. *See* Cyclin-dependent kinases
- Cdx2 polymorphism, 1130, 1131t  
 bone fracture risk v., 1144  
 in Caucasians, 1125f, 1126, 1130  
 in Japanese, 1126, 1130  
 polymorphism functionality parameters associated with, 1135f, 1137
- Celiac disease  
 Ca malabsorption in, 1297  
 clinical features of, 1300–1301  
 D deficiency development in, 1301  
 management, 1301
- Cell cycle  
 apoptosis v. differentiation at block in, 1580  
 compartments/checkpoints, 1640–1641, 1641f  
 D influencing, 1577–1580, 1578f–1579f  
 deltanoid-induced differentiation v., 1640–1650  
 deltanoids modulating events in, 1646–1650  
 differentiation v., 1635–1651  
 20-epi D analogs regulating, 1498  
 G1 arrest v. c-Myc expression down-regulation, 1649–1650  
 G1 block controlled by retinoblastoma protein, 1649  
 G2 retardation v. polyploidization, 1650  
 G1/S block, 1646–1650, 1646f  
 machinery features, 1640–1642  
 1,25(OH) $_2$ D $_3$ /EB1089 in arrest of breast cancer, 1663–1664, 1672f  
 oncogenes/tumor suppressor genes in, 1577–1580
- Cell cycle progression  
 G2/M phase transition in, 1645, 1645f  
 G1/S phase transition in, 1643–1644, 1643f  
 mechanisms driving, 1642, 1642f  
 regulation of, 1643–1645  
 S phase DNA licensing in, 1644–1645
- Cell cycle traverse  
 Cdks controlling, 1642, 1642f  
 checkpoints controlling, 1641, 1641f  
 1,25(OH) $_2$ D $_3$  inhibiting, 1646–1649, 1646f
- Cells. *See also specific types of cells*  
 antioxidant mechanisms of, 762  
 D in oxidative stress response of, 761–768  
 DBP associated with, 123  
 higher D levels in health of, 1370–1371  
 HVDRR studies using various, 1218  
 1,25(OH) $_2$ D $_3$  v. growth/differentiation of cells, 696  
 PTHrP expressed by normal/cancer, 739–740, 739t  
 PTHrP stimulators/inhibitors in normal/cancer, 740–742, 741f  
 redox state of, 761–762  
 ROS causing death of, 761
- cementoblasts, cementum elaborated by, 599
- Cementum  
 bone sharing matrix components with, 602  
 D bioinactivation causing hypomineralization in, 602  
 in tooth root/periodontium, 601–602
- Central nervous system (CNS)  
 neurodegenerative disease etiology/physiopathology in, 1779–1780  
 1,25(OH) $_2$ D $_3$  actions in, 1781–1783  
 1,25(OH) $_2$ D $_3$  v. tumors in, 1783–1784  
 VDR/1,25(OH) $_2$ D $_3$  targets in, 1780–1781

- Cerebrotendinous xanthomatosis (CTX), *CYP27A1* expression v., 58–59
- CGRP. *See*  $\alpha$ -Calcitonin gene-related peptide
- Checkpoints, cell cycle traverse controlled by, 1641, 1641f
- CHF. *See* Congestive heart failure
- Chickens
- D deficiency v. fertility in, 854–855
  - embryonic development/egg hatchability v. D in, 851–852
- Chief complaint (CC), in metabolic bone disease diagnosis, 915
- Children. *See also* Infants; Puberty
- adolescent
    - Ca absorption in, 815–817
      - factors influencing, 815–816
    - early hypocalcemia in, 1036t, 1037
    - inadequate Ca/D intake in, 816
    - nutritional rickets in, 968, 969f
    - soda v. Ca intake by, 817
  - Ca absorption in prepubertal, 815
  - Ca/D-fortified foods for, 817–818
  - CA intake by developing countries', 817
  - D deficiency and nutritional rickets in, 1065–1077
  - D deficiency/Ca absorption in, 811–818
  - deficiency in breast-fed, 1067
  - PTH resistance in rachitic, 1069
- Chinese
- bone mass in, 793
  - Bsm1 RFLP v. nephrolithiasis in, 1142
  - Buddhist vegetarians v. metabolic bone disease, 917t
  - Ca v. colorectal cancer in, 1622
  - D metabolism in, 793
  - PCa mortality/incidence in, 1624–1625
  - sunlight exposure v. rickets in, 1066–1067
  - VDR polymorphism v. PCa risk in, 1682
  - VDR polymorphisms v. colon cancer in, 1145
- Chloride channel (ClC)-5, in Ca homeostasis, 159
- Chloride channels,  $1\alpha,25(\text{OH})_2\text{D}_3$  opening ROS 17/2.8 cell, 393, 394f
- Cholecalciferol. *See* Vitamin D<sub>3</sub>
- Cholesterol
- bile acids converted from, 863, 864, 864f
  - D<sub>3</sub> derived from, 931
  - D endocrine system having low concentration of, 1001, 1001f
- Chondrocytes
- in bone growth, 498–499, 499f
  - cartilage produced by, 575
  - cell maturation specific Ca<sup>2+</sup> ion kinetics in, 585
  - chickens/rats modeling growth plate, 577
  - D metabolite action mechanisms in, 587–588, 587f, 588f
  - lineage of, 575–577
  - maturation of growth plate, 108
  - maturation rates of, 575–576
  - membrane signaling in, 586–587
  - mineralization v. hypertrophic, 576–577, 576f
  - $1,25(\text{OH})_2\text{D}_3$ -deficient matrix vesicles produced by, 580
  - $1,25(\text{OH})_2\text{D}$  hormone v. differentiation/function of, 112–113
  - phospholipids altering membrane fluidity in, 585
  - stereospecific membrane receptors in, 586
  - zone of maturation v. D<sub>3</sub> metabolite response of, 582
- Chondrodysplasias, rickets v. differential diagnoses for, 984, 987f
- Chromatin
- architecture in nucleus, 328, 329f, 330f
  - ATP-dependent remodeling complexes for, 267–268
  - binding v. NR co-repressors, 292, 293f
  - in comodulator activity integrated model, 300, 300f
  - Mediator-D HAT activity v. remodeling, 267, 295, 299–300
  - osteocalcin gene organized by, 330–332
- Chromatin (*Continued*)
- PBAF repressing, 238–240, 239f
  - remodeling facilitating promoter accessibility/regulatory integration, 329–332
  - remodeling in VDR promoter/VDR targeting, 305–312, 306f
  - remodeling in VDR transcription model, 268–269, 269f
  - remodeling v. DNA repair/replication, 307
  - RUNX elements in remodeling, 332
  - WINAC in reorganizing, 310, 311f
  - WINAC inducing ATP-dependent remodeling of, 308–309, 309f
- Chromatin immunoprecipitation (ChIP)
- coactivator/transcription factor assembly details from, 299–300
  - NCoA62SKIP/VDR-activated transcription influence shown by, 297
  - OC gene promoter organization remodeling v., 332
  - VDR/WINAC association shown by, 309
- Chronic kidney disease (CKD). *See also* Chronic renal failure
- abnormal  $1,25(\text{OH})_2\text{D}_3$ /VDR activity in, 1320–1322, 1320f
  - bone loss in, 1325
  - D bioactivation to  $1,25(\text{OH})_2\text{D}$  in, 1313–1317
    - decreased renal mass/GFR v., 1313–1314, 1314f
    - PTH/Ca induction of renal  $1\alpha$ -hydroxylase v., 1315–1316
    - renal  $1\alpha$ -hydroxylase substrate availability v., 1315
  - defective homologous VDR up-regulation in, 1317–1318
  - mechanisms impairing  $1,25(\text{OH})_2\text{D}_3$ /VDR transcriptional activity, 1320–1321, 1320f
  - megalyn expression/ $1,25(\text{OH})_2\text{D}_3$  resistance in, 1319
  - $1,25(\text{OH})_2\text{D}$ /VDR action altered in, 1317–1322
  - TGF $\alpha$ /EGFR expression v. parathyroid hyperplasia in, 1323–1324, 1323f, 1324f
  - uremia v.  $1,25(\text{OH})_2\text{D}_3$ /VDR transcriptional activity in, 1320–1321, 1321f
  - VDR polymorphisms v. expression/function in, 1318–1319
- Chronic renal failure
- D therapy in, 1327–1332
  - $1,25(\text{OH})_2\text{D}_3$  v. secondary hyperparathyroidism in, 1327–1331, 1330f, 1331–1332, 1332f
- Chugai OCT
- cell-specific catabolism of, 1459–1460
  - DBP affinity v. plasma levels, 1457–1458, 1457f
  - hypercalcemia of malignancy v., 1450–1451
  - mouse primary immune response v., 1451
  - PTH suppression/low calcemic activity by, 1449–2898, 1450f
  - SAR in design of, 1412, 1413f
- Cimetidine, D metabolism influenced by, 1255t, 1270
- Cirrhosis, hypocalcemia/secondary hyperparathyroidism in primary biliary, 1056
- CKD. *See* Chronic kidney disease
- ClC-5. *See* Chloride channel-5
- CNS. *See* Central nervous system
- Coagulation cascade, cardiovascular disease v. D regulating blood, 902
- Cod liver oil
- historical importance of, 70
  - rickets v., 4
- Collagen
- in bone matrix scaffolding, 485
  - D influencing, 485–486, 486f
  - factors modulating synthesis of, 703–704
  - molecular mechanisms regulating, 705–706
  - $1,25(\text{OH})_2\text{D}_3$  inhibiting organ culture synthesis of, 704
  - $1,25(\text{OH})_2\text{D}_3$  regulating expression of type I, 703–705
  - $1,25(\text{OH})_2\text{D}_3$  regulating matrix proteins in type I, 703
  - synthesis regulation in bone, 704–705
- Colon
- dietary Ca absorption in, 424

- Colon (*Continued*)  
 1 $\alpha$ -hydroxylase expression in human, 1718–1719, 1719f  
 1 $\alpha$ -hydroxylase/VDR/Ki-67 coexpression in, 1718–1719, 1719f  
 1 $\alpha$ ,25(OH) $_2$ D $_3$ -mediated rapid response in, 386t  
 1 $\alpha$ ,25(OH) $_2$ D $_3$  VDR<sub>nuc</sub> in, 385t  
 VDR's clinical relevance to, 246–249
- Colon cancer  
 D supplementation v. fat-promoted, 246  
 D v., 1709–1721  
 D/VDR v., 866–867  
 EB1089 v., 1500  
 20-epi D analogs v. IGF-II in, 1498–1499  
 high-fat diet v., 866–867, 1572  
 rationale for Gemini analogs treating, 1521–1522  
 sunlight/latitude v. death rate from, 1571–1572  
 sunlight v. incidence of, 246  
 VDR/EGFR expression in, 1710–1711, 1711f, 1711t  
 VDR gene polymorphisms v., 1619–1620  
 VDR polymorphisms v., 1145–1146  
 VDR polymorphisms v. development of, 1712
- Colon cancer cells  
 D metabolism in lines/primary cultures of, 1715–1717, 1716f  
 metabolic/catabolic D hydroxylases expressed in, 1717  
 1,25(OH) $_2$ D $_3$ /analog antiproliferative activity v., 1521–1522, 1522f, 1523f, 1523t  
 1,25(OH) $_2$ D $_3$ /deltanoid-induced differentiation modeled in, 1637t  
 1,25(OH) $_2$ D $_3$ /Ro-26-9228 v., 1480, 1480f
- Colon cells  
 D metabolism in normal/neoplastic, 1715–1719  
 1,25(OH) $_2$ D $_3$  action on neoplastic, 1710–1715  
 1,25(OH) $_2$ D $_3$ /D analogs v. proliferation/differentiation/apoptosis of, 1712–1715  
   clinical studies of, 1715  
   *in vitro*, 1712–1714  
   *in vivo* animal models for, 1714–1715  
 VDR in normal/malignant, 1710–1712
- Colorectal adenoma  
 Ca v., 1622–1623  
 D plasma markers v., 1619  
 dietary D v., 1619  
 intervention studies of Ca v., 1623–1624  
   evidence interpretation in, 1623  
   implications of, 1624  
   mechanism in, 1623–1624  
 VDR gene polymorphisms v., 1619–1620
- Colorectal cancer, 1618–1619  
 Ca v., 1621–1624  
 case-control/cohort studies of Ca v., 1622  
 circulating D v., 1618–1619  
 D dietary/supplementary intake v., 1618  
 dietary Ca v., 1621–1622  
 risk epidemiology v. D/Ca, 1617–1629  
 sunlight exposure v., 1618
- Colorectal neoplasms, 1618–1624
- Combination therapy  
 advanced cancer v. 1,25(OH) $_2$ D $_3$ /carboplatin, 1745, 1746f  
 in animal PCa models, 1689  
 calcipotriol in psoriasis, 1504, 1504t  
 cancer cell differentiation v., 1582–1583  
 falls v. D $_3$ /Ca, 1814, 1814f  
 leukemia v. D compounds in, 1733–1734  
 PCa, 1695–1698  
 PCa v. 1,25(OH) $_2$ D $_3$ /taxane, 1745–1746  
 psoriasis, 1504, 1504t
- COMP. *See* Cartilage oligomeric matrix protein
- Competitive chemiluminescence immunoassay (CLIA), 25OHD quantitation using  $^{125}$ I-RIA v. automated, 939, 939f, 940f, 940t
- Competitive protein binding assays (CPBAs)  
 for D/25OHD, 931–932  
 25OHD assay consistency v., 1023
- Computerized tomography (CT), tumors causing TIO v., 988
- Congestive heart failure (CHF), VDR polymorphisms v., 1148
- Cortical thick ascending limbs (CTAL), CaR controlling Ca/Mg reabsorption in, 557, 557f
- Corticosteroids  
 active intestinal Ca absorption v., 445  
 D metabolism influenced by, 1255t, 1265–1266
- CPBAs. *See* Competitive protein binding assays
- Crohn's disease  
 bone disease in, 1302  
 Ca malabsorption in, 1297  
 D/25OHD/Ca malabsorption in, 1302  
 hypercalcemia/D hypersensitivity in, 1361  
 management of, 1302  
 VDR polymorphisms v., 1147
- CT. *See* Calcitonin; Computerized tomography
- CT/CGRP gene  
 alternative RNA processing of, 689, 689f  
 cAMP-induced enhancer, 691  
 cAMP/neuroendocrine enhancers in 1,25(OH) $_2$ D $_3$ -inhibited transcription of, 693, 695f  
 cAMP responsive enhancer, 690f  
 mapping negative VDRE of, 694–696, 695f  
 neuroendocrine-specific enhancer, 690f  
 neuroendocrine-specific HLH enhancer, 691–692  
   MAP kinase stimulation/sumatriptan repression, 692, 692f  
 1,25(OH) $_2$ D $_3$  transcription repression mechanism v., 696, 696f, 696t
- CT gene. *See* Calcitonin gene
- CTAL. *See* Cortical thick ascending limbs
- CTE. *See* C-terminal extension
- CTX. *See* Cerebrotendinous xanthomatosis
- Cubilin, 158–159, 158f
- Cyclin-dependent kinases (Cdks), cell cycle restriction points v., 1642, 1642f
- CYP24. *See* 24-Hydroxylase
- CYP27. *See* 25-Hydroxylase
- CYP $_{1\alpha}$   
 mRNA v. 1 $\alpha$ ,25(OH) $_2$ D $_3$ , 75, 75t  
 mRNA v. PTH, 76, 76t  
 promoter activity v. 1 $\alpha$ ,25(OH) $_2$ D $_3$ , 76, 76t  
 promoter activity v. PTH, 76–77, 77f
- CYP24A1. *See* 24-Hydroxylase
- CYP24A1  
 human, 91  
 rat, 91
- cyp24A1*, 24-hydroxylation v., 107–109
- CYP27A1. *See* 25-Hydroxylase
- CYP27A1  
 intraacinar localization, 58–59  
 1,25(OH) $_2$ D $_3$  administration v., 57–58, 58f, 59f  
 regulation/enzyme activity, 56–58  
 transcription v. bile acids, 57
- cyp27A1*, hepatic 25-hydroxylation v., 105–106
- CYP1 $\alpha$  gene, extrarenal 1,25(OH) $_2$ D synthesis v., 1380
- CYP24A1 promoter, rat, 93–97  
 mutational analysis v., 95–97, 96f, 97f
- CYP27B1. *See* 1 $\alpha$ -Hydroxylase
- CYP27B1, structure, 74, 74f
- cyp27B1*, 1 $\alpha$ -hydroxylation v., 109–113
- CYP2C11. *See* 25-Hydroxylase

CYP2D25. *See* 25-Hydroxylase  
 CYP2R1. *See* 25-Hydroxylase  
 Cytochrome P4501 $\alpha$ , 1442  
   cloning/gene structure, 73–75, 74f  
 Cytochromes P450  
   function of, 88  
   isoform modeling studies of, 1443  
   molecular modeling of, 88–89, 89f  
   nomenclature for, 105, 106t  
   in 25OHD<sub>3</sub> 1 $\alpha$ -hydroxylation, 71–72, 71f  
   ROS generation implicating, 762  
 Cytokines  
   in keratinocyte growth/differentiation, 614  
   in macrophage 1 $\alpha$ -hydroxylase regulation, 1384–1385  
 Cytoplasm, protein import retarded by docking in, 374  
 Cytotoxic T cells, 1,25(OH)<sub>2</sub>D<sub>3</sub> autoimmunity v., 1755  
 Cytotoxic therapy, hyperphosphatemia in, 1178

## D

D. *See* Vitamin D  
 D<sub>2</sub>. *See* Vitamin D<sub>2</sub>  
 D<sub>3</sub>. *See* Vitamin D<sub>3</sub>  
 Daivobet, in combination therapy of psoriasis, 1504, 1504t  
 DBDs. *See* DNA binding domains  
 DBP. *See* Vitamin D binding protein  
 DBP-A, DBP-B structure compared with, 135–136  
 DBP-actin complexes, 122t, 123, 142–149  
   other actin complexes compared with, 147  
   structure of, 143–147, 143f  
      $\beta/\gamma$ -actin v., 145t, 146–147  
     hydrophobic DBP residue interaction v., 144t–145t, 146, 146f  
   structures reported for, 149  
   tissue necrosis/cell disruption increasing, 126, 142  
 DBP-B, DBP-A structure compared with, 135–136  
 DBP-vitamin D complex, D binding site structure in, 137–142, 139f–140f  
   biological implications of, 142  
   VDR D pocket structure v., 142  
 DCs. *See* Dendritic cells  
 DCT. *See* Distal convoluted tubule  
 Deficiency, 968–974  
   abnormal fetal organ development v., 852–853  
   adolescent, 816  
   age-dependent signs/symptoms of, 916t  
   animal fertility reduced by, 854–855, 854t  
   bisphosphonate antiresorptive effect v., 1114  
   in breast-fed children, 1067  
   Ca deprivation increasing susceptibility to, 1051–1052, 1052f  
   cartilage v., 579  
     resorption of, 581  
   in celiac disease, 1301  
   classifying states of, 1024–1026  
   correction in osteoporosis treatment, 1110–1111  
   D absorption/input v. risk of, 784  
   development of acquired, 1296, 1296f  
   development of depletion and, 1293–1296  
   diet and contemporary, 777–778  
   ECF [Ca<sup>2+</sup>] demand response mediated by, 776–777, 777f  
   in elderly v. D synthesis/lifestyle, 823–824  
   epidemic in industrialized countries, 42  
   epidemiology of nutritional rickets/D, 1066–1067  
   HDM v. insulin resistance in, 1816  
   immune abnormalities associated with, 1389  
   in infancy/childhood, 811–818

Deficiency (*Continued*)  
   insufficiency v., 1085–1086  
   intrinsic/extrinsic, 1029  
   in last trimester of pregnancy, 803–804  
   many diseases causing, 968  
   mild/moderate/severe stages of, 1024, 1025t  
   mineralization v., 487–488  
   muscle myopathies in, 893  
   myopathy in, 1805  
   neonatal Ca metabolism v. maternal, 841  
   nutritional rickets in children v., 1065–1077  
   radiographic abnormalities of rickets v. treating, 970f, 971, 974f, 982f  
   RAS v. blood pressure/cardiovascular function in, 875  
   risk groups, 1026  
   spiral of developing, 1294, 1295f  
   ubiquity of, 796, 1024–1026, 1025f  
   *in vivo*  $\beta$  cells v., 1764  
 7-Dehydrocholesterol (7-DHC)  
   D<sub>3</sub> biosynthesis from, 1405, 1408f  
   decreased in elderly subjects, 823  
   keratinocytes producing D<sub>3</sub> from, 609, 610f  
 Dehydroepiandrosterone (DHEA)  
   OCT production using, 1526  
   as steroid precursor in deltanoid synthesis, 1412, 1413f  
 Delayed-type hypersensitivity (DTH), 1,25(OH)<sub>2</sub>D<sub>3</sub> v. passive transfer of, 1754, 1755f  
 Deltanoids  
   c-Myc v. differentiation/G1 arrest induced by, 1649–1650  
   catabolism-inhibiting, 1406–1408  
   CDKs up-regulated by, 1646–1649, 1647t–1648t  
   cell cycle events modulated by, 1646–1650  
   cell cycle v. differentiation induced by, 1640–1650  
   cell type v. proliferation inhibition by, 1650  
   cellular models of differentiation induced by, 1635–1636, 1637t  
   differentiation induced by, 1635–1640  
   generalized structure of, 1405, 1407f  
   metabolic rationale guiding development of, 1405–1408  
   molecular biology rationale in development of, 1408–1411, 1410f  
   multistep synthesis of hybrid, 1416–1418, 1416f, 1417f, 1418f, 1419f  
   nearby structural changes v. catabolism of, 1407–1408, 1407f, 1410f  
   neoplastic cell proliferative quiescence induced by, 1635  
   1,25(OH)<sub>2</sub>D<sub>3</sub> hypercalcemia/calcification v., 1405  
   organic chemistry rationale in development of, 1411–1418  
   physiologically active metabolites of, 1408  
   potency of 22-ethyl, 1409, 1411f  
   prodrugs/indications in, 1405, 1406f  
   rational design of, 1405–1418  
   remote structural changes v. catabolism of, 1407, 1410f  
   6-*s*-cis-locked, 1412, 1412f  
   SAR in design of 22-oxa, 1412  
   steroid precursors in constructing, 1412–1416, 1413f, 1414f, 1415f  
 Dendritic cells (DCs)  
   in acute allograft rejection, 1519  
   adaptive immune responses mediated by, 631  
   in generating effector/regulatory T cells, 634, 634f  
   immunointervention targeting, 632–633, 632t  
   1,25(OH)<sub>2</sub>D<sub>3</sub> inducing tolerogenic, 1519  
   VDR ligand immunoregulation of, 633–635  
 Dengue fever, VDR polymorphism v. hemorrhagic form of, 246  
 Dentin  
   characteristics, 600–601  
   odontocytes elaborating, 599  
   in tooth root/periodontium, 601–602



- Dentin phosphoproteins (DPPs), high degree of phosphorylation in, 600–601
- Dentin sialoprotein (DSP), in dentin, 601
- Dento-alveolar bone complex, 599–605  
formation/functions, 599–602
- Depression, D<sub>3</sub> preventing, 999t
- DEXA. *See* Dual energy x-ray absorptiometry
- Dexamethasone  
high dose intermittent 1,25(OH)<sub>2</sub>D<sub>3</sub> with, 1744–1745  
WT mouse intestinal Ca absorption v., 445, 447f
- 7-DHC. *See* 7-Dehydrocholesterol
- DHEA. *See* Dehydroepiandrosterone
- Diabetes  
in animal models v. 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs, 1768–1772  
calbindin-D<sub>28K</sub> Ca buffering v. type I, 726  
calbindin-D<sub>28K</sub> v. apoptotic cell death in, 727  
D/immune system in type I, 1767–1773  
D signaling in regulating, 899  
D v., 1763–1774  
early intervention with 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs, 1768–1770, 1768t  
incidence v. sunlight exposure, 1766  
insulin v. 1 $\alpha$ -hydroxylation in, 1259  
late 1,25(OH)<sub>2</sub>D<sub>3</sub> intervention v., 1770  
1,25(OH)<sub>2</sub>D<sub>3</sub> analogs v., 1772–1773  
1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs with immune modulators v., 1771–1772, 1771t  
1,25(OH)<sub>2</sub>D<sub>3</sub> v. NOD mouse, 1404  
risk v. D<sub>3</sub>, 999t  
risk v. VDR polymorphism, 1773  
VDR ligand treatment v. type I, 637–638, 637t  
VDR polymorphism associated with, 246  
VDR polymorphism v., 1146–1147
- Diabetic ketoacidosis, hypophosphatemia in, 1177
- Diet  
age-related 25OHD decrease v., 1101  
bone mass v. macrobiotic/vegetarian, 795  
Ca deficient, 1074–1076  
Ca in paleolithic/contemporary, 777–778  
celiac disease v., 1300–1301  
colon cancer v. high-fat, 866–867, 1572  
colorectal cancer v. Ca from, 1621–1622  
D hormonal system dependent on high Ca, 780–781, 781f  
D insufficiency v., 1087–1088, 1087f  
D<sub>3</sub> intake from, 1026  
D metabolism influenced by, 789–796  
D metabolism v. vegetarian/omnivorous, 795  
D negligible in Western, 1599  
D status v. normal, 1066  
D supplied by, 1294, 1294f, 1617  
D toxicity from, 1356  
ECF [Ca<sup>2+</sup>] demand response mediated by, 777–778  
elderly v. D intake from, 824  
groups/sects/ethnicities with vegetarian, 917t  
25OHD half-life reduced by high fiber, 1076  
osteoporosis v. Ca/D supplements to, 1112–1113, 1113t  
as PCa risk factor, 1681  
PCa v. Ca/D from dairy products in, 1627–1629  
PCa v. D from, 1606, 1625  
rickets v. macrobiotic/vegetarian, 1067, 1077  
VDR expression affected by, 204–205  
vegetarian, 795, 917t, 1067, 1077
- Differentiation  
cell cycle v., 1635–1651  
cell cycle v. deltanoid-induced, 1640–1650  
cellular models of 1,25(OH)<sub>2</sub>D<sub>3</sub>/deltanoids-induced, 1635–1636, 1637t
- Differentiation (*Continued*)  
1,25(OH)<sub>2</sub>D<sub>3</sub>/deltanoids inducing, 1635–1640  
1,25(OH)<sub>2</sub>D<sub>3</sub> influencing tumor cell, 1580–1581  
1,25(OH)<sub>2</sub>D<sub>3</sub> signal propagation pathways v., 1636–1639  
1,25(OH)<sub>2</sub>D<sub>3</sub> synthesis/catabolism v., 1717  
1,25(OH)<sub>2</sub>D<sub>3</sub> v. PCa cell, 1691–1692  
signals for 1,25(OH)<sub>2</sub>D<sub>3</sub> influences on, 1636  
TF role in 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced differentiation, 1639–1640
- DiGeorge sequence, hypocalcemia v., 1052–1053
- Digital rectal exam (DRE), in PCa diagnosis, 1679
- Dihydrotachysterol, metabolism, 1429–1430, 1430f
- 1,25-Dihydroxy-16-ene-23-yne D<sub>3</sub> (BXL-353)  
BPH cell apoptosis/Bcl-2 expression v., 1836–1837, 1838f  
BPH cells v. antiproliferative influence of, 1836–1837, 1837f  
*in vivo* prostate growth v., 1837–1840, 1839f
- 10,19-dihydro-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, activity, 1544
- 19-Nor-1,25-dihydroxyvitamin D<sub>3</sub>, early 2-carbon analogs of, 1545
- 19-Nor-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>  
2-carbon-modified analogs of, 1543–1554  
synthesis, 1544
- 23(*S*),25(*R*)-1,25-Dihydroxyvitamin D<sub>3</sub>-26,23-lactone, in C-23  
oxidative pathway discovery, 23
- 2 $\alpha$ -Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D<sub>3</sub> (2 $\alpha$ MD),  
1545–1546  
bone selectivity by, 1546–1547  
structure, 1545f
- 1 $\alpha$ ,24R-Dihydroxyvitamin D<sub>3</sub> [1 $\alpha$ ,24R(OH)<sub>2</sub>D<sub>3</sub>], 1425t–1426t, 1439  
C24 oxidation steps in catabolism of, 1426f, 1439  
metabolism, 1439  
psoriasis treatment using OCT v., 1533  
skin irritation in psoriasis treatment with, 1785
- 2 $\beta$ -Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D<sub>3</sub> (2BMD),  
1545–1546  
structure, 1545f
- 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D<sub>3</sub> (2MD),  
1545–1546  
bone anabolic activity of, 1546–1547, 1547f  
bone selectivity by, 1546–1547  
1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1546, 1546f  
ovariectomized rat bone mass v., 1547, 1548f  
structure, 1545f  
tissue selectivity/enhanced potency, 1548–1551  
VDR binding to promoters stimulated by, 1549–1550, 1549f  
VDR conformation induced by, 1550, 1550f  
VDR interactions promoted by, 1550–1551, 1551f
- 1,25-Dihydroxyvitamin D [1,25(OH)<sub>2</sub>D], 1389–1390  
age v., 1102–1103  
as autocrine hormone in prostate, 1607–1610  
Ca absorption v. age-related decrease in, 1104  
Ca absorption v. age-related resistance to, 1104–1105, 1105f  
CKD altering VDR-mediated actions of, 1317–1322  
CKD v. D bioactivation to, 1379–1383  
clearance v. age, 1103  
clinical evidence for dysregulated overproduction of, 1381  
concentration having clinical relevance, 948t, 949  
cutaneous production of, 609–613  
CYP1 $\alpha$  gene cloning v. extrarenal synthesis of, 1380  
detecting, 942–947  
competing approaches, 946–947, 946f, 947f  
issues/improvements v., 946–947  
diseases v. hypercalcemia/hypercalciuria mediated by, 1390–1392, 1390t  
estimating human serum, 942, 943t  
Gemini as analogs of, 1511–1522  
gene expression regulated by, 1212, 1213f  
in GHS rats, 1348, 1348f

1,25-Dihydroxyvitamin D [1,25(OH)<sub>2</sub>D] (*Continued*)

- granulomatous disease inflammation sites accumulating, 1389
  - as HDM cause, 1815–1816
  - health v. changed concentration of, 1102
  - heightened immunoreactivity elevating, 1387f, 1389
  - hormonal regulation of, 610–611
  - hypercalcemia in lymphoma v., 1362
  - hypocalcemia due to hereditary resistance to, 1056
  - IH elevating, 1341–1342, 1342f
  - inflammatory arthritis/RA inflammation sites accumulating, 1389–1390
  - inhibiting its own production, 20
    - in keratinocytes, 611
  - intracrine/autocrine action on monocytes/macrophages, 1387–1388, 1387f
  - intravenous therapy v. renal failure, 1822–1823
  - levels v. Ca absorption in IH, 1342, 1343f
  - macrophages lacking 24-hydroxylase activity directed by, 1383–1384
  - mechanism of action, 1210–1212
  - mechanisms of age-related changes in, 1102–1103
  - metabolism kinetics, 828
  - in muscle regeneration, 1816
  - 25OHD hydroxylation producing, 1599
  - 25OHD plasma half-life v. concentration of, 1104, 1104f
  - 25OHD seasonality tracked by, 1019–1020, 1020f
  - paracrine suppression of lymphocytes, 1387f, 1388–1389
  - PCa v., 1610–1611, 1611f
  - PCa v. serum, 1602–1604
  - in PDDR, 1198–1199, 1199f
  - plasma concentration, 28t
  - production v. diseases, 1359–1362
  - psoriasis v. serum, 1784
  - resistance causing secondary hyperparathyroidism in renal failure, 1821–1823
  - resistance mechanisms in chronic renal failure, 1822, 1822f
  - RIA methodology for detecting, 945–947, 945f
    - assay calibrator preparation for, 945
    - sample/calibrator extraction/pretreatment in, 945
    - solid-phase extraction/silica purification chromatography in, 945
  - RRA methodology for detecting, 943–945, 944f
    - calf thymus VDR preparation for, 943
    - RRA in, 944f
    - sample extraction for, 943
    - solid-phase extraction/purification chromatography in, 943, 944f
  - SCC keratinocytes producing, 612
  - serum concentration/PR/MCR v. aging, 828, 828f
  - substrate-dependent synthesis of, 1019–1020, 1020f
  - trophic factors influencing synthesis of, 828–831
    - in vitro* correlates for dysregulated overproduction of, 1381–1387
- 1,25-Dihydroxyvitamin D<sub>2</sub> [1,25(OH)<sub>2</sub>D<sub>2</sub>], isolation/identification, 19
- 1,25-Dihydroxyvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>], 167–184, 412
- A-ring in VDR transactivation, 1472f, 1473–1474
  - action mechanisms in autoimmunity, 1754–1756
  - actions in CNS, 1781–1783
  - actions in VSMCs, 902–903
  - as active form of vitamin D, 19, 782
  - in analog synthesis, 1490, 1490f
  - analogs in oncology, 1746–1747
  - angiogenesis v., 1574–1576, 1693
  - in animal cancer models, 1573, 1574t
  - animal model diabetes prevented by, 1768–1772
  - as antioxidant, 764t, 765–767
  - AUC for lowest anti-tumor dose in mice, 1744, 1744t

1,25-Dihydroxyvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>] (*Continued*)

- autoimmunity v., 1753–1759
  - animal models of, 1756, 1757t
  - human, 1756–1759
- avian parathyroid PTH/VDR gene expression regulated by, 541–542
- β cells v., 1764–1767
- basis for 25OHD interaction with, 783
- biological effects in psoriasis, 1781, 1781f
- biphasic effects on osteoblasts, 650
- blood pressure inversely associated with, 874, 874f
- bone apposition rates influenced by, 656–657
- brain calbindins/Ca-binding proteins v., 1781
- in brain detoxification, 1783
- in brain homeostasis control, 1784, 1785f
- in breast cancer angiogenesis/invasion/metastasis, 1666–1667
- breast cancer cell apoptosis induced by, 1665–1666, 1666f, 1672f
- breast cancer cell proliferation v., 1663–1665, 1672f
- breast cancer cells acted on by, 1663–1667, 1664t
- breast cancer sensitivity to, 1667–1668
- breast cancer v., 1663–1672
- C-/D-/E-ring modifications of, 1562–1565, 1563f
- C-3 epimerization, 24, 25f
- Ca/P demand regulating, 566
- calbindin-D<sub>9K</sub> gene expression regulated by, 729
- calbindin-D<sub>28K</sub> gene expression regulated by, 728
- calcium channels regulated by, 1782–1783
- in cancer combination therapy, 1582–1583
- cancer growth/development v., 1573, 1574t, 1575t
- 20-carbon epimerization, 1544
- cartilage differentiation requiring, 582
- cartilage regulated by, 575–591
- catabolism, 1406, 1409f, 1424–1427
  - C-26 hydroxylation/26,23-lactone formation, 1427, 1427f
- CDKs up-regulated by, 1646–1649, 1647t–1648t
- cell cycle influenced by, 1577–1580, 1578f–1579f
- cell growth/differentiation v., 696
- cell type v. proliferation inhibition by, 1650
- cellular effects on leukemic cells, 1731, 1731t
- cellular models of differentiation induced by, 1635–1636, 1637t
- CKD v. catabolism of, 1316–1317
- clinical use in psoriasis, 1784–1787
- CNS activity v. *in vitro* investigations, 1781–1783
- CNS tumors v., 1783–1784
- colon cancer cells v. antiproliferative activity by, 1521–1522, 1522f, 1523f, 1523t
- colon cancer v., 1709–1721
  - epidemiology of, 1709–1710
- colon cell proliferation/differentiation/apoptosis v.
  - clinical studies of, 1715
  - in vitro*, 1712–1714
  - in vivo* animal models for, 1714–1715
- colon tumors prevented by, 1709–1710
- concentration v. immunosuppression/hypercalcemia, 1753
- conformationally flexible seco-B-ring of, 1408f, 1412
- CT/CGRP gene transcription repression mechanism of, 696, 696f, 696t
- CT levels regulated by, 689–691
- CYP24A1 expression induced by, 93–97
- cytotoxic agents combined with, 1745–1746
- D endocrine system VSCCs influenced by, 751–757
- D mediation v., 1040–1042
- D-ring in VDR transactivation, 1475
- in diabetes early intervention, 1768–1770, 1768t
- in diabetes late intervention, 1770
- diabetes v., 1763–1774

1,25-Dihydroxyvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>] (*Continued*)

diabetes v. immune modulators combined with, 1771–1772, 1771t  
 differential cell response to, 651  
 differentiation induced by, 1635–1640  
 differentiation signal propagation pathways, 1636–1639  
 DNA motifs mediating stimulatory effects of, 705–706  
 dose escalation using QOD schedule, 1742–1743, 1743t  
 early clinical trials of, 1742  
 epidermal keratinocytes/dermal inflammation v., 1781, 1782f  
 20-epimerization, 1494–1495, 1496t  
 factors influencing concentration of, 517t  
 fat/bone progenitor cell commitment v., 650f, 655–656  
 formation, 516–517  
 G1 block v. transient p21Cip1 up-regulation by, 1646–1648, 1646f  
 GADD45 expression stimulated by, 1577, 1578f–1579f  
 genomic actions' molecular basis, 313–314  
 GFR v. serum, 1314, 1314f  
 growth inhibition effect requiring 1 $\alpha$ -hydroxylase, 744, 745f  
 high dose intermittent, 1743f, 1743t, 1744–1745  
 high dose intermittent regimens of, 1742–1743  
 hormone/GF influence on osteoblasts v., 654–655  
 human PCa cell line proliferation v., 1683, 1683f  
 hypercalcemic effect limiting use, 542  
 hyperparathyroidism v. intravenous, 1330–1331  
 IGF system interacting with, 1581–1582  
 immunosuppressive agents synergistically influencing, 1520  
 insulin secretion influenced by, 1764–1765  
 in intestinal Ca absorption, 411–424  
 intestinal calbindin increased by, 722–723  
 isolation/identification, 291  
 keratinocyte growth/VDR expression regulation linked in, 1781  
 kidney/parathyroid VDR regulated by, 522–523, 525t  
 laboratory/clinical extrapolations of exposure to, 1744, 1744f, 1744t  
 leukemic cell lines v., 1730–1731, 1730t  
 ligand availability v. breast cancer sensitivity, 1666–1667  
 low-affinity neurotrophin receptor regulated by, 1781  
 2MD v., 1546, 1546f  
 membrane-initiated Ca<sup>2+</sup> responses to, 753–754  
 metabolically influencing  $\beta$  cells, 1764–1767  
 metastasis v., 1576  
 2-methylene/2 $\alpha$ -methyl/2 $\beta$ -methyl derivatives of, 1545–1546, 1545f  
 molecular mechanisms for leukemic cell influence by, 1731–1733  
 in MS pathophysiology, 1784  
 multiple membrane receptors for, 1462  
 as negative endocrine regulator of RAS, 875–878  
 as neuroactive hormone, 1779–1785, 1785f  
 normal hematopoiesis influenced by, 1729–1730  
 NOS II v., 1783  
 novel target genes of, 1693–1695, 1694t  
 oncogene expression regulated by, 1577–1579  
 oncology using 1,25(OH)<sub>2</sub>D<sub>3</sub> analogs and, 1741–1747  
 in osteoblast differentiation/activity, 649–658  
 osteoblast differentiation pathway/status *in vitro* v., 649–653, 650f  
 osteoblast heterogeneity not caused by, 652  
 osteoblast proliferation/differentiation-associated genes v., 653–654  
 in osteoporosis treatment, 1111  
 parathyroid glands influenced by low, 1324–1325, 1325f  
 parathyroid size correlating with resistance to, 1823  
 PCa cell apoptosis v., 1691  
 PCa cell growth arrested by, 1690–1691  
 PCa cell growth inhibition mechanisms, 1690–1695

1,25-Dihydroxyvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>] (*Continued*)

PCa cell invasion/metastasis inhibited by, 1693  
 PCa cell resistance to antiproliferative effect of, 1684–1685  
 PCa growth inhibited *in vitro* by, 1683–1685  
 PCa treatment clinical trials, 1698–1699, 1698t  
 PCa v. androgen interaction with, 1687–1688  
 phytoestrogens regulating synthesis of, 1720–1721, 1720t  
 pleiotropism, 1403  
 in postmenopausal osteoporosis treatment, 1111–1112  
 potency/toxicity in PCa treatment, 1689–1690  
 pre-pro PTH mRNA v., 1527, 1528f  
 primary PCa cell cultures v., 1683–1684, 1684f  
 as prooxidant, 763–765, 764t  
 prooxidant/antioxidant activities, 764t, 768  
 proposed hormonal mechanism, 167, 168f  
 prostate cells synthesizing, 1607, 1608f  
 prostate cells v. antiproliferative influence of, 1607–1608, 1609f  
 psoriasis v. oral, 1785, 1785f  
 psoriasis v. topical, 1784–1785  
 PTH gene expression regulated by, 539–543  
 PTH in chronic renal failure v. intravenous, 1329–1330, 1330f  
 PTH-induced Ca<sup>2+</sup> influx primed by, 755, 755f  
 PTHrP production inhibited by, 741t, 743, 1576–1577  
 PTHrP production v. EB1089 analog of, 744  
 rapid action on growth-zone chondrocytes, 587–588, 587f  
 reformulation for high dose intermittent regimens, 1746  
 renal Ca/P handling influenced by, 518–519  
 renin activity inversely associated with, 874, 874f  
 resistance in breast cancer cells, 1667–1668  
 resistance mechanisms besides VDR mutation, 1226–1227  
 resistance v. uremia in CKD, 1320–1321, 1321f  
 retinoids/thyroid hormones effects interdependent with, 655  
 ROS levels/redox-associated molecules v., 767, 767t  
 Runx2/Cbfa1 TF modulated by, 566–567  
 19-nor/10,19-saturated derivatives of, 1544  
 secondary hyperparathyroidism in chronic renal failure v., 1327–1331, 1330f  
 self-induced metabolism, 22  
 sex steroids synergistically stimulating synthesis of, 1260  
 side chain in VDR transactivation, 1474–1475  
 side effects v. medical applications, 142  
 signals of differentiation influences by, 1636  
 in skin, 1780  
 structural requirements for VDR transactivation by, 1472–1475, 1472f  
 structure, 1472f, 1490f, 1558f  
 supplementation safety, 1112–1113  
 targets in CNS, 1780–1781  
 TFs in differentiation induced by, 1639–1640  
 Th subset lymphokine production v., 1754, 1755f  
 therapeutic use v. calcemic/phosphatemic activities, 1449  
 therapy in chronic renal failure, 1327–1332  
 tissue v. abnormal VDR function/low, 1322–1327  
 toxicity, 1357  
 tumor cell differentiation v., 1580–1581  
 tumor growth factors/receptors v., 1581–1582  
 tumor suppressor gene expression regulated by, 1579  
 VDR expression affected by, 201–204, 202t  
 VDR mediated growth inhibition v. differentiation, 1713, 1713f  
 virally transformed prostate cells v., 1684  
*in vitro* D metabolism/catabolism v., 1717  
*in vitro* osteoblasts influenced by, 649–656  
 VSCCs Ca<sup>2+</sup>/transcriptional responses to, 756–757  
 VSCCs v., 753–754  
 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> [1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>], 381  
 biological actions mediated by VDR<sub>nuc</sub>, 384–385, 386t

- 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> [1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>] (*Continued*)  
 biological response generation pathways, 383, 385f  
 biosynthesis, 1408f  
 bonds in 16-ene, 23-yne analog of, 1425t–1426t, 1436  
 bone matrix protein target genes, 711–717  
 conformational flexibility, 382f, 383, 388, 391, 399–400, 399f  
 deltanoids emulating conformational flexibility of, 1411–1412, 1412f  
 dual role in osteoblast differentiation, 713–714, 714f  
 20-epi-1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> biological activity advantages over, 1433–1434, 1433f  
 20-epi compound analogs v., 285–287, 286f  
 Geminis v., 287–288, 878  
 growth plate effects of 24R,25(OH)<sub>2</sub>D<sub>3</sub> v., 582–583  
 kidney 1 $\alpha$ -hydroxylase activity regulated by, 75–76, 75t, 76t  
 muscle Ca homeostasis regulated by, 886–887  
 muscle cell proliferation/differentiation influenced by, 887–889  
 osteoblasts as source of, 717  
 production of  
   extrarenal, 69–70  
   renal, 69, 70f  
 rapid response v. 6-*s-cis*-shaped, 391, 398f  
 rapid responses mediated by, 381–400  
   molecular tools for study of, 392, 393f  
   schematic model of, 399–400, 399f  
   structure-function evaluation of, 392–397  
 rational design of analogs for, 1405–1418  
 side chain modifications v. VDR transcription, 1474–1475, 1474t  
 skeletal homeostasis v., 711–712  
 structure, 381–383, 382f  
 VDR binding to, 313  
 24,25-Dihydroxyvitamin D<sub>3</sub> [24,25(OH)<sub>2</sub>D<sub>3</sub>]  
 bone mineralization stimulated by, 16  
 cartilage regulated by, 575–591  
 rapid action on resting-zone chondrocytes, 588–589, 588f  
 24,25-Dihydroxyvitamin D [24,25(OH)<sub>2</sub>D]  
 concentration lacking clinical relevance, 948t, 949  
 detecting, 940–942, 941t  
   preparative normal-phase HPLC in, 941  
   RIA for, 941–942, 942f  
   sample extraction for, 941  
   solid-phase extraction chromatography in, 941  
 25,26-Dihydroxyvitamin D<sub>3</sub> [25,26(OH)<sub>2</sub>D<sub>3</sub>], *R/S* isomer mixture in natural, 24  
 24R,25-Dihydroxyvitamin D<sub>3</sub> [24R,25(OH)<sub>2</sub>D<sub>3</sub>]  
 growth plate effects of 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> v., 582–583  
 in quail/chicken embryonic development/hatchability, 851  
 Disabled-2, megalin function in PCT requiring, 159  
 Diseases  
   extrarenal 1 $\alpha$ -hydroxylase activity in human, 1379–1394  
   extrarenal D metabolite overproduction v. human, 1390–1392  
   VDR gene association analysis v. phenotypes of, 1138  
   VDR polymorphism association analysis v. states of, 1137–1148  
   VDR polymorphisms v. hyperproliferative, 1145–1146  
   VDR polymorphisms v. immune-related, 1146–1148  
   VDR polymorphisms v. risk of, 1121–1149  
 Distal convoluted tubule (DCT), transcellular Ca/Mg reabsorption in, 557–558  
 DNA  
   chromatin packaging genomic, 329, 329f  
   VDR binding, 171  
 DNA binding domains (DBDs)  
   dimerizing in presence of DNA, 314  
   DNA binding role v point mutations in, 233, 234f  
   as homodimers bound to mouse osteopontin VDRE, 223t, 230, 231f  
 DNA binding domains (*Continued*)  
   hVDR nuclear translocation mediated by, 231f, 232–233  
   hVDR zinc finger, 229–233, 231f  
   HVDRR-related mutations in VDR, 1218–1220  
     Arg50Gln, 1219, 1219f  
     Arg80Gln, 1219, 1219f  
     description of, 1218–1220, 1219f  
     Gly46Asp, 1219–1220, 1219f  
     His35Gln, 1219, 1219f  
     Lys45Glu, 1219, 1219f  
     structural analysis of, 1220  
     sequence similarity of hVDR, 229–230, 231f  
     VDR, 1210–1211, 1211f  
 DNA licensing, control of, 1644–1645  
 DPPs. *See* Dentin phosphoproteins  
 DRE. *See* Digital rectal exam  
 DRIP coactivator complex. *See* Mediator-D coactivator complex  
 Drugs  
   D analog metabolism v. design of, 1442–1443  
   D metabolism influenced by, 1253, 1255t, 1263–1274  
   deltanoids as, 1405, 1406f  
   deltanoids as candidate, 1405, 1407f  
   leukemia combination therapy with chemotherapeutic, 1734  
   mineral/skeletal homeostasis influenced by, 915t, 917  
   PCa combination therapy with chemotherapeutic, 1697–1698  
 DSP. *See* Dentin sialoprotein  
 DTH. *See* Delayed-type hypersensitivity  
 Dual energy x-ray absorptiometry (DEXA), BMD assessment with, 922–924  
 Duodenum  
   Ca absorption by VDR-null mouse, 435  
   high Ca absorption rate in, 778  
   transcellular/paracellular Ca absorption in, 422–424, 423f  
 Dutch  
   dietary Ca intake of French v., 1096  
   hypovitaminosis D in institutionalized elderly, 1094
- ## E
- EAE. *See* Experimental allergic encephalomyelitis  
 Early neonatal hypocalcemia (ENH), premature infants affected by, 805–806  
 EB1089  
   antiproliferative activity v. IGF-II, 1714  
   bone mass loss in microgravity v., 1501–1502  
   breast cancer cell progression arrested by, 1663–1664, 1672f  
   breast cancer cells/tumors v., 1669  
   cancer models v., 1499–1500  
   cell cycle regulated by, 1498  
   double bond system, 1425t–1426t, 1436  
   early clinical trials of, 1742  
   efficacy/safety of D analogs treating, 1504–1505  
   GADD45 expression stimulated by, 1577, 1578f–1579f  
   hypercalcemia of malignancy v., 1450–1451  
   IGF system interacting with, 1581–1582  
   LNCaP xenograft growth inhibited by, 1688–1689, 1688f  
   mechanism of action, 1478–1479  
   metastasis v., 1576  
   as 1,25(OH)<sub>2</sub>D<sub>3</sub> analog in cancer/tumor treatment, 1746–1747  
   1,25(OH)<sub>2</sub>D<sub>3</sub> v., 744  
   PCa v., 1690  
   pharmacokinetics/metabolism in clinical development of, 1503, 1503f, 1503t  
   PTHrP expression/production inhibited by, 741t  
   structure, 1479f, 1560, 1560f

- EB1089 (*Continued*)  
 as superagonist, 1477–1478  
 VDR transcriptional activity v., 1474t  
*in vitro* metabolism, 1436–1437, 1437f  
*in vivo* colon cells influenced by, 1714  
 as weak calcemic analog, 1440, 1441t  
 Wittig reaction introducing side chains to, 1490, 1491f, 1494t
- EBT. *See* Electron beam tomography
- ECaC. *See* Epithelial calcium channel
- ECaC1, functional properties, 431–432
- ECaC2  
 expression in WT/VDR KO mice, 434f, 436t, 438  
 fast initial phase in Ca-dependent inactivation of, 432  
 functional properties, 431–432  
 tissue distribution, 431
- ECD. *See* Extracellular domain
- ecologic fallacy, PCa risk v., 1602
- ECs. *See* Endothelial cells
- ED-71  
 action mechanism, 1535–1537, 1537f  
 convergent synthesis, 1534, 1534f  
 development, 1525, 1534–1539  
 17 $\beta$ -estradiol bone metabolism influence v., 1536, 1536f  
 linear synthesis, 1534, 1534f  
 metabolism, 1439–1440  
 osteoporosis treatment using 1 $\alpha$ OHD<sub>3</sub> v., 1534–1535, 1535f  
 ovariectomized rat bone mass v., 1537, 1537f  
 as strong calcemic analog, 1440, 1441t  
 structure, 1425t–1426t, 1439, 1525, 1526f
- EDAX. *See* Energy dispersive X-ray analysis
- EGF. *See* Epidermal growth factor
- EGF receptor (EGFR), 1710–1712  
 D compounds v. signaling through, 1499  
 expression in colon cancer, 1710–1711, 1711t
- EGFR. *See* EGF receptor
- EKG. *See* Electrocardiogram
- Electrocardiogram (EKG), changes in D toxicity v. myocardial ischemia, 1368
- Electron beam tomography (EBT), coronary artery calcification v., 979
- Electron microscopy, crystal size/shape shown by, 481
- Enamel  
 ameloblasts producing, 599, 601  
 apatite crystal size/impurities in, 480  
 D bioinactivation causing dysplasia/hypomaturation/hypomineralization in, 602
- Endothelial cells (ECs), 1,25(OH)<sub>2</sub>D<sub>3</sub> responses by, 903–904
- Endothelin-1 (ET-1), parathyroid cell proliferation v., 545
- Energy dispersive X-ray analysis (EDAX)  
 growth plate ion concentrations monitored by, 487–488  
 mineral composition information from, 481
- English, winter hypovitaminosis D in adult, 1091, 1091f
- ENH. *See* Early neonatal hypocalcemia
- Enterocyte  
 Ca extrusion across basolateral membrane of, 419–421, 420f  
 structure v. Ca flux, 413–414  
 vesicular CA transport in, 422
- Enterohepatic circulation  
 bile acids reclaimed through, 863–864  
 D/D metabolites in, 1295–1296
- Enzymes  
 D analog selectivity v. metabolic, 1460–1461  
 metabolic  
 future study directions for, 112–113  
 mutant mouse models of, 105–114  
 microsomal, 51t–52t
- Enzymes (*Continued*)  
 mitochondrial, 54–59  
 sex hormones regulating, 61
- Epidermal differentiation, 1,25(OH)<sub>2</sub>D hormone likely to influence, 112
- Epidermal growth factor (EGF)  
 20-epi D analogs interfering with, 1498–1499  
 keratinocyte proliferation stimulated by, 614  
 mitogenic activity inhibited by D compounds, 1665  
 PTHrP expression/production stimulated by, 741t  
 VDR expression/cell differentiation v., 1713, 1713f  
*in vitro* D metabolism/catabolism v., 1717
- Epidermis  
 microanatomy of, 613, 613f  
 1,25(OH)<sub>2</sub>D<sub>3</sub> antioxidant activities in, 764t  
 regulatory Ca gradient in, 609, 613, 615  
 vitamin A influencing development of, 614
- Epithelial calcium channel (ECaC), 527–528  
 architecture, 430, 431f  
 in CA absorption, 415–416  
 Ca influx v., 430–432  
 molecular architecture, 431f, 432  
 nomenclature, 415n  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating expression of, 558  
 S100A10-annexin 2 required for functional expression of, 432  
 TRP superfamily/TRPV family, 430  
 VDREs in human, 527
- Epithelial cells, mouse/human gastrointestinal ECaC2 expression restricted to, 431
- ER. *See* Estrogen receptor
- EREs. *See* Estrogen response elements
- Ergocalciferol. *See* Vitamin D<sub>2</sub>
- ERKO $\alpha$  hull mice, reduced duodenal ECaC2 mRNA expression in, 441f, 445
- ERKO $\beta$  hull mice, duodenal gene expression unchanged in, 441f, 445
- Estradiol, D metabolism influenced by, 1254t, 1259–1261
- Estrogen. *See also* Estradiol  
 Ca absorption v. deficiency of, 1105  
 deficiency increasing PTH with age, 1108–1109, 1108f  
 intestinal Ca absorption v., 441f, 441t, 444–445, 444f  
 1,25(OH)<sub>2</sub>D v. deficiency of, 1103  
 PTHrP expression/production stimulated by, 741t  
 serum PTH influenced by, 1024  
 VDR expression affected by, 202t, 206
- Estrogen receptor (ER)  
 localization in plasma membrane caveolae, 400  
 signaling down-regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub>/EB1089, 1665  
 signaling v. breast cancer cell proliferation, 1663, 1672f
- Estrogen response elements (EREs)  
 hVDR promoter, 200  
 optimal VDREs resembling half-sites of, 222
- ET-1. *See* Endothelin-1
- Ethanol  
 D metabolism influenced by, 1255t, 1266  
 hypocalcemia/hypomagnesemia v., 1057  
 hypomagnesemia associated with abuse of, 1054
- Ethiopians  
 climate v. D in, 1026  
 low serum 25OHD in, 1026  
 sunlight exposure v. rickets in, 1066–1067
- Eucalcemia  
 Ca/D supplements for stable, 1059, 1059t, 1060t  
 D in long-term maintenance of, 1050–1051
- Europeans. *See also specific nationalities*  
 D deficiency in, 1025–1026

Europeans (*Continued*)  
 hypovitaminosis D in institutionalized elderly, 1093, 1093f  
 PCa mortality in northern, 1600, 1600f  
 PCa mortality/incidence in, 1625  
 Every-other-day (QOD) schedule, 1,25(OH)<sub>2</sub>D<sub>3</sub> dose escalation permitted by, 1742–1743, 1743t  
 Exercise  
   bone density influenced by, 796  
   D metabolism influenced by, 789–796  
 Exosome, hnRNP role in, 359  
 Experimental allergic encephalomyelitis (EAE)  
   D analogs treating, 1784  
   1,25(OH)<sub>2</sub>D<sub>3</sub> down-regulating NOS II in, 1783  
   1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1755, 1784  
   VDR ligand treatment v., 637t, 638–639  
 Export receptors, nuclear export mediated by, 366–368, 367f  
 Extracellular domain (ECD), CaRs' large amino-terminal, 551, 552f  
 Extracellular fluid (ECF)  
   [Ca<sup>2+</sup>] demand response, 776–778  
   Ca<sup>2+</sup> homeostasis in, 553f, 554–555, 555f  
   Ca<sup>2+</sup> obligatory loss from, 774–776  
   [Ca<sup>2+</sup>] regulation in, 774–778, 775f  
   driving transfers of Ca<sup>2+</sup> in, 774–776

## F

26,27-F<sub>6</sub>-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>. *See* 26,26,26,27,27,27-Hexafluoro-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>  
 Falls, D status in risk of, 1814, 1814f  
 Familial hypocalciuric hypercalcemia (FHH), heterozygous inactivating CaR mutations causing, 552–553  
 Family history (FH), in approaching metabolic bone disease, 918  
 Famine, 777  
 Fanconi syndrome (FS)  
   phosphate homeostasis in, 1174–1175  
   treatment, 1175  
   type I, 1174  
   type II, 1174–1175  
 Farnesoid X receptor (FXR), bile acid synthesis/flow regulated by, 865  
 Fat, progenitor cell commitment v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 650f, 655–656  
 Fatty acids, VDR expression affected by, 202t, 205  
 FCA. *See* Fractional calcium absorption  
 Ferredoxin  
   mitochondrial  
     characteristics of, 72  
     hormones regulating, 72–73  
   in 25OHD<sub>3</sub> 1 $\alpha$ -hydroxylation, 71f, 72–73  
 Fertility  
   D in, 854–855  
   in mice with poor D function, 852  
 Fetus  
   Ca homeostasis in mother and, 853–854  
   CaR in, 854  
   D synthesis v. development of, 852–853  
   low maternal D/Ca intake v., 841–843  
   maternal Ca economy v. bone mineralization by, 841, 841f  
 FFAs. *See* Free fatty acids  
 FGF-23. *See* Fibroblast growth factor-23  
 FGF-23 gene  
   ADHR caused by, 1190  
   FLAG-tagged native/R176Q mutant, 1190, 1191f  
 FH. *See* Family history  
 FHH. *See* Familial hypocalciuric hypercalcemia

Fibroblast growth factor (FGF)-23  
   in ADHR, 468, 1164–1165  
   biological activity, 1165  
   in OHO pathogenesis, 468  
   as PHEX substrate, 1166–1167  
   as phosphatonin, 1164–1166  
   in XLH, 1193  
 Fibroblasts, in HVDRR studies, 1212–1217  
 Fibromyalgia, D<sub>3</sub> mitigating, 999t  
 Fibrous dysplasia, pathogenesis of hypophosphatemia in, 1192  
 FISH. *See* Fluorescent *in situ* hybridization  
 Fish  
   D<sub>3</sub> in fatty, 1026  
   in diet v. PCa, 1601, 1606  
 Fluorescence resonance energy transfer (FRET)  
   cytoplasmic VDR-RXR heterodimer shown by, 364–365, 365f  
   GFP-VDR/RXR-BFP focal binding v., 374–375, 375f  
 Fluorescent *in situ* hybridization (FISH), VDR gene mapping with, 1122, 1124f  
 Fluoride, D metabolism influenced by, 1255t, 1273  
 FokI RFLP, 1130–1135, 1131t, 1133t, 1134t  
   BMD v., 1142–1143  
   bone fracture risk v., 1143–1144  
   Japanese young adult height v., 1143  
   polymorphism functionality parameters associated with, 1135f, 1137  
 Foods  
   Ca absorption enhancers in, 818  
   Ca/D fortification of, 817–818  
     rationale for, 817–818  
   D content of selected, 996t–997t  
   D fortification of, 1065–1066  
   D toxicity v. natural/D-fortified, 1356  
   targeted/untargeted fortification of, 1073–1074  
 Formation period (FP)  
   in osteoid indices, 1034  
   prolonging, 1034–1035  
 Fos family proteins, in osteoclastogenesis, 677–678  
 Founder effect  
   PDDR, 1200  
   Tyr295stop mutation v., 1221  
 FP. *See* Formation period  
 Fractal analysis, in bone structure assessment, 962  
 Fractional calcium absorption (FCA), response to 1,25(OH)<sub>2</sub>D v. aging, 832, 832f  
 Free fatty acids (FFAs), DBP-A/B binding sites for, 136  
 French  
   dietary Ca intake of Dutch v., 1096  
   hypovitaminosis D in adult urban, 1091, 1092t  
   hypovitaminosis D in elderly, 1092–1093  
   hypovitaminosis D in institutionalized elderly, 1094  
 FRET. *See* Fluorescence resonance energy transfer  
 FS. *See* Fanconi syndrome  
 FXR. *See* Farnesoid X receptor

## G

G protein-couple receptor (GPCR) superfamily  
   CaR as member of, 551–552  
   large ECDs in, 551–552  
 Gastrointestinal disease  
   acquired bone disease in, 1297–1299  
   metabolic bone disease development in, 1298–1299  
   metabolic disturbances in, 1293–1297

- Gastrointestinal disease (*Continued*)  
 non-Ca/D bone disease factors in, 1298  
 secondary hyperparathyroidism accompanying, 1297  
 type of acquired bone disease in, 1297–1298  
 Gc-globulin. *See* Vitamin D binding protein  
 GDNF. *See* Glial cell-derived neurotrophic factor  
 Gelsolin  
 in actin-scavenger system, 143  
 growth nucleation v. DBP, 147  
 Geminis, 1511–1522  
 colon cancer treatment with, 1521–1522  
 20-epimeric-24R-hydroxy/19-nor, 1513, 1513f  
 23-yne-26,27-hexafluoro, 1514, 1514f, 1516f, 1517f  
 24R-hydroxy metabolite of, 1513–1514  
 configuration of, 1513, 1514f  
 hypertension v., 1518  
 $1\alpha,25(\text{OH})_2\text{D}_3$  v., 287–288, 878  
 renin expression suppressed by 19-nor, 1518, 1518t  
 as renin inhibitors, 1514–1518  
 synthesis of, 1511–1513, 1512f  
 vascularized heart allograft rejection v. 19-nor, 1520–1521, 1520t, 1521f  
 Gene expression  
 20-epi D analogs v., 1495–1498  
 VDR-mediated control mechanisms influencing, 235–243  
 Gene inactivation, tissue-specific, Cre/lox strategy for, 112, 113f  
 Genetic hypercalciuric stone-forming (GHS) rats  
 bone resorption in, 1349  
 establishment of colony of, 1347  
 as IH animal model, 1346–1350  
 intestinal Ca transport in, 1348, 1348t  
 low Ca diet response by, 1349, 1350f  
 mineral balance in, 1348  
 pathogenesis in, 1350, 1350f  
 serum  $1,25(\text{OH})_2\text{D}$  in, 1348, 1348f  
 serum/urine chemistries in, 1347–1348  
 VDR in, 1348–1349, 1349f  
 Geography  
 adult D insufficiency v., 1091–1094, 1091f, 1092f  
 D metabolism influenced by, 790–795  
 D nutrition/acquired bone disease v., 1297–1298  
 diabetes incidence v., 1766  
 hip fracture risk v., 1813  
 hypertension/stroke v., 873  
 low D intake v., 1087–1088, 1087f  
 as PCa risk factor, 1601, 1601t  
 rickets/colon cancer similarity in, 866  
 serum 25OHD v. Argentine, 795  
 Gestation, VDR WT/KO mouse intestinal Ca absorption during, 440–442, 441f, 441t, 442f  
 GFR. *See* Glomerular filtration rate  
 GFs. *See* Growth factors  
 GH. *See* Growth hormone  
 GHS rats. *See* Genetic hypercalciuric stone-forming rats  
 GIO. *See* Glucocorticoid-induced osteoporosis  
 Glass, vitamin D photosynthesis v., 41, 42f  
 Glial cell-derived neurotrophic factor (GDNF)  
 in C cell migration, 687–688  
 RET/GDNFR- $\alpha$  signaling system, 688, 688f  
 Glomerular filtration rate (GFR),  $1,25(\text{OH})_2\text{D}_3$  v., 1380, 1380f  
 Glucocorticoid-induced osteoporosis (GIO)  
 D as treatment for, 1243–1248  
 D metabolism v., 1239–1248  
 D preparations' efficacy v., 1247–1248  
 studies of serum D metabolites in, 1241, 1242t  
 Glucocorticoid receptor (GR), 1239–1240  
 actions in bone, 1240  
 Glucocorticoid response elements (GREs), hVDR promoter, 200  
 Glucocorticoids  
 Ca absorption v., 1244–1245  
 CYP27A1 regulated by, 57  
 D metabolism influenced by, 1241–1243  
 genomic/nongenomic effects of, 1239  
 GIO v. effects mediated by, 1239  
 mineral/skeletal metabolic indices v., 1243, 1243f  
 non-GR TFs mediating, 1239–1240  
 $1,25(\text{OH})_2\text{D}_3$  influenced by, 1741  
 osteoblasts/osteoblast progenitors influenced by, 1240  
 in PCa combination therapy, 1696  
 PKC activity/CYP24A1 expression v., 99  
 proximal tubular  $\text{P}_i$  transport v., 461t  
 PTHrP expression/production inhibited by, 741t  
 renal  $\text{P}_i$  excretion decreased by, 516t  
 type I collagen synthesis v., 704  
 VDR expression affected by, 202t, 205–206  
 Glucose, serum phosphate depressed by insulin and, 1177  
 Gluten, celiac disease v., 1300–1301  
 Goats, Ca balance v. sunlight in lactating, 4  
 Granulomatous diseases  
 extrarenal D metabolite overproduction v., 1390–1391, 1390t  
 $1,25(\text{OH})_2\text{D}$  accumulation in, 1389  
 $1,25(\text{OH})_2\text{D}$  production v., 1359–1361  
 Grave's disease  
 D deficiency v. subtotal thyroidectomy for, 1262  
 VDR polymorphisms v., 1148  
 GREs. *See* Glucocorticoid response elements  
 Growth, VDR ablation v., 341–345, 342f  
 Growth factor receptors,  $1,25(\text{OH})_2\text{D}_3$  influencing tumor, 1581–1582  
 Growth factors (GFs)  
 20-epi D analogs interfering with, 1498–1499  
 human BPH cells v., 1834  
 $1,25(\text{OH})_2\text{D}_3$  influencing tumor, 1581–1582  
 $1,25(\text{OH})_2\text{D}_3$  v. signaling by, 1665  
 PCa v. actions of, 1692–1693  
 PTHrP expression/production stimulated by, 741t  
 PTHrP inhibition v. signaling interference in, 743  
 VDR expression affected by, 207–208  
 Growth hormone (GH)  
 acromegalic/normal  $1,25(\text{OH})_2\text{D}_3$  v., 1257–1258  
 D metabolism influenced by, 1254t, 1257  
 D metabolism influenced by IGF-I and, 1254t, 1258  
 renal  $\text{P}_i$  excretion decreased by, 516t  
 VDR expression affected by, 208  
 Growth plates, 108  
 calbindin-D<sub>9K</sub>/D<sub>28K</sub> in, 724, 730t  
 chondrocyte differentiation in, 576, 576f  
 chondrocytes changing extracellular matrix composition of, 576f, 577–578  
 cyp24A1-null mouse, 108–109, 108f  
 D actions influencing, 581–582, 581t  
 dietary Ca increasing thickness of, 112  
 formation of, 575  
 in growing skeleton, 1031  
 horizontal/vertical organization of, 498, 499f  
 $24,25(\text{OH})_2\text{D}_3$  targeting cartilage in, 582–583  
 $24R,25(\text{OH})_2\text{D}_3$  v.  $1\alpha,25(\text{OH})_2\text{D}_3$  in, 582–583  
 rickets v. disorganization of, 1071, 1071f  
 subperiosteal erosions near, 976f, 977  
 VDR ablation affecting, 343, 343f  
 GS 1500, VDR DNA-binding complex induced by, 1496, 1497t

GS 1790, bone loss/strength v., 1497t, 1501, 1502t  
Gy mice, XLH modeled by, 463, 463t

## H

### Habitus

bone histomorphometry v., 795–796  
bone mass v., 795  
D metabolism influenced by, 789–796, 795

### Hair cycle

D endocrine system in, 291  
regulation of, 621–622  
  factors implicated in, 621  
  VDR's different role in, 622  
VDR mediating, 234–235  
VDR-RXR triggering mechanism unknown, 249  
VDR triggering telogen/anagen transition in, 247f, 248–249

### Hair follicles

development of mouse, 347  
1 $\alpha$ ,25(OH) $_2$ D $_3$  VDR $_{nuc}$  in, 385t  
VDR ablation effect mouse on, 346–348, 346f  
VDR in function of, 224–225  
VDR's clinical relevance to, 246–249

### Hairless gene (hr), as NR co-repressor, 299

### Haplotypes

polymorphic variation/disease risk v., 1126–1127  
polymorphic variation encapsulated by, 1125f, 1127, 1128f  
VDR gene v. gene-wide, 1135–1137, 1136f

Harrison's sulcus, 1067–1068, 1068f

HAT coactivator complexes. *See* Histone acetyltransferase coactivator complex

HD. *See* Hemodialysis; Huntington's disease

HDM. *See* Hypovitaminosis D myopathy

### Health

claiming D influence on, 999–1000  
D dose/response curve for cardiovascular, 905, 905f  
D $_3$  nutrition effects anticipated on, 1009t  
D signaling in cardiovascular, 899–901  
D synthesis/absorption v., 1294  
FGF-23 in, 1193–1194  
serum 25OHD directly related to, 825  
sunlight/dietary vitamin D affecting, 42  
VDR-mediated signaling implications for, 243–249

### Heart

D supplementation benefiting, 874  
19-nor Gemini v. allograft rejection in, 1520–1521, 1520t, 1521f  
1,25(OH) $_2$ D $_3$ /analog immunoregulatory properties in, 1519

Heat shock-70 proteins (hsp70s), in macrophage 1 $\alpha$ -hydroxylase regulation, 1386–1387

Helix-loop-helix (HLH) proteins, in CT gene transcription, 691

### Helper T cells

interaction/regulation by Th subsets, 1753–1754  
1,25(OH) $_2$ D $_3$  in autoimmunity v., 1754–1755  
1,25(OH) $_2$ D $_3$  v. lymphokine production by Th, 1754, 1755f

Hematological malignancy, D v., 1727–1736

Hematopoiesis, 1727–1728, 1728f

bone remodeling resembling, 505–506  
D compounds influencing, 1729–1730

Hemochromatosis, hypoparathyroidism/hypocalcemia v., 1053

Hemodialysis (HD), long-term OCT dose in, 1530–1531, 1531f  
HEP 187

bone loss/strength v., 1494t, 1501  
bone mineral metabolism influenced by, 1493, 1494t

Heparin, D metabolism influenced by, 1255t, 1269–1270

Hepatic osteodystrophy, 1303–1304

Hereditary 1,25-dihydroxyvitamin D-resistant rickets.

*See* Hereditary vitamin D-resistant rickets

Hereditary hypophosphatemic rickets with hypercalciuria (HHRH), 469

genetic defect underlying, 1173–1174  
pathophysiology, 1173  
phosphate homeostasis in, 1169t, 1173–1174  
treatment, 1174  
XLH/ADHR/OHO v., 469

Hereditary vitamin D-resistant rickets (HVDRR), 224, 1207–1231

alopecia associated with, 1229–1230  
arginine altered to leucine in, 233, 234f  
bisphenol analogs v., 1561–1562, 1561f  
Ca absorption efficiency in, 782  
Ca/P/lactose v., 111–112, 111f  
cases described, 1212–1213, 1214t–1216t  
cell lines suppressing RXR-VDR transactivation/VDRE binding, 354f, 355–356  
cellular basis of, 1212–1218  
clinical/biochemical findings in, 1208–1209  
clinical features, 1208–1210  
cultured fibroblasts in initial studies of, 1212–1217  
D-resistant human with signs of, 355  
D v. Ca/phosphate absorption in, 566  
defective mineralization/rickets in, 1208, 1208f  
environmental causes v. disease resembling, 1226–1227  
first recognition of, 1212  
first report of, 1208  
functional domains, 1197, 1198f  
glutamate 420 altered to lysine in, 233, 234f  
ligand contact point disruption as basis for, 1224  
molecular basis for, 1218–1227  
non-VDR protein mutations causing, 1226–1227  
25OHD 1 $\alpha$ -hydroxylase enzyme activity v. PDDR, 1199f  
1,25(OH) $_2$ D/1,25(OH) $_2$ D $_3$ -regulated processes in, 1210  
pathophysiology of, 1209  
prenatal diagnosis of, 1228  
R391C mutant hVDR-RXR heterodimerization impaired in, 233, 234f

recognition/semantics of, 1197  
serum biochemistry levels in, 1208, 1209t  
severity correlating with alopecia, 1210  
spontaneous healing of Tyr295stop/Arg73Gln, 1228  
terminology, 1207  
therapy for, 1227–1229  
  Ca in, 1227–1228  
  D analogs in future, 1229  
  D in, 1227  
VDR/1 $\alpha$ (OH)ase ablation causing symptoms of, 429  
VDR arginine/cysteine mutation in, 233, 234f  
VDR gene defects causing, 224, 429, 1207

Herodotus, sunlight effects v. bone recognized by, 565

Heterogeneous nuclear ribonucleoproteins (hnRNPs), 357–359

classical view of, 357  
HVDRR v. abnormal expression of, 1226  
as multifunctional proteins, 357–359

26,26,26,27,27,27-Hexafluoro-1 $\alpha$ ,25-(OH) $_2$ D $_3$  [26,27-F $_6$ -1 $\alpha$ ,25-(OH) $_2$ D $_3$ ], potency/metabolism, 1440

HHM. *See* Humoral hypercalcemia of malignancy

HHRH. *See* Hereditary hypophosphatemic rickets with hypercalciuria

High-performance liquid chromatography (HPLC)

D/25OHD analyzed with, 932  
D v. quantitative reversed-phase, 934, 934f  
deficiency/depletion evaluated by, 1086



- High-performance liquid chromatography (*Continued*)  
 24R-monohydroxylated Gemini metabolite configuration determined by, 1513–1514, 1514f, 1515f  
 25OHD assay consistency v., 1023
- Hispanics  
 bone mass in, 794  
 D metabolism in, 793–794  
 metabolic bone disease v. lactose intolerance in, 917t
- Histone acetyltransferase (HAT) coactivator complex  
 enzymatic activity in SRC/p160 family, 264–265  
 VDR linkage to, 176, 264–265  
 in VDR transcription model, 268–270, 269f
- History of present illness (HPI)  
 in approaching metabolic bone disease, 916  
 nutritional factors in, 916, 917t
- HLH proteins. *See* Helix-loop-helix proteins
- hnRNP A (hnRNPA) family  
 direct repeat half-site specificity in, 357  
 New World primate VDRE-BPs in, 354  
 REBiP similar to proteins in, 355
- hnRNPs. *See* Heterogeneous nuclear ribonucleoproteins
- Hodgkin's disease, extrarenal D metabolite overproduction in, 1390t, 1391–1392
- Homer, rickets described by, 1065
- Hopkins QW-1624F<sub>2</sub>-2, 1410f  
 24F<sub>2</sub>-1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1407–1408, 1410f  
 large-scale synthesis/availability of, 1408
- Hormone resistance, concept evolution, 1207
- Hormones. *See also specific hormones*  
 D metabolism influenced by, 1253–1263, 1254t  
 proximal tubular P<sub>i</sub> transport regulated by, 461–462, 461t
- HPI. *See* History of present illness
- HPLC. *See* High-performance liquid chromatography
- HPLCs. *See* Human periodontal ligament cells
- hr. *See* Hairless gene
- HSA. *See* Human serum albumin
- hsp70s. *See* Heat shock-70 proteins
- Human periodontal ligament cells (HPLCs), osteoblast-like differentiation in, 602
- Human physiology, 773–905
- Human serum albumin (HSA), DBP structural similarity to, 135–136, 136–137, 136f, 137f, 138f
- Human VDR (hVDR)  
 ablated in rodents/humans, 224–225  
 HVDRR v. point mutations in, 233–235, 234f  
 putative NLSs in, 368–369, 368f  
 structure of superagonist ligands complexed to, 285–287, 286f
- Humans  
 D requirements from evolution of, 995  
 D resistance in, 355–356  
 D supply in genomic selection of, 1006  
 intestinal Ca absorption in, 429–437
- Humoral hypercalcemia of malignancy (HHM), Ca reabsorption in, 1256
- Huntington's disease (HD), 1779
- hVDRA  
 biological properties, 280–281  
 LBD topology, 281, 283f  
 ligand-binding pocket, 281–282, 283f  
 radii of gyration, 281, 282f  
 solution studies, 281
- hVDRA-1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> complex, crystal structure, 281–282
- HVDRR. *See* Hereditary vitamin D-resistant rickets
- HVO. *See* Hypovitaminosis D osteopathy
- Hydroxyapatite  
 apatite v. natural, 477, 478–480, 478f
- Hydroxyapatite (*Continued*)  
 chondrocyte matrix supporting, 577  
 crystal formation in matrix vesicles, 578  
 crystal growth in dentin, 600  
 crystal growth in enamel, 601  
 lattice structure in bone mineral, 1030
- 2-Methylene-19-nor-(20S)-1 $\alpha$ -hydroxybishomopregnacalciferol (2Mbisp), 1551–1552, 1552f  
 tissue selectivity, 1552–1553, 1553f
- 25-Hydroxycholecalciferol, in HVO evolution, 1038t, 1041–1042
- 2-Methylene-19-nor-1 $\alpha$ -hydroxyhomopregnacalciferol (2MP), 1551–1552, 1552f  
 tissue selectivity, 1552–1553, 1553f
- 25-Hydroxylase, 47–62  
 activity v. sex, 61  
 D molecule interaction model, 56  
 human/mouse, 54  
 identifying novel types of, 106–107  
 microsomal, 50t–51t  
 expression sites for, 48, 49t  
 porcine, 53–54, 54f  
 sex differences in, 52–53  
 mitochondrial, 51t–52t  
 expression sites for, 48, 49t  
 ontogeny, 60  
 specificity, 55–56  
 vitamin D activated by, 17–19
- 26-Hydroxylase, 24
- 24-Hydroxylase (CYP24), 20–21, 85–100  
 activity in kidney, 517–518  
 catabolic pathway/Ca restriction in D toxicity, 1365–1367, 1366t  
 cellular expression, 86–87  
 in CYP24A1 KO/transgenic animals, 90–91  
 cellular metabolism by, 1459–1461, 1460f  
 distribution in kidney, 528  
 enzyme  
 functional in PDDR patients, 1199  
 kinetic analysis, 89–90  
 metabolic analysis, 89  
 spectral analysis, 90  
 structure/function, 88–90  
 enzyme pathways, 87–88, 88f  
 enzyme structure/function, 88–90  
 expression regulators, 93, 94f  
 function/regulated expression, 85–86, 86f  
 human intestine expressing, 1717–1719  
 in 23-hydroxylation, 23  
 inhibitors in PCa combination therapy, 1695–1696  
 keratinocyte differentiation v. activity of, 611–612, 611f  
 macrophages lacking 1,25(OH)<sub>2</sub>D-directed activity of, 1383–1384  
 molecular aspects, 93–100  
 mouse proximal/distal colon expressing, 1719  
 mRNA expression evaluation for, 1718  
 nutritional regulation, 1719–1721  
 1,25(OH)<sub>2</sub>D actions terminated by, 22  
 25OHD<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub>-, 528  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating  
 Ca deficiency v., 21  
 intestinal., 21  
 PCa growth-inhibitory responses influenced by, 1685–1686, 1686f  
 physiological role, 21–22  
 properties, 87  
 responsiveness v. VDREs, 316t, 320  
 terminal reaction, 87, 87f  
 ubiquity, 20–21

- 1 $\alpha$ -Hydroxylase (CYP27B1), 69–78  
 age v. activity of renal, 1103, 1109  
 in breast cancer, 1667  
 CKD directly inhibiting, 1316  
 CKD v. PTH/Ca induction of, 1315–1316  
 cytokines stimulating macrophage, 1384–1385  
 in D toxicity v. restricted Ca diet, 1365, 1365t, 1366t  
 deficiency v. HVDRR, 1208, 1209t  
 enzyme v. 24-hydroxylase enzyme, 1199  
 factors influencing activity of, 517t  
 functional diversity, 1392  
 hsp70s regulating macrophage, 1386–1387  
 human disease/extrarenal activity of, 1379–1394  
 human intestine expressing, 1717–1719  
 immune cell regulators v. macrophage, 1384–1387  
 importance of phosphorus in regulating, 1161  
 keratinocyte differentiation v. activity of, 611–612, 611f  
 levels in PCas/noncancerous prostates, 1608–1609  
 LPS amplifying macrophage, 1385–1386, 1385f  
 in macrophages, 1381–1382, 1382f  
 mouse proximal/distal colon expressing, 1719, 1719f  
 mRNA expression evaluation for, 1718  
 new developments in disease v., 1379  
 NO regulating macrophage, 1386  
 nutritional regulation, 1719–1721  
 1,25(OH)<sub>2</sub>D<sub>3</sub> growth inhibition requiring, 744, 745f  
 PCa growth-inhibitory responses influenced by, 1686–1687, 1687f  
 PCa v., 1626–1627  
 in prostate, 1607  
 PTH/Ca not regulating prostatic, 1609–1610  
 renal phosphate transport/phosphorus v., 1161, 1163f  
 species distribution, 70–71  
 substrate availability/1,25(OH)<sub>2</sub>D bioactivation in CKD, 1315  
 TLR expression/signaling v. extrarenal, 1385  
 in vitamin D metabolism, 19–20
- 23-Hydroxylation, vitamin D<sub>3</sub>, 23
- 2-Methylene-19-nor-1 $\alpha$ -hydroxypregnacalciferol (2Mpregna), 1551–1552, 1552f  
 tissue selectivity, 1552–1553, 1553f
- 1,25-Hydroxyvitamin D<sub>3</sub>, urinary loss in megalin KO mice, 154, 155t
- 23(S),25(R)25-Hydroxyvitamin D<sub>3</sub>-26,23-lactone, in C-23 oxidative pathway discovery, 23
- 1 $\alpha$ -Hydroxyvitamin D<sub>2</sub> [1 $\alpha$ OHD<sub>2</sub>]  
 as 1,25(OH)<sub>2</sub>D<sub>3</sub> analog in cancer/tumor treatment, 1747  
 toxicity, 1358
- 1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> [1 $\alpha$ OHD<sub>3</sub>]  
 early clinical trials of, 1742  
 in GIO treatment, 1247–1248  
 leukemic cells v., 1734  
 osteoporosis treatment using ED-71 v., 1534–1535, 1535f  
 PDDR treatment with, 1201t, 1202  
 toxicity, 1357–1358
- 25-Hydroxyvitamin D<sub>3</sub>/DBP complexes  
 cubilin as endocytic receptor for, 158–159, 158f  
 glomerular filtration of, 153–154, 154f  
 megalin as endocytic receptor for, 154–156, 157–158, 157f, 158f  
 megalin influencing cellular uptake of, 156–157, 156f  
 receptors/co-receptors for, 157–159  
 two-receptor model for, 159, 159f
- 25-Hydroxyvitamin D<sub>3</sub> [25OHD<sub>3</sub>]  
 basis for 1,25(OH)<sub>2</sub>D<sub>3</sub> interaction with, 783  
 biological static/dynamic methods v. normal serum, 1020t  
 BMD v. normal, 1022, 1022f  
 Bone fracture risk defining normal, 1022–1023
- 25-Hydroxyvitamin D<sub>3</sub> [25OHD<sub>3</sub>] (*Continued*)  
 Ca intake v. serum, 1023–1024  
 colon cancer v., 1709–1710  
 CYP27A1 disruption v., 60  
 D3/metabolite plasma concentrations v., 1362, 1363t  
 desirable target plasma concentration of, 1009t  
 dose-response relationship with D<sub>3</sub>, 1003, 1005f  
 early 2-carbon analogs of, 1545  
 endocytic pathways, 153–160, 160f  
 as hormonally active form of vitamin D<sub>3</sub>, 16  
 interlaboratory assay variability v., 1023, 1023f, 1023t, 1025  
 intestinal Ca absorption efficiency correlated with, 783  
 metabolism in human colon cancer cells, 1716–1717, 1716f  
 neoplastic colonocytes acted on by, 1710–1715  
 nutritional status improvement v., 1003–1005, 1004t  
 PDDR treatment with, 1201–1203, 1201t, 1202f, 1203f  
 proteins in 1 $\alpha$ -hydroxylation of, 71–73  
 renal endocytosis, 153–159  
 renal handling of Ca/P influenced by, 518–519  
 secondary hyperparathyroidism in defining normal, 1020–1022  
 serum concentration indicating nutritional status, 1003, 1004t  
 serum concentration of  
   D status clinical outcomes v. normal, 1019  
   defining normal, 1019–1026, 1020t  
   sampling biases v. reference value, 1019  
   strategies increasing concentration of, 1003, 1004t  
   urinary loss in megalin KO mice, 154, 155t  
   variables influencing normal values of, 1023–1024
- 25-Hydroxyvitamin D [25OHD]. *See also* 25-Hydroxyvitamin D<sub>3</sub>  
 age v., 1101–1102, 1102f  
 age v. synthesis of, 826, 1617  
 automated instrumentation CLIA methodology for detecting, 939–940, 939f, 940f, 940t  
 bone fracture risk v. serum, 1370, 1370f  
 Ca absorption role of, 1106  
 clearance v. age, 1102  
 clinical implications of keratinocytes producing, 612–613  
 concentration having clinical relevance, 948t, 949  
 cytokines regulating, 610f, 612  
 deficiency caused by defective CYP27A1, 61–62  
 deficiency v. age, 1103, 1109  
 detecting, 935–939  
 endogenous production in hypervitaminosis D, 1359  
 as HDM cause, 1816  
 HPLC methodology for detecting, 936  
   quantitative normal-phase HPLC in, 936, 937f  
   sample extraction for, 936  
   silica cartridge chromatography in, 933f, 936  
   solid-phase extraction chromatography in, 936  
 hydroxylation, 1599  
 keratinocyte differentiation regulating, 611–612  
 kidney in metabolism of, 516–518  
 liver production, 17–19  
 mechanisms of age-related decrease in, 1101–1102  
 metabolism/identification of products, 609–610  
 muscle power/MVC v., 1812–1813, 1812f  
 1,25(OH)<sub>2</sub>D concentration v. plasma half-life of, 1296, 1296f  
 parent D/25OHD toxicity due to, 1362  
 PCa v., 1610–1611, 1611f  
 PCa v. serum, 1602–1604  
 plasma concentration, 28t  
 poor assay performance v., 939–940, 940t  
 prostate cells v. antiproliferative influence of, 1607–1608, 1609f  
 psoriasis v. serum, 1796  
 RIA methodology for detecting, 936–938  
   assay calibrator preparation for, 936

- 25-Hydroxyvitamin D [25OHD] (*Continued*)  
    other D compounds v., 937–938, 938f, 938t, 939t  
    radioimmunoassay in, 937, 938f  
    sample/calibrator extraction for, 936  
    seasonal variation, 1019–1020, 1020f, 1069  
    serum concentration influenced by aging, 826–827
- Hyp* mice  
    abnormal 24-hydroxylase regulation in, 465  
    XLH modeled by, 463, 463t, 464f, 465
- Hypercalcemia. *See also* Humoral hypercalcemia of malignancy  
    calcipotriol/related analogs v., 1493–1494  
    causes of, 1355, 1356t  
    clinical manifestations of D toxicity from, 1368  
    D-induced, 568–569, 986, 988f  
    D metabolite use limited by, 1403  
    D single dose rickets therapy v., 1072, 1073  
    D toxicity causing, 1355–1372  
    dehydration worsening pathophysiology of, 1368  
    early detection/prevention of, 1393  
    EB1089 v., 744  
    20-*epi* 1,25(OH)<sub>2</sub>D<sub>3</sub> analogs v., 1494–1495, 1496t  
    excessively fortified milk causing, 1065  
    identifying patients at risk for, 1393  
    lowest D<sub>3</sub> dose causing, 1005f, 1008–1009  
    nonsecosteroid analogs v., 1565–1567  
    in *Npt2a* KO mice, 462  
    1,25(OH)<sub>2</sub>D<sub>3</sub> allograft rejection therapy v., 1518  
    1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs influencing, 542–543  
    24F<sub>2</sub>-1,25(OH)<sub>2</sub>D<sub>3</sub> and Hopkins QW-1624F<sub>2</sub>-2 v., 1407–1408, 1410f  
    1,25(OH)<sub>2</sub>D<sub>3</sub> causing, 744  
    preventing, 1393  
    SCCs associated with, 612  
    screening patients at risk for, 1393  
    stanniocalcin v., 462  
    therapeutic 1,25(OH)<sub>2</sub>D<sub>3</sub> inducing, 1449  
    treating, 1393–1394
- Hypercalciuria. *See also* Idiopathic hypercalciuria  
    D metabolite use limited by, 1403  
    early detection/prevention of, 1393  
    as early sign of D toxicity, 1368  
    identifying patients at risk for, 1393  
    IH diagnosis v. causes of normocalcemic, 1340, 1340t  
    in *Npt2a* KO mice, 462  
    1,25(OH)<sub>2</sub>D<sub>3</sub> causing, 744  
    screening patients at risk for, 1393  
    treating, 1393–1394
- Hyperesthesia, hypovitaminosis D associated with, 1090
- Hyperkalemia, hypocalcemia v., 1049
- Hypermagnesemia  
    CaR mutation causing, 553–554  
    hypocalcemia masked by, 1049
- Hyperparathyroidism. *See also* Secondary hyperparathyroidism  
    D insufficiency in elderly v. mild, 825  
    D supplementation v., 1094  
    high-Ca diet preventing KO mouse, 429  
    intracortical bone resorption in, 975f, 977  
    intravenous 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1330–1331  
    management of severe/refractory, 1823–1826  
    in megalin KO mice, 154–156, 155t  
    models, 544  
    in renal osteodystrophy, 976–979  
    resorbed distal phalangeal tufts v. treated, 975f, 977  
    subperiosteal erosions in, 975f, 976–977  
    VDR ablation v., 342, 343f  
    in VDR KO mice, 433, 488  
    VDR polymorphisms v., 1146
- Hyperphosphatemia  
    in altered phosphate load disorders, 1179–1180  
    dystrophic calcification associated with, 478  
    1 $\alpha$ -hydroxylase inhibited by, 1316  
    hypocalcemia induced by, 1056–1057  
    1,25(OH)<sub>2</sub>D inhibited by, 1161  
    P<sub>i</sub> vs., 454–455  
    therapeutic 1,25(OH)<sub>2</sub>D<sub>3</sub> inducing, 1449
- Hyperproliferative skin disorders, VDR-RXR heterodimer-activating ligands v., 241
- Hypertension  
    D analogs v., 878  
    D signaling in regulating, 899  
    Gemini compounds v., 1518  
    inappropriate RAS activation leading to, 871  
    low calcemic D analogs v., 1514–1516
- Hypervitaminosis D<sub>2</sub>, hypervitaminosis D<sub>3</sub> v., 1364–1365
- Hypervitaminosis D<sub>3</sub>  
    cartilage/bone v., 582  
    23-hydroxylation in, 23  
    hypervitaminosis D<sub>2</sub> v., 1364–1365
- Hypocalcemia. *See also* Early neonatal hypocalcemia;  
    Late neonatal hypocalcemia  
    biochemical changes induced by, 1051–1052  
    breast milk/formula v. neonatal, 841–842, 842f  
    CYP27B1 gene mutation v., 109  
    in CYP27B1-null mice, 703  
    dermatopathy in chronic, 920, 920f  
    differential diagnosis/D therapy v., 1049–1060  
    differential diagnosis of, 1052–1058  
    early/late neonatal, 1055  
    fasting/famine/drought causing, 777  
    of IDM, 807  
    long-term treatment of, 1058–1060  
    management of acute, 1058  
    in megalin KO mice, 154–156, 155t  
    in 1 $\alpha$ (OH)ase-null mice, 438, 489  
    1,25(OH)<sub>2</sub>D<sub>3</sub> production increased by, 19–20  
    1,25(OH)<sub>2</sub>D<sub>3</sub> v. HVDRR patient's, 357  
    parathyroid cell proliferation stimulated by, 545  
    physiology of, 1049–1050  
    PTH gene expression increased by, 544  
    PTH increasing 1,25(OH)<sub>2</sub>D<sub>3</sub> production in, 703  
    rickets/osteomalacia v. chronic, 1049  
    signs/symptoms, 919–920, 919t  
    skeletal homeostasis/D metabolism/illness causing, 1054–1058  
    therapy for, 1058–1060  
    uncalcified osteoid v. 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment of, 1041, 1041f  
    in VDR KO mice, 433, 488
- Hypokalemia, hypocalcemia masked by, 1049
- Hypolipidemics, D metabolism influenced by, 1255t, 1267–1268
- Hypomagnesemia  
    in alcoholics, 1177  
    CaR mutation causing, 553–554  
    hypocalcemia v., 1049, 1053–1054, 1054
- Hypoparathyroidism  
    hypocalcemia v. idiopathic, 1053  
    in *Npt2a* KO mice, 462
- Hypophosphatemia  
    in altered phosphate load disorders, 1178–1179  
    bone mineralization abnormalities in, 488  
    causes of chronic, 924, 924t  
    correction v. therapeutic objectives, 928, 928f  
    in CYP27B1-null mice, 703  
    dental defects associated with familial, 602  
    GH regulating 1,25(OH)<sub>2</sub>D<sub>3</sub> in, 1258

- Hypophosphatemia (*Continued*)  
 in *Npt2a* KO mice, 462  
 in  $1\alpha(\text{OH})_2\text{D}$ -null mice, 438  
 $1,25(\text{OH})_2\text{D}$  increased by, 1161  
 pathogenesis in fibrous dysplasia, 1192  
 $\text{P}_i$  vs., 454  
 radiology of renal tubular defect, 981–984  
 in stage II rickets, 1070  
 TIO/XLH/ADHR characterized by, 1162–1163  
 transcellular shift in, 1176–1177  
 Hypophosphatemic bone disease, FGF-23 gene mutation detection in, 1190  
 Hypophosphatemic diseases, 1162–1176  
   common pathway of pathogenesis in, 1163–1168  
   FGF-23 activity v. phenotypic abnormalities of, 1166  
 Hypovitaminosis D, urinary loss of  $25\text{OHD}_3$  causing, 153  
 Hypovitaminosis D myopathy (HDM), 1805–1817  
   clinical studies of, 1811–1813  
   biopsies in, 1811  
   muscle function in, 1811–1813  
   D deficiency insulin resistance v., 1816  
   misdiagnosis, 1805–1806  
   muscle physiology v., 1806–1808, 1806f, 1807f  
    $25\text{OHD}/1,25(\text{OH})_2\text{D}/\text{PTH}$  causing, 1814–1816  
   sunlight v., 1813–1814  
   symptoms/signs, 1805–1806  
 Hypovitaminosis D osteopathy (HVO), 1035  
   biochemical evolution of, 1036–1039, 1038t  
   D metabolism in, 1039–1040  
   pathogenesis of, 1029–1044  
   stages of, 1036, 1036t
- ## I
- IBD. *See* Inflammatory bowel disease  
 Ichthyosis, D therapy v., 1787  
 IDBPs. *See* Intracellular vitamin D binding proteins  
 Idiopathic hypercalciuria (IH), 1339–1346  
   Ca absorption v.  $1,25(\text{OH})_2\text{D}$  in, 1342, 1343f  
   diagnosis v. causes of normocalcemic hypercalciuria, 1340, 1340t  
   dietary Ca restriction v., 1351  
   elevated  $1,25(\text{OH})_2\text{D}$  in, 1341–1342, 1342f  
   genetic hypercalciuric rats as animal model of, 1346–1350  
   human genetic, 1346f, 1350–1351, 1351t  
   inheritance, 1340–1341, 1340f  
   intestinal Ca absorption in, 1341, 1341f  
   low bone mass associated with, 1342–1343  
   nephrolithiasis in, 1142, 1339–1352  
   overview, 1339–1341  
   pathogenesis of human, 1341–1346  
   pathogenetic models of, 1343–1346, 1344f  
     external Ca balance v., 1344–1345, 1345f  
     fasting PTH/urine Ca v., 1344  
      $1,25(\text{OH})_2\text{D}$  excess v., 1344f, 1345–1346, 1347f  
     tests of, 1344–1346  
     urine Ca/Ca balance/low Ca diet v., 1345, 1345f, 1346f  
   renal Ca reabsorption decreased by, 1342  
   therapeutics v. Ca metabolism, 1351  
   thiazides v., 1351  
 IDM. *See* Infants of diabetic mothers  
 IFN $\gamma$ . *See* Interferon- $\gamma$   
 IGF. *See* Insulin-like growth factor  
 IGF-I  
   D metabolism influenced by GH and, 1254t, 1258  
   20-epi D analogs interfering with, 1498–1499  
 IGF-II  
   in EB1089 antiproliferative activity, 1714  
   20-epi D analogs interfering with, 1498–1499  
 IH. *See* Idiopathic hypercalciuria  
 Ileum  
   high Ca absorption quantity in, 778  
   transcellular/paracellular Ca absorption in, 422–424, 423f  
 Ilium, fracture suggesting D deficiency, 973  
 IMCal. *See* Intestinal membrane calcium-binding protein  
 IMCD. *See* Inner medullary collecting duct  
 Immune diseases  
   D analogs v., 1500–1501  
   VDR polymorphisms v., 1146–1148  
 Immune responses  
   cardiovascular disease v. D modulating, 902  
   innate/adaptive layers of, 631  
   selective intervention in, 631–633, 632t  
   VDR ligands mediating, 631–643  
     mechanisms involved in, 643, 643f  
 Immune system  
   CKD/ $1,25(\text{OH})_2\text{D}_3$  deficiency/resistance in, 1326–1327  
   D-deficiency-associated abnormalities in, 1389  
   D/diabetes v., 1767–1773  
   D endocrine system involved in, 291  
   D metabolite local regulatory effects on, 1387–1390  
   DBP role in, 126–127  
   VDR ablation effect on, 346  
 Immunosuppressants  
   D analogs combined with, 1500  
   D metabolism influenced by, 1255t, 1272–1273  
 Import receptors, nuclear import mediated by, 366, 367f  
 Importins. *See* Import receptors  
 Infants  
   acute hypocalcemia therapy for, 1058  
   Ca absorption in human milk/formula-fed, 813, 814t  
   D actions in perinatal, 803–808  
   D deficiency/Ca absorption in, 811–818  
   D $_3$  dosage considerations for, 1002–1003, 1009t  
   D supplementation for formula-fed, 808  
   D supplementation for low-birth-weight, 808  
   early/late neonatal hypocalcemia in, 1055  
   infant/maternal D supplementation v.  $25\text{OHD}$  in, 846–847, 846f  
   low maternal D/Ca intake v., 841–843  
   maternal Ca intake v. BMC in, 843, 843f  
   normal term, 804–805  
     Ca absorption in, 813–814  
     Ca intake recommendations for, 813, 813t  
     D deficiency/Ca absorption in, 813–814  
     D in, 814  
     supplemental D sources for, 814, 814t  
   premature, 805–807  
     D deficiency/Ca absorption in, 812–813  
     D in, 806, 806f  
     early neonatal hypocalcemia v., 805–806  
     nutritional rickets in, 968  
     osteopenia risk criteria for, 812, 812t  
     postnatal D supplementation for, 806–807  
   rickets and Chinese, 793  
   term growth-retarded, 805  
   VDDR v. black, 791  
 Infants of diabetic mothers (IDM), pathogenic factors in, 807  
 Infections  
   children with rickets v., 1068  
   VDR polymorphisms v., 1148  
 Inflammation, 126  
   DBP role in, 126–127

- Inflammatory bowel disease (IBD). *See also* Crohn's disease  
clinical/biochemical features of, 1302  
VDR ligand treatment v., 637t
- Infrared spectroscopy, tissue mineralization quantified with, 481, 482–483, 482f
- Inner medullary collecting duct (IMCD), vasopressin-stimulated water reabsorption v. CaR, 558
- Inorganic phosphate ( $P_i$ )  
aging v. serum concentration of, 455  
chemistry, 453  
circadian rhythm in serum concentration of, 455  
disorders associated with renal wasting of, 467–470  
common metabolic pathway hypothesized in, 469–470  
distribution in body, 453  
extracellular homeostasis of, 453–455, 454f  
homeostasis, 453–469  
regulation, 1159–1161  
v. NPT2a-related signaling, 1161  
 $1\alpha$ -hydroxylase activity v. restricted, 464, 464f  
intestinal absorption of, 455–457  
cellular aspects in, 455  
molecular mechanisms in, 456, 456t  
NPT2b gene expression v., 455–456, 456t  
regulation of, 455–456  
kidney excreting, 516, 516t  
kidney reabsorbing, 516  
NPT2a regulating reabsorption of, 459, 461t  
renal transport of, 457–463  
cellular aspects of, 457–458, 458f  
molecular aspects of, 456t, 458–459  
physiology/tubular localization in, 457  
supplementation in metabolic bone disease, 927  
transport in bone, 465–467  
type II cotransporter in handling, 1160
- Insufficiency  
in adults/elderly, 1085–1097  
consequences of, 1088–1090  
deficiency v., 1085–1086  
determinants, 1086–1088  
elderly v. consequences of, 825–826  
medical causes of, 1088  
muscle weakness in, 1090  
prevalence, 1090–1094  
preventing, 1094–1096, 1097
- Insulin  
D metabolism influenced by, 1254t, 1259  
EGF keratinocyte proliferation stimulation enhanced by, 614  
proximal tubular  $P_i$  transport v., 461t  
renal  $P_i$  excretion decreased by, 516t  
resistance in D deficiency v. HDM, 1816  
secretion influenced by  $1,25(\text{OH})_2\text{D}_3$ , 1764–1765  
secretion stimulated by  $1\alpha,25(\text{OH})_2\text{D}_3$ , 394–395, 395f  
serum phosphate depressed by glucose and, 1177  
synthesis/secretion in NOD mice, 1765, 1766f  
synthesis/secretion in VDR KO mice, 1765, 1765f  
type I collagen synthesis increased by, 704
- Insulin-like growth factor (IGF)  
mitogenic activity inhibited by D compounds, 1665  
in  $1,25(\text{OH})_2\text{D}_3$  actions on prostate cells, 1692–1693, 1692f  
system interacting with  $1,25(\text{OH})_2\text{D}_3/\text{EB1089}$ , 1581–1582
- Integument  
D's role in, 609–622  
VDR ablation effect on, 346–348, 346f
- Interferon- $\gamma$  (IFN $\gamma$ )  
CYP24A1 up-regulation inhibition v., 100  
D metabolism influenced by, 1254t, 1263
- Intestinal membrane calcium-binding protein (IMCaI),  
Ca entry v., 416
- Intestine. *See also* Colon; Duodenum; Ileum  
active Ca transport in, 414  
age v.  $1,25(\text{OH})_2\text{D}$  resistance/Ca absorption by, 1104–1105, 1105f  
calbindin- $\text{D}_{9\text{K}}/\text{D}_{28\text{K}}$  in, 722–724, 730t  
CaR in, 559  
CKD with low  $1,25(\text{OH})_2\text{D}_3$  or  $1,25(\text{OH})_2\text{D}_3/\text{VDR}$  resistance in, 1322  
corticosteroids influencing Ca absorption in, 445  
CYP27B1/CYP24 expression in, 1717–1719  
D analogs v. induced tumors in, 1451  
D deficiency/depletion v., 1294  
D-dependent Ca absorption mechanisms in, 433–440  
dexamethasone influencing Ca absorption in, 445, 447f  
ECaC2/calbindin- $\text{D}_{9\text{K}}$  mediating CA absorption by, 430f, 440  
estrogens v. Ca absorption in, 444–445  
gestation v. Ca absorption in, 440–442, 441f, 441t, 442f  
24-hydroxylase enzyme regulation in, 92  
lactation v. Ca absorption in, 441f, 441t, 442–444, 442f, 443f  
LCA detoxification in, 867–868, 868f  
 $1,25(\text{OH})_2\text{D}_3$  and Ca absorption by, 411–424  
 $1,25(\text{OH})_2\text{D}_3$  antioxidant activities/CA absorption in, 764t, 767  
25OHD correlated with Ca absorption efficiency in, 783  
paracellular path in Ca absorption, 421–422  
 $P_i$  absorption in, 455–457  
cellular aspects of, 455  
molecular mechanisms of, 456, 456t  
NPT2b gene expression v., 456–457, 457t  
regulation of, 455–456  
segments v. Ca absorption, 413, 422–424, 423f  
transcellular/paracellular Ca absorption in, 429, 430f
- Intoxication  
Ca/24-hydroxylase catabolic pathway in, 1365–1367, 1366t  
Ca v. renal  $1\alpha$ -hydroxylase in, 1365, 1365t, 1366t  
clinical manifestations of, 1368  
D absorption/input v. risk of, 784  
D $_2$  causing most cases of, 1008  
DBP/free metabolite level in, 1367–1368  
diagnosis of, 1369  
diagnosis of endogenous D, 1392–1393  
diagnosis/prevention/treatment v. endogenous, 1392–1394  
excessively fortified milk causing, 1009t–1010, 1066  
forms of exogenous, 1355–1359  
hypercalcemia due to, 1355–1372  
metabolic bone disease patient SH v., 917  
myocardial ischemia v. EKG changes in, 1368  
sarcoidosis associated with endogenous D, 1379–1380  
target tissue response to 25OHD in, 1364  
TPTX rat 24-hydroxylase activity v., 1366–1367, 1367t  
treatment of, 1369–1370  
VDR in, 1362–1365
- Intracellular receptor gene family, VDR in, 172–173
- Intracellular vitamin D binding proteins (IDBPs)  
D analog selectivity influenced by, 1462–1463  
in D-resistant New World primates, 359–360  
hsp70 family members homologous to, 359, 360f  
in intracellular D trafficking model, 360  
in 25OHD $_3$   $1\alpha$ -hydroxylation, 73  
“sink”/“swim” hypotheses for, 359–360, 360f
- Intragenic interaction, VDR gene analysis v., 1136f, 1138
- Irish, winter hypovitaminosis D in adult, 1091, 1091f
- Isoflavones, PCa combination therapy with soy, 1697
- Italians  
Ca v. colorectal cancer in, 1622

Italians (*Continued*)

- climate v. D in, 1026
- hypovitaminosis D in elderly, 1092–1093
- winter hypovitaminosis D in adult, 1091, 1091f

**J**

## Japanese

- Buddhist vegetarians v. metabolic bone disease, 917t
- Cdx2 polymorphism in, 1126
- CKD/VDR polymorphisms/expression in, 1319
- FokI RFLP v. height in young adult, 1143
- hypovitaminosis D in adult, 1091
- PCa risk for indigenous, 1681
- PCa risk in, 1601
- VDR gene polymorphism v. BMD in, 243
- VDR polymorphism v. PCa risk in, 1682
- VDR polymorphisms v. diabetes in, 1146
- VDR polymorphisms v. MS in, 1147
- VDR polymorphisms v. PCa in, 1139t, 1145
- VDR polymorphisms v. psoriasis in, 1146
- VDR polymorphisms v. renal cell carcinoma in, 1146
- westernization v. PCa in, 1600, 1600f

## Jejuno-ileal bypass

- bone disorders associated with, 1302–1303
- clinical features of, 1302–1303
- management, 1303

## Jejunum, high Ca absorption quantity in, 778

## Jews

- metabolic bone disease v. lactose intolerance in, 917t
- serum 25OHD in light-skinned, 794–795

JG cells. *See* Juxtaglomerular cellsJNK. *See* Jun-N-terminal kinase

## Jun-N-terminal kinase (JNK), in RANKL-induced osteoclastogenesis, 678

## Juxtaglomerular (JG) cells, renin synthesized/secreted by, 871, 872f

**K**

## Kellgren score, OA diagnosed with, 1144

## Keratinocyte-GF (KGF)

- BPH cells v. BXL–353 and, 1836–1837, 1837f
- human BPH cells v., 1834, 1835f

## Keratinocytes

- Ca regulating proliferation/differentiation of, 609
- Ca sensing mechanism of, 615–616, 615f
- Ca switch inducing changes in, 616
- Ca switch stimulating phosphoinositide metabolism in, 617–618
- clinical implications of 1,25(OH)<sub>2</sub>D production by, 612–613
- DRIP205/p160 recruitment in differentiation of, 273
- epidermal layers of, 613, 613f
- growth/differentiation regulators of, 613–615
- 24-hydroxylase enzyme regulation in, 93
- 1,25(OH)<sub>2</sub>D<sub>3</sub>/deltanoid-induced differentiation modeled in, 1637t
- 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibiting differentiation of, 1781
- 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibiting PTHrP production in, 741t
- 1,25(OH)<sub>2</sub>D production by transformed, 612
- 1,25(OH)<sub>2</sub>D production regulated by differentiation of, 611–612
- 1,25(OH)<sub>2</sub>D<sub>3</sub> protecting epidermal, 764t, 766–767
- 1,25(OH)<sub>2</sub>D regulating differentiation of, 619–621, 620f
- regulation of differentiation by, 613–621
- retinoic acid receptors identified in, 614
- VDRs in mammalian/lamprey, 228

## Ketoconazole

- D metabolism influenced by, 1255t, 1266–1267
- kidney 1 $\alpha$ -hydroxylase activity regulated by, 78

KGF. *See* Keratinocyte-GF

## KH1060

- analog-VDR complex stabilized by, 1496
- autoimmune type I diabetes prevented by, 1500
- breast cancer cells/tumors v., 1669
- in leukemia combination therapy, 1733
- leukemic cells v., 1735
- metabolism, 1438, 1439f
- metastasis v., 1576
- as noncalcemic analog, 1440, 1441t
- structure v. 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>, 285–287, 286f
- synthesis, 1490–1491, 1492f, 1496t

## Kidney

- aging v. D responsiveness by, 833
- Ca handling by, 515–516
- calbindin-D<sub>9K</sub>/D<sub>28K</sub> in, 724, 730t
- CaR in, 556–558
- CKD with low 1,25(OH)<sub>2</sub>D<sub>3</sub> or 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR resistance in, 1325–1326
- D analogs treating chronic disease of, 1827
- D-dependent protein distribution/regulation in, 519–528
- D-responsive proteins in, 520t
- D v., 515–528
- DBP uptake in megalin-deficient, 154, 154f, 155f
- dystrophic mineral deposits in, 477–478, 478t
- ECaC1 expression restricted to mouse, 431
- function deteriorating with aging, 827
- glucocorticoids directly affecting, 1243, 1243f
- 1 $\alpha$ -hydroxylase/24-hydroxylase expression in fetal, 852–853, 853f
- 24-hydroxylase distribution in, 528
- 24-hydroxylase enzyme regulation in, 91–92
- 24-hydroxylase expression in, 86–87
- 24-hydroxylation in, 21–22
- JG apparatus producing renin in, 871
- keratinocyte 1,25(OH)<sub>2</sub>D negative feedback loop v., 611
- mass/CKD v. 1,25(OH)<sub>2</sub>D bioactivation, 1379–1380
- mouse models with defective phosphate transport by, 462–463
- 1,25(OH)<sub>2</sub>D<sub>3</sub>/analog immunoregulatory properties in, 1519
- 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-mediated rapid response in, 386t
- in 25OHD metabolism, 516–518
- 1,25(OH)<sub>2</sub>D<sub>3</sub> produced by, 782
- 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> produced in, 69, 70f
- 1,25(OH)<sub>2</sub>D v. phosphate transport in, 1161–1162, 1162f
- 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR-mediated signal termination in, 221f, 222
- 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> VDR<sub>nuc</sub> in, 385t
- P<sub>i</sub> flux in human, 453–455, 454f
- P<sub>i</sub> handling by, 516, 516t
- P<sub>i</sub> homeostasis arbitrated by, 1159
- P<sub>i</sub> transport in, 457–463
  - cellular aspects of, 457–458, 458f
  - molecular aspects of, 456t, 458–459
  - physiology/tubular localization of, 457
- PTHrP expression in, 739t
- rejection inhibited by 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs, 641t
- tubular defects and hypophosphatemia, 981–984
- VDR in, 520–523
  - polyclonal antibodies detecting, 521, 521f

## Kidney disease

- 1,25(OH)<sub>2</sub>D secretion v., 1313
- secretory control/hormonal interactions v., 1313, 1314f

Klotho gene, kidney 1 $\alpha$ -hydroxylase activity v., 78

Knockout (KO) mice  
 alopecia in, 1229–1230  
 c-src, osteopetrosis in, 677  
 calbindin D<sub>28K</sub>, urinary Ca/creatinine ratio in, 525  
*cyp24A1*  
   growth plate architecture in, 108–109, 108f  
   24-hydroxylation in, 107–109  
   phenotype of, 107–109, 107t  
*cyp27A1*  
   hepatic 25-hydroxylation in, 105–106  
   phenotype of, 106  
*cyp27B1*  
   D-dependent gene expression in, 110  
   1 $\alpha$ -hydroxylation in, 109–113  
   hypocalcemia/hypophosphatemia/secondary hyperparathyroidism in, 703  
   phenotype of, 109–110  
   phenotype rescue in, 110–112  
 DBP, 149  
   serum D metabolites v. bone abnormalities in, 489f  
   viable immune function in, 127  
 ER $\alpha$ /ER $\beta$ , 441f, 445  
 FGF-23, phosphate homeostasis in, 1193–1194  
 full-length CaR, 616–617  
 intestinal Ca absorption in, 429–437, 446t  
 JNK1, RANKL-induced osteoclastogenesis in, 678  
 megalin, 154–156  
 Npt2  
   Ca absorption in, 440  
   generation/characteristics of, 439–440  
   phosphate homeostasis in, 439–440  
*Npt2a*  
   intrinsic osteoclast defect in, 467  
   Npt2c expression in NHERF and, 1162  
   renal phosphate transport defects in, 462  
   renal P<sub>i</sub> reabsorption v. P450c1 $\alpha$  gene expression in, 464f, 465  
 1 $\alpha$ (OH)ase  
   ECaC1 expression reduced in, 438  
   generating, 438  
   hypocalcemia/rickets/osteomalacia in, 489  
   lower calbindins-D expression in, 525  
   mineral homeostasis in, 438–439  
   PDDR in, 438–439, 489  
 prehypertrophic chondrocytes showcased by, 578  
 RXR $\alpha$  conditional, alopecia in, 233  
 SRC coactivator family models in, 294–295  
 VDR, 224–225, 341–348  
   alopecia in, 620, 621, 665  
   Ca absorption in, 433–437, 434f  
   Ca absorption v. Ca transporter gene expression in, 435–437, 436t, 437t  
   Ca entry v. Ca transport in, 417  
   Ca/P ameliorating skeletal abnormalities in, 1403–1404  
   calbindin D<sub>28K</sub> expression v. age in, 525  
   D-dependent active intestinal Ca absorption in, 433–438  
   dietary intervention v. Ca absorption in, 434f, 436t, 437–438  
   estrogen deficiency in, 441f, 445  
   generating, 433  
   gestation/intestinal Ca absorption in, 440–442, 441f, 441t, 442f  
   HVDRR/alopecia link in, 621  
   hypocalcemia in, 665  
   infertility in, 665  
   intraoperative glucose tolerance test in, 1765, 1765f  
   lactation/intestinal Ca absorption in, 441f, 441t, 442–444, 442f, 443f  
   renin expression/Ang II production in, 875–877, 876f

KO mice. *See* Knockout mice  
 Koreans  
   VDR polymorphisms v. psoriasis in, 1146  
   VDR polymorphisms v. RA in, 1147  
 Kuwaitis, sunlight exposure v. rickets in, 1066–1067

## L

Lactation  
   BMC/BMD during, 843f, 844–845  
   Ca homeostasis v., 204  
   D/Ca metabolism during, 843–844  
   D metabolism in, 839, 843–847  
   maternal Ca economy v., 845, 845f  
   PRL v. D metabolism during, 1258  
   VDR WT/KO mouse intestinal Ca absorption during, 441f, 441t, 442–444, 442f, 443f  
 Lactose intolerance, Ca intake v., 1026  
 Lampreys, VDRs in, 227–228, 279  
 Late neonatal hypocalcemia (LNH), 807–808  
 Latinas, hVDR polymorphisms v. breast cancer risk in U.S., 245  
 LBDs. *See* Ligand binding domains  
 LC/MS. *See* Liquid chromatography/mass spectrometry  
 LCA. *See* Lithocholic acid  
 LD. *See* Linkage disequilibrium  
 Lebanese  
   climate v. D in, 1026  
   D metabolism in, 794  
   hypovitaminosis D in, 1087  
   low serum 25OHD in, 1026  
 Leo KH-1060, SAR in design of, 1412, 1413f  
 Leprosy  
   extrarenal D metabolite overproduction v., 1390t, 1391  
   hypercalcemia/D hypersensitivity in, 1361  
 Leukemia  
   D analogs effective against, 1734–1736  
   D compound combination therapy v., 1733–1734  
   RUNX TF localization in acute myelogenous, 335  
 Leukemia cells  
   bisphenol compounds v. differentiation of, 1559, 1559f  
   calcipotriol v., 1734  
   D compounds v., 1730–1734, 1730t, 1731, 1731t  
   molecular mechanisms of D compounds v., 1731–1733  
   1,25(OH)<sub>2</sub>D<sub>3</sub> v. myeloid, 1731  
   1 $\alpha$ OHD<sub>3</sub> v., 1734  
 Leukocytes, antigenic stimulants activating phagocytic function in, 127  
 Libyans, rickets in infant, 795  
 Ligand binding domains (LBDs)  
   coactivator binding v. HVDRR-related mutations in VDR, 1225–1226  
   Glu420Lys, 1226  
   connecting region poorly conserved in, 279–280  
   crystal structure of D NR, 279–288, 280f  
   D analogs inducing conformational change in VDR, 1452f, 1453, 1550, 1550f  
   deltanoids v. nuclear VDR, 1408–1411, 1410f  
   16-ene-24-sulfone deltanoid v. rickets mutant VDR, 1411, 1411f  
   human/rat VDR, 174–176, 175f  
   HVDRR/alopecia from Glu329Lys/366delC mutations in VDR, 1221f, 1226  
   HVDRR-related mutations in VDR, 1222–1226  
   hypothetical conformations of VDR, 1473, 1473f  
   ligand binding changing conformation of VDR, 176, 279, 280f, 293, 294f, 313, 321

Ligand binding domains (*Continued*)

- NRs dimerizing via, 314
- 1,25(OH)<sub>2</sub>D<sub>3</sub> binding v. HVDRR-related mutations in VDR, 1222–1224, 1223f
  - Arg274Leu, 1222–1223, 1223f
  - Cys190Trp, 1223f, 1224
  - His305Gln, 1223, 1223f
  - Ile314Ser, 1223, 1223f
  - Ile268Thr, 1223f, 1224
  - structural analysis of, 1224
  - Trp286Arg, 1223f, 1224
- 1,25(OH)<sub>2</sub>D<sub>3</sub> stabilizing VDR, 313
- proteins with 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>, 387–392
- putative alternative VDR, 400
- “squenching” in NR, 291–292
- structures in hVDR $\Delta$ /zVDR, 284–285, 284f
- topology of hVDR $\Delta$ , 281, 283f
- VDR, 1211–1212, 1211f
- in VDR/DNA binding, 178
- VDR-RXR heterodimerization v. HVDRR-related mutations in VDR, 1224–1225
  - Arg391Cys, 1221f, 1224
  - Gln259Pro, 1221f, 1225
  - Phe251Cys, 1221f, 1225
  - structural analysis of, 1225
- VDR<sub>nuc</sub> v. DBP, 387, 387f
- zVDR, 284, 284f
- zVDR-Gemini channel showing adaptability in, 287–288

## Ligands

- allograft tolerance induced using VDR, 1519
- BPH inhibited by VDR, 1833–1840
- classes of nonsecosteroid D, 1565
- genomic/nongenomic action specificity of, 1461
- hVDR $\Delta$  binding, 280–281
- identification of ODF, 670–673
- immune responses regulated by VDR, 631–643
- immunoregulation by VDR, 633, 643, 643f
- immunosuppressive agents combining with VDR, 642
- nonsecosteroid VDR, 1557, 1558f
- novel mammalian VDR, 225–227, 227f
- potential uncharacterized novel VDR, 234f, 235
- regulatory T cells enhanced by, 636
- structure of hVDR complexed to superagonist, 285–287, 286f
- tissue selectivity in VDR, 271
- VDR immunomodulatory mechanisms in autoimmune disease models, 636–640, 637t
- VDR signaling activated by, 235–237, 236f

## Linkage disequilibrium (LD)

- FokI RFLP surrounded by small, 1128f, 1130
- polymorphisms predicted by, 1126–1127

## Lipids, bile acids in digesting/absorbing, 863

## Lipopolysaccharide (LPS)

- in macrophage 1 $\alpha$ -hydroxylase amplification, 1385–1386, 1385f
- 1,25(OH)<sub>2</sub>D<sub>3</sub> down-regulating NOS II in injection of, 1783

## Liquid chromatography/mass spectrometry (LC/MS),

- 20-methyl-1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> metabolite, 1434, 1435f

## Lithium, D metabolism influenced by, 1255t, 1274

## Lithocholic acid (LCA)

- detoxification amplified by supplemental D, 246, 247f
- in ED-71 synthesis, 1534, 1534f
- intestinal detoxification of, 867–868, 868f
- as nonsecosteroid VDR agonist, 1557, 1558f
- VDR regulating CYP3A-dependent detoxification of, 867

## Liver

- D 25-hydroxylation in, 17–19
- in D metabolism, 1294–1296

Liver (*Continued*)

- D metabolites secreted in, 1295
- D<sub>3</sub> uptake by, 47–48
- DBP production in, 121
- enterohepatic circulation in, 863–864, 1295–1296
- 1,25(OH)<sub>2</sub>D<sub>3</sub>/analog immunoregulatory properties in, 1519
- 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-mediated rapid response in, 386t
- PTHrP expression in, 739t
- rejection inhibited by 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs, 641t
- Liver disease. *See also specific liver diseases*
  - bone disorders associated with, 1303–1306
- Liver X receptor (LXR), cholesterol/bile acid levels controlled by, 865
- LNH. *See* Late neonatal hypocalcemia
- Locke, John, rickets reported by, 967
- Looser's zones
  - impaired mineralization ambiguously shown by, 1043
  - in osteomalacia, 971–973, 972f–973f
  - radionuclide bone scans detecting, 986–988, 989f
  - in severe rickets, 1071
  - in XLH patients, 981, 982f, 984f
- LPS. *See* Lipopolysaccharide
- LXR. *See* Liver X receptor
- Lymphocytes, paracrine 1,25(OH)<sub>2</sub>D suppression of, 1387f, 1388–1389
- Lymphoma, hypercalcemia in, 1361–1362
- Lysosomes, DBP degradation in, 157, 157f
- Lythgoe coupling, in steroid precursors, 1414–1416, 1414f, 1415f

## M

## Macrophages

- 24-hydroxylase enzyme regulation in, 92
- D-1 $\alpha$ -hydroxylase in, 1381–1382, 1382f
- 1 $\alpha$ -hydroxylase v. immune cell regulators in, 1384–1387
- intracrine/autocrine 1,25(OH)<sub>2</sub>D activation of, 1387–1388, 1387f
- 1,25(OH)<sub>2</sub>D-directed 24-hydroxylase activity in, 1383–1384
- PTH/Ca/Phosphate responsiveness lacking in, 1382–1383, 1383f

Magnesium (Mg). *See also* Hypermagnesemia; Hypomagnesemia

- CaR v., 553–554
- jejuno-ileal bypasses reducing serum, 1303
- in PTH secretion, 1053
- supplementation in acute hypocalcemia therapy, 1058

## Magnetic resonance imaging (MRI)

- acid phosphate distribution/crystal structure from, 483
- in evaluating bone metabolic disease, 924
- tumors causing TIO v. whole body, 988

## Malignant hyperthermia, hyperphosphatemia in, 1178

## Malnutrition

- hypocalcemia due to, 1052f, 1055–1056
- in last trimester of pregnancy, 803

## Mammary gland

- D in, 857–858
- development role of D endocrine system, 291
- development v. VDR, 345–346
- VDR expression/role in normal, 1669–1670, 1670t

MAP kinase. *See* Mitogen-activated protein kinaseMAR. *See* Mineral apposition rateMARRS. *See* Membrane-associated rapid response steroid binding protein

## Matrix attachment regions (MARs)

- chromatin units between, 314, 315f
- genomic domain/nuclear scaffold association mediated by, 329f

## Matrix extracellular phosphoglycoprotein (MEPE),

- as phosphatonin/minhibin, 1164, 1166



- Matrix Gla protein (MGP), in mineralization v.  $1\alpha,25(\text{OH})_2\text{D}_3$ , 716
- Matrix metalloproteinase-9 (MMP-9) gene,  $1,25(\text{OH})_2\text{D}_3$  targeting, 566, 567
- Matrix vesicles
- D metabolites modulating PKC in, 586
  - extracellular matrix growth factors activated by, 589–590
  - genomically controlled production of, 589
  - in matrix calcification, 589
  - nongenomic regulation of, 589–591
    - proposed mechanism for, 590–591, 590f
  - $1,25(\text{OH})_2\text{D}_3$  accelerating crystal formation in, 591
  - $1,25(\text{OH})_2\text{D}_3/24,25(\text{OH})_2\text{D}_3$  affecting matrix calcification through, 590–591
  - $\text{P}_i$  transport in, 466
- Maturation (mitosis) promoting factor (MPF), cell cycle G2/M transition regulated by, 1645, 1645f
- Maxacalcitol. *See* 22-Oxa-calcitriol
- Maximum voluntary contraction (MVC)
- D v. veiled Danish Arabs', 1812, 1812f
  - 25OHD v., 1812
- 2MbisP. *See* 2-Methylene-19-nor-(20S)- $1\alpha$ -hydroxybishomopregnacalciferol
- MC1288
- analog-VDR complex stabilized by, 1496
  - chronic graft rejection inhibited by, 642
  - structure v.  $1\alpha,25(\text{OH})_2\text{D}_3$ , 285–287, 286f
  - as superagonist, 1477–1478
  - VDR transcriptional activity v., 1474t
- MC-903
- cellular differentiation assay v., 1543
  - psoriasis v., 1543
- McCollum, E. V., in vitamin A/B/D discoveries, 4
- McCune-Albright syndrome, fibrous dysplasia as component of, 1192
- MCM proteins. *See* Mini-chromosome maintenance proteins
- MCR. *See* Metabolic clearance rate
- 2MD. *See* 2-Methylene-19-nor-(20S)- $1,25$ -dihydroxyvitamin  $\text{D}_3$
- $2\alpha\text{MD}$ . *See*  $2\alpha$ -Methyl-19-nor-(20S)- $1,25$ -dihydroxyvitamin  $\text{D}_3$
- Mediator-D coactivator complex, 265–267
- in comodulator activity integrated model, 300, 300f
  - D analogs recruiting, 1455
  - functionality, 266–267
  - HAT activity absent in, 267, 295
  - identification, 265–266
  - MC1288 enhancing recruitment of, 272–273
  - multiple binding motifs in, 269
  - other complexes closely related to, 266
  - subunit composition, 265t
  - transcription factors interacting with, 269–270
  - unified nomenclature v. DRIP, 295
  - VDR linkage to, 176
  - VDR-RXR heterodimers interacting with, 296, 296f
  - in VDR transcription model, 268–270, 269f
- Medullary thick ascending limbs (MTAL), CaR inhibiting NaCl reabsorption in, 557
- Medullary thyroid carcinoma (MTC)
- 5-HT1 receptor activation v. Ca in, 693, 694f
  - C cells v., 688
  - D analogs v., 696
  - hereditary/sporadic, 688
- Megalin, 157–158, 157f, 158f
- expression v.  $1,25(\text{OH})_2\text{D}_3$  resistance in CKD, 1319
  - in 25OHD $_3$   $1\alpha$ -hydroxylation, 73
  - as 25OHD $_3$ /DBP complex endocytic receptor, 154–156
- Megalin-DBP complexes, in 25OHD $_3$ / $1,25(\text{OH})_2\text{D}_3$  conversion, 125
- Melanin, vitamin D photosynthesis v., 38–39, 40–41
- Melanoma, VDR polymorphisms v., 1146
- Membrane-associated rapid response steroid binding protein (MARRS), odontocytes expressing, 599, 600f
- Membrane VDR (VDR<sub>mem</sub>), 391–392
- membrane-initiated responses v.  $1\alpha,25(\text{OH})_2\text{D}_3$  interacting with, 383
  - rapid responses v.  $1\alpha,25(\text{OH})_2\text{D}_3$  interacting with, 399–400, 399f
- Men. *See also* Prostate cancer
- D intake v. PCa risk in American, 1681
  - normative histomorphometric data for, 956t
  - $1,25(\text{OH})_2\text{D}$  concentration/MCR/PR in young/elderly, 827, 827f
  - PCa in American, 1679
  - testosterone v.  $1,25(\text{OH})_2\text{D}_3$  in hypogonadal, 1261
- Metabolic bone disease
- adverse influences on mineral/skeletal homeostasis in, 915, 915t
  - approaching patients with, 913–928
  - biochemical investigation of, 924–926
  - diagnostic evaluation of, 913–926
  - epidemic, 913
  - histopathological assessment of, 926
  - HPI in addressing, 916
  - laboratory testing for, 921, 921t
  - medical history in evaluating, 914, 915–918, 915t
  - patient complaints in addressing, 915, 916t
  - physical examination for, 916t, 919–921, 919t
  - radiological examination for, 921–924
  - review of systems in addressing, 918
  - treatment, 926–928
- Metabolic clearance rate (MCR), young/elderly men's  $1,25(\text{OH})_2\text{D}$ , 827, 827f
- Metabolism, 15–29, 1000f, 1423–1424
- aging v., 823–833
  - aging v.  $1,25(\text{OH})_2\text{D}$ , 826–831
  - Al v., 1255t, 1270–1271
  - analog, 1423–1443
    - biological systems in studying, 1428–1429, 1428t
    - drug design implications of, 1442–1443
    - examples of, 1429–1440
    - general considerations in, 1423–1429
    - implications from studying, 1440–1443
    - invalid *in vivo/in vitro* comparisons in, 1442
    - non-D-related, 1428–1429
    - pharmacokinetic information correlating with, 1440–1441, 1441t
    - questionably valid assumptions in, 1442
    - radioactive analogs in studying, 1428–1429
  - anticonvulsants v., 1255t, 1264–1265
  - antituberculous agents v., 1255t, 1271
  - bisphosphonates v., 1255t, 1268
  - Ca channel blockers v., 1255t, 1269
  - caffeine v., 1255t, 1271–1272
  - calcitonin v., 1254t, 1256–1257
  - cimetidine v., 1255t, 1270
  - corticosteroids v., 1255t, 1265–1266
  - cyclopropane ring-containing analogs', 1431–1433, 1432f
  - D, 15–29, 16–17
    - mutant mouse metabolic enzyme models v., 105
    - overview, 15–17
    - species variation in, 27–29, 28t
  - D $_2$ 
    - D $_3$  metabolism v., 16–17
    - pathways of, 18f
    - unique aspects in, 25–26
  - D $_3$ , 69–70, 70f, 85–86, 86f, 1000–1002, 1000f
    - pathways of, 16–17, 17f
  - D $_3$  abundance v., 1000f, 1001
  - D $_2$  derivative, 1430–1431

- Metabolism (*Continued*)  
 dihydrotachysterol, 1429–1430, 1430f  
 drugs influencing, 1255t, 1263–1274  
 20-*epi*-/20-methyl analog, 1433–1434, 1433f, 1435f  
 estradiol v., 1254t, 1259–1261  
 ethanol v., 1255t, 1266  
 exogenous/stimulated PTH v., 1253–1255, 1254t  
 fluoride v., 1255t, 1273  
 gastrointestinal disease v., 1293–1297  
 GH/IGF-I v., 1254t, 1258  
 GH v., 1254t, 1257  
 GIO v., 1239–1248  
 heparin v., 1255t, 1269–1270  
 homologated analog, 1434–1436  
 hormones influencing, 1254t, 1263–1274  
 in HVO, 1039–1040  
 D-24-hydroxylase in, 1459–1461, 1460f  
 hypolipidemics v., 1255t, 1267–1268  
 IFN $\gamma$  v., 1254t, 1263  
 immunosuppressants v., 1255t, 1272–1273  
 insulin v., 1254t, 1259  
 ketoconazole v., 1255t, 1266–1267  
 kinetics of 1,25(OH) $_2$ D, 828  
 lithium v., 1255t, 1274  
 liver's roles in, 1294–1296  
 in normal/neoplastic colon cells, 1715–1719  
 olestra v., 1255t, 1273  
 orlistat v., 1255t, 1274  
 oxa-group containing analog, 1438  
 phosphate homeostatic disorders v. paradoxical regulation of, 1161  
 P $_i$ -dependent modulation of, 1161–1162  
 progesterone v., 1254t, 1261–1262  
 prolactin v., 1254t, 1258  
 prostaglandins v., 1254t, 1262–1263  
 PTHrP v., 1254t, 1255–1256  
 reciprocal regulation of phosphate homeostasis, D, 1159  
 sex steroids v., 1254t, 1259–1262  
 testosterone v., 1254t, 1261  
 theophylline v., 1255t, 1272  
 thiazide diuretics v., 1255t, 1268–1269  
 thyroid hormone v., 1254t, 1262  
 TNF $\alpha$  v., 1254t, 1263  
 unsaturated analog, 1436–1437  
*in vitro* regulation by 1,25(OH) $_2$ D $_3$ /EGF, 1717  
 Metabolites, early evidence of converted, 6–7  
 Metastasis, D compounds v., 1576  
 Metastatic calcification  
   in arteries/around joints, 979, 980f  
   chronic renal failure causing, 979  
   treating, 979, 980f  
 Mg. *See* Magnesium  
 MGP. *See* Matrix Gla protein  
 MI. *See* Mineralization index; Myocardial infarction  
 Mice. *See also specific types of mice*  
   in coculture system recruiting osteoclasts, 666–667, 667f  
   1,25(OH) $_2$ D $_3$  v. diabetes/MS in NOD, 1404  
 Michaelis-Menten equation  
   Ca flux described by, 412  
   high dose intermittent 1,25(OH) $_2$ D $_3$  fitted to, 1742, 1743f  
 Miconazole, kidney 1 $\alpha$ -hydroxylase activity regulated by, 78  
 Microcomputerized tomography ( $\mu$ CT), bone structural data  
   provided by, 481  
 Microvillar membrane. *See* Brush border  
 Middle Easterners  
   low 25OHD in immigrant, 1026  
   rickets in immigrant, 968–971  
 Migraine, 1,25(OH) $_2$ D $_3$  repression of CT/CGRP expression v., 690  
 Mineral apposition rate (MAR)  
   bone formation indices derived from, 955–956  
   ED-71 v. ovariectomized rat, 1537, 1537f  
   in Mlt, 1033  
   OCT v., 1528, 1529t  
 Mineral homeostasis, 411–559, 453–469  
   adverse influences on, 915, 915t  
   clinical disorders of phosphate, 1159–1180, 1164t  
   ECaCs v. Ca, 430–432  
   factors causing disorders in phosphate, 1162, 1164t  
   fetal/maternal Ca, 853–854  
   kidney in, 515–528  
   maternal D status v. neonatal Ca, 843  
   metabolic bone disease diagnosis v., 914  
   1,25(OH) $_2$ D $_3$  regulating Ca/P, 1403  
   P $_i$ , 453–469  
     extracellular, 453–455, 454f  
   PTHrP in fetal C9, 3–4  
   regulation of P $_i$ , 1159–1161  
   systemic/intracellular Ca $^{2+}$ , 751  
   VDR ablation v., 341–345  
   VDR-null mice skin change v., 346f, 347  
   VDR-null mice with normal, 344  
 Mineralization, 477–490  
   bone histomorphometry assessing, 954–957  
   complex mineral transport in, 1044  
   D/D metabolites influencing, 478–480, 565–571  
   D-deficiency decreasing, 484, 485f  
   D-deficiency v., 487–488  
   D influencing, 483–487, 565–566  
   D v. cell/matrix molecule, 479t, 484–487  
   D v. pathogenesis of impaired, 1040–1044  
   definitions/terminology, 477–478  
   dynamic indices of, 955–957  
   epitaxial/heterogeneous crystal formation in, 477  
   gene expression v. 1 $\alpha$ ,25(OH) $_2$ D $_3$  during, 715–716  
   histology, 1036t  
   hypocalcemia due to accelerated skeletal, 1057  
   maternal D status v. infant, 842–843  
   microscopic examination of *in situ*, 1029–1030  
   in model systems with D alterations, 487–490  
     variations/dependencies, 487  
   morphologic/biochemical aspects of, 1029–1031  
   normocalcemic/D-deficient, 1043  
   1 $\alpha$ ,25(OH) $_2$ D $_3$  v. available Ca in, 711  
   osteoblasts influencing, 1044  
   osteoid indices in recognizing impaired, 1034–1035  
   as phase transformation, 1030  
   phosphatonins/minhibins regulating, 1163  
   physical chemistry of, 478, 479t  
   possible D targets influencing, 509–510  
   precipitation in, 483–484  
   primary/secondary, 1032  
   quantifying tissue, 480–483  
     ash weight/density in, 481  
     mineral characterization in, 481–483, 482f  
     questions in, 480  
   radiographic methods showing, 480–481  
   two types of bone, 1030–1031  
   type I collagen required for bone matrix, 703  
   unexpected/dystrophic, 477–478  
   VDR alteration v., 488–489, 489f  
   *in vitro*, 483  
 Mineralization index (MI), osteomalacia diagnosed with,  
   1035–1036

Mineralization lag time (Mlt), 957  
 in osteoid accumulation/osteomalacia pathogenesis, 1033–1034, 1033f  
 osteomalacia defined using, 1035–1036  
 Mini-chromosome maintenance (MCM) proteins, in DNA licensing/replication, 1644–1645  
 Mitogen-activated protein (MAP) kinase  
 cascade up-regulation, 888  
 CGRP transcription controlled by, 692–693, 692f  
 pathways in  $1,25(\text{OH})_2\text{D}_3$  differentiation signaling, 1638–1639, 1638f  
 Mitosis, MPF regulating cell cycle transition to, 1645, 1645f  
 Mixed-function oxidases, in  $25\text{OHD}_3$   $1\alpha$ -hydroxylation, 71–73, 71f  
 Mlt. *See* Mineralization lag time  
 MMP-9 gene. *See* Matrix metalloproteinase-9 gene  
 Monocytes  
 24-hydroxylase enzyme regulation in, 92  
 intracrine/autocrine  $1,25(\text{OH})_2\text{D}_3$  interaction with, 1387–1388, 1387f  
 Moroccans, serum  $25\text{OHD}/\text{PTH}$  in dark-skinned Dutch, 794  
 2MP. *See* 2-Methylene-19-nor- $1\alpha$ -hydroxyhomopregnacalciferol  
 MPF. *See* Maturation (mitosis) promoting factor  
 2Mpregna. *See* 2-Methylene-19-nor- $1\alpha$ -hydroxypregnacalciferol  
 MRI. *See* Magnetic resonance imaging  
 MS. *See* Multiple sclerosis  
 MTAL. *See* Medullary thick ascending limbs  
 MTC. *See* Medullary thyroid carcinoma  
 $\mu\text{CT}$ . *See* Microcomputerized tomography  
 Multiple sclerosis (MS), 1780  
 $\text{D}_3$  v., 999t  
 EAE role supporting  $1,25(\text{OH})_2\text{D}_3$  involvement in, 1784  
 $1,25(\text{OH})_2\text{D}_3$  v. NOD mouse, 1404  
 VDR polymorphisms v., 1147  
 Muscle  
 biopsies in HDM clinical studies, 1811  
 Ca v. D deprivation/repletion, 1810f, 1811  
 cell culture/animal studies of D, 1809–1811  
 contraction, 1807, 1807f, 1808f  
 contraction/relaxation v. D, 1809, 1809f  
 D influencing, 883–894  
 D influencing striated, 1809–1811  
 $\text{D}_3$  metabolites v. phosphate uptake by, 887  
 dystrophic mineral deposits in, 478t  
 falls v. D's influence on, 1805–1817  
 fiber types, 1808  
 filament components, 1807, 1807f  
 function in HDM clinical studies, 1811–1813  
 function v. VDR polymorphisms, 1813  
 genomic/nongenomic D influence on striated, 1809  
 $1\alpha,25(\text{OH})_2\text{D}_3$  mechanisms in, 889–893  
 genomic, 889–890  
 nongenomic, 890–893, 890f  
 $1\alpha,25(\text{OH})_2\text{D}_3$  regulating Ca homeostasis in, 886–887  
 $1\alpha,25(\text{OH})_2\text{D}_3$ -stimulated signaling in growth of, 888–889, 889  
 physiology v. HDM, 1806–1808, 1806f, 1807f  
 power v. serum  $25\text{OHD}$ , 1812–1813, 1812f  
 proliferation/differentiation influenced by  $1\alpha,25(\text{OH})_2\text{D}_3$ , 887–889  
 regeneration v.  $1,25(\text{OH})_2\text{D}$ , 1816  
 tyrosine phosphorylation mediating  $1\alpha,25(\text{OH})_2\text{D}_3$  in growth of, 888  
 VDR in, 885–886  
 VDR polymorphisms v. strength of, 1143  
 weakness with D insufficiency, 1090

Muscle cells  
 ATP supplying energy to, 1808  
 Ca homeostasis in, 1807–1808, 1808f  
 $1,25(\text{OH})_2\text{D}_3$ /deltanoid-induced differentiation modeled in, 1637t  
 MVC. *See* Maximum voluntary contraction  
 Myelodysplasia,  $1\alpha$ -(OH) $\text{D}_3$  v., 1573  
 Myocardial infarction (MI), VDR polymorphisms v., 1148  
 Myopathies  
 animal model studies of, 884–885  
 clinical background of, 883–884  
 D-dependent, 883–885, 893

## N

Na. *See* Sodium  
 $\text{Na}/\text{P}_i$  cotransporters, type I/II/III, 1159–1160  
 $\text{NaCl}$ . *See* Sodium chloride  
 NADPH-ferredoxin reductase, in  $25\text{OHD}_3$   $1\alpha$ -hydroxylation, 71f, 73  
 Native Americans. *See* American Indians  
 NCoA62/SKIP coactivator complex, 296, 297f  
 in comodulator activity integrated model, 300, 300f  
 transcription/mRNA slicing coupled by, 298  
 VDR gene expression comodulated by, 296–297, 297f  
 VDR interaction independent of AF-2 domain, 296  
 NCoR, NR co-repressor, 298–299  
 NDOs. *See* Non-digestible oligosaccharides  
 Necrosis, as inflammatory process component, 126  
 Negative VDRE (nVDRE)  
 as complex VDR binding site, 321–322  
 positive VDREs v., 321–322  
 VDR-RXR heterodimer repressing transcription through, 309–310, 310f  
 Neonatal severe hyperparathyroidism (NSHPT), homozygous inactivating CaR mutations causing, 553  
 Nephrolithiasis  
 in IH, 1142, 1339–1352  
 renal histopathology in Ca oxalate, 1341  
 Nephron  
 Ca reabsorption in, 519, 520f  
 $25\text{OHD}_3$  in, 519  
 Nerve growth factor (NGF),  $1,25(\text{OH})_2\text{D}_3$  stimulating, 1781–1782  
 Nervous system  
 calbindin- $\text{D}_{28\text{K}}$  in, 726–727, 730t  
 CKD/ $1,25(\text{OH})_2\text{D}_3$  deficiency/resistance in, 1327  
 Neurotrophic factors,  $1,25(\text{OH})_2\text{D}_3$  influencing, 1781–1782  
 Neurotrophin receptor,  $1,25(\text{OH})_2\text{D}_3$  regulating low-affinity, 1782  
 New World primates  
 biochemical phenotype of rachitic, 352–353, 353f  
 D hormone resistance in, 352, 354–355  
 early evolution of, 351, 352f  
 high  $1,25(\text{OH})_2\text{D}_3$  levels in, 353, 353f  
 IDBP function in, 359–360, 360f  
 IDBPs over-expressed by, 359  
 VDP carrying  $25\text{OHD}$  in, 352  
 NF- $\kappa\text{B}$ , activation in osteoclast differentiation, 678  
 NGF. *See* Nerve growth factor  
 Nigerians, sunlight exposure v. rickets in, 1066–1067  
 Nitric oxide (NO), in macrophage  $1\alpha$ -hydroxylase regulation, 1386  
 NLSs. *See* Nuclear localization sequences  
 NMR. *See* Nuclear magnetic resonance  
 NO. *See* Nitric oxide  
 Non-digestible oligosaccharides (NDOs), enhancing Ca absorption from foods, 818

Non-Hodgkin's lymphoma  
 extrarenal D metabolite overproduction in, 1390t, 1391–1392  
 $1\alpha$ -(OH) $D_3$  v., 1573  
 PTHrP associated with end-stage, 740  
 Nongenomic response, steroid hormones in, 98–99  
 Normocalcemia, CaR in restoring, 551  
 NOS II. *See* Type II nitric oxide synthase  
 NPC. *See* Nuclear pore complex  
*NPT2a*, not responsible for HHRH, 469  
*NPT2a* gene, expression/protein production regulation in kidney, 1160–1161, 1160f  
*NPT2a* protein  
   mediating Na/P<sub>i</sub> cotransport, 459  
   Na/P<sub>i</sub> transport changes v., 1160–1161  
   PTH/AKAP79/RAP retrieving, 461  
   regulation, 459–462, 461t  
   signaling mechanisms in insertion/retrieval of, 1161  
   structure-function, 459, 460f  
*NPT2b* protein, molecular mechanisms regulating, 456–457, 457t  
 NRs. *See* Nuclear receptors  
 NSHPT. *See* Neonatal severe hyperparathyroidism  
 Nuclear localization sequences (NLSs)  
   calcitriol-induced transcription v. mutant, 372f  
   hVDR putative, 368–369, 368f  
   RXR, 369, 370f  
 Nuclear magnetic resonance (NMR), acid phosphate  
   distribution/crystal structure from, 483  
 Nuclear pore complex (NPC)  
   nucleocytoplasmic macromolecule transport through, 365–374, 367f  
   VDR/RXR exiting nucleus through, 366f, 369  
 Nuclear receptors (NRs), 279  
   apo/holo forms of, 279  
   bile acid metabolism regulated by, 865–866  
   co-repressors in, 292, 293f, 298–299  
     Alien, 299  
     hr, 299  
     SMRT/NCoR class of, 298–299  
   comodulators linking VDR/PIC, 292, 293f  
   crystal structures of LBDs in, 279–288, 280f  
   DNA response element recognition by, 230, 231f  
   everted repeats in, 317–319, 318f  
   export of, 368  
   first described defect in superfamily of, 1218  
   human, 225, 226f–227f  
   interaction domains/coactivators in, 235–237  
   N-terminal variants of, 195  
    $1,25(OH)_2D_3$  inducing focal accumulation of, 374–375, 375f  
   protein interactions facilitating export of, 374  
   RNA processing linked to coactivators in, 297–298  
   RXR as heterodimeric partner for, 291, 292f  
   VDRs in superfamily of, 225–228  
 Nuclear VDR (VDR<sub>nuc</sub>)  
    $1\alpha,25(OH)_2D_3$  gene transcription mediated by, 383  
   deltanoids selectively modulating, 1408–1411, 1410f  
   LBD of human, 387–388, 387f, 389f, 390f–391f, 398f  
   LBD v. DBP LBD, 387, 387f  
    $1\alpha,25(OH)_2D_3$  biological actions mediated by, 384–385, 386t  
   structure v. DBP structure, 391, 392t  
   tissue distribution of  $1\alpha,25(OH)_2D_3$ , 384–385, 385t  
 Nucleosome, hnRNP insertion in, 358  
 Nucleus  
   acceptor sites in, 334  
   architectural parameters in, 335–336  
   gene expression in architecture of, 328–329, 329f, 330f  
   gene expression regulatory component scaffolding in, 332–333

Nucleus (*Continued*)  
   import/export mechanisms in, 365–368, 367f  
   protein export retarded by docking in, 374  
   signal pathway targeting/integration in compartments of, 335  
   skeletal gene expression regulatory machinery organization in, 327–336  
   skeletal regulatory factor trafficking in, 334–335  
   transcription machinery/factor complexes compartmentalized in, 332  
   transcriptionally active compartments in, 334–335  
   VDR translocation to, 1452f, 1454  
 Nutrition, early research in, 3  
 Nutritional recovery syndrome, hypophosphatemia in, 1177  
 nVDRE. *See* Negative VDRE

## O

OA. *See* Osteoarthritis  
 Obesity  
   bone histomorphometry in, 795–796  
   bone mass v., 795  
   D metabolism v., 795  
 OC. *See* Osteocalcin  
 OC gene  
   chromatin organization of, 330–332  
   nuclear/gene expression relationship represented by, 328–329, 331f  
 OCIF. *See* Osteoclastogenesis inhibitory factor  
 OCIF/OPG  
   characterization, 668–670  
   discovery, 668–670  
 OCT. *See* 22-Oxa-calcitriol  
 ODF. *See* Osteoclast differentiation factor  
 Odontoblasts  
   D-dependent molecules in, 602–604, 603f  
   dentin elaborated by, 599  
   PHEX expressed in, 467  
   VDR gene/MARRS expressed in, 599, 600f  
 Odontogenesis, process/functions, 599–602  
 $1,25(OH)_2D_3$ . *See*  $1,25$ -Dihydroxyvitamin D  
 $1,25(OH)_2D_2$ . *See*  $1,25$ -Dihydroxyvitamin D<sub>2</sub>  
 $1,25(OH)_2D_3$ . *See*  $1,25$ -Dihydroxyvitamin D<sub>3</sub>  
 $1\alpha,25(OH)_2D_3$ . *See*  $1\alpha,25$ -Dihydroxyvitamin D<sub>3</sub>  
 25OHD. *See* 25-Hydroxyvitamin D  
 25OHD<sub>3</sub>. *See* 25-Hydroxyvitamin D<sub>3</sub>  
 25,26(OH) $_2D_3$ . *See* 25,26-Dihydroxyvitamin D<sub>3</sub>  
 OHO. *See* Tumor-induced osteomalacia  
 Olestra, D metabolism influenced by, 1255t, 1273  
 Omt. *See* Osteoid maturation time  
 Oncogenes  
   in cell cycle/apoptosis control, 1577–1580  
    $1,25(OH)_2D_3$ /EB1089 regulating breast cancer cell, 1664–1665  
    $1,25(OH)_2D_3$  regulating expression of, 1577–1579  
 Oncogenic hypophosphatemic osteomalacia (OHO).  
   *See* Tumor-induced osteomalacia  
 Oncology,  $1,25(OH)_2D_3$ / $1,25(OH)_2D_3$  analogs in, 1741–1747  
 OPG. *See* Osteoprotegerin  
 OPN. *See* Osteopontin  
 ORC proteins. *See* Origin recognition complex proteins  
 Origin recognition complex (ORC) proteins, in DNA  
   licensing/replication, 1644–1645  
 Orlistat, D metabolism influenced by, 1255t, 1274  
 OS/BS. *See* Osteoid surface per unit of bone surface  
 Osteoarthritis (OA)  
   VDR polymorphisms v., 1144–1145  
   in XLH patients, 983

- Osteoblast genes, D *in vivo* response in, 566
- Osteoblasts
- in BMU termination, 503
  - BMUs assembling teams of, 501–502
  - bone formation by, 498
  - calbindin-D<sub>9K</sub>/D<sub>28K</sub> in, 724–725, 730t
  - as D analog therapy target, 1501
  - D compounds v. apoptosis of, 1498
  - D-dependent molecules in, 602–604, 603f
  - D influencing differentiation/activity of, 649–658
  - death of, 506
  - different dexamethasone/1,25(OH)<sub>2</sub>D<sub>3</sub> influences on, 652
  - differentiation of, 712–713
    - dual role of 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> in, 713–714, 714f
    - gene expression sequence v., 328
    - nuclear architecture v. transcription during, 335
    - 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> v., 712–714, 712f
  - factors stimulating Na/P<sub>i</sub> transport in, 466, 466t
  - glucocorticoids increasing differentiation of, 1240
  - L-type VSCC v. Ca<sup>2+</sup> influx into, 754–755, 755f
  - 2MD inducing mineralization in, 1546–1547, 1547f
  - Mlt v. age of, 1033–1034, 1033f
  - Na/P<sub>i</sub> transport in renal proximal tubular cells v., 461t, 466, 466t
  - nonadherent marrow cells in 1,25(OH)<sub>2</sub>D<sub>3</sub> influencing, 652–653
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> causing gene up-regulation in mature, 650f, 652–653
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> deficiency v. mineralization by, 1043–1044
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> directly affecting, 703
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> having biphasic effects on, 650
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> influencing, 1240–1241
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> influencing *in vitro*, 649–656
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> influencing proliferation of precursors to, 653–654
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> modifying hormone/GF responsiveness of, 654–655
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> “pushing” maturity of, 651–652
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating genes influencing proliferation/differentiation of, 653–654
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating products of, 654
  - as 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> source, 717
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> target proteins with *in vitro*, 566
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. heterogeneity of, 652
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. *in vitro* differentiation pathway/status of, 649–653, 650f
  - 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> v. gene expression in proliferating, 714–715
  - osteocalcin promoter remodeling v. phenotype development in, 331f
  - osteoclast differentiation/activation regulated by, 677, 677f
  - PHEX expressed in, 467
  - site-dependent differential activity of, 599
  - VSCC/VICC interactions in, 755, 755f
- Osteocalcin (OC), 176
- D deficiency rickets v., 1070
  - expression stimulated by 1,25(OH)<sub>2</sub>D<sub>3</sub>, 486–487
  - human gene promoter induced by 1,25(OH)<sub>2</sub>D<sub>3</sub>, 176–177
  - human/rat 1,25(OH)<sub>2</sub>D<sub>3</sub>/PTH v., 567, 567f
  - mineral properties in KO animals, 479t
  - in mineralization, 479t
  - in mineralization v. 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>, 715–716
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> inducing/glucocorticoids suppressing, 1240
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating matrix protein expression in, 703
  - regulation as VDR-regulated transcription model, 176–178
  - VDR target gene polymorphism associated with, 246
- Osteoclast differentiation factor (ODF)
- ligand identification, 670–673
  - molecular cloning, 670–672, 671f
  - OPG-binding protein as candidate, 670
  - in osteoclastogenesis hypothesis, 667–668, 668f
- Osteoclastogenesis, 665–681
- factors in molecular mechanism of, 668–676
  - RANK as signaling receptor in *in vitro*, 673–674, 673f
  - RANKL-RANK signal transduction pathways in, 676–678
- Osteoclastogenesis inhibitory factor (OCIF), isolation/cloning, 668
- Osteoclasts
- in BMU origination, 503
  - bone resorption by, 498
  - molecular mechanisms forming/activating, 674, 676f
  - mouse coculture system recruiting, 666–668, 667f
  - Na/P<sub>i</sub> transport in, 466–467
  - OC recruiting, 487
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. bone resorption by, 678–680, 679f
  - RANKL/ODF differentiating osteoclast progenitors to, 672
- Osteocytes, PHEX expressed in, 467
- Osteoid
- accumulation indices, 1034–1035
  - accumulation of unmineralized, 1031–1035
  - in growing skeleton, 1031
  - histomorphometric measurement of, 954–955, 955f
  - kinetics, 1031
  - Mlt in understanding accumulation of, 1033–1034, 1033f
- Osteoid-bone interface, 1031–1032
- Osteoid maturation time (Omt), 957
- human Mlt v., 1032f, 1033
- Osteoid seams, 1032
- in adult skeleton, 1031–1034
  - in bone formation, 1032–1033, 1032f
  - D metabolites’ influence on BMAR v., 657
  - width measurement of, 955f
- Osteoid surface per unit of bone surface (OS/BS)
- osteoid seam life span/FP determining, 1034
  - O.Th v., 1035, 1035f
- Osteoid thickness (O.Th)
- in Mlt, 1033
  - osteomalacia defined using, 1035–1036
- Osteoid volume per unit of bone volume (OV/BV),
- aging/osteoporosis increasing, 1034
- Osteomalacia, 967. *See also* Tumor-induced osteomalacia
- Al toxicity in, 980, 1270
  - biochemical evolution of, 1036–1039
  - causes of, 925–926, 925t–926t
  - characteristics in CYP27B1-null mice, 703
  - D<sub>3</sub> curing, 999t
  - D deficiency causing, 566
  - D/intestinal Ca absorption v., 703
  - D metabolism in, 1039–1040
  - focal, 958
  - generalized, 957–958, 957f
  - histological diagnosis of, 957–958
  - histological evolution/kinetic definition of, 1035–1036
  - histomorphometric diagnosis of, 955
  - hypovitaminosis D causing, 154, 156t
  - Looser’s zones in, 971–973, 972f–973f, 981, 982f, 984f
  - mean Mlt/mean O.Th in defining, 1035–1036
  - mineralization index in diagnosing, 1035–1036
  - mineralization v. bone properties in, 489–490, 490f
  - Mlt in understanding pathogenesis of, 1033–1034, 1033f
  - in 1 $\alpha$ (OH)ase-null mice, 489
  - osteoid seam width/Mlt in, 957
  - pathogenesis, 1029–1044
  - in postgastrectomy bone disease, 1299, 1300
  - radiology of, 967–990
  - radiology of D-deficiency, 971–973
  - rickets defined v., 1031
  - risk v. race/population, 789, 790t

- Osteomalacia (*Continued*)  
 secondary hyperparathyroidism in, 973, 975f  
 VDR ablation v., 342–343
- Osteopenia  
 atrophic rickets characterized by, 1071  
 D deficiency v., 510  
 premature infant risk criteria for, 812, 812t  
 renal disease/bone resorption causing, 979
- Osteopetrosis  
 bone formation/resorption imbalance causing, 665  
 in c-src KO mice, 677
- Osteophytosis, VDR in, 1144–1145
- Osteopontin gene, VDR homodimer-mediated activation v., 179–180
- Osteopontin (OPN)  
 mineral properties in KO animals, 479t  
 in mineralization, 479t  
 1,25(OH)<sub>2</sub>D<sub>3</sub> increasing synthesis of, 567–568  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating matrix protein expression in, 703  
 1,25(OH)<sub>2</sub>D<sub>3</sub> up-regulating, 487
- Osteoporosis, 1101–1114. *See also* Glucocorticoid-induced osteoporosis  
 in African-Americans/Caucasians, 816  
 bone formation/resorption imbalance causing, 665  
 calbindin-D<sub>28K</sub> v. apoptotic cell death in, 727  
 D in treatment of established, 1109–1114  
 D supplementation in treatment of, 1113–1114  
 D v. mineralization in, 489–490  
 D<sub>3</sub> v., 999t  
 ED-71 v.  
   clinical results using, 1537–1539, 1538f  
   development of, 1525, 1534–1539  
   planned studies of, 1539  
   preclinical results using, 1534–1537  
   safe dosage for, 1537–1538  
 increased net bone resorption in type I, 1109, 1109f  
 1,25(OH)<sub>2</sub>D<sub>3</sub> in treating, 1111  
 1,25(OH)<sub>2</sub>D safety margin v., 998  
 PTH/25OHD in type II, 1109  
 rationale/principles of D treatment of, 1109–1111  
 renal disease/bone resorption causing, 979  
 Ro 26–9228 hybrid deltanoid v., 1416–1417, 1417f  
 VDR gene association studies in, 1141–1144  
 VDR gene polymorphisms predicting, 184  
 VDR target gene polymorphism associated with, 246
- Osteoprotegerin (OPG)  
 bone-resorbing factors regulating, 675–676, 676t  
 clinical trials, 676  
 discovery, 668  
 as RANKL decoy receptor, 568  
 regulating expression of, 674–676  
 structure of human, 668, 669f  
 in TNF receptor family, 668
- Osteosclerosis  
 radiology of, 981, 982f  
 in renal disease/secondary hyperparathyroidism, 977, 977f
- O.Th. *See* Osteoid thickness
- OV/BV. *See* Osteoid volume per unit of bone volume
- Ovarian cancer, VDR in, 856
- Ovary  
 D in, 856  
 VDR ablation reducing aromatase activity in, 345
- 22-Oxa-calcitriol (OCT)  
 adverse reactions to topical, 1533–1534  
 angiogenesis v., 1574  
 BFR v., 1528, 1529t
- 22-Oxa-calcitriol (*Continued*)  
 bone influenced by, 1527–1529, 1529t  
 bone metabolism marker changes v., 1531, 1532f  
 breast cancer cells/tumors v., 1669  
 cortical bone formation rate v., 1531, 1533f  
 development, 1525–1534  
 MAR v., 1528, 1529t  
 mechanism of action, 1479–1480  
 metabolism, 1438  
 as noncalcemic analog, 1440, 1441t  
 PCa v., 1690  
 psoriasis vulgaris v., 1531–1534, 1533f  
 PTH v., 1527, 1527f, 1528f  
 PTHrP gene expression/secretion inhibited by, 1576  
 reduced parathyroid VDR v., 1317, 1318f  
 secondary hyperparathyroidism v., 1527–1531  
 structure, 1479f, 1525, 1526f  
 synthesis for large-scale production, 1525–1526, 1526f
- Oxidation-reduction (redox) homeostasis  
 D/cellular response to, 761–768  
 ROS v., 761–763
- P**
- P. *See* Phosphorus
- PAD. *See* Peripheral arterial vascular disease
- Paget's disease of bone, calcitonin treating, 1257
- Pakistanis, D metabolism in, 790t, 792–793
- Pancreas  
 calbindin-D<sub>28K</sub> in, 725–726, 730t  
 CKD/1,25(OH)<sub>2</sub>D<sub>3</sub> deficiency/resistance in, 1326
- Pancreatic disease, metabolic bone disease v., 1301
- Pancreatitis, hypocalcemia/tetany in, 1057
- Paracellular path, CA absorption by, 421–422  
 D-dependency of, 412f, 421–422  
 thermodynamic parameters of, 421
- Parathyroid gland. *See also* Hyperparathyroidism;  
 Hypoparathyroidism; Neonatal severe hyperparathyroidism  
 Ca<sup>2+</sup> elevation v., 553f, 554–555, 555f  
 CaR activity v. D effect on, 543  
 CaR in, 554–556  
 cell proliferation v. secondary hyperparathyroidism, 544–547  
 CKD with low 1,25(OH)<sub>2</sub>D<sub>3</sub> or 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR resistance in, 1322–1325, 1323f, 1324f, 1325f  
 D in, 537–547  
 hyperplasia v. TGFα/EGFR expression in CKD, 1323–1324, 1323f, 1324f  
 low 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1324–1325, 1325f  
 model of factors regulating, 546f  
 1,25(OH)<sub>2</sub>D<sub>3</sub> deficiency v. VDR content in, 1317, 1318f  
 as 1,25(OH)<sub>2</sub>D<sub>3</sub> target organ, 539, 540f  
 physiological insights from homozygous null mice, 545–547  
 PTHrP expression in, 739t  
 removal v. rat 1,25(OH)<sub>2</sub>D synthesis, 463–464  
 VDR/CaR interactions in, 556, 556t
- Parathyroid hormone (PTH)  
 age/glomerular filtration rate v. serum, 1024  
 age v., 1106–1107  
 biosynthesis, 537  
 blacks showing decreased skeletal sensitivity to, 791  
 bone loss/D deficiency v., 509–510  
 bone loss v. age-related increase in, 1107, 1108f  
 Ca channel blockers v., 1269  
 Ca reabsorption in D-replete/deficient rats v., 518–519, 519f  
 Ca v., 552, 553f

Parathyroid hormone (*Continued*)

- CaR mutations v., 555
- CaR v., 537–538
- CKD impairing 1 $\alpha$ -hydroxylase induction by, 1315–1316
- CYP24A1 expression regulated by, 93, 94f
- CYP24A1 promoter expression/CYP24A1 activity v., 99–100
- D bone resorption inhibition v., 570
- as D deficiency/insufficiency/repletion index, 1085–1086
- D insufficiency increasing serum, 1088–1089
- D metabolism influenced by exogenous/stimulated, 1253–1255, 1254t
- degradation in PTH control, 544
- 24,25-dihydroxyvitamin D<sub>3</sub> suppressing secretion of, 16
- diuretics v. serum, 1024
- early D deficiency associated with normal, 1069
- ECF [Ca<sup>2+</sup>] demand response mediated by, 776
- effector mechanism independence/redundancy, 778
- estrogen deficiency v. age-related increase in, 1108–1109, 1108f
- estrogen influencing serum, 1024
- function v. age, 1106
- as HDM cause, 1815
- hypocalcemia due to abnormal availability of, 1052–1054
- hypocalcemia due to resistance to, 1054
- hypocalcemia v. defective secretion of, 1053–1054
- hypocalcemia v. postsurgery reduction in, 1053
- intravenous 1,25(OH)<sub>2</sub>D<sub>3</sub> in renal failure v., 1329–1330, 1330f
- kidney 1 $\alpha$ -hydroxylase activity regulated by, 76–77, 76t, 77t
- kidney/parathyroid VDR regulated by, 522–523
- long-term OCT administration v., 1530–1531, 1530f
- macrophages unresponsive to, 1382–1383, 1383f
- mechanisms of age-related increases in, 1106–1107
- 2MP/2Mbisp/2Mpregna v., 1552–1553
- noncalcemic D analogs suppressing, 1449–2898
- OCT v., 1527, 1527f
- in 1,25(OH)<sub>2</sub>D<sub>3</sub> feedback loop, 539
- 1,25(OH)<sub>2</sub>D<sub>3</sub> production increased by, 19–20
- 1,25(OH)<sub>2</sub>D synthesis influenced by, 830–831, 830f
- 25OHD v., 1088, 1088f
- osteoblast Ca<sup>2+</sup> entry stimulated by, 755, 755f
- osteoblast Na/P<sub>i</sub> transport stimulated by, 466, 466t
- during pregnancy, 839
- renal P<sub>i</sub> excretion decreased by, 516t
- renal P<sub>i</sub> reabsorption regulated by, 460–461, 461t
- resistance in rachitic children, 1069
- secretion control in dialysis patients, 1822–1823
- secretion suppression set-point v. age, 1107
- secretion v. cardiovascular disease, 901–902
- serum Ca defended by, 1050
- serum 25OHD v. serum, 1020–1022, 1021f
- type I collagen synthesis inhibited by, 704
- VDR expression affected by, 208
- VDR level 1,25(OH)<sub>2</sub>D<sub>3</sub> regulation of, 540f, 541–542
- Parathyroid hormone-related peptide (PTHrP), 737–746
  - antisense RNA technology inhibiting production of, 743
  - D compounds inhibiting expression/secretion of, 1576–1577
  - D therapy v. production of, 741t, 743–746
  - gene/gene products, 737–738
  - hypercalcemic cancer patient survival v., 740–742, 740f
  - immunotherapy neutralizing, 742–743
  - mechanism, 738–739
  - normal/cancer cells/tissues expressing, 739–740, 739t
  - production regulation, 739–742
  - SCCs elaborating, 612
  - stimulators/inhibitors in normal/cancer cells/tissues, 740–742, 741f
  - therapeutic strategies inhibiting production of, 742–746, 742f

## Parathyroid hormone-related protein (PTHrP)

- D metabolism influenced by exogenous/stimulated, 1254t, 1255–1256
- in placental Ca transport, 853
- synthetic molecules' actions v., 1256
- Parathyroid hyperplasia
  - in D therapy prognosis, 1823, 1824f
  - regression of, 1825–1826
- Parkinson's disease (PD), 765, 1779
  - D analogs treating, 1785
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> antioxidant activities in, 764t, 766–767
- Past medical history (PMH), in approaching metabolic bone disease, 917
- PBAF. *See* Polybromo- and BAF-containing complex
- PBC. *See* Primary biliary cirrhosis
- p450c24. *See* 24-Hydroxylase
- PCa. *See* Prostate cancer
- PCIT. *See* Percutaneous calcitriol injection therapy
- PCR. *See* Polymerase chain reaction
- PCTs. *See* Proximal convoluted tubules
- PD. *See* Parkinson's disease
- PDDR. *See* Pseudo-vitamin D-deficiency rickets
- PEIT. *See* Percutaneous ethanol injection therapy
- PENK. *See* Proenkephalin
- Peptide growth factors, in keratinocyte growth/differentiation, 614–615
- Peptide hormones, VDR expression affected by, 207–208
- Percutaneous calcitriol injection therapy (PCIT), nodule hyperplasia v., 1825
- Percutaneous ethanol injection therapy (PEIT)
  - nodule hyperplasia v. selective, 1824–1825
  - severe hyperparathyroidism v. selective, 1825f
- Perinatal period, 803
  - D actions, 803–808
  - recommended D intake in, 808
- Periodontium
  - cementum in, 601–602
  - D influencing, 604–605
  - dentin in, 601–602
- Peripheral arterial vascular disease (PAD), D deficiency associated with, 900
- Peripheral quantitative computerized tomography (pQCT), peripheral cortical/trabecular density measured with, 481
- Peroxisome proliferator-activated receptor (PPAR), ligands in PCa combination therapy, 1696–1697
- Phagocytic cells
  - DBP allele activation v. recruiting, 127
  - tissue damage causing recruitment/activation of, 126–127
- Pharmacology, 995–1010
  - D<sub>3</sub> dosage considerations in, 1002–1006, 1009t
  - D<sub>3</sub> nutrition questions in, 1009t
  - DBP in, 1002
  - pharmacokinetic principles in, 1006–1007
- PHEX, in XLH/TIO/ADHR pathogenesis model, 1165–1166
- PHEX gene, responsible for XLH, 463t, 467
- Phorbol ester
  - PKC activity/CYP24A1 expression v., 99
  - PTHrP expression/production stimulated by, 741t
- Phosphate. *See also* Autosomal dominant hypophosphatemic rickets; Hereditary hypophosphatemic rickets with hypercalciuria; Hyperphosphatemia; Hypophosphatemia; Inorganic phosphate (P<sub>i</sub>); Phosphaturia; Tumor-induced osteomalacia; X-linked hypophosphatemia
  - absorption v. 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR binding, 220–221, 221f
  - D<sub>3</sub> metabolites modifying muscle uptake of, 887
  - deficiency-related disorders, 467–470

Phosphate (*Continued*)

- common metabolic pathway in, 469–470
  - deprivation, 1176
  - disorders in homeostasis of, 1159–1180, 1164t
  - disorders in metabolism of, 1189–1194
  - disorders in renal transport of, 1162–1175
  - disorders of decreased, 1176
  - disorders of increased, 1177–1178
  - disorders related to altered, 1176–1180
  - gastrointestinal malabsorption of, 1176
  - homeostasis
    - FGF-23 in maintaining, 1193–1194
    - in Npt2-null/*Hyp* mice, 439–440
  - homeostasis v. cardiovascular disease, 901
  - macrophages unresponsive to, 1382–1383, 1383f
  - mineralization v. low plasma, 1042
  - mouse models with defective transport of, 462–463
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> production v. plasma, 20
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> promoting absorption of, 291
  - 1,25(OH)<sub>2</sub>D v. renal transport of, 1161–1162, 1162f
  - phosphatonins/minihibins regulating renal transport of, 1163
  - renal D metabolism regulation v., 463–465, 464f
  - retention from chronic renal failure, 979
- Phosphatidylinositol 3-kinase (PI3-K), in 1,25(OH)<sub>2</sub>D<sub>3</sub>
- differentiation signal propagation, 1638
- Phosphatonin/minihibin protein
- candidate biological activity, 1167–1168, 1167t
  - sFRP-4 as, 1164
- Phosphatonin/minihibin proteins
- FGF-23 as, 1164–1166
  - MEPE as, 1164, 1166
  - postulated, 1163
- Phosphaturia
- in 1 $\alpha$ (OH)ase-null mice, 438
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 519
- Phosphorus (P)
- absorption v. vitamin D<sub>3</sub>, 5
  - abundance/ubiquity in tissues, 1159
  - aging v., 829, 829t
  - altered phosphate load disorders causing abnormal, 1178–1180
  - combined mechanisms decreasing serum, 1177
  - D/25OHD<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub> influencing renal handling of, 518–519
  - disorders related to transcellular shift of, 1176–1177
  - kidney 1 $\alpha$ -hydroxylase activity regulated by dietary, 77
  - 1,25(OH)<sub>2</sub>D synthesis influenced by, 828–830, 829f
  - PTH infusion/recovery v., 830, 831f
  - renal reabsorption of, 6
  - treatment of abnormal serum, 1180
  - VDR ablation v., 342
  - VDR expression affected by, 202t, 205
- Photobiology, 37–43
- history, 37–38
- Photosynthesis, 38–41, 38f
- latitude/season/time v., 39, 40f
  - ultraviolet B-absorbing materials v., 40–41, 41f, 42f
- Phytoestrogens, 1,25(OH)<sub>2</sub>D<sub>3</sub> synthesis regulated by, 1720–1721, 1720t
- P<sub>i</sub>. *See* Inorganic phosphate
- PI3-K. *See* Phosphatidylinositol 3-kinase
- PIC. *See* Preinitiation complex
- PKA. *See* Protein kinase A
- PKC. *See* Protein kinase C
- PKC $\alpha$ , 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> muscle stimulation translocating, 890f, 891
- Placenta
- Ca transport using PTHrP/CaR in, 853–854
  - calbindin-D<sub>9K</sub> in, 726, 730t

Placenta (*Continued*)

- 1,25(OH)<sub>2</sub>D<sub>3</sub> production in, 859
  - PTHrP expression in, 739t
- Plants, vitamin D<sub>2</sub> synthesized by, 15
- Plasma membrane calcium (PMCa) pump, 419–420, 525–527
- activity modulators, 420–421
  - CA transported across basolateral membrane by, 419–420
  - calbindins stimulating, 420
  - distribution, 527, 527t
  - in duodenal/ileal Ca absorption, 422–424, 423f
  - epitopes in distal tubular cell basolateral membrane, 525–527, 526f
- Plasma membrane sodium-calcium exchanger, CA transported across basolateral membrane by, 421
- Plasma membranes
- Ca<sup>2+</sup> response to 1,25(OH)<sub>2</sub>D<sub>3</sub> initiated by, 754–755
  - resting potential “left-shifting” in, 754–755, 755f
- PMCa pump. *See* Plasma membrane calcium pump
- PMH. *See* Past medical history
- Pneumonia
- hypercalcemia/D hypersensitivity in pneumocystis carinii, 1361
  - resistance influenced by D<sub>3</sub>, 999t
- Polybromo- and BAF-containing complex (PBAF)
- in 1,25(OH)<sub>2</sub>D<sub>3</sub>-liganded VDR-RXR heterodimer transactivation, 238–240, 239f
  - in VDR transcriptional function, 268
- Polymerase chain reaction (PCR), in HVDRR studies, 1218
- Polynesians
- bone mass in, 794
  - D metabolism in, 794
- Postgastrectomy bone disease, 1299–1300
- biochemistry, 1300
  - bone turnover in, 1299
  - clinical features, 1299–1300
  - D metabolism of, 1299
  - management, 1300
  - osteomalacia in, 1299
  - pattern of, 1299
- PPAR. *See* Peroxisome proliferator-activated receptor
- pQCT. *See* Peripheral quantitative computerized tomography
- PR. *See* Production rate
- Prednisone, Ca absorption v., 1244–1245, 1245f
- Pregnancy
- bone mineral content/density during, 840–841
  - Ca homeostasis v., 204
  - D/Ca metabolic adaptations during, 839–841
  - D metabolism in, 839–843
  - last trimester, 803–804
    - D deficiency in, 803–804
    - D supplementation in, 804, 808
    - malnutrition in, 803
  - 1,25(OH)<sub>2</sub>D v. Ca absorption during, 839–840, 840f
- Pregnane X receptor (PXR)
- accumulated toxins v., 865–866
  - VDR ligand binding/heterodimerization/transactivation domains compared with, 233–235, 234f
- Preinitiation complex (PIC)
- in comodulator activity integrated model, 300, 300f
  - VDR contacts with, 291–292
- Previtamin D<sub>3</sub>, vitamin D<sub>3</sub> produced from, 38, 38f, 39f
- Primary biliary cirrhosis (PBC)
- bone disorders associated with, 1304–1306
  - clinical features of, 1304
  - D metabolism in, 1305, 1305f
  - management of, 1305–1306
- Primates. *See* New World primates
- PRL. *See* Prolactin



- Production rate (PR), young/elderly men's 1,25(OH)<sub>2</sub>D, 827, 827f
- Proenkephalin (PENK), 1,25(OH)<sub>2</sub>D<sub>3</sub>/other osteotropic hormones regulating, 655
- Progesterone, D metabolism influenced by, 1254t, 1261–1262
- Prolactin (PRL), D metabolism influenced by, 1254t, 1258
- Promyelocytic leukemias (APLs), RAR  $\alpha$  fusion proteins marking, 1732
- Prooxidant, 1,25(OH)<sub>2</sub>D<sub>3</sub> as, 763–765, 764t
- Prostaglandins, D metabolism influenced by, 1254t, 1262–1263
- Prostate
- D endocrine/autocrine systems in, 1608
  - as D target, 1682–1683
  - 1 $\alpha$ -hydroxylase in, 1607
  - 1,25(OH)<sub>2</sub>D as autocrine hormone in, 1607–1610
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> synthesized from 25OHD<sub>3</sub> in, 1607, 1608f
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. virally transformed cells of, 1684
  - VDR in, 1682–1683
- Prostate cancer cells
- D analogs v. growth of, 1451
  - enzymes in D metabolite response by, 1685–1687
  - growth factor actions in regulating, 1692–1693
  - mechanisms of D-mediated growth inhibition v., 1690–1695
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> arresting growth of, 1690–1691
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/deltanoid-induced differentiation modeled in, 1637t
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibiting invasion/metastasis by, 15
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. apoptosis in, 1691
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. differentiation in, 1691–1692
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. primary cultured, 1683–1684, 1684f
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. proliferation of human, 1683, 1683f
  - resistance to 1,25(OH)<sub>2</sub>D<sub>3</sub> antiproliferative effect in, 1684–1685
- Prostate cancer (PCa)
- animal models/*in vivo* studies of, 1688–1689
  - Ca/dairy products v., 1627–1629
  - circulating D v., 1625–1626
  - clinical trials evaluating 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs, 1698–1699
  - combination therapy v., 1695–1698
  - D analogs v., 1689–1690
  - D<sub>3</sub> protecting against, 999t
  - D/sunlight/natural history v., 1599–1611
  - D v., 1679–1700
  - dietary D v., 1625
  - D's antiproliferative/prodifferentiation actions in, 1682
  - EB1089 v., 1499
  - epidemiology, 1680–1681
  - epidemiology v. age/race/place, 1599–1600
  - etiology/treatment/hormonal factors, 1679–1680
  - genetic factors v., 1681–1682
  - high dose intermittent 1,25(OH)<sub>2</sub>D<sub>3</sub> v. androgen-dependent, 1745
  - high incidence of incidental, 1600
  - mortality/incidence, 1624–1625
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibiting *in vitro* growth of, 1683–1685
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1742
  - 25OHD v. risk of, 1000f, 1002
  - risk epidemiology v. D/Ca, 1617–1629
  - risk factors v. vitamin D hypothesis, 1601, 1601t
  - risk v. D, 1600–1601
  - sunlight v., 1617, 1625
  - VDR gene polymorphisms/1 $\alpha$ -hydroxylase v., 1626–1627
  - VDR genetic polymorphisms associated with, 1261, 1681–1682
  - VDR polymorphisms v., 1139t, 1145
  - vitamin D hypothesis, 1600–1602, 1610–1611, 1611f
  - dietary D studies, 1606
  - observational studies, 1602–1606
  - seroepidemiological studies, 1602–1604
  - sunlight exposure studies, 1605–1606
  - VDR polymorphism studies, 1604–1605
- Prostate cells
- BXL–353 v. *in vivo* growth of, 1837–1840, 1839f
  - VDR expression in, 1834–1836
- Prostate specific antigen (PSA)
- doubling time v. 1,25(OH)<sub>2</sub>D<sub>3</sub> PCa treatment, 1698, 1698t
  - in early PCa diagnosis, 1679
- Protein kinase A (PKA)
- PKC interaction v. VDR regulation by, 209–210
  - VDR expression affected by, 209
- Protein kinase C (PKC)
- activity v. 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> muscle stimulation, 890f, 891
  - D metabolites modulating matrix vesicle, 586
  - glucocorticoid/CYP24A1 expression v., 99
  - hVDR phosphorylation v. nuclear localization/DNA binding, 231f, 232–233
  - keratinocyte differentiation mechanism unclear in, 618–619
  - in keratinocyte growth/differentiation, 618–619, 620f
  - in 1,25(OH)<sub>2</sub>D<sub>3</sub> differentiation signal propagation, 1637–1638
  - in 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-mediated rapid responses, 386t
  - phorbol ester/CYP24A1 expression v., 99
  - PKA interaction v. VDR regulation by, 209–210
  - VDR expression affected by, 209
- Protein kinases, 1,25(OH)<sub>2</sub>D<sub>3</sub>/mitogen-activated, 97–98
- Protein sulfhydryl (-SH) groups, Ca entry v., 416
- Protusio acetabulae, 972f–973f, 973
- Provitamin D<sub>3</sub>, photolysis, 38, 39f
- Proximal convoluted tubules (PCTs), in 25OHD<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub> conversion, 153
- PSA. *See* Prostate specific antigen
- Pseudo-vitamin D-deficiency rickets (PDDR), 1197–1204
- biochemical findings in, 1198–1199
  - clinical manifestations, 1197–1198
  - CYP27B1* gene causing, 109
  - D/1,25(OH)<sub>2</sub>D<sub>3</sub> v. 1,25(OH)<sub>2</sub>D<sub>3</sub> in, 1199, 1199f
  - defective 25OHD<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub> conversion in, 1197, 1198f
  - founder effect in Northeastern Quebec, 1200
  - genetic studies, 1199–1200
  - HVDRR v., 1208, 1209t
  - 1 $\alpha$ -hydroxylase gene defects in, 1200–1201, 1201f
  - hypocalcemia in, 1056
  - in 1 $\alpha$ (OH)ase-null mice, 438–439, 489
  - 1,25(OH)<sub>2</sub>D in, 16
  - 1,25(OH)<sub>2</sub>D replacement therapy v., 110
  - 1 $\alpha$ (OH)D replacement therapy v., 111
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> therapy v. rickets phenotype in, 1202, 1203f
  - placenta studies, 1199, 1200f
  - recognition/semantics, 1197
  - tooth enamel dysplasia in, 1202, 1203f
  - treatment, 1201–1203
- Pseudohypoparathyroidism, hypocalcemia v., 1054
- Psoriasis, 1791–1801
- calcipotriol/betamethasone dipropionate treating, 1500
  - calcipotriol treating scalp, 1785–1786
  - clinical use of 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs v., 1784–1787
  - D/analog biological effects in, 1781, 1781f
  - D analogs treating, 1450
  - D analogs v., 744
  - efficacy/safety of D analogs treating, 1504, 1504t
  - MC–903 v., 1543
  - OCT development for, 1525–1534
  - OCT v., 1531–1534, 1533f
  - pathogenesis of, 1791–1792
  - safe VDR ligand treatments for, 643
  - serum 1,25(OH)<sub>2</sub>D<sub>3</sub>/25OHD in, 1784
  - skin lesion histology in, 1791–1792
  - specific therapies for, 1785–1787

Psoriasis (*Continued*)

- Thérámex hybrid deltanoid v., 1416, 1416f
- therapies increasing topical D analog efficacy in, 1786–1787
- topical 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs v., 1784–1785
- topical 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1785, 1785f
- treatment response v. VDR genotypes, 1784
- VDR ligand treatment v., 637t, 640
- VDR polymorphisms v., 1146
- PTH. *See* Parathyroid hormone
- PTH gene, 538–539
  - abnormalities v. hypocalcemia, 1053
  - expression v. VDREs, 539
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating, 539
    - calreticulin v., 543–544
    - in vivo* studies of, 539, 540f
  - promoter sequences, 538–539
  - regulation, 538
  - structure, 538
- PTHrP. *See* Parathyroid hormone-related peptide; Parathyroid hormone-related protein
- PTHrP gene, 737–738
  - organization/structure-function relationships, 737–738, 738f
- Puberty, Ca absorption efficiency/utilization during, 815–816, 815f, 816f
- Purdah, rickets incidence v., 1067
- PXR. *See* Pregnane X receptor

## Q

- qBEI. *See* Quantitative backscattered electron imaging
- QCT. *See* Quantitative computed tomography
- QOD schedule. *See* Every-other-day schedule
- Quantitative backscattered electron imaging (qBEI)
  - localized mineral measurement with, 483
  - old bone mineralization measured with, 489
- Quantitative computed tomography (QCT), BMD assessment with, 922–924
- Québécois, PDDR in, 1199–1200

## R

- RA. *See* Retinoic acid; Rheumatoid arthritis
- 9-*cis*-RA, in leukemia combination therapy, 1733
- RAA axis. *See* Renin-angiotensin-aldosterone axis
- Race. *See also* Blacks; Whites; *specific nationalities*
  - D metabolism influenced by, 790–795, 790t
  - as PCa risk factor, 1601, 1601t
  - rickets/osteomalacia risk v., 789, 790t
- Radiation, hypocalcemia v., 1053
- Radioimmunoassays (RIAs)
  - <sup>125</sup>I-labeled tracers coupled with, 932
  - improved antibody for, 946, 946t
  - metabolites assayed as 1,25(OH)<sub>2</sub>D by, 946–947, 947f
  - 25OHD assay consistency v., 1023
  - 1,25(OH)<sub>2</sub>D measured by RRA v., 946, 946f
  - 25OHD/1,25(OH)<sub>2</sub>D quantitated with, 932
- Radiology
  - imaging, 986–990
  - nuclear medicine in, 986–988
  - plain radiographs in, 986
  - rickets/osteomalacia v., 967–990
- Radioreceptor assays (RRAs), for 1,25(OH)<sub>2</sub>D, 932, 942–947, 943t
- Raman spectroscopy, tissue mineralization quantified with, 481, 482–483, 482f
- RANK. *See* Receptor activator of NFκB
- RANKL. *See* Receptor activator of NFκB ligand
- RANKL/ODF
  - bone resorption signal transduced by, 672–673
  - cloning/structure, 670–672, 671f
  - osteoclast progenitors/osteoclasts differentiated by, 672
  - receptor identified as RANK, 673–674
  - as sole *in vivo* RANKL receptor, 674
- RANKL-RANK signaling, alternations v. skeletal phenotype, 678, 679t
- Rapid response, 381
  - 6-*s-cis*-shaped 1α,25(OH)<sub>2</sub>D<sub>3</sub> optimal agonist for, 391, 398f
  - case studies, 392–397, 397t
  - 1α,25(OH)<sub>2</sub>D<sub>3</sub>-mediated, 381–400, 386t
    - molecular tools for study of, 392, 393f
    - structure-function evaluation of, 392–397
  - in ROS 17/2.8 cells, 392–394, 394f
  - schematic model, 399–400, 399f
  - steroid hormones generating, 386
  - VSMC v. 1α,25(OH)<sub>2</sub>D<sub>3</sub>-mediated, 395–397, 396f
- RAREs. *See* Retinoic acid response elements
- RAS. *See* Renin-angiotensin system
- Rat calvaria cells
  - biphasic 1,25(OH)<sub>2</sub>D<sub>3</sub>/osteoblast relationship confirmed in, 651
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/dexamethasone stimulating adipogenesis in, 655–656
  - 1,25(OH)<sub>2</sub>D<sub>3</sub>/osteoblast relationship modeled by, 649–650, 650f
- Rat osteoblastic osteosarcoma (ROS), 1,25(OH)<sub>2</sub>D<sub>3</sub> inhibiting collagen synthesis in, 704
- Rats. *See also* Genetic hypercalciuric stone-forming rats
  - D deficiency v. fertility of male/female, 855
  - vitamin D<sub>3</sub> discriminated against by, 29
- RDA. *See* Recommended dietary allowance
- Reactive oxygen species (ROS), 761
  - generation/degradation of, 762
  - Janus face of, 761
  - in neurodegenerative diseases, 1779–1780
  - redox homeostasis v., 761–763
    - as signaling cascade messengers, 762–763
- REBiP. *See* Response element binding protein
- Receptor activator of NFκB ligand (RANKL), 568
  - bone-resorbing factors regulating, 675–676, 676t
  - mRNA/serum Ca v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 680, 680f
  - 1α,25(OH)<sub>2</sub>D<sub>3</sub> inducing expression of, 713
  - osteoblasts regulating osteoclasts through inducing, 568
  - RANK as sole *in vivo* receptor for, 674
  - regulating expression of, 674–676
- Receptor activator of NFκB (RANK)
  - RANKL/ODF receptor identified as, 673–674
  - as RANKL/ODF signaling receptor in *in vitro* osteoclastogenesis, 673–674, 673f
- Receptor interacting domain (RID), NCoA62/SKIP, 296, 297f
- Recommended dietary allowance (RDA), 1357
  - calls for increasing, 1357
- Redox homeostasis. *See* Oxidation-reduction homeostasis
- Redox state, cellular, 761–762
- Regulator of G protein signaling (RGS)–2, 1,25(OH)<sub>2</sub>D<sub>3</sub> inversely modulating, 654
- Regulatory T cells
  - in autoimmunity, 1754
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> autoimmunity v., 1755
- Renal cell carcinoma, VDR polymorphisms v., 1146
- Renal endocytosis, 25OHD<sub>3</sub>, 153–159
  - cell biology of, 156–157
  - molecular biology of, 157–159
  - physiology of, 153–156

- Renal failure  
 D analog action/tissue specificity v. chronic, 1826–1827  
 D in, 1313–1333  
 future D analog roles in chronic, 1826–1827  
 hyperparathyroidism v. D in, 1821  
 intravenous 1,25(OH)<sub>2</sub>D therapy v., 1822–1823  
 mechanisms of 1,25(OH)<sub>2</sub>D resistance in chronic, 1822, 1822f  
 OCT in dog model of chronic, 1527  
 1,25(OH)<sub>2</sub>D resistance causing secondary hyperparathyroidism in, 1821–1823  
 1,25(OH)<sub>2</sub>D resistance in chronic, 1821–1822  
 parathyroid hyperplasia in chronic, 1823, 1824f  
 secondary hyperparathyroidism v., 1821–1827
- Renal osteodystrophy, 974  
 aluminum toxicity in, 979–981  
 metastatic calcification in, 979  
 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR action in, 1322–1326  
 periosteal new bone formation in, 979  
 radiology of, 974–981, 975f
- Renin  
 19-nor Gemini suppressing expression of, 1518, 1518t  
 D suppression v. other mechanisms regulating, 877  
 Gemini analogs inhibiting, 1514–1518  
 RAS cascade rate limited by, 871  
 synthesis/secretion control, 872–873
- Renin-angiotensin-aldosterone (RAA) axis, D regulating, 901
- Renin-angiotensin system (RAS), 871–879  
 CKD/1,25(OH)<sub>2</sub>D<sub>3</sub> deficiency/resistance in, 1326  
 components in hypertension treatment, 1514  
 D endocrine system interaction with, 877–878, 878f  
 Gemini compounds inhibiting, 1516–1518, 1518t  
 1,25(OH)<sub>2</sub>D<sub>3</sub> as negative endocrine regulator of, 875–878  
 animal studies evaluating, 875–877  
 hypothesis of, 875  
 physiological implications of, 877–878  
 overview, 871–872, 871f
- Renin gene  
 expression regulation, 873  
 expression suppressed by D, 877
- Reproduction  
 active Ca absorption during, 440–445  
 VDR ablation affecting, 345–346
- Reproductive organs, D's role in, 851–860
- Resistance  
 humans having New World primate-like, 355–356  
 hypocalcemia due to hereditary, 1056  
 index case in humans, 355  
 in New World primates, 352  
 biochemical nature of, 354–355  
 VDRE-BP-2 causing, 355
- Response element binding protein (REBiP)  
 binding in *cis*, 356, 356f  
 D-resistant human patient over-expressing, 355  
 human, 356–357  
 overexpression v. HVDRR patient 1,25(OH)<sub>2</sub>D<sub>3</sub> resistance, 356–357, 356f
- Restriction fragment length polymorphisms (RFLPs)  
 HVDRR-related VDR gene mutation v., 1220  
 in prenatal VDR gene mutation diagnosis, 1228  
 VDR gene, 1124, 1125f
- Retinoblastoma protein, deltanoid-induced G1 block controlled by, 1649
- Retinoic acid (RA), VDR expression affected by, 202t, 206–207
- Retinoic acid response elements (RAREs), human VDR promoter, 200
- Retinoid X Receptor (RXR)  
 import/export receptors interacting with, 368–371  
 intranuclear trafficking of, 374–376  
 as NR/VDR heterodimeric partner, 291, 292f  
 nucleocytoplasmic trafficking regulation, 371–374  
 “piggyback” nuclear import of, 369, 371f  
 putative NLSs in, 369, 370f  
 shuttling v. transcription, 371  
 subcellular trafficking, 363–376  
 in VDR/DNA binding, 178–180, 179f, 220, 220f
- Retinoids  
 in PCa combination therapy, 1696  
 VDR expression affected by, 206–207
- RFLPs. *See* Restriction fragment length polymorphisms
- RGS-2. *See* Regulator of G protein signaling–2
- Rhabdomyolysis, hyperphosphatemia in, 1178
- Rheumatoid arthritis (RA)  
 1,25(OH)<sub>2</sub>D accumulation in, 1389–1390  
 subperiosteal erosions simulating, 975f, 976  
 VDR ligand treatment v., 637, 637t  
 VDR polymorphisms v., 1147
- RIAs. *See* Radioimmunoassays
- Rickets, 967. *See also* Osteopenia; *specific types of rickets*  
 Al toxicity in, 980  
 biochemical abnormalities in nutritional, 1069–1070  
 biochemical evolution of, 1036–1039  
 bone turnover markers elevated in nutritional, 1069–1070  
 Ca<sup>2+</sup> availability v. mineralization in, 579  
 Ca v. D deficiency in, 1077, 1077f  
 cartilage prehypertrophic/hypertrophic zones increased in, 579, 580f  
 causes of, 925–926, 925t–926t  
 Chinese incidence of infantile, 793  
 in cities, 967, 1065  
 classical features of, 1067–1068, 1068f  
 clinical presentation of nutritional, 1067–1069  
 D<sub>3</sub> curing, 999t  
 D deficiency and children's nutritional, 1065–1077  
 D deficiency causing, 566  
 D deficiency impairing bone resorption in, 777, 777f  
 D/intestinal Ca absorption v., 703  
 D metabolism in, 1039–1040  
 D single dose therapy v., 1072  
 deltanoids v. VDR mutants associated with, 1409, 1411f  
 dental phenotype of, 602, 602f  
 dietary Ca deficiency causing, 1074–1075, 1075f  
 epidemiology of D deficiency/nutritional, 1066–1067  
 in exclusively breast-fed children, 777  
 geographical distribution of colon cancer and, 866  
 high-Ca diet preventing KO mouse, 429  
 history, 4, 37–38, 967, 1065–1066  
 HVOii/HVOiii v. infantile, 1038  
 in Los Angeles Zoo New World primates, 352–353, 353f  
 mineralization in healing, 1071–1072, 1071f  
 oncogenic, 983–984  
 pathogenesis, 1029–1044, 1076–1077, 1077f  
 pathophysiological progression of D-deficiency, 1070  
 PDDR v. nutritional, 1197  
 premature infants v. nutritional, 812, 812t  
 prevention of nutritional, 1072–1074  
 radiology of, 967–990, 981, 982f, 1070–1072  
 radiology of D-deficiency, 968–971, 969f, 970f, 971f  
 restricted definition of, 1031  
 risk v. race/population, 789, 790t  
 sunlight v. incidence of, 246  
 symptoms caused by defective *CYP27A1*, 61–62

- Rickets (*Continued*)  
 treatment of nutritional, 1072  
 ultraviolet/sunlight v., 4–5  
 VDR ablation v., 342–343  
 in VDR-null mice v. mineral homeostasis, 433  
 vitamin D<sub>3</sub> activity v. vitamin D-dependency, 7  
 RID. *See* Receptor interacting domain  
 Ro-26–9228  
 mechanism of action, 1480  
 osteoporosis v., 1451  
 potency in intestinal cells, 1480, 1480f  
 structure, 1479f  
 target tissue gene expression v., 1480, 1481f  
 ROS. *See* Rat osteoblastic osteosarcoma; Reactive oxygen species  
 RRAs. *See* Radioreceptor assays  
 RUNX proteins  
 chromatin remodeling due to, 332  
 gene expression suppressed by, 333  
 intranuclear targeting signal v. function of, 335  
 localization, 334  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulation dependent on osteoblast maturity, 651  
 promoter element/co-regulatory protein interactions by, 332  
 promoter regulatory complex organization determined by, 333

## S

- SAGE. *See* Serial analysis of gene expression  
 SAR. *See* Structure-activity relationship  
 Sarcoidosis  
 active D metabolite produced extrarenally in, 1380  
 disordered Ca balance pathophysiology in, 1381–1387  
 dysregulated overproduction of 1,25(OH)<sub>2</sub>D in, 1381  
 endogenous D intoxication associated with, 1379–1380  
 extrarenal D metabolite overproduction v., 1390, 1390t  
 hypercalcemia/D hypersensitivity in, 1359–1360  
 VDR polymorphisms v., 1147  
 Saudi Arabians  
 bone mass in, 794  
 D metabolism in, 794  
 low serum 25OHD in, 1026  
 sunlight exposure v. rickets in, 1066–1067  
 winter hypovitaminosis D in adult, 1091  
 Scandinavians  
 hypovitaminosis D in adult, 1091, 1091f  
 hypovitaminosis D in healthy elderly, 1092, 1092f  
 hypovitaminosis D in institutionalized elderly, 1093, 1093f  
 Scanning small-angle X-ray scattering (scanning-SAXS), mineral  
 particle thickness/alignment from, 481–482  
 SCCs. *See* Squamous cell carcinomas  
 Scleroderma  
 D analog therapy v., 1787  
 1,25(OH)<sub>2</sub>D<sub>3</sub> treating, 1758–1759, 1758f, 1758t, 1759t  
 SCP. *See* Start codon polymorphism  
 Scurvy, nutrition v., 3  
 Secondary hyperparathyroidism  
 bone turnover due to, 509–510  
 CaR expression v. primary/uremic, 556  
 in chronic renal failure v. 1,25(OH)<sub>2</sub>D<sub>3</sub> analogs,  
 1331–1332, 1332f  
 CYP27B1 gene mutation v., 109  
 CYP27B1-null mice developing, 703  
 D insufficiency v. senile, 1088, 1088f  
 gastrointestinal diseases associated with, 1297  
 normal serum 25OHD v., 1020–1022  
 OCT ameliorating osteopathy in, 1531, 1533f  
 Secondary hyperparathyroidism (*Continued*)  
 OCT development for, 1525–1534  
 OCT v., 1527–1531  
 clinical results of, 1529–1531  
 preclinical results of, 1527–1529  
 1 $\alpha$ (OH)ase-null mice demonstrating severe, 438  
 1,25(OH)<sub>2</sub>D<sub>3</sub> deficiency/CKD v., 1324–1325, 1325f  
 parathyroid cell proliferation v., 544–547  
 parathyroid gland hyperplasia in, 1823  
 radiology of D deficiency, 973–974, 975f, 980f  
 renal disease stimulating, 974–976  
 renal failure and, 1821–1827  
 treatment in chronic renal failure  
 before dialysis, 1327–1328  
 during hemodialysis, 1328–1331, 1330f  
 Secreted frizzles-related protein (sFRP)–4, as phosphatonin/  
 minihibin, 1164  
 Selective estrogen receptor modulators (SERMs), in VDR ligand  
 tissue selectivity, 270–271  
 Selective progesterone receptor modulators (SPRMs), in VDR  
 ligand tissue selectivity, 270–271  
 Seocalcitol. *See* EB1089  
 Sepsis, hypocalcemia in acute, 1057  
 Serial analysis of gene expression (SAGE), TIO tumors v., 1192  
 SERMs. *See* Selective estrogen receptor modulators  
 Sex steroids  
 D metabolism influenced by, 1254t, 1259–1262  
 1,25(OH)<sub>2</sub>D synthesis influenced by, 828  
 sFRP–4. *See* Secreted frizzles-related protein–4  
 SH. *See* Social history  
 Shwachman-Diamond syndrome, rickets v. differential diagnoses  
 for, 984–985, 987f  
 Side-chain cleavage, vitamin D<sub>2</sub>/D<sub>3</sub>, 25–26  
 Side-chain oxidation  
 vitamin D<sub>2</sub>, 25  
 vitamin D<sub>3</sub>, 17f  
 Simian bone disease, 351–352  
 D deficiency v., 351–352  
 New World primates susceptible to, 351–352  
 Single dose therapy, 1066  
 hypercalcemia v., 1072, 1073  
 patient compliance problem avoided by, 1072  
 Skeletal genes  
 controlling *in vivo* expression of, 327–328  
 intranuclear organization of D-mediated regulatory machinery  
 for, 327–336  
 Skeletal muscle, as D target tissue, 883–894  
 Skin  
 D analog actions in normal/psoriatic, 1781–1784  
 D system in normal/psoriatic, 1792–1793  
 dystrophic mineral deposits in, 478t  
 1,25(OH)<sub>2</sub>D<sub>3</sub>/analog immunoregulatory properties in, 1519  
 psoriasis/other diseases of, 1791–1801  
 rejection inhibited by 1,25(OH)<sub>2</sub>D<sub>3</sub>/analogs, 641t  
 structure/function deteriorating with age, 823  
 VDR in human, 1792f, 1793  
 Skin cancer  
 D analog therapy v., 1787  
 D photosynthesis v. recommendations for reducing, 1087  
 vitamin D photosynthesis v., 42–43  
 Skin lesions  
 in children v. 1,25(OH)<sub>2</sub>D<sub>3</sub> ointment, 1786  
 in HIV patients v. oral 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1786, 1786f  
 Skull, subperiosteal erosions causing “pepper pot,” 975f, 977  
 SLE. *See* Systemic lupus erythematosus  
 SMRT, NR co-repressor, 298–299

Social history (SH)  
 in approaching metabolic bone disease, 917–918  
 vegetarianism in, 917t, 918  
 vertebral crush deformity correction guided by, 918, 918f  
 Soda, v. Ca intake by adolescents, 817  
 Sodium chloride (NaCl), CaR inhibiting MTAL reabsorption of, 557  
 Sodium (Na), excretion v. 1,25(OH)<sub>2</sub>D<sub>3</sub> in TPTX dogs, 518  
 Software, VDRE screening, 322  
 Sp1 transcription factor, in 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced differentiation, 1640  
 Spanish, hypovitaminosis D in elderly, 1092–1093  
 Spermatogenesis, SRC-2 deletion resulting in, 295  
 Spliceosome, hnRNPs associated with, 358–359  
 SPRMs. *See* Selective progesterone receptor modulators  
 Squamous cell carcinomas (SCCs), 1,25(OH)<sub>2</sub>D produced by keratinocytes from, 612  
 SRC-1  
   *See* Steroid receptor coactivator 1  
 Stanniocalcin  
   hypercalcemia v., 462  
   proximal tubular P<sub>i</sub> transport regulated by, 461t  
 Star volume, in bone structure assessment, 961–962, 962f  
 Start codon polymorphism (SCP), 1124  
 Steroid hormones  
   calbindin-D<sub>28K</sub>/D in producing, 726  
   calbindin-D<sub>9K</sub> regulated by, 729–730  
   calbindin-D<sub>28K</sub> regulated by, 728–729  
   CYP24A1 transcription regulated by, 97  
   D structure v., 381, 382f  
   kidney 1 $\alpha$ -hydroxylase activity regulated by, 77–78  
   nongenomic actions reported for, 98–99  
   VDR expression affected by, 205–206  
 Steroid precursors, in daltanoids, 1412–1416, 1413f, 1414f, 1415f  
 Steroid receptor coactivator 1 (SRC-1), VDR stabilization v. interaction with, 1472–1473, 1472f  
 Sterols. *See also* Steroid hormones  
   equilibrium of bound/free, 124  
   interpretation/relevance of measurements of antirachitic, 947–949  
   plasma proteins v. transport/function of, 124–125  
 Stomach, Ca absorption v. aging, 1105–1106  
 Store-operated Ca<sup>2+</sup> (SOC)  
   anti-INAD antibody v. 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-dependent influx from, 893, 893f  
   INAD-based signaling complexes in 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-modulated influx from, 893, 894f  
   muscle influx mediated by TRPC3 proteins/VDR, 892–893, 892f  
 Stosstherapie. *See* Single dose therapy  
 Structure-activity relationship (SAR), in daltanoid design, 1412  
 Strut analysis, in bone structure assessment, 961, 962f  
 Sunlight  
   alcoholics lacking exposure to, 1266  
   blood pressure v. D and, 873–874, 874f  
   colon cancer death rate v., 1571–1572  
   colon cancer v., 1709–1710  
   D from UVB component of, 1006–1007  
   D intake from food v., 995, 996t–997t  
   D nutrition/acquired bone disease v., 1297–1298  
   D supplementation required by high latitude, 784–785  
   deprivation determining D insufficiency, 1086–1087  
   diabetes incidence v., 1766  
   exposure increasing D<sub>3</sub> status, 1009t  
   exposure v. age, 1102, 1109  
   exposure v. colorectal cancer, 1618  
   fatal breast/prostate cancer v., 1572  
   glass v. D synthesis induction by, 823

Sunlight (*Continued*)  
   HDM v., 1813–1814  
   high rickets incidence despite, 1066–1067  
   25OHD v. excessive, 1356  
   PCa v., 1599–1611, 1617, 1625  
   PCa v. exposure to, 1680–1681  
   rickets/colon cancer incidence v., 246  
   rickets v., 777  
   vitamin D photosynthesis regulated by, 38–39  
 Sunscreen, vitamin D photosynthesis v., 40–41, 41f  
 Superagonists, 1475–1476, 1476f  
   differential VDR activation by, 1475–1478, 1476f  
   20-epi, 1477–1478  
   20-natural, 1476–1477  
 Suppressor T cells, 1,25(OH)<sub>2</sub>D<sub>3</sub> autoimmunity v., 1755  
 Swiss, hypovitaminosis D in adult, 1091  
 Systemic lupus erythematosus (SLE), VDR ligand treatment v., 637t, 639–640

## T

T cell response, VDR KO mice showing abnormal, 246  
 T cells. *See also specific types of T cells*  
   in acute allograft rejection, 1519  
   immunosuppressive therapy v. pathogenic, 631–632, 632t  
   VDR ligand immunoregulation of, 635–636, 635t  
   VDR ligands enhancing regulatory, 636  
 T-cells, in psoriasis, 1791–1792  
 T lymphocytes, antigens recognized by, 631  
 Tacalcitol. *See* 1 $\alpha$ ,24R-Dihydroxyvitamin D<sub>3</sub>  
 Taq polymorphisms, 1131t–1132t, 1135–1137  
   BMD v., 1142–1143  
 Taxanes, 1,25(OH)<sub>2</sub>D<sub>3</sub> in combination with, 1745–1746  
 TC. *See* Tumoral calcinosis  
 TEI 9647, 1481–1482, 1481f  
 Testis  
   calbindin-D<sub>28K</sub> in, 726  
   D in, 855–856  
   1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> VDR<sub>nuc</sub> in, 385t  
   SRC-2 deletion causing defects in, 295  
   VDR ablation reducing aromatase activity in, 345  
 Testosterone, D metabolism influenced by, 1254t, 1261  
 Tetany  
   in hypocalcemia, 920, 1049  
   in PDDR, 1197  
 TFs. *See* Transcription factors  
 TGF. *See* Transforming growth factor  
 TGF $\alpha$ , keratinocytes producing, 614  
 Theophylline, D metabolism influenced by, 1255t, 1272  
 Thiazide diuretics  
   D metabolism influenced by, 1255t, 1268–1269  
   as IH therapeutics, 1351  
 Thyroid C cells, 687  
   D controlling CT gene in, 687–697  
   embryonic development of, 687–688  
   neoplasia of, 688  
   origin/function of, 687–688  
 Thyroid gland  
   C cells in normal adult, 688  
   PTHrP expression in, 739t  
 Thyroid hormone, D metabolism influenced by, 1254t, 1262  
 Thyroid receptor-associated proteins (TRAP) coactivator complex.  
   *See* Mediator-D coactivator complex  
 Thyroparathyroidectomized (TPTX) dogs, 1,25(OH)<sub>2</sub>D<sub>3</sub> v. phosphate/Ca/Na excretion in, 518

- Thyroparathyroidectomized (TPTX) rats  
 24-hydroxylase activity v. D toxicity in, 1366–1367, 1367t  
 1,25(OH)<sub>2</sub>D<sub>3</sub> v. Ca excretion in, 518, 518f
- TIO. *See* Tumor-induced osteomalacia
- TLRs. *See* Toll-like receptors
- TNF. *See* Tumor necrosis factor
- TNF receptor-associated factor (TRAF) family proteins,  
 in osteoclastogenesis, 676–677
- TNF receptor family. *See* Tumor necrosis factor receptor family
- TNF $\alpha$ , D metabolism influenced by, 1254t, 1263
- Toddlers, Ca absorption in, 815
- Toll-like receptors (TLRs)  
 LPS-induced 1,25(OH)<sub>2</sub>D production supported by, 1385  
 pathogens recognized by, 631
- Tooth  
 crown influenced by D, 604  
 D in formation/mineralization of, 601–602  
 dentin/cementum in root of, 601–602  
 eruption delayed by rickets, 1068  
 eruption delayed in PDDR, 1198
- Tooth enamel hypoplasia  
 in HVDRR, 1208  
 1,25(OH)<sub>2</sub>D<sub>3</sub> partially correcting PDDR, 1202, 1203f
- Total parenteral nutrition (TPN)  
 bone disease caused by AI in, 1270, 1303  
 bone disorders associated with, 1303  
 clinical features of, 1303  
 management, 1303
- Toxicity, 26–27. *See also* Intoxication  
 adipose tissue loss v., 1007, 1010  
 arterial dystrophic calcification induced by, 478  
 biological markers for monitoring, 1009t  
 Ca/D supplementation v., 1059  
 cardiovascular, 899, 904–905  
 D<sub>2</sub>/D<sub>3</sub>, 26–27, 1356–1357  
 D effects on bone v. hypercalcemia in, 510  
 D/25OHD, 1356–1357  
 D osteolytic response/hypercalcemic effects in, 569  
 EAE v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1784  
 factors affecting, 27  
 high dose intermittent 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1743, 1743t  
 increased serum phosphorus associated with, 1177–1178  
 mechanisms of D, 1362–1368  
 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1357  
 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration v., 1008  
 overview, 26  
 PCa treatment v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1689–1690  
 pharmacological issues of safety and, 1007–1010  
 psoriasis treatment v., 1791  
 radiology of, 986, 988f  
 synthetic analog, 1357–1359  
 thresholds in adults/infants, 1357  
 topically applied/systemically administered D compound, 1450
- TPN. *See* Total parenteral nutrition
- TPTX dogs. *See* Thyroparathyroidectomized dogs
- Trabecular bone pattern factor, in bone structure assessment, 962
- TRAF family proteins. *See* TNF receptor-associated factor family proteins
- Transactivation  
 coregulators in VDR/RXR, 180–181  
 HVDRR cell lines suppressing RXR-VDR-mediated, 354f, 355–356  
 1,25(OH)<sub>2</sub>D<sub>3</sub>-liganded VDR-RXR, 237–243, 239f  
 REBiP squelching hormone-directed, 358, 358f  
 RXR's direct involvement in, 181  
 squelching VDR-directed VDRE-reporter-driven, 355, 355f
- Transcaltachia  
 cell-surface receptor in analog-stimulated, 1461  
 structure-function summary analysis, 397, 397t
- Transcription apparatus, REBiP in, 358, 358f
- Transcription factors (TFs)  
 intranuclear pathways directing, 335–336  
 in 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced differentiation, 1639–1640  
 osteoblast differentiation status varying, 653  
 as regulatory component scaffolding, 332–333
- Transcription start sites (TSSs), 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene VDREs  
 near, 314, 315f, 316t
- Transforming growth factor (TGF), in 1,25(OH)<sub>2</sub>D<sub>3</sub> actions on  
 prostate cells, 1692–1693
- Transient Receptor Potential (TRP) channel superfamily, Ca<sup>2+</sup>  
 influx v., 430  
 muscle, 892–893, 892f
- Transient Receptor Potential Vanilloid (TRPV) family, Ca influx v.  
 TRPV5/TRPV6 members of, 430
- Translation, hnRNPs as ribosome recognition proteins in, 359
- Transport receptors  
 in nucleocytoplasmic VDR/RXR trafficking, 365–376  
 Ran-GTPase regulating, 365–366, 367f
- TRAP coactivator complex. *See* Mediator-D coactivator complex
- TRP channel superfamily. *See* Transient Receptor Potential channel superfamily
- TRPV5. *See* ECaC1
- TRPV6. *See* ECaC2
- TRPV family. *See* Transient Receptor Potential Vanilloid family
- TSSs. *See* Transcription start sites
- Tuberculosis  
 D<sub>3</sub> preventing, 999t  
 extrarenal D metabolite overproduction v., 1390–1391, 1390t  
 hypercalcemia/D hypersensitivity in, 1360  
 VDR polymorphisms v., 1148
- Tumor cells  
 D influences on, 1577–1582  
 D influencing, 1577–1582  
 D resistance/metabolism in, 1583–1584  
 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulating proliferation of, 1574t, 1584–1585, 1585f
- Tumor-induced osteomalacia (TIO), 463t, 468, 983–984  
 benign/malignant tumors in, 983, 986f  
 as disorder of phosphate metabolism, 1190–1192  
 genes overexpressed in, 1192  
 phosphatonin secretion resulting in, 1190  
 tumors eluding detection in, 983–984, 989f
- Tumor necrosis factor (TNF)  
 causing apoptosis v. calbindin-D<sub>28K</sub>/osteoblasts, 725, 725f  
 type I collagen synthesis inhibited by, 704
- Tumor necrosis factor (TNF) receptor family  
 nomenclature, 674, 675f  
 OPG in, 668
- Tumor suppressor genes  
 in cell cycle/apoptosis control, 1577–1580  
 1,25(OH)<sub>2</sub>D<sub>3</sub>/EB1089 regulating breast cancer cell, 1664–1665  
 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating expression of, 1579
- Tumoral calcinosis (TC), hyperphosphatemic, 1175–1176
- Tumors  
 D/analog differentially influencing canine/human, 1577  
 D preventing colon, 1709–1710  
 1,25(OH)<sub>2</sub>D<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub> analogs v., 1741  
 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulating development of, 1574t, 1584–1585, 1585f  
 prognosis v. VDR expression in breast cancer, 1668  
 VDR in, 1572t  
 VDR-RXR heterodimer-activating ligands v., 241

## Turks

- serum 25OHD/PTH in dark-skinned Dutch, 794
- sunlight exposure v. rickets in, 1066–1067
- sunlight exposure v. serum 25OHD in, 794

Type II nitric oxide synthase (NOS II), 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 1783

## U

UL. *See* Upper limit

## Ultraviolet (UV) light

- age/serum D v., 823, 824f
- PCa mortality v., 1601–1602, 1602f, 1603f
- PCa v., 1605–1606
- rickets v., 565
- serum 25OHD directly related to, 825

Upper limit (UL), conservative safety margin of, 1008

Uremia, 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR-mediated transcription v., 1320–1321, 1321f

## Uterus

- calbindin-D<sub>9K</sub>/D<sub>28K</sub> in, 726, 730t
- D in, 856–857
- PTHrP expression in, 739t

3'UTR polymorphisms, 1131t–1132t, 1135–1137

BAt/baT haplotype expression in, 1131t–1132t, 1135

UV light. *See* Ultraviolet light

## UVB

- in combination psoriasis therapy, 1504, 1504t
- as D<sub>3</sub> dose, 1006–1007
- D status in elderly improved by, 1087

## V

## Vascular calcification, 899

- calcitropic hormones v., 904–905
- D regulating, 904–905
- overview, 904
- regression v. treatment, 979

Vascular endothelial growth factor (VEGF) gene, 1,25(OH)<sub>2</sub>D<sub>3</sub> targeting, 566, 567

Vascular inflammation, D signaling in regulating, 899

## Vascular smooth muscle cells (VSMCs)

- 1,25(OH)<sub>2</sub>D<sub>3</sub> actions in, 902–903
- 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> promoting migration of, 395–397, 396f

Vasculature, direct D actions in, 902–904

Vasopressin. *See* Antidiuretic hormone

VDCCs. *See* Voltage-dependent calcium channels

VDR. *See* Vitamin D receptor

## VDR gene, 182–184

- arrangement, 1210, 1211f
- complexity v. polymorphism identification, 1125f, 1129
- defects causing HVDRR, 1207
- exon-intron structure/polymorphism position, 1124, 1125f
- gene deletion prematurely terminating, 1222
- genomic mapping to chromosome 12q13.1, 1122, 1123f
- haplotype importance in, 1135–1137, 1136f
- HVDRR caused by mutated, 111
- LD measured across, 1125f, 1127
- LD strength display across Caucasian, 1127, 1128f
- locus, 194–201
  - structure, 194–195, 195f
- nephrolithiasis v., 1142
- odontoblasts expressing, 599
- organization, 182–183, 183f
- polymorphism association analysis in disease states, 1137–1148

VDR gene (*Continued*)

- polymorphism in human, 172, 183–184, 200–201, 200f, 244f
    - disease risk/functional consequences v., 243–246
    - ethnic variation v., 1127–1129, 1128t
    - undiscovered/functionally significant, 245
  - polymorphisms/1 $\alpha$ -hydroxylase v. PCa, 1626–1627
  - polymorphisms associated with cancer, 1572–1573
  - polymorphisms v. colorectal cancer/adenoma, 1619–1620
  - polymorphisms v. disease risk, 1121–1149
  - polymorphisms v. sequence comparisons, 1124–1126, 1125f
  - premature termination v. HVDRR-related mutations, 1220–1222
  - promoters v. D analog selectivity, 1452f, 1453
  - 12q13 locus, genomic structure, 1122, 1123f, 1124f
  - RFLPs, 1124, 1125f
  - sequence variations near anonymous markers, 1125f, 1135
  - splice site mutations prematurely terminating, 1222
    - Glu92fs, 1221f, 1222
    - Leu233fs, 1221f, 1222
  - stop mutations prematurely terminating, 1220–1222, 1221f
    - Arg30stop, 1221–1222, 1221f
    - Arg73stop, 1221, 1221f
    - Gln152stop, 1221, 1221f
    - Gln317stop, 1221f, 1222
    - Tyr295stop, 1220, 1221f
    - Tyr295stop ochre, 1214t–1216t, 1220–1221
  - structural complexity, 193
  - structure, 194–196
  - structure/polymorphisms, 1122–1137
  - study size v. analysis of, 1137–1138
- VDR homodimers
- D analog selectivity v., 1454–1455
  - RXR-independent 1,25(OH)<sub>2</sub>D<sub>3</sub> signaling v., 319
- VDR promoters, 196–200
- human, 197–200, 198f, 199f
  - nonhuman, 197, 198f
  - targeting VDR through chromatin remodeling complex, 305–312, 306f
- VDR-RXR heterodimers
- 9-*cis* RA stimulating, 241
  - allosteric model of, 235–237, 236f
  - cyclic model for transactivation by 1,25(OH)<sub>2</sub>D<sub>3</sub>-liganded, 237–243, 239f
    - limits of, 241
  - cytoplasmic dimerization of, 369, 371f
  - D ligands influencing DNA interaction with, 1455
  - DNA binding v. hexameric core binding motifs, 319
  - DNA complex formation of, 318f
  - everted repeats, 317–319, 318f
  - FRET experiments showing cytoplasmic, 364–365, 365f
  - hVDR $\Delta$  in, 281
  - intestinal CYP enzymes regulated by, 246–248, 247f
  - Mediator-D complex interacting with, 296, 296f
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> signaling mediated by, 319
  - in 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR control of D responsive genes, 1320, 1320f
  - structure/function of, 230–236, 231f, 234f
  - therapeutic potential of ligands activating, 241
  - VDR signaling v. 1,25(OH)<sub>2</sub>D<sub>3</sub>/9-*cis* RA binding in, 237
  - VDR superagonist ligand v. enhanced formation of, 271–272, 272f
  - VDRE binding sites for, 222–224, 223t
  - VDRE interacting with, 539–541
  - VDRM-like activity-originating mechanisms in, 273
- VDRE. *See* Vitamin D response element
- VDRE-BP. *See* Vitamin D response element binding protein
- VDR<sub>mem</sub>. *See* Membrane VDR
- VDR<sub>nuc</sub>. *See* Nuclear VDR

## Vegetarians

## diet for

- bone mass v. macrobiotic/vegetarian, 795
- D metabolism v. vegetarian/omnivorous, 795
- groups/sects/ethnicities, 917t
- rickets v., 1067, 1077

## metabolic bone disease v. Chinese Buddhist, 917t

VEGF gene. *See* Vascular endothelial growth factor gene

Vertebrates, vitamin D<sub>3</sub> synthesized by, 15

VICCs. *See* Voltage-independent calcium channels

## Vitamin A

deficiency inducing squamous metaplasia, 614

in keratinocyte growth/differentiation, 614

McCollum/Davis discovering, 3–4

Vitamin B, McCollum/Osborne/Mendel discovering, 4

Vitamin D autocrine system, in prostate, 1608

Vitamin D binding protein (DBP), 117–128

actin-binding property conserved in vertebrates, 146

analog interaction with, 1456–1459

asymmetric unit having DBP-A/B molecules, 135

binding v. D compound structure, 1457

C-/D-/E-ring analogs binding poorly with, 1563–1565, 1567

changes with age, 1102–1103

concentration v. ecological factors, 126

D analogs' affinity for, 1440–1441, 1441–1442, 1441t

D<sub>3</sub> metabolite/analog affinity for, 138, 141t

in D<sub>3</sub> pharmacology, 1002

D toxicity/free metabolite level v., 1367–1368

20-epi-1,25(OH)<sub>2</sub>D<sub>3</sub>/1,25(OH)<sub>2</sub>D<sub>3</sub>-induced hGH reporter gene

expression v., 1433–1434, 1433f

functional features, 121–127

gene, 117–121

allele distribution, 120–121

chromosomal location/linkages, 117–119

evolution within gene family, 118f, 119–120, 119f

polymorphisms, 120–121

structural features, 117, 118f

transcriptional orientation, 119, 119f

hepatic failure/multiple trauma risk v., 148–149

interactions v. free hormone theory, 125–126

isoforms v. disease susceptibility, 121

LBD v. VDR<sub>nuc</sub> LBD, 387, 387f

molecular interactions, 122–123, 122t

as multifunctional protein, 124

overview, 117

in PCa etiology, 1681

physiological roles, 124–127

polymorphisms, 120–121

primate D hormone movement from, 354–355

proteolysis after receptor/ligand scavenging, 125

species variation in, 29

structural features, 117, 388–391, 390f–391f, 398f

structure explaining unique functions, 149, 150f

structure v. VDR<sub>nuc</sub> structure, 391, 392t

synthesis/turnover, 121–122

three-dimensional structure, 135–149, 136f

in vertebrate evolution, 120

Vitamin D (D). *See also* Hypovitaminosis D

absorption v. age, 1101–1102

adolescents v. inadequate intake of, 816

analog development, 1489–1505

basic screening strategy, 1489–1492

strategy, 1489–1492

synthesis strategy, 1490–1492

analog selectivity mechanisms, 1449–2911

animal/cell culture muscle influenced by, 1809–1811

Vitamin D (*Continued*)

aromatase expression v., 859

β cell characteristics influenced by, 1767

β cells v., 1764–1767

benefits of higher levels of, 1370

in bone fracture clinical trials, 1112, 1113t

bone fracture risk v., 1813–1814

bone mass influenced by, 1245–1247

cancer/differentiation v., 1571–1586

in cancer risk epidemiology, 1617–1629

cancer v., epidemiology of, 1571–1573

in cardiovascular medicine, 899–905

cell cycle influenced by, 1577–1580, 1578f–1579f

chemistry/metabolism/circulation, 15–160

chicken embryonic development/egg hatchability v., 851–852

colon cancer v., 1709–1721

epidemiology of, 1709–1710

colon cancer v. protective role of, 866

colorectal adenoma v. dietary, 1619

colorectal adenoma v. plasma, 1619

colorectal cancer v. dietary/supplementary, 1618

colorectal cancer v. plasma, 1618–1619

compounds v. leukemic cell lines, 1730–1734, 1730t

concentration lacking clinical relevance, 947–948, 948t

controlling factors in supply of, 1293–1294

cutaneous production v. age, 823–824

definitions/models for studying rapid actions of, 583–585

detecting, 933–935

methodology for, 933–934, 935f

sample extraction for, 933

silica cartridge chromatography in, 933–934, 934f

detecting D metabolites and, 931–949

diabetes v., 1763–1774

dietary intake by elderly, 824

discovery, 4, 291

disease states v. D metabolites and, 948t

diseases/conditions prevented by, 998–1000, 999t

drug-oriented perspective on, 995–997

ED-71 as “long-lived,” 1440

epidemiology of breast cancer v., 1671

estimated requirement v. recommended intake, 785

estimating human serum, 933, 933t

factors influencing metabolism of, 789–796

in fertility, 854–855

fetuses/neonates v. low maternal intake of, 841–843

FGF-23 in homeostasis of, 1193

food fortification with, 817–818

genomic/nongenomic influence on striated muscle, 1809

as GIO treatment, 1243–1248

in granuloma-forming disease, 1379–1380

hematological malignancy v., 1727–1736

high latitude summer generation of, 1087

historical perspective on, 3–8

in human physiology, 773–905

in HVDRR therapy, 1227

hydroxylation, 1599

25-hydroxylation, 17–19

in hyperparathyroidism development in renal failure, 1821

hypocalcemia due to malabsorption of, 1056

immune system in type 1 diabetes v., 1767–1773

insufficiency v. low intake of, 1087–1088, 1087f

intestinal absorption by elderly, 824–825

intracellular trafficking in IDBP model, 360

ligands, interacting with DBP, 122–123

in mammary gland, 857–858

maternal D intake v. breast milk, 846–847



Vitamin D (*Continued*)

- mechanism, 167–400
  - metabolically influencing  $\beta$  cells, 1764–1767
  - metabolism, 789–790
    - during pregnancy, 839–840
  - metabolism during lactation/weaning, 843–846
  - metabolism in pregnancy/lactation, 839–847
  - metabolism v. race/geography, 790–795
  - metabolites influencing  $\beta$  cells *in vitro*, 1764–1765
  - metabolites v.  $\beta$  cells in clinical trials, 1765–1767
  - mineralization influenced by, 478–480
  - molecular mechanisms in leukemia v., 1731–1733
  - mouse models lacking function of, 852
  - muscle contraction/relaxation v., 1809, 1809f
  - muscle influenced by, 883–894
  - naming conventions, 15
  - non-bone effects of, 998–1000
  - not a vitamin, 4–5
  - optimal status of, 782–785, 784f
  - osteoblast differentiation/activity influenced by, 649–658
  - in osteoporosis, 1101–1114
  - in ovary, 856
  - in parathyroid gland, 537–547
  - pathogenesis of impaired mineralization v., 1040–1044
  - in PCa, 1599–1611
  - PCa risk v. circulating, 1625–1626
  - PCa v., 1610–1611, 1611f, 1679–1700
  - PCa v. dietary, 1625
  - PDDR treatment with, 1201t
  - perinatal actions, 803–808
  - pharmacology, 995–1010
  - photobiology, 37–43
  - physiological sources for activity of, 782–783
  - plasma half-life, 27
  - preparations v. GIO, 1247–1248
  - prostate targeted by, 1682–1683
  - rapid actions/nongenomic mechanisms, 583–589
  - in renal failure, 1313–1333
  - renal handling of Ca/P influenced by, 518–519, 518f
  - replete/deficient state classification, 1024–1026
  - in reproductive organs, 851–860
  - resistance in breast cancer cells, 1667–1668
  - in rickets management, 1072
  - striated muscle influenced by, 1809–1811
  - supplementation/fortification, 784–785
  - supplements for related agents and, 1060t
  - synthesis, 1599
  - synthesis v. fetal development, 852–853
  - target organs/actions, 565–768
  - in testis, 855–856
  - therapy in chronic renal failure, 1327–1332
  - tissue responsiveness/role in aging, 831–833
  - tumor cells influenced by, 1577–1582
  - in uterus, 856–857
  - winter oral intake v. photosynthesis of, 1087
- Vitamin D<sub>2</sub> (D<sub>2</sub>), 5f, 16f
- assays not monitoring therapeutic, 939–940, 940t
  - clinical use, 11, 12t
  - D intoxication v., 1108
  - derivatives' metabolism, 1430–1431
  - in diet, 1599
  - isolation/identification, 5
  - molecular structure, 931
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> analog synthesis from, 1490, 1491f
  - 25OHD/VDR concentration/hypercalcemia v. supraphysiological, 1364, 1364f, 1364t

Vitamin D<sub>2</sub> (*Continued*)

- PDDR treated with, 1199f, 1201
  - skin diseases treated with, 1791
- Vitamin D<sub>3</sub> (D<sub>3</sub>), 5f, 16f. *See also* Hypervitaminosis D<sub>3</sub>
- activation, 7, 8f
  - in autoimmunity, 1753–1759
  - benefits overlooked, 1000
  - C-25 hydroxylation, monooxygenase activity, 48
  - clinical use of D<sub>2</sub> v., 1005, 1006t
  - D3/metabolite plasma concentrations v., 1362, 1363t
  - deltanoids v. interconverting 6-*s*-cis/trans, 1408f, 1412, 1412f
  - derivatives functionalized at C-24, 22–23
  - dietary/photosynthesized, 1599
  - differentiation/proliferation regulation pathways dissociated, 1581
  - distribution, 1006–1007
  - dose-response relationship with 25OHD<sub>3</sub>, 1003, 1005f
  - dose v. tissue stores, 1007
  - falls v. Ca and, 1814, 1814f
  - half-life, 1007, 1009t
  - indications/clinical use, 997–1000, 1009t
  - isolation/identification, 5, 7
  - metabolic transformations, 931, 932f
  - metabolism in vertebrates, 220–222, 221f
  - metabolism/regulation, 1000–1002, 1000f
  - metabolite/analog formulas/DBP affinity, 141t
  - metabolites, 8
  - molecular structure, 931
  - as new drug, 995–997
  - “normal” disease prevalence v. increased, 999t, 1001
  - 24R,25(OH)<sub>2</sub>D<sub>3</sub> as inactive metabolite of, 851–852
  - 25OHD/VDR concentration/hypercalcemia v. supraphysiological, 1364, 1364f, 1364t
  - in osteoclastogenesis, 665–681
  - as prosteroid hormone, 15
  - recommendations v. public health, 1026
  - serum 25OHD levels ensured by, 1003, 1004t
  - skin diseases treated with, 1791
  - storage/25OHD conversion, 1007
  - supplementation safety margin, 1010
- Vitamin D-dependent rickets type II. *See* Hereditary vitamin D-resistant rickets
- Vitamin D endocrine system, 383–386
- adapting to 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration, 1000f, 1001
  - calbindin-D<sub>28K</sub>/VDR colocalization in understanding, 721
  - description of, 383, 384f
  - discovery, 7
  - implicated in OA, 1144
  - osteoporosis/fracture v., 1141–1144
  - physiological process role, 291
  - pleiotropic effects v. VDR gene association analysis, 1138–1141, 1139t–1140t
  - in prostate, 1608
  - RAS interaction with, 877–878, 878f
  - VSCCs v. 1,25(OH)<sub>2</sub>D<sub>3</sub>, 751–757
- Vitamin D hormone receptors, new functions indicated by, 6
- Vitamin D hypothesis
- colorectal cancer v., 1618
  - experimental studies, 1606–1607
  - observational studies v., 1602–1606
  - PCa risk factors in, 1601, 1601t
  - PCa v., 1599–1611, 1611f
  - studies v., 1626
- Vitamin D pseudodeficiency. *See* Pseudo-vitamin D-deficiency rickets (PDDR)
- Vitamin D-receptor interacting protein coactivator complex. *See* Mediator-D coactivator complex

- Vitamin D receptor (VDR), 167–184, 219–250, 1210–1212. *See also* Human VDR (hVDR); VDR gene; *specific types of VDR*
- ablated in rodents/humans, 224–225
  - ablation in mice, 341–348
  - absent in tibial dyschondroplasia, 579
  - activation functions, 176
  - affinity v. D analog activity, 1452f, 1453
  - allosteric model of signaling activation in, 235–237, 236f
  - analog activity v. increased, 1456
  - analog selectivity in ligand-dependent regulation of, 1452f, 1456
  - analog selectivity v. RXR heterodimerization of, 1452f, 1454
  - analogs modulating, 1482–1483
  - antagonist/partial agonist response paradigms, 271
  - basal gene transcription apparatus contacting, 263
  - baT haplotype allele v. nephrolithiasis, 1142
  - as bile acid receptor, 866–867
  - binding sites in
    - classical, 314–319
    - complex, 319–322
  - binding v. 20-epi D analogs, 1495–1498
  - binding v. deltanoid A-ring conformation, 1412, 1412f
  - binding v. 1,25(OH)<sub>2</sub>D<sub>3</sub> 20-carbon epimerization, 1544
  - biochemical properties, 170–171, 170t
  - bisphenol analogs as agonists of mutant, 1561–1562, 1561f
  - in blood cells, 1728–1729
  - in cancer, 1571, 1572t
  - in cancer cell growth regulatory response, 1583–1584
  - cardiovascular disease and genetics of, 900–901
  - cellular/tissue distribution, 168–170, 169t
  - characterization, 168–171
  - chromatin remodeling v. transcriptional control by, 305–307, 306f
  - CKD altering 1,25(OH)<sub>2</sub>D<sub>3</sub> mediation by, 1317–1322
  - cloning, 171–172
  - in CNS, 1780–1781
  - coactivators associating with, 242–243, 264–268, 293–298
    - different means of recruitment for, 273
    - Ets-1, 298
    - interaction mechanism for, 293, 294f
    - ligand-induced/tissue-selective recruitment of, 270–271
    - Mediator-D, 265–267, 265t
    - multifunctional HAT activity assemblies of, 264–265
    - NCoA62/SKIP, 265–267
    - Smad 3, 298
    - SRC family of, 293–295, 295f
    - SRC/p160 family of, 264
    - TFIIA/TFIIB/TFIID, 298
    - WSTF, 309–310, 310f
  - cofactor complexes affecting, 263–274
    - ATP-dependent remodeling, 267–268
  - colonic hyperproliferation/tumorigenesis v., 1711–1712, 1712f
  - comodulators, 242–243, 291–300
    - integrated model for activity by, 299–300, 300f
  - in cultured metanephros, 521–522, 524f
  - cyclic dynamics, 181–182, 181f, 182f
  - D analog selectivity determined by interaction with, 1452–1456, 1452f
  - D endocrine system v. calbindin colocalizing with, 721
  - D pocket structure, 142
  - defects causing hypocalcemia, 1056
  - deltanoids v. rickets-associated mutants of, 1409, 1411f
  - in developing rodent kidney, 521–522, 522f, 523f
  - differential activation by analogs, 1475–1482, 1476f
  - differential activation by antagonists, 1480–1482
  - differential activation by noncalcemic selective agonists, 1478–1480
  - differential activation by superagonists, 1475–1478, 1476f
- Vitamin D receptor (*Continued*)
- discovered, 8–9, 167–168, 219–220
  - DNA binding, 171, 313–314
    - capacity in normal/renal failure rats, 543
  - endogenous gene promoters binding to, 177–178, 178f
  - ethnic variation in polymorphisms of, 1127–1129, 1128t
  - evolutionary insights from, 227–228
  - expression/abundance regulation, 193–210, 202t
    - heterologous, 204–210
    - homologous, 201–204
  - expression in colon cancer, 1710–1711, 1711f, 1711t
  - expression in prostate cells, 1834–1836
  - expression/regulation in breast cancer cells, 1667
  - expression/role in normal mammary gland, 1669–1670, 1670t
  - functional analysis, 176–182
  - Gemini/1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> binding efficiency, 287
  - gene targets/biological actions, 220–225
  - genomic structure surrounding, 1122, 1123f
  - genotype responses as serum marker differences, 1133t, 1135–1136
  - genotypes v. psoriasis treatment response, 1784
  - in GHS rats, 1348–1349, 1349f
  - GR sharing coactivators/corepressors with, 1240
  - group 1I/1H
    - cholesterol derivatives recognized by, 227f, 229
    - similarities in, 229, 229f
  - growth inhibition v. differentiation, 1713, 1713f
  - helix 12's intramolecular interactions in, 281, 283f
  - homologous up-regulation defective in CKD, 1317–1318
  - in human BPH cells, 1834, 1835f
  - import/export receptors interacting with, 368–371
  - import v. coactivators, 369, 370f
  - interactions v. 20-epi analog binding, 1477–1478, 1478f
  - intranuclear trafficking of, 374–376
  - in kidney, 520–523
  - lamprey, 227–228, 279
  - LBD hypothetical conformation, 1473, 1473f
  - ligand immunomodulation v. graft rejection, 1519–1520
  - ligand-triggered protein-protein interactions, 313
  - ligands as immunoregulatory agents, 633
  - ligands enhancing regulatory T cells, 636
  - ligands inhibiting BPH, 1833–1840
  - localization, 363–365, 364f
    - models, 363–365, 364f
    - in shuttle model, 364–365, 364f
  - localization in plasma membrane caveolae, 400
  - 2MD inducing unique conformation of, 1550, 1550f
  - 2MD promoting interactions by, 1550–1551, 1551f
  - 2MD stimulating promoter binding by, 1549–1550, 1549f
  - mineralization v. altered, 488–489, 489f
  - mouse proximal/distal colon expressing, 1719
  - muscle, 885–886
  - muscle SOC influx v. TRPC3 proteins and, 892–893, 892f
  - myeloid development v. expression of, 1729
  - neocyttoplasmic trafficking, 365–374
  - nonsecosteroidal D mimics differentially regulating, 1565
  - nonsteroidal analogs inducing unique conformation of, 1567
  - normal/leukemic hematopoietic cells expressing, 1728–1729
  - in normal/malignant colon cells, 1710–1712
  - novel co-regulatory complexes interacting with, 307–308, 307f
  - nuclear export, 369–370, 372f
  - nuclear export v. transcription, 371, 372f
  - nucleocytoplasmic trafficking regulation, 371–374
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> A-ring in transactivation of, 1472f, 1473–1474
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> D-ring in transactivation of, 1475
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> deficiency reducing parathyroid, 1317, 1318f

Vitamin D receptor (*Continued*)

- 1,25(OH)<sub>2</sub>D<sub>3</sub> inducing focal accumulation of, 374–375, 375f
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> ligand binding by v. hair cycle regulation, 234–235
  - in 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>-modulated SOC influx, 893, 894f
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating PTH gene at, 540f, 541–542
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> side chain in transactivation of, 1474–1475
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> up-regulation, 201–204, 202t
  - parathyroid CaR interacting with, 556, 556t
  - phenotype v. fracture risk, 1143–1144
  - phosphorylation possibly regulating activity, 1454
  - PIC linked to, 291–292
  - “piggyback” nuclear import of, 369, 371f
  - polymorphism association analysis in disease states, 1137–1148
  - polymorphism functionality, 1129–1137, 1131t–1134t
  - polymorphism testing levels, 1129, 1135f
  - polymorphism v. diabetes risk, 1773
  - polymorphisms, 1122–1126
  - polymorphisms influencing breast cancer risk, 1671–1672
  - polymorphisms influencing muscle function, 1813
  - polymorphisms/intestinal Ca absorption v. BMD, 1141–1142
  - polymorphisms v. cancer/hyperproliferative disease, 1145–1146
  - polymorphisms v. colon cancer development, 1712
  - polymorphisms v. disease risk, 1121–1149
  - polymorphisms v. PCa, 1604–1605
  - polymorphisms v. PCa risk, 1681–1682
  - polymorphisms v. structure/function in CKD, 1318–1319
  - in prostate, 1682–1683
  - shuttling v. transcription, 371
  - skeletal homeostasis not requiring, 344
  - species having characterized, 279–280
  - stabilization v. SRC–1 interaction, 1472–1473, 1472f
  - structural domains, 173–176, 173f
    - DNA binding, 174
    - Ligand binding, 174–176, 175f
    - PXR v. ligand binding/heterodimerization/transactivation, 233–235, 234f
    - zinc finger DNA binding, 229–233, 231f
  - structural gene, 171–176
  - structural organization, 171
  - structural requirements for 1,25(OH)<sub>2</sub>D<sub>3</sub> transactivation of, 1472–1475, 1472f
  - structure/function, 229–236
  - subcellular distribution, 168f, 170
  - subcellular trafficking, 363–376
  - superagonist/selective coactivator recruitment paradigms, 271–273
  - target gene diversity, 313–322
  - tissue distribution, 193–194, 228
  - tissue effects of low 1,25(OH)<sub>2</sub>D<sub>3</sub>/abnormal, 1322–1327
  - tissue selective ligands in, 270–273
    - established paradigms for, 270–271
  - tissue source/species conservation, 172
  - as toxic bile acid sensor, 863–869
  - in toxicity, 1362–1365
  - transcription regulated by integrated pathways, 268–270, 269f
  - transcription v. 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>/analog side chain modification, 1474–1475, 1474t
  - translocation mechanisms determining analog selectivity, 1452f, 1454
  - variants, 195–196, 195f, 196f
  - VDR promoter targeting, 305–312, 306f
  - VDRE interaction v. interference footprinting protocols, 542
- Vitamin D response element binding protein (VDRE-BP)
- dominant negative action, 354, 354f
  - compensation for, 359–360
  - New World primate, 354–355

## Vitamin D response element (VDRE)

- analogy selectivity v. genes with, 1454–1455
  - binding proteins in intracellular, 351–361
  - in bone proteins, 712, 713t
  - clusters, 320–321
  - complex, 316t
  - as complex/multiple TF binding site structures, 320
  - direct 1,25(OH)<sub>2</sub>D<sub>3</sub> osteoblast modulation v., 654
  - DNA bend induced by VDR-RXR bonding to, 541
  - DNA binding polarity, 180, 317–318
  - DR6/DR3-type, 316t, 317
  - DR3-type, 314–315
    - classical VDRE structure in, 314
    - DBD-DBD distance in, 318, 318f
    - multiple signaling pathways v., 316–317
    - strongest VDR-RXR heterodimer binding in, 314–315
  - DR4-type, 316t, 317
  - ER9-type, 316t
    - DBD-DBD distance in, 318, 318f
  - in human ECaC promoter region, 527
  - human VDR promoter, 200
  - known natural types of, 316t
  - location/sequence of positive natural, 177, 177t
  - mapping CT/GRP gene, 694–696, 695f
  - neuroendocrine-specific/cAMP enhancers in, 693–696
  - nonhuman VDR promoter, 197
  - in 1,25(OH)<sub>2</sub>D<sub>3</sub> regulation of PTH gene expression, 539–541
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene promoter regions having, 314
  - positive/negative/optimal, 222–224, 223t
  - rat *CYP24A1* proximal promoter region, 93–97, 94f, 95f
  - simple v. complex, 319–320
  - software v. identifying complex, 322
  - VDR interaction v. interference footprinting protocols, 542
  - VDR-regulated genes originating, 222–224, 223t
  - VDR/RXR recognition by PTHrP, 743–744
  - VDR structure supporting specific binding to, 230–232, 231f
    - whole-genome screening for putative, 322
- Vitamins, discovery of, 3–4
- Voltage-dependent calcium channels (VDCCs), in nongenomic 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> actions in muscle, 890–893, 890f
- Voltage-independent calcium channels (VICCs), Osteoblast VSCCs interacting with, 755, 755f
- Voltage-sensitive calcium channels (VSCCs), 751–753
- $\alpha_1$  subunit types/functions of, 752, 752t
  - L-type
    - Ca<sup>2+</sup> inactivating, 755–756, 756f
    - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. open time in, 754–755, 755f
    - pore-forming  $\alpha_1$  subunit transmembrane organization in, 752, 752f
    - subunit structure of, 752, 752f
  - membrane/nuclear action cross-talk in, 757
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> Ca<sup>2+</sup>/transcriptional responses by, 756–757
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> regulating, 1782–1783
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v., 753–754
  - 1,25(OH)<sub>2</sub>D<sub>3</sub> v. D endocrine system, 751–757
- VSCCs. *See* Voltage-sensitive calcium channels
- VSMCs. *See* Vascular smooth muscle cells

## W

## Weaning

- BMC/BMD after, 845–846, 845f
- D/Ca metabolism after, 845
- maternal Ca economy after, 846, 846f

Weight, serum 25OHD v., 1007  
 Whites, dietary calcium reduction response by, 778  
 Wild-type (WT) mice  
   dexamethasone influencing Ca absorption in, 445, 447f  
   dietary intervention v. Ca absorption in, 434f, 436t, 437–438  
   intraperitoneal glucose tolerance test in, 1765, 1765f  
   low- $P_i$  diet v. *Hyp* and, 464f, 465  
 Williams syndrome  
   defective chromatin remodeling complex WINAC in, 238–240  
   hypervitaminosis D/hypercalcemia in, 1359  
   1,25(OH) $_2$ D $_3$  repression of CT/GRP expression v., 690  
   WSTF gene deleted in patients with, 267–268  
 Williams syndrome transcription factor (WSTF)  
   as VDR interactant, 307–308, 307f  
   VDR ligand-induced transactivation coactivated by, 309–310, 310f  
   WINAC/VDR interaction through, 268  
 Wilson's disease, hypoparathyroidism/hypocalcemia v., 1053  
 WINAC coactivator complex  
   components, 308, 308f  
   cooperative function with co-regulator complexes, 311–312  
   nucleosome arrays disrupted by, 309, 309f, 310, 311f  
   purification/identification, 308, 308f  
   VDR promoter targeting mechanism, 310–311, 310f, 311f  
   in VDR transcription model, 268–270  
   Williams syndrome associated with defective, 238–240  
   WSTF in VDR interaction with, 268  
 Women. *See also* Latinas  
   BMD/insufficiency/secondary hyperparathyroidism in, 1089  
   bone remodeling markers in young/elderly, 1089–1090, 1090t  
   Ca absorption v. intake in, 779–780, 779f, 780f  
   Ca absorption v. load in, 779–780, 780f  
   Ca v. age-related 1,25(OH) $_2$ D resistance in, 1104–1105, 1105f  
   cervical cell carcinoma common in, 857  
   D deficiency in black, 791  
   D metabolism in Iranian, 794  
   D supplementation reducing bone mass loss in, 1094  
   D v. risk of falls in postmenopausal, 1114  
   estrogen v. 1,25(OH) $_2$ D $_3$  in postmenopausal, 1260  
   estrogen v. PTH/bone resorption in, 1108–1109, 1108f  
   normative histomorphometric data for, 956t  
   1,25(OH) $_2$ D $_3$  v. postmenopausal osteoporosis in, 1111–1112  
   25OHD v. age in, 1101, 1102f  
   25OHD v. PTH in French post-menopausal, 1021–1022, 1021f  
   OPG v. breast carcinoma-related bone metastases in, 676  
   postmenopausal  
     OPG clinical trials in, 676  
     VDR target gene associated with osteoporosis in, 246  
   rickets prevention strategies v., 1072  
   serum 1,25(OH) $_2$ D in, 827  
   winter hypovitaminosis D in young/elderly, 1093, 1093t

WSTF. *See* Williams syndrome transcription factor  
 WT mice. *See* Wild-type mice

## X

X-linked hypophosphatemia (XLH), 467, 981  
   bone modeling abnormalities in, 982, 983f  
   extraskeletal ossification in, 982–983, 984f, 985f  
   FGF-23 in, 1193  
   genetic defect underlying, 1170–1172  
   *Hyp/Gy* mouse models for, 463, 463t  
   *Hyp* mouse models for, 464f, 465  
   in original D-resistant rickets case, 1207  
   osteoarthritis in, 983  
   pathogenesis, 1172  
   pathophysiology, 1168–1170  
   phosphate homeostasis in, 1168–1173, 1169t  
   radiography of rickets v., 922, 923f, 924f  
   reinforcing FGF-23 as phosphatonin, 1165  
   treatment, 467, 1172–1173  
 X-linked recessive hypophosphatemia (XLRH), phosphate homeostasis in, 1175  
 X-ray diffraction, bone mineral presence determined by, 481, 482f  
 X-rays  
   D-deficient osteomalacia revealed by, 481  
   discovery of, 967  
   metabolic bone disease evaluated with, 914, 921–922, 923f, 924f  
 Xenobiotic detoxification, VDR in, 228, 229f  
 XLH. *See* X-linked hypophosphatemia  
 XLRH. *See* X-linked recessive hypophosphatemia

## Y

Yeast  
   higher eukaryote complex diversity v., 266  
   Mediator-D/related complex function studied in, 266

## Z

Zebrafish VDR (zVDR)  
   bound to 1 $\alpha$ ,25(OH) $_2$ D $_3$ , 284–285, 284f  
   characterized, 279  
 ZK 159222, 1481f, 1482  
 zVDR. *See* Zebrafish VDR  
 zVDR-1 $\alpha$ ,25(OH) $_2$ D $_3$  complex, crystal structure, 284–285, 284f  
 zVDR-Gemini complex  
   channel extending original pocket in, 287–288  
   structure, 287–288  
   zVDR-1 $\alpha$ ,25(OH) $_2$ D $_3$  structure v., 287